
<html lang="en"     class="pb-page"  data-request-id="bec19f35-fdfd-4da9-8c6f-0309b97e01a7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-4;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01465;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma" /></meta><meta name="dc.Creator" content="Dizhong  Chen" /></meta><meta name="dc.Creator" content="Chang Kai  Soh" /></meta><meta name="dc.Creator" content="Wei Huang  Goh" /></meta><meta name="dc.Creator" content="Haishan  Wang" /></meta><meta name="dc.Description" content="Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activa..." /></meta><meta name="Description" content="Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activa..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 6, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01465" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01465" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01465" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01465" /></link>
        
    
    

<title>Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01465" /></meta><meta property="og:title" content="Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0019.jpeg" /></meta><meta property="og:description" content="Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib. A series of purine or 5H-pyrrolo[3,2-d]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway. Among 39 cell lines screened, the molecules (e.g., 20e, 20f, and 20q) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors. Compound 20f in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated. These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of 20f." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib. A series of purine or 5H-pyrrolo[3,2-d]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway. Among 39 cell lines screened, the molecules (e.g., 20e, 20f, and 20q) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors. Compound 20f in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated. These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of 20f." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0019.jpeg" /></meta><meta name="twitter:title" content="Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01465"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01465">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01465&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01465&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01465&amp;href=/doi/10.1021/acs.jmedchem.7b01465" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1552-1575</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01422" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01463" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dizhong++Chen">Dizhong Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chang+Kai++Soh">Chang Kai Soh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei+Huang++Goh">Wei Huang Goh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haishan++Wang">Haishan Wang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-7959-7377" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Drug Development Unit, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Probit Pharmaceuticals Pte. Ltd., 10 Anson Road no. 26-04, Singapore 079903, Republic of Singapore</span></div><div class="corresp-info"><strong>*</strong>Phone: +65-98265986. Fax: +65-62261209. Email: <a href="/cdn-cgi/l/email-protection#a1ccc2c3d6c9d2e1c6ccc0c8cd8fc2cecc"><span class="__cf_email__" data-cfemail="b4d9d7d6c3dcc7f4d3d9d5ddd89ad7dbd9">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01465&amp;href=/doi/10.1021%2Facs.jmedchem.7b01465" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1552â1575</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 23, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 October 2017</li><li><span class="item_label"><b>Published</b> online</span>6 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01465" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01465</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1552%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDizhong%2BChen%252C%2BChang%2BKai%2BSoh%252C%2BWei%2BHuang%2BGoh%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D4%26contentID%3Dacs.jmedchem.7b01465%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BPreclinical%2BEvaluation%2Bof%2BFused%2BPyrimidine-Based%2BHydroxamates%2Bfor%2Bthe%2BTreatment%2Bof%2BHepatocellular%2BCarcinoma%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1575%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01465"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2011</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01465" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dizhong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chang&quot;,&quot;last_name&quot;:&quot;Kai Soh&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Huang Goh&quot;},{&quot;first_name&quot;:&quot;Haishan&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1552-1575&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01465&quot;},&quot;abstract&quot;:&quot;Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib. A series of purine or 5H-pyrrolo[3,2-d]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway. Among 39 cell lines screened, the molecules (e.g., 20e, 20f, and 20q) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors. Compound 20f in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated. These encouraging results, along with its favorable target pro&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01465&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01465" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01465&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01465" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01465&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01465" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01465&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01465&amp;href=/doi/10.1021/acs.jmedchem.7b01465" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01465" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01465" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01465%26sid%3Dliteratum%253Aachs%26pmid%3D29360358%26genre%3Darticle%26aulast%3DChen%26date%3D2018%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BPreclinical%2BEvaluation%2Bof%2BFused%2BPyrimidine-Based%2BHydroxamates%2Bfor%2Bthe%2BTreatment%2Bof%2BHepatocellular%2BCarcinoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D4%26spage%3D1552%26epage%3D1575%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/4" title="Go to Volume 61, Issue 4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/jmcmar.2018.61.issue-4/20180222/jmcmar.2018.61.issue-4.largecover.jpg" alt="Go to Volume 61, Issue 4"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC. Activation of phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway was involved in the development of HCC and acquired resistance to sorafenib. A series of purine or 5<i>H</i>-pyrrolo[3,2-<i>d</i>]pyrimidine based hydroxamates were designed and developed as multitarget drugs to modulate both HDACs and the PI3K/Akt/mTOR pathway. Among 39 cell lines screened, the molecules (e.g., <b>20e</b>, <b>20f</b>, and <b>20q</b>) were the most selective against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors. Compound <b>20f</b> in particular showed significant single agent oral efficacy in hypervascular liver cancer models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated. These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of <b>20f</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hepatocellular carcinoma (HCC) is the third most fatal cancer worldwide, with sorafenib being the first and only approved systemic therapy for advanced HCC since 2007.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Only recently in April 2017 was regorafenib, a fluorinated version of sorafenib, approved to treat HCC patients who fail sorafenib treatment (sorafenib resistance).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> However, there is currently no established systemic therapy for HCC patients who tolerate neither sorafenib nor regorafenib or fail regorafenib therapy.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Class I histone deacetylases (HDACs) are highly expressed and/or upregulated in hepatocellular carcinoma (HCC) and are associated with aggressiveness, spread, and increased mortality of HCC.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6-9)</a> Drug resistance to sorafenib involves pathways such as PI3K/Akt and JAK/STAT, and PI3K/Akt/mTOR signaling pathway activation has been found in a subset of HCC tumor samples.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10-13)</a> The above data thus suggest that both HDACs and PI3K/Akt/mTOR are relevant targets for the treatment of advanced HCC.</div><div class="NLM_p">HDACs are validated oncology targets and there are already approved HDAC inhibitors for the treatment of lymphoma and multiple myeloma (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), with new indications, including HCC, being explored and further validated in clinics.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In preclinical studies, both HDAC inhibitors vorinostat (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) ansd <i>N</i>-hydroxy-4-[[(2<i>S</i>)-3-methyl-2-phenylbutanoyl]amino]benzamide (OSU-HDAC42)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> were efficacious in HCC models, while HDAC inhibitor panobinostat (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) used in combination with sorafenib demonstrated the highest preclinical efficacy in HCC models.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In completed clinical trials, HDAC inhibitor belinostat (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) demonstrated disease stabilization with a tolerable toxicity profile among patients with HCC,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> while resminostat (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> in combination with sorafenib was found to be safe and showed early signs of efficacy in advanced HCC patients.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples and chemical structure features of HDAC inhibitors (HDACi), PI3K/mTOR inhibitors, and HDAC/PI3K dual inhibitor. <b>3</b> (CUDC-907) is considered to be a hybrid derivative of pictilisib and quisinostat. Both idelalisib and panobinostat were issued with a boxed warning by FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both PI3K and mTOR are also validated cancer targets: currently there are two approved PI3K inhibitors, idelalisib (PI3KÎ´ selective)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and copanlisib (pan-class I PI3K inhibitor with preferential activity against PI3KÎ± and PI3KÎ´)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Combination of mTOR inhibitor (5-(2,4-bis((<i>S</i>)-3-methylmorpholino)pyrido[2,3-<i>d</i>]pyrimidin-7-yl)-2-methoxyphenyl)methanol (AZD8055)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> with HDAC inhibitor vorinostat in vivo almost completely inhibited tumor-growth without obvious adverse effects. Furthermore, the combination of dual PI3K/mTOR inhibitor 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (PKI-587)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> with sorafenib targeting both PI3K/AKT/mTOR and Ras/Raf/MAPK pathways showed synergistic inhibition of HCC cell proliferation. These results suggest that it is feasible and effective to target both HDACs and PI3K/AKT/mTOR pathways together for the treatment to advanced HCC.</div><div class="NLM_p">From a medicinal chemistâs perspective, a multitarget drug (single molecule) is an alternative approach to achieve multitargeted therapy as compared to combination therapy (multiple molecules). On the basis of our knowledge and experience in the development of HDAC inhibitors<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> and PI3K/mTOR inhibitors (e.g., SB2343 (<b>1</b>), <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> we designed and synthesized a series of fused-pyrimidine based hydroxamates to target both HDACs and the PI3K/Akt/mTOR pathway for the treatment of cancer as well as nononcology applications.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">As illustrated in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, a typical HDAC inhibitor (vorinostat) comprises three parts: zinc-binding group (ZBG), linker, and a lipophilic and surface recognition âCAPâ group. As the CAP sits outside of the binding pocket of HDAC enzymes,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> it can be replaced with a kinase inhibitor core structure to afford a novel HDAC-kinase inhibitor.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Purine and fused-pyrimidine are scaffolds used to build up competitive kinase inhibitors (e.g., <b>1</b> (SB2343), PI103 (<b>2</b>),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> pictilisib,<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which compete with adenosine triphosphate (ATP). Hence, the HDAC inhibitor moieties (linker + ZBG) can be used to replace the sugar part of ATP to construct a kinase-HDAC inhibitor. The general chemical types of the designed HDAC-PI3K/mTOR inhibitors are depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. Previous SAR studies on purine-based PI3K/mTOR inhibitors (<b>4</b>, as analogues of <b>1</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) had shown that the 9-position can accommodate rings and chains,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> thus HDAC inhibitor moieties were introduced to the 9-position to generate HDAC-PI3K/mTOR inhibitors (<b>5</b>). Because both Cpd-38 (<b>6</b>) and Cpd-51 (<b>8</b>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> two representative examples of <b>4</b>, are potent PI3K and mTOR inhibitors, two expanded chemical series <b>7</b> and <b>9</b> were designed to establish the SARs for HDAC, PI3K, and mTOR inhibitory activities as well as tune target profile (HDAC vs PI3K vs mTOR) by exploring a variety of combination of functional groups (i.e., linker and R<sup>2</sup>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Series <b>10</b> was designed to explore potential morpholine replacement. As the best combination profile of HDAC/PI3K/mTOR is unknown or yet to be validated, the inhibitors were designed to have a broad range of potency or strength against each target (i.e., HDAC, PI3K, and mTOR) in order to mimic the combination of single-target inhibitors. The optimal combination was then determined in preclinical studies. Even though every drug candidate has to address its toxicity preclinically, there remain concerns of potential combined toxicity of designed multitarget drugs in clinics. Fortunately, the latest phase I results of CUDC-907 (<b>3</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) demonstrated tolerability and antitumor activity across all dosing schedules studied in patients with relapsed or refractory lymphoma or multiple myeloma.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a><b>3</b> (CUDC-907)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> is the first HDAC/PI3K dual inhibitor entered clinical trials,<a onclick="showRef(event, 'ref34 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref36 ref37">(34, 36, 37)</a> being considered as a hybrid derivative of PI3K inhibitor pictilisib and HDAC inhibitor quisinostat (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design and chemical types of inhibitors targeting HDACs, PI3Ks, and mTOR. IC<sub>50</sub> data of Cpd-38 (<b>6</b>) and Cpd-51 (<b>8</b>) were extracted from ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">26</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Here we report the synthesis and preclinical evaluation of hydroxamates <b>7</b>, <b>9</b>, and <b>10</b> series (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), which have been designed and developed to modulate both HDACs and the PI3K/Akt/mTOR pathway. Among 39 cancer cell lines screened, the molecules (e.g., <b>20e</b>, <b>20f</b>, and <b>20q</b>) were more potent against leukemia, lymphoma, and HCC cells; they also demonstrated target modulation in cancer cell lines and in mice bearing MV4-11 and HepG2 tumors. Compound <b>20f</b> in particular showed significant single-agent oral efficacy in hypervascular HCC models (e.g., HepG2, HuH-7, and Hep3B) and was well-tolerated. These encouraging results, along with its favorable target profile and tissue distribution, warrant further development of <b>20f</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">A wide range of substituted purines and pyrrolo[2,3-<i>d</i>]pyrimidines were prepared in a straightforward four- or five-step procedure starting from 2,6-dichloropurine (<b>11a</b>) or 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>11b</b>), which were commercially available. As depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, a typical procedure used an alkyl halide in the presence of a suitable base such as potassium carbonate to alkylate the NH group of compound <b>11a</b> or <b>11b</b>. The major products were N-9 alkylated <b>13a</b>â<b>d</b> when purine <b>11a</b> was used. The two chlorine atoms of <b>13a</b>â<b>d</b> were displaced selectively or sequentially under optimal reaction conditions. Under Suzuki reaction conditions, a boronic ester (<b>14a</b>) reacted with the more reactive chlorine atom to form monochloro compound <b>15a</b>â<b>d</b>. The second chlorine atom was displaced by an amine (e.g., morpholine) at elevated temperature to give the esters <b>16a</b>â<b>d</b>, which were further converted to the hydroxamic acids <b>17a</b>â<b>d</b> by hydroxylaminolysis in the presence of excessive hydroxylamine.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of N-9 Substituted Purines <b>17a</b>â<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaI (0.2 equiv), anhydrous K<sub>2</sub>CO<sub>3</sub> (2 equiv), Br(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>5</sup> (<b>12a</b>â<b>d</b>, m = 3,4,5,6, R<sup>5</sup> = Et or Me; 1.1 equiv), DMF, 40 Â°C, 12 h, 61â78%; (b) <b>14a</b> (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), 82 Â°C for 6 h, 24â72%; (c) morpholine, DMF, 80 Â°C, 12 h, 56â72%; (d) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt, 21â38%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> depicted an alternative displacement sequence of the two chlorine atoms of compounds <b>13c</b>â<b>e</b>. The more reactive chlorine was displaced first by morpholine to give <b>18c</b>â<b>e</b>, and the second chlorine was used to introduce aryl groups via Suzuki coupling by reaction with boronic acid or ester <b>14a</b>â<b>o</b> to afford esters <b>19a</b>â<b>t</b> which were subsequently converted to the hydroxamic acids <b>20a</b>â<b>s</b>. For those aryl groups that could not directly derive from the readily available <b>14a</b>â<b>o</b>, one additional step was applied to modify the analogues of <b>19a</b>â<b>t</b>. The reactive phenol group in <b>19t</b> or <b>19p</b> was alkylated by 2-bromoethanol, and subsequently the resulting product <b>19t2</b> or <b>19u</b> was converted to <b>20t</b> or <b>20u</b>, which was extended with a neutral hydroxyl group. The aldehyde <b>19v</b> was reduced to the benzyl alcohol <b>19w</b>, which was subsequently converted to the final hydroxamate <b>20v</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2-Aryl-9-substituted Purines and Pyrrolo[2,3-<i>d</i>]pyrimidines <b>20a</b>â<b>v</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine (3 equiv), DCM, 40 Â°C, 3 h or rt overnight, 87â99%; (b) boronic acid or ester <b>14a</b>â<b>o</b> (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), 82 Â°C for 6 h, 28â90%; (c) neat morpholine (excess), 78 Â°C, overnight; (d) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt; (e) 2-bromoethanol (3 equiv), K<sub>2</sub>CO<sub>3</sub> (5 equiv), DMF, 90 Â°C; (f) NaBH<sub>4</sub> (10 equiv), MeOH, rt, 95%.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> depicted another modification: replacing the commonly used morpholine at the 6-position of the purine ring with other cyclic amines. Both piperidin-4-ylmethanol and piperidin-4-ol were used to react with <b>13d</b> to afford <b>21a</b> and <b>21b</b>, which were further converted to hydroxamates <b>23a</b> and <b>23b</b> via Suzuki coupling and hydroxylaminolysis.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 6-Substituted Purines <b>23a</b> and <b>23b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>13d</b> (1 equiv), piperidin-4-ylmethanol or piperidin-4-ol (6 equiv), Et<sub>3</sub>N (6 equiv), DCM, 40 Â°C, overnight; (b) <b>14a</b> (3 equiv), K<sub>2</sub>CO<sub>3</sub> (4 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), microwave 150 Â°C, 10â30 min; (c) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> depicted the approaches to introduce aryl linked hydroxamates at the 9-position of the purine ring. The more reactive 6-Cl of <b>11a</b> was first replaced with morpholine, and then the resulting 6-morpholinopurine <b>24</b> was subjected to further alkylation. This approach was also applied to make individual compounds described in both <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Nitrile <b>25</b> was prepared by N-9 alkylation of <b>24</b> with 2-iodoacetonitrile and was further reduced to amine <b>26</b>. By reductive amination with aldehyde and alkylation with alkyl bromide, amine <b>26</b> was converted to intermediates <b>27</b> and <b>32</b> with aryl linkers, respectively. After Suzuki coupling with either boronic ester <b>14a</b> or boronic acid <b>14d</b>, and subsequent hydroxylaminolysis, <b>27</b> and <b>32</b> were eventually converted to hydroxamates <b>29</b>, <b>31</b>, and <b>34</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of N-9 Aryl linked Purine Hydroxamates <b>29</b>, <b>31</b>, and <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine (3 equiv), rt, THF; (b) ICH<sub>2</sub>CN (2 equiv), anhydrous K<sub>2</sub>CO<sub>3</sub> (2 equiv), MeCN-DMSO (19:1, v/v), 60 Â°C; (c) NiCl<sub>2</sub>Â·6H<sub>2</sub>O (0.1 equiv), NaBH<sub>4</sub> (7 equiv), THF/MeOH (1:2); (d) methyl 3-(4-formylphenyl)acrylate (1.2 equiv), NaBH(OAc)<sub>3</sub> (1.5 equiv), HOAc (1 equiv), DCE, rt; (e) <b>14a</b> or <b>14d</b> (2.0 equiv, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), microwave 15â30 min; (f) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt; (g) <i>p</i>-BrCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>CH<sub>3</sub> (1.1 equiv), Et<sub>3</sub>N (1.2 equiv), THF, rt, 2 h.</p></p></figure><div class="NLM_p last">The acid (RCO<sub>2</sub>H) was identified as the major impurity in the final target hydroxamate (RCONHOH) product. In general, the hydroxamic acid was slightly more polar than the acid and was separated by preparative HPLC with purity >95%. The acid (<b>20w</b>) corresponding to <b>20f</b> was prepared by hydrolysis of the ester <b>19f</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Supporting Information</a>), was a very poor HDAC inhibitor as compared to the respective hydroxamic acid <b>20f</b>; it still maintained majority of the PI3K inhibitory potency, but its contribution to biological activity was insignificant or negligible (<b>20f</b> vs <b>20w</b>, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Table S1</a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Inhibition of HDAC1 and PI3KÎ±, SAR, and Antiproliferative Activity</h3><div class="NLM_p">HeLa nuclear extract and HDAC isozyme HDAC1 as well as PI3KÎ± (p110Î±/p85Î±) were used as routine enzymatic screening tests for HDAC and PI3K inhibitory activities. Cancer cell lines MV4-11 (acute monocytic leukemia), PC-3 (prostate cancer), and MCF7 (breast cancer) were used to evaluate antiproliferative activities as well as modulation of targets (HDACs, PI3K, mTOR) in cancer cells. HDAC inhibitor vorinostat and PI3K inhibitor pictilisib were used as positive control in all experiments.</div><div class="NLM_p">To establish SAR, we tried to optimize HDAC inhibitory activity first and started from a PI3K inhibitor core structure with fixed functional groups which were good for PI3K inhibition. According to our previous study, purine-based PI3K/mTOR inhibitor <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) or <b>4</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), the 2-aminopyrimidin-5-yl group was good for PI3KÎ± and mTOR inhibition (e.g., <b>6</b> and <b>8</b>), and 9-position could accommodate substituents such as rings or chains of reasonable size,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and thus a batch of compounds <b>17a</b>â<b>d</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) were first synthesized. Their PI3KÎ± inhibitory IC<sub>50</sub> values were comparable to that of <b>1</b>, however, their HDAC IC<sub>50</sub> values were correlated with the length of carbon linker. It was found that C6 (six methylenes) or six atoms linker was optimal; these results were in line with the previous reported SAR for acylurea linked hydroxamates.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The antiproliferative potencies were also improved along with the linker length, but even the best compound <b>17d</b> which showed better HDAC inhibitory potency than vorinostat was less potent than vorinostat in cells. Besides target potency, the physicochemical properties may also affect cellular potency. Polar group 2-aminopyrimidin-5-yl at 1-position and linker-hydroxamic acid at 9-position of the purine molecule may not be the best arrangement. Next we tried to swap the morpholine and 2-aminopyrimidine groups to create molecules like <b>8</b> or <b>9</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). A series of compounds <b>20a</b>â<b>v</b> were thus made to further confirm the optimal linker for HDAC inhibition and explore PI3K/mTOR inhibitory potency SAR (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of N-9 Substituted Purines <b>17a</b>â<b>d</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">m</th><th class="colsep0 rowsep0" align="center">HDAC1<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">PI3KÎ±<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">MV4-11<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">PC-3<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">MCF7<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> IC<sub>50</sub> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">>9257</td><td class="colsep0 rowsep0" align="center">12.8Â Â±Â 12.0</td><td class="colsep0 rowsep0" align="center">20.3Â Â±Â 2.5</td><td class="colsep0 rowsep0" align="center">>25</td><td class="colsep0 rowsep0" align="center">12.9Â Â±Â 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">1754Â Â±Â 299</td><td class="colsep0 rowsep0" align="center">8.7Â Â±Â 4.6</td><td class="colsep0 rowsep0" align="center">9.81Â Â±Â 0.25</td><td class="colsep0 rowsep0" align="center">18.1Â Â±Â 6.1</td><td class="colsep0 rowsep0" align="center">11.1Â Â±Â 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">60Â Â±Â 58</td><td class="colsep0 rowsep0" align="center">9.2Â Â±Â 6.3</td><td class="colsep0 rowsep0" align="center">2.81Â Â±Â 0.39</td><td class="colsep0 rowsep0" align="center">9.28Â Â±Â 3.03</td><td class="colsep0 rowsep0" align="center">7.37Â Â±Â 1.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17d</b></td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">17Â Â±Â 9</td><td class="colsep0 rowsep0" align="center">19.0Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="center">0.25Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="center">2.33Â Â±Â 0.46</td><td class="colsep0 rowsep0" align="center">2.08Â Â±Â 0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">50Â Â±Â 30</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">0.43Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="center">3.07Â Â±Â 1.08</td><td class="colsep0 rowsep0" align="center">1.60Â Â±Â 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wortmannin</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">10.1Â Â±Â 7.1</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">7.8Â Â±Â 3.5</td><td class="colsep0 rowsep0" align="center">0.20Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="center">0.18Â Â±Â 0.06</td><td class="colsep0 rowsep0" align="center">0.13Â Â±Â 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pictilisib</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">18.7Â Â±Â 8.6</td><td class="colsep0 rowsep0" align="center">1.46Â Â±Â 1.09</td><td class="colsep0 rowsep0" align="center">0.75Â Â±Â 0.36</td><td class="colsep0 rowsep0" align="center">0.22Â Â±Â 0.18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are expressed as mean Â± standard deviation (SD) of at least two independent experiments. NT: not tested.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Values are expressed as mean Â± SD of at least two independent duplicate experiments. NT: not tested.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of 2-Aryl-9-substituted Purines and Pyrrolo[2,3-<i>d</i>]pyrimidines <b>20a</b>â<b>v</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0014.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0016.gif" alt="" id="GRAPHIC-d163e1323-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Values are expressed as mean Â± standard deviation (SD) of at least two independent experiments. NT: not tested.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Values are expressed as mean Â± SD of at least two independent duplicate experiments. NT: not tested.</p></div></div><div></div></div><div class="NLM_p">The C6 linker for hydroxamate was still preferred (<b>20b</b> vs <b>20c</b>, <b>20d</b> vs <b>20e</b>, and <b>20s</b> vs <b>20p</b>), and the HDAC1 IC<sub>50</sub> value went down to 1 nM, and this was still valid for most of the compounds with C6 linker in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. The IC<sub>50</sub> value did not change significantly with a variety of substituents at the 2-position of the purine nor pyrrolo[2,3-<i>d</i>]pyrimidine ring, as these lipophilic purines or pyrrolo[2,3-<i>d</i>]pyrimidines were excellent CAPs for HDAC inhibitors. Therefore, there was leeway to tune PI3K/mTOR inhibitory potency in these SARs. 2-Aminopyrimidin-5-yl group was still one of the best groups for PI3K inhibition (e.g., <b>20h</b> and <b>20q</b>), metabolically labile <i>meta</i> phenol group was also good (<b>20r</b>) for PI3KÎ± inhibition (similar to <b>2</b>), and <i>meta</i> benzyl alcohol (<b>20f</b>) was found to be a good replacement of the phenol and demonstrated comparable PI3KÎ± potency. The binding site cannot tolerate big or bulky groups as we reported earlier,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> such compounds (<b>20i</b>â<b>l</b>, <b>20n</b>, <b>20t</b>, and <b>20u</b>) did not show any appreciable potency against PI3KÎ±. Adding <i>para</i> substituent to <i>meta</i> phenol (<b>20p</b> and <b>20s</b>) or benzyl alcohol (<b>20v</b>) actually reduced the PI3KÎ± potency. Compound <b>20g</b> with <i>para</i> benzyl alcohol group was no longer active against PI3KÎ±. Compounds <b>20f</b>, <b>20h</b>, <b>20q</b>, <b>20e</b>, and <b>20o</b> were very potent HDAC inhibitors with variable PI3KÎ± potency and showed good cellular activates as well and were worthy further profiling and evaluation.</div><div class="NLM_p">Morpholine ring was commonly used in PI3K inhibitors,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> it also showed good activity at purine 6-position in above-mentioned series. A few substituents were tried to replace the morpholine, such as <b>23a</b> and <b>23b</b>; unfortunately, they significantly destroyed PI3KÎ± affinity but still kept the HDAC inhibitory effect intact (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of 6-Substituted Amino Purines <b>23a</b> and <b>23b</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0017.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0018.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values are expressed as mean Â± standard deviation (SD) of at least two independent experiments. No data as NT.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Values are expressed as mean Â± SD of at least two independent duplicate experiments. No data as NT.</p></div></div><div></div></div><div class="NLM_p">Besides aliphatic linkers, aryl linker was also commonly used for HDAC inhibitors. We made several compounds with aryl linker at N-9 position to investigate the HDAC potency. Both <b>29</b> and <b>31</b> with cinnamic linkers showed moderate HDAC potency, but the PI3KÎ± potency was affected even with the best 2-aminopyrimidine group, and the N-9 substituent was too big and basic (secondary amine). <b>34</b> was linked with a shorter benzylamine linker unit and showed even poorer HDAC inhibitory potency (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of N-9 Aryl Linked Purine Hydroxamates <b>29</b>, <b>31</b>, and <b>34</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="Â±" /></col><col align="center" /></col><col align="char" char="Â±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="Â±">HDAC1<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">PI3KÎ±<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="Â±">MV4â11<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">PC-3<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char="Â±">84Â Â±Â 40</td><td class="colsep0 rowsep0" align="center">>8956</td><td class="colsep0 rowsep0" align="char" char="Â±">0.24Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="center">1.72Â Â±Â 0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char="Â±">136Â Â±Â 10</td><td class="colsep0 rowsep0" align="center">307Â Â±Â 57</td><td class="colsep0 rowsep0" align="char" char="Â±">5.44Â Â±Â 1.73</td><td class="colsep0 rowsep0" align="center">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="Â±">1082Â Â±Â 192</td><td class="colsep0 rowsep0" align="center">4543Â Â±Â 1136</td><td class="colsep0 rowsep0" align="char" char="Â±">5.78Â Â±Â 0.64</td><td class="colsep0 rowsep0" align="center">18.5Â Â±Â 6.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Values are expressed as mean Â± standard deviation (SD) of at least two independent experiments. No data as NT.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Values are expressed as mean Â± SD of at least two independent duplicate experiments. No data as NT.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Molecular Docking Study</h3><div class="NLM_p">To better understand the above observed SAR for PI3KÎ± inhibition, molecular docking study was performed using AutoDock Vina software<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and crystal structure of PI3KÎ±â<b>3</b> complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4L23">4L23</a>)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2</a>). For these morpholino-pyrimidine based PI3K inhibitors, there are two major binding modes. One is represented by <b>2</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2A,B</a>), and the other is represented by <b>1</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2D</a>). The backbone NH group of Val851 in the hinge region is a hydrogen bond donor, it forms a hydrogen bond with the 1-position nitrogen atom of the ATP purine ring, and this interaction is critical to kinase activity. The oxygen of the morpholine group of <b>2</b> is a hydrogen bond acceptor and forms a hydrogen bond with the NH group of Val851 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2B</a>). Forming this bond enables <b>2</b> to compete with ATP in the ATP binding pocket. The hydroxyl group of the phenol ring of <b>2</b> also forms another two key hydrogen bonds with the residues of Tyr836 and Asp810. Compound <b>10r</b>, which has a <i>meta</i> phenol group as well, shows a similar binding mode (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2E</a>). <b>20p</b> has similar interactions with the key residues, but the inhibitory potency is lower, probably due to the unfavorable interaction between the fluorine atom and the hydroxyl group (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2F</a>). The <i>meta</i> benzyl alcohol group of <b>20f</b> interacts with the residues of Asp810, Tyr836, and Asp933 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2G</a>), which makes <b>20f</b> a potent PI3KÎ± inhibitor. In contrast, the <i>para</i> benzyl alcohol group of <b>20g</b> is far away from Tyr836 and only forms a hydrogen bond with Asp810. Furthermore, the oxygen of benzyl alcohol group is unfavorably close to the carboxylic group of Asp933 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2H</a>). This is why <b>20g</b> loses PI3KÎ± inhibitory activity dramatically as compared to <b>20f</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2I</a>). Pictilisib does not have a hydroxyl group, but its 1<i>H</i>-indazol-4-yl group forms two hydrogen bonds with Tyr836 and Asp810 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2C</a>), and therefore it is also a potent PI3KÎ± inhibitor. Compound <b>20n</b> also has an indazole group, but it is 1<i>H</i>-indazol-6-yl and thus only forms a hydrogen bond with Asp810 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2J</a>). The hydrogen bond with Tyr836 is very important in achieving a ligandâs inhibitory activity; for example, an Y836A mutation resulted in 44-fold reduction of <b>2</b>âs potency against PI3KÎ±.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p last">Compound <b>1</b> represents the second binding mode; its <i>para</i> amino group of the 2-aminopyrimidine group forms two hydrogen bonds with Asp810 and Asp933, and the two nitrogen atoms in the pyrimidine ring form additional hydrogen bonds, one with Lys802 and the other with the NH group of Asp933 or hydroxyl group of Tyr836 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2D</a>). Compounds <b>17d</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2K</a>), <b>20h</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2L</a>), and <b>20q</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2M</a>) all have 2-aminopyrimidine groups: they show similar binding mode as that of <b>1</b> and are also potent PI3KÎ± inhibitors. <b>20e</b> has an amino-pyridine group, and it forms fewer hydrogen bonds as compared to 2-aminopyrimidine group (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2N</a>), therefore its potency is lower than <b>20h</b> or <b>20q</b>. <b>23a</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2O</a>) and <b>23b</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2P</a>) are two analogues of <b>20h</b>, with the morpholine group being replaced by piperidines. To make similar contact with Val851, the hydroxyl group repels the entire molecule away from the binding pocket (i.e., Trp780, Met772, Met922, Ile800, Ile932, Tyr836, and Asp933) but pushes it slightly closer to Lys802 as compared to <b>20h</b>. Furthermore, the piperidine has to adopt a conformation notably different from that of the morpholine in <b>20h</b>. In contrast, all rings including the morpholine of <b>20h</b> superpose well on <b>2</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S2L</a>). Hence, <b>23a</b> and <b>23b</b> are poor PI3KÎ± inhibitors. Interestingly, <b>23a</b> is about 4-fold as potent as <b>23b</b>. Its flexible primary alcohol may allow it to adopt a more favorable conformation in order to form a hydrogen bond with the NH group of Val851 in contrast to that of the rigid secondary alcohol in <b>23b</b>. It is thus clear that piperidine is not a suitable replacement for the morpholine group in the current chemical series.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vitro Profiling against HDACs and Kinases</h3><div class="NLM_p">Besides in house assays, the HDAC isoform profiling was done at BPS Bioscience. In additional to routine controls such as vorinostat and trichostatin A (TSA), <b>3</b> and pracinostat were also included for comparison. The data for <b>3</b>, except for class IV HDAC11, were generally in line with reported data generated with a different substrate.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> IC<sub>50</sub> values of pracinostat were also in line with the trend of our previous reported <i>K</i><sub>i</sub> values which were derived from IC<sub>50</sub> values, except for HDACs 4, 5, 7, 8, and 11, which were tested using class 2a substrate. <b>20e</b>, <b>20f</b>, and <b>20q</b> were potent nanomolar inhibitors for HDACs 1, 2, 3, 6, and 10 but poor inhibitors for classes IIa and IV HDACs (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibition of HDAC Isozymes by Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="11" align="center">IC<sub>50</sub> (nM) for HDAC isozymes<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">1</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">3</th><th class="colsep0 rowsep0" align="center">4</th><th class="colsep0 rowsep0" align="center">5</th><th class="colsep0 rowsep0" align="center">6</th><th class="colsep0 rowsep0" align="center">7</th><th class="colsep0 rowsep0" align="center">8</th><th class="colsep0 rowsep0" align="center">9</th><th class="colsep0 rowsep0" align="center">10</th><th class="colsep0 rowsep0" align="center">11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20e</b></td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">4.0</td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">4.6</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">184</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">1.7</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">6.0</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">4591</td><td class="colsep0 rowsep0" align="center">4800</td><td class="colsep0 rowsep0" align="center">4.2</td><td class="colsep0 rowsep0" align="center">2305</td><td class="colsep0 rowsep0" align="center">320</td><td class="colsep0 rowsep0" align="center">1,282</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">9700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20q</b></td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">4.1</td><td class="colsep0 rowsep0" align="center">0.66</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">6.6</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">270</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">2.3</td><td class="colsep0 rowsep0" align="center">6300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="center">220</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TSA</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">490</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">10900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pracinostat</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center">290</td><td class="colsep0 rowsep0" align="center">70</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">5113</td><td class="colsep0 rowsep0" align="center">93</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">2835</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">82</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">8.0</td><td class="colsep0 rowsep0" align="center">3.2</td><td class="colsep0 rowsep0" align="center">479</td><td class="colsep0 rowsep0" align="center">581</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">528</td><td class="colsep0 rowsep0" align="center">54</td><td class="colsep0 rowsep0" align="center">639</td><td class="colsep0 rowsep0" align="center">4.1</td><td class="colsep0 rowsep0" align="center">1267</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">HDAC profiling was done by BPS Bioscience (6042 Cornerstone Court West, Suite B, San Diego, CA 92121), HDAC substrate 3 (BPS catalogue no. 50037) was used for class I HDACs (HDACs 1, 2, and 3) and class IIb HDACs (HDACs 6 and 10) and vorinostat as positive control; substrate class 2a (catalogue no. 50040) was used for class IIa HDACs (HDACs 4, 5, 7, and 9) as well as HDACs 8 (class I) and 11 (class IV), using TSA as positive control. TSA, trichostatin A; NT, not tested.</p></div></div></div><div class="NLM_p">Selected compounds <b>20f</b> and <b>20q</b> were also profiled against a panel of 97 kinases: both were found selective against lipid kinases (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Table S2</a>), and their <i>K</i><sub>d</sub> values were determined (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). The PI3K and mTOR inhibitory IC<sub>50</sub> values were determined at both Reaction Biology Corp and Life Technologies, and the data agreed well from two different assay platforms. Additional kinase profiling was done at Life Technologies with <b>3</b> as positive control. Pictilisib was the most potent PI3K inhibitor but a poor mTOR inhibitor. <b>3</b> showed reasonable potency against mTOR and was still a pan-inhibitor for PI3K. Compounds <b>20h</b>, <b>20e</b>, and <b>20q</b> were active against mTOR, <b>20f</b> was a weaker mTOR inhibitor and thus more selective for PI3K and was also potent against PI3K2Î², which was confirmed by two different assay platforms.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of Lipid and Relevant Kinases by Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>K</i><sub>d</sub> (nM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="8" align="center" char=".">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinases</th><th class="colsep0 rowsep0" align="center"><b>20f</b></th><th class="colsep0 rowsep0" align="center"><b>20q</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20h</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20e</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20f</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20o</b></th><th class="colsep0 rowsep0" align="center" char="."><b>20q</b></th><th class="colsep0 rowsep0" align="center">pictilisib</th><th class="colsep0 rowsep0" align="center"><b>3</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3KÎ±</td><td class="colsep0 rowsep0" align="center">3.5</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">198</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">136</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="center">4.7</td><td class="colsep0 rowsep0" align="center">7.9</td><td class="colsep0 rowsep0" align="center">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3KÎ²</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char=".">648</td><td class="colsep0 rowsep0" align="char" char=".">1656</td><td class="colsep0 rowsep0" align="char" char=".">212</td><td class="colsep0 rowsep0" align="char" char=".">1403</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3KÎ³</td><td class="colsep0 rowsep0" align="center">86</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">793</td><td class="colsep0 rowsep0" align="char" char=".">177</td><td class="colsep0 rowsep0" align="char" char=".">692</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">112</td><td class="colsep0 rowsep0" align="center">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3KÎ´</td><td class="colsep0 rowsep0" align="center">41</td><td class="colsep0 rowsep0" align="center">240</td><td class="colsep0 rowsep0" align="char" char=".">133</td><td class="colsep0 rowsep0" align="char" char=".">301</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">331</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">6.3</td><td class="colsep0 rowsep0" align="center">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char=".">288</td><td class="colsep0 rowsep0" align="char" char=".">374</td><td class="colsep0 rowsep0" align="char" char=".">1946</td><td class="colsep0 rowsep0" align="char" char=".">4945</td><td class="colsep0 rowsep0" align="char" char=".">101</td><td class="colsep0 rowsep0" align="center">959</td><td class="colsep0 rowsep0" align="center">185</td><td class="colsep0 rowsep0" align="center">141</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3K2Î±</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI3K2Î²</td><td class="colsep0 rowsep0" align="center">4.9</td><td class="colsep0 rowsep0" align="center">260</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">1046</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNA-PK</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">594</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">3,673</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PIK3C3</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">6295</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PI4KÎ²</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>K</i><sub>d</sub> values were determined by DiscoverX Corporation (42501 Albrae Street, Fremont, CA 94538, United States).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">PI3K and mTOR IC<sub>50</sub> values were determined by Reaction Biology Corp. (One Great Valley Parkway Suite 2, Malvern, PA 19355, United States) and Life Technologies. NT: not tested.</p></div></div></div><div class="NLM_p last">Compounds <b>20f</b>, <b>20h</b>, <b>20e</b>, <b>20o</b>, and <b>20q</b> achieved dual or multi inhibitions of HDACs and PI3K/mTOR. They were very potent pan-HDAC inhibitors with a different degree of inhibitory potency against PI3K/mTOR and thus were good examples for further evaluation in order to identify the optimal combination of HDAC and PI3K/mTOR.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vitro Antiproliferation Profiling</h3><div class="NLM_p">Lead compounds were screened against 39 cancer cell lines (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Table S3</a>) in antiproliferative assays (cellular IC<sub>50</sub>) and were found more sensitive/potent against leukemia, lymphoma, and HCC cell lines (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). For instance, <b>20e</b>, <b>20f</b>, and <b>20q</b> were very active against leukemia cell line MV4-11 and were much more potent than pictilisib and vorinostat. Sorafenib in general was much less potent than these compounds as its mechanism is mainly antiangiogenesis in vivo. Sorafenibâs exceptional activity against MV4-11 might be due to its inhibition of multikinase particularly FLT3. Among liver cancer cell lines, <b>20f</b> was more potent against HepG2, HuH-7, and SK-HEP1.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferative IC<sub>50</sub> (Î¼M) of Selected Compounds<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="center" /></col><col align="char" char="Â±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cancer</th><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center" char="Â±"><b>20e</b></th><th class="colsep0 rowsep0" align="center" char="Â±"><b>20f</b></th><th class="colsep0 rowsep0" align="center" char="Â±"><b>20q</b></th><th class="colsep0 rowsep0" align="center">pictilisib</th><th class="colsep0 rowsep0" align="center" char="Â±">vorinostat</th><th class="colsep0 rowsep0" align="center">sorafenib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="char" char="Â±">0.60Â Â±Â 0.30</td><td class="colsep0 rowsep0" align="char" char="Â±">0.35Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="char" char="Â±">0.44Â Â±Â 0.32</td><td class="colsep0 rowsep0" align="center">6.34Â Â±Â 3.09</td><td class="colsep0 rowsep0" align="char" char="Â±">1.02Â Â±Â 0.12</td><td class="colsep0 rowsep0" align="center">5.08Â Â±Â 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MOLT4</td><td class="colsep0 rowsep0" align="char" char="Â±">0.16Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="char" char="Â±">0.14Â Â±Â 0.11</td><td class="colsep0 rowsep0" align="char" char="Â±">0.15Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="center">0.18Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="char" char="Â±">0.52Â Â±Â 0.16</td><td class="colsep0 rowsep0" align="center">5.94Â Â±Â 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MV4-11</td><td class="colsep0 rowsep0" align="char" char="Â±">0.045Â Â±Â 0.036</td><td class="colsep0 rowsep0" align="char" char="Â±">0.047Â Â±Â 0.030</td><td class="colsep0 rowsep0" align="char" char="Â±">0.044Â Â±Â 0.027</td><td class="colsep0 rowsep0" align="center">1.46Â Â±Â 1.09</td><td class="colsep0 rowsep0" align="char" char="Â±">0.43Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="center"><0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lymphomas</td><td class="colsep0 rowsep0" align="left">Raji</td><td class="colsep0 rowsep0" align="char" char="Â±">0.35Â Â±Â 0.15</td><td class="colsep0 rowsep0" align="char" char="Â±">0.24Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="char" char="Â±">0.28Â Â±Â 0.08</td><td class="colsep0 rowsep0" align="center">6.50Â Â±Â 3.23</td><td class="colsep0 rowsep0" align="char" char="Â±">1.11Â Â±Â 0.48</td><td class="colsep0 rowsep0" align="center">3.94Â Â±Â 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Ramos</td><td class="colsep0 rowsep0" align="char" char="Â±">0.60Â Â±Â 0.18</td><td class="colsep0 rowsep0" align="char" char="Â±">0.40Â Â±Â 0.13</td><td class="colsep0 rowsep0" align="char" char="Â±">0.49Â Â±Â 0.18</td><td class="colsep0 rowsep0" align="center">4.86Â Â±Â 1.79</td><td class="colsep0 rowsep0" align="char" char="Â±">0.62Â Â±Â 0.07</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">SU-DHL-6</td><td class="colsep0 rowsep0" align="char" char="Â±">0.23Â Â±Â 0.12</td><td class="colsep0 rowsep0" align="char" char="Â±">0.19Â Â±Â 0.06</td><td class="colsep0 rowsep0" align="char" char="Â±">0.25Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="center">0.03Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char="Â±">0.58Â Â±Â 0.17</td><td class="colsep0 rowsep0" align="center">3.82Â Â±Â 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver cancer</td><td class="colsep0 rowsep0" align="left">Hep3B</td><td class="colsep0 rowsep0" align="char" char="Â±">1.55Â Â±Â 0.15</td><td class="colsep0 rowsep0" align="char" char="Â±">1.25Â Â±Â 0.20</td><td class="colsep0 rowsep0" align="char" char="Â±">2.87Â Â±Â 0.26</td><td class="colsep0 rowsep0" align="center">2.03Â Â±Â 1.02</td><td class="colsep0 rowsep0" align="char" char="Â±">2.60Â Â±Â 0.56</td><td class="colsep0 rowsep0" align="center">4.33Â Â±Â 1.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="char" char="Â±">0.96Â Â±Â 0.29</td><td class="colsep0 rowsep0" align="char" char="Â±">0.59Â Â±Â 0.11</td><td class="colsep0 rowsep0" align="char" char="Â±">1.05Â Â±Â 0.25</td><td class="colsep0 rowsep0" align="center">6.22Â Â±Â 1.83</td><td class="colsep0 rowsep0" align="char" char="Â±">1.27Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="center">3.66Â Â±Â 0.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">HuH-7</td><td class="colsep0 rowsep0" align="char" char="Â±">0.50Â Â±Â 0.19</td><td class="colsep0 rowsep0" align="char" char="Â±">0.48Â Â±Â 0.13</td><td class="colsep0 rowsep0" align="char" char="Â±">0.65Â Â±Â 0.20</td><td class="colsep0 rowsep0" align="center">1.72Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="char" char="Â±">1.95Â Â±Â 0.39</td><td class="colsep0 rowsep0" align="center">2.68Â Â±Â 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">PLC/PRF/5</td><td class="colsep0 rowsep0" align="char" char="Â±">1.57Â Â±Â 0.24</td><td class="colsep0 rowsep0" align="char" char="Â±">1.24Â Â±Â 0.08</td><td class="colsep0 rowsep0" align="char" char="Â±">3.05Â Â±Â 0.41</td><td class="colsep0 rowsep0" align="center">3.07Â Â±Â 0.74</td><td class="colsep0 rowsep0" align="char" char="Â±">1.87Â Â±Â 0.16</td><td class="colsep0 rowsep0" align="center">7.51Â Â±Â 2.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">SK-HEP1</td><td class="colsep0 rowsep0" align="char" char="Â±">1.16Â Â±Â 0.23</td><td class="colsep0 rowsep0" align="char" char="Â±">0.79Â Â±Â 0.20</td><td class="colsep0 rowsep0" align="char" char="Â±">1.46Â Â±Â 0.54</td><td class="colsep0 rowsep0" align="center">4.30Â Â±Â 0.24</td><td class="colsep0 rowsep0" align="char" char="Â±">1.85Â Â±Â 0.28</td><td class="colsep0 rowsep0" align="center">8.37Â Â±Â 3.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">SNU-387</td><td class="colsep0 rowsep0" align="char" char="Â±">3.15Â Â±Â 2.16</td><td class="colsep0 rowsep0" align="char" char="Â±">2.64Â Â±Â 1.50</td><td class="colsep0 rowsep0" align="char" char="Â±">3.90Â Â±Â 0.79</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char="Â±">2.45Â Â±Â 0.69</td><td class="colsep0 rowsep0" align="center">8.29Â Â±Â 0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">SNU-398</td><td class="colsep0 rowsep0" align="char" char="Â±">1.52Â Â±Â 0.63</td><td class="colsep0 rowsep0" align="char" char="Â±">1.38Â Â±Â 0.57</td><td class="colsep0 rowsep0" align="char" char="Â±">1.66Â Â±Â 0.54</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="char" char="Â±">1.39Â Â±Â 0.31</td><td class="colsep0 rowsep0" align="center">3.38Â Â±Â 0.43</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Values are expressed as mean Â± SD of at least two independent duplicate experiments. NT: not tested.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Caspase Activity Induction and Cell Death</h3><div class="NLM_p">HDAC inhibitors can induce cell apoptosis.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Caspase-3/7 activity was used as a surrogate for apoptotic cell death induction (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Cells were treated with <b>20f</b>, vorinostat, and pictilisib, respectively, and caspase activity was monitored at different time points. The maximal activity was found and shown at 24 h. The caspase induction effective concentrations (EC<sub>50</sub>) were 0.40, 0.90, and 10.7 Î¼M for <b>20f</b>, vorinostat, and pictilisib, respectively. Maximal cell death as fold of treated vs vehicle occurred at 48 h, and the cell death potency EC<sub>50</sub> was estimated as 0.064, 0.53, and 2.71 Î¼M for <b>20f</b>, vorinostat, and pictilisib, respectively. <b>20f</b> was much more potent than vorinostat and pictilisib in terms in induction of caspase active and cell death in MV4-11 cells.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Caspase activity induction and cell death in MV4-11 cells. (A) Maximal caspase activity at 24 h. MV4-11 cells were treated with <b>20f</b> (blue downward pointing triangles), vorinostat (red circles), and pictilisib (black tilted squares), respectively. Caspase 3/7 activity was monitored at 6, 24, 48, and 72 h, respectively. Maximal activity was found and shown at 24 h, expressed as fold of change (treated vs vehicle, mean Â± SD). (B) Maximal cell death occurred at 48 h. MV4-11 cells were treated with <b>20f</b> (blue downward pointing triangles) vorinostat (red circles), and pictilisib (black tilted squares), respectively. Cell death was monitored at 24, 48, and 72 h. Maximal cell death as fold of treated vs vehicle was occurred at 48 h. <i>y</i>-Axis is expressed as mean Â± SD. EC<sub>50</sub> value was calculated by fitting the doseâresponse curve with Prism 4.0.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Clonogenic and Soft Agar Assays</h3><div class="NLM_p">Anchorage-dependent clonogenic assay was used to determine cell reproductive death after treatment with <b>20f</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Liver cancer cells Hep3B and HuH-7 after treatment with a series dilution of <b>20f</b> showed IC<sub>50</sub> values of 0.61 and 0.39 Î¼M, respectively, and these values were lower than their respective in vitro cellular assay IC<sub>50</sub> values of 1.25 and 0.48 Î¼M, respectively (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). One of the hallmark characteristics of cellular transformation and uncontrolled cell growth is anchorage independent growth of cancer cells in soft agar. When <b>20f</b> was tested in a three-dimensional (3D) soft agar format, it inhibited colony formation of NCI-H460 and 4T1 cells with IC<sub>50</sub> values of 0.31 and 0.91 Î¼M, respectively. Again, these IC<sub>50</sub> values were lower than the normal in vitro cellular assay IC<sub>50</sub> values (0.89 and 1.29 Î¼M for NCI-H460 and 4T1, respectively). These data suggested that <b>20f</b> could inhibit a variety of cancer cells under both anchorage-dependent and anchorage-independent conditions.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Clonogenic and soft agar assays and IC<sub>50</sub> values. <b>20f</b> inhibited colony formation of Hep3B and HuH-7 cells under anchorage-dependent conditions and inhibited colony formation of NCI-H460 and 4T1 (murine triple negative breast cancer) cells in soft agar assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Modulation of HDACs and PI3K/mTOR in Cancer Cells and Tumors</h3><div class="NLM_p">Inhibition of HDACs will result in hyperacetylation of histones and other substrates such as Î±-tubulin, and the latter is the result of inhibition of HDAC6. Inhibition of PI3K/Akt/mTOR axis may reduce the phosphorylated Akt level as well as the phosphorylation levels of downstream proteins such as P70S6K, S6, and 4-EBP1. The effect on target modulation was first studied in PC-3 (PTEN deficient) and MCF7 (PIK3CA, E545K mutation) cells, and most of the compounds were screened for target modulation.</div><div class="NLM_p">In PC-3 cells, after 24 h of drug treatment, <b>20f</b>, <b>20g</b>, and <b>20h</b> were confirmed to be potent HDAC inhibitors as their effects on hyperacetylation of histone 3 (AcH3) and Î±-tubulin were similar to those of vorinostat at 10 Î¼M (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S1A</a>). <b>17d</b> was a much weaker HDAC inhibitor as compared to <b>20f</b>â<b>h</b> in terms of enzymatic potency and cellular target modulation. Pictilisib was a very potent PI3K inhibitor and a weak mTOR inhibitor; it almost completely depleted pAkt at 1 Î¼M. The order of potency in PC-3 cells for pAkt reduction was pictilisib > <b>20f</b> > <b>17d</b> > <b>20h</b> > <b>20g</b>. Vorinostat showed no effect on pAkt level in this experiment. In MCF7 cells, <b>20q</b> appeared as a potent effector on pAkt and pS6 reduction, as it was more potent than <b>20f</b> and also an mTOR inhibitor (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Figure S1B</a>). During the short period of time of treatment, these compounds did not change the total protein levels in MCF7 cells (e.g., Î±-tubulin, Akt, P70S6K, and S6).</div><div class="NLM_p">In liver cancer HepG2 cells, <b>20f</b> and <b>20q</b> were potent HDAC inhibitors in terms of hyperacetylation of H3 and Î±-tubulin (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A), while <b>3</b> was a weaker inhibitor on HDAC6. Acid <b>20w</b> is a potential impurity or degradation product of <b>20f</b> and still maintained the majority of PI3K inhibitory activity, but it showed much weak activity against HDAC6 and HDACs 1, 2, and 3 in HepG2 cells. In HuH-7 cells (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B), the overall effect on phosphorylated Akt, P70S6K, and S6 was in the order of <b>20q</b> > <b>20f</b> > <b>20e</b> > <b>20o</b>, which was in line with their respective in vitro enzymatic IC<sub>50</sub> potency against PI3KÎ± and mTOR. Sorafenib reduced pAkt level (gel normalized intensity 42% vs vehicle) at lower concentration (1 Î¼M) but enhanced pAkt (S473) level (252% vs vehicle) at higher concentration (10 Î¼M). These data further support that a PI3K/mTOR inhibitor is necessary to combine with sorafenib to reduce pAkt level.<a onclick="showRef(event, 'ref13 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref13 ref44 ref45">(13, 44, 45)</a></div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Modulation of HDACs and PI3K/Akt/mTOR pathway in liver cancer cells. (A) HepG2 cells were serum starved overnight (20 h), then treated with vehicle (0.1% DMSO) or compounds for 4 h, followed by stimulation with growth factors FGF2 (50 ng/mL), IGF-1 (100 ng/mL), and EGF (50 ng/mL) for 15 min, respectively. Veh: vehicle. (B) HuH-7 cells were treated with vehicle (0.1% DMSO) or compounds in serum-free media for 4 h including last 12 min stimulated with VEGF (20 ng/mL). Vor, vorinostat; Pic, pictilisib; Sor, sorafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The effective concentration (EC<sub>50</sub>) to modulation the targets in cancer cells were also determined by in-cell ELISA. For instance, after 3 h drug treatment of MCF7 cells, EC<sub>50</sub> values for Ac-Î±-tubulin were 0.43, 0.19, 0.22, and >30 Î¼M for vorinostat, <b>20f</b>, <b>20q</b>, and pictilisib, respectively. In HepG2 cells, after 3 h of drug treatment and EGF stimulation, EC<sub>50</sub> values for pAkt(S473) reduction were >30, 0.58, 0.13, and 0.17 Î¼M for vorinostat, <b>20f</b>, <b>20q</b>, and pictilisib, respectively.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Modulation of Targets in Mice Bearing Tumors</h3><div class="NLM_p">MV4-11 tumor bearing mice were treated with <b>20f</b> via iv (50 mg/kg), ip (100 mg/kg), and po (150 mg/kg) routes and <b>20q</b> via both iv (25 mg/kg) and po (100 mg/kg) routes for pharmacodynamics (PD) assessment. All three routes of administration of <b>20f</b> resulted in hyperacetylation of H3 in MV4-11 tumors (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A). <b>20q</b> also induced hyperacetylation of H3 via both routes of administration. The Western blot data of AcH3 were normalized and presented in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B, and it was apparent the iv route was more efficient due to its bioavailability. <b>20f</b> was also evaluated via two route of administration in HepG2 xenograft model (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C) and further confirmed the modulation of HDACs (i.e., hyperacetylation of H3 and Î±-tubulin, gain of signal), while modulation of Akt/mTOR was less significant (reduction of signal).</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Modulation of HDACs in tumor-bearing mice models. (A) Hyperacetylation of H3 in MV4-11 tumors induced by <b>20f</b> and <b>20q</b>. Tumor bearing BALB/c nude mice were treated with vehicle [DMSO/PEG400/sterile water (10:40:50)] (3 h, po, 10 mL/kg), <b>20f</b>, which was administered in three routes (po, 150 mg/kg; iv, 50 mg/kg and ip, 100 mg/kg), and <b>20q</b>, which was administered in two routes (po, 100 mg/kg and iv, 25 mg/kg). (B) Intensity of normalized AcH3 (Lys9) bands in A. (C) Hyperacetylation of H3 and Î±-tubulin in HepG2 tumors induced by <b>20f</b>. Tumor bearing NCr nude mice were treated with vehicle (3 h, po, 10 mL/kg) and <b>20f</b>, which was administered in two routes: po (150 mg/kg, 1 and 3 h) and ip (75 mg/kg, 4 and 19 h).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vitro ADME Profiling</h3><div class="NLM_p">In general, these compounds (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) have reasonable lipophilicity and were very stable in human liver microsomal stability assays. They did not show significant inhibition of the hERG channel protein (IC<sub>50</sub> > 100 Î¼M), while <b>3</b> had an IC<sub>50</sub> of 79.5 Î¼M. In human liver microsomes (HLM) based CYP3A4 inhibition assay (IPA CYP3A4 substrate), compounds <b>20h</b>, <b>20f</b>, <b>20e</b>, and sorafenib did not show significant inhibition on CPY3A4 (IC<sub>50</sub> > 10 Î¼M). <b>20f</b> demonstrated low clearance in human liver microsomal stability assays (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) as compared to its mouse and rat liver microsomal data. As CYP3A4 is responsible for metabolism of majority of the drugs, <b>20f</b> was tested with human recombinant CYP3A4 and found to be of low clearance (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>), while CYP3A4 substrates verapamil, midazolam, and sorafenib showed higher clearance. Sorafenib and regorafenib are mainly metabolized by CYP3A4; hence it is less likely that <b>20f</b> would affect their metabolism in vivo when either of them combines with <b>20f</b> in a combination therapy.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Microsomal Stability (<i>t</i><sub>1/2</sub>, min), Lipophilicity. and hERG Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">microsomal stability (<i>t</i><sub>1/2</sub>, min)</th><th class="rowsep1 colsep0" colspan="2" align="center">lipophilicity</th><th class="rowsep1 colsep0" align="center">safety (hERG)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HLM<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">MLM<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">RLM<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">LogÂ <i>P</i><a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">LogÂ <i>D</i><sub>pH7.4</sub><a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20c</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">36</td><td class="colsep0 rowsep0" align="center">2.52</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20e</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">37</td><td class="colsep0 rowsep0" align="center">1.80</td><td class="colsep0 rowsep0" align="center">1.71</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="center">2.34</td><td class="colsep0 rowsep0" align="center">2.07</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20h</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">0.75</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20m</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">8.7</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">1.83</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20n</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center">3.30</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20o</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">1.47</td><td class="colsep0 rowsep0" align="center">2.14</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20q</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">39</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">1.63</td><td class="colsep0 rowsep0" align="center">1.97</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20t</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">2.35</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">2.64</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DXM</td><td class="colsep0 rowsep0" align="center">>60</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">3.56</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">verapamil</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="center">4.66</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">1.78</td><td class="colsep0 rowsep0" align="center">1.05</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">1.53</td><td class="colsep0 rowsep0" align="center">3.07</td><td class="colsep0 rowsep0" align="center">79.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">See <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>, microsomes protein 0.5 mg/mL.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Log <i>P</i> (Molecular Networks) Calculated using ChemBioOffice Ultra 13.0.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last"><i>n</i>-Octanol/water, pH 7.4.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Tested by Life Technologies using the Predictor hERG fluorescence polarization assay. NT, not tested; DXM, dextromethorphan.</p></div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Metabolic Stability of <b>20f</b> and Reference Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center">clearance</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" colspan="3" align="center">microsomes (Î¼L/min/mgÂ ofÂ protein)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">P450 (Î¼L/min/pmol-P450)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compd</td><td class="colsep0 rowsep0" align="center">HLM</td><td class="colsep0 rowsep0" align="center">MLM</td><td class="colsep0 rowsep0" align="center">RLM</td><td class="colsep0 rowsep0" align="center">rCYP3A4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="center">10.4</td><td class="colsep0 rowsep0" align="center">26.8</td><td class="colsep0 rowsep0" align="center">25.5</td><td class="colsep0 rowsep0" align="center">0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">verapamil</td><td class="colsep0 rowsep0" align="center">73.0</td><td class="colsep0 rowsep0" align="center">99.1</td><td class="colsep0 rowsep0" align="center">93.9</td><td class="colsep0 rowsep0" align="center">2.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DXM</td><td class="colsep0 rowsep0" align="center">20.2</td><td class="colsep0 rowsep0" align="center">111.8</td><td class="colsep0 rowsep0" align="center">140.8</td><td class="colsep0 rowsep0" align="center">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">midazolam</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">3.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sorafenib</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">NT</td><td class="colsep0 rowsep0" align="center">4.38</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Test compounds (5 Î¼M) were incubated with human liver microsomes (0.5 mg/mL) and NADPH (1.3 mM) at pH 7.4.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Test compounds (5 Î¼M) were incubated with recombinant human CYP3A4 (25 nM) and NADPH (1.3 mM) at pH 7.4. Compound concentration was determined by LCâMS. NT: not tested. DXM: dextromethorphan.</p></div></div></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Pharmacokinetics (PK) and Tissue Distribution</h3><div class="NLM_p">The lead compounds were scaled up and evaluated in a number of animals studies, and the initial efforts were focused on <b>20f</b>. PKs (po, ip, and iv) in a variety of formulations were investigated. <b>20f</b> is a hydroxamate and its PK profile was similar to that of hydroxamate-based oral HDAC inhibitors such as vorinostat and panobinostat: fast absorption and higher clearance in plasma (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). In a quick 4 h PK study, the bioavailability of <b>20f</b> was 5.8% when dosed as a suspension at 50 mg/kg. When dosed as a clear formulation at 150 mg/kg, the 24 h bioavailability was 18% and the terminal half-life was 4.4 h, which was similar to the intravenous terminal half-life of 4.6 h. The PK profile in mice was more or less similar to hydroxamates such as vorinostat, belinostat, and panobinostat, which showed <i>F</i>% = 8.3%, 6.7%, and 4.6%, respectively.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Limited tissue distribution and PK/PD studies confirmed the favorable drug enrichment in tumors and target tissues (i.e., liver for HCC). For example, Hep3B tumor bearing mice were treated with <b>20f</b> (po, 100 mg/kg), and AUCs (1 to 24 h) of liver and Hep3B tumor were 21- and 5.4-fold that of plasma, respectively (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Drug in tumor tissue had a similar terminal half-life as that of plasma (6.5 h vs 6.0 h), but the drug in liver had a much longer terminal half-life of 11.1 h. The drug concentrations in the tumor were significantly higher than the enzymatic IC<sub>50</sub> values (HDAC1, 1.1 nM; PI3KÎ±, 28 nM) as well as cellular IC<sub>50</sub> values (Hep3B, 1.25 Î¼M; HepG2, 0.59 Î¼M) or colony formation IC<sub>50</sub> values (Hep3B, 0.61 Î¼M; HepG2, 0.10 Î¼M). Thus, drug concentration was reasonably high enough to inhibit the tumor growth even though the protein binding was yet to be considered.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. PK Parameters of Compound <b>20f</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">routes of administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center">iv</th><th class="colsep0 rowsep0" align="center">po</th><th class="colsep0 rowsep0" align="center">po</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (Î¼mol/kg)</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">330</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">formulation<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">DPW</td><td class="colsep0 rowsep0" align="left">DMCTW</td><td class="colsep0 rowsep0" align="left">DSW</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0ââ</sub> (Î¼MÂ·h)</td><td class="colsep0 rowsep0" align="left">16.68</td><td class="colsep0 rowsep0" align="left">0.97</td><td class="colsep0 rowsep0" align="left">9.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub>Â (h)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub>Â (h)</td><td class="colsep0 rowsep0" align="left">4.59</td><td class="colsep0 rowsep0" align="left">2.01</td><td class="colsep0 rowsep0" align="left">4.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>last</sub>Â (h)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">4<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub>Â (Î¼M)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">3.90</td><td class="colsep0 rowsep0" align="left">10.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="left">6.60</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="left">3.06</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">18.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">Formulation: DPW = DMSO/PEG400/sterile water [10:40:50 (v/v)]; DMCTW = DMSO/MC-TW (0.5% methyl cellulose + 0.1% Tween 80 in water) [5:95 (v/v)]; DSW = DMSO/solutol HS15/sterile water [7:18:45 (v/v)].</p></div><div class="footnote" id="t10fn2"><sup>b</sup><p class="last">Quick PK analysis, incomplete terminal elimination curve.</p></div></div></div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Tissue distribution of <b>20f</b> (po, 100 mg/kg) in Hep3B tumor bearing NCr nude mice. AUCs (1â24 h) of liver (blue upward pointing triangles) and Hep3B tumor (green downward pointing triangles) were 21- and 5.4-fold that of plasma (red circles), respectively. Drug in tumor tissue had a similar terminal half-life as plasma (6.5 vs 6.0 h), but the drug in liver had a longer terminal half-life of 11.1 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Maximum Tolerable Dose (MTD)</h3><div class="NLM_p last"><b>20e</b>, <b>20f</b>, <b>20o</b>, and <b>20q</b> were scaled up and evaluated their MTD in BALB/c mice. When <b>20f</b> was formulated in DMSO/solutol HS15/water (DSW, v/v, 7:18:45), both dosage regimens 150 mg/kg QD Ã 5 and 200 mg/kg QD Ã 5 were found to be well-tolerated, but both dosage regimens 150 mg/kg BID and 100 mg/kg BID Ã 5 were lethal, thus 200 mg/kg QD Ã 5 was the MTD and 150 mg/kg QD Ã 5 per week was selected as the highest dose for long-term of treatment. <b>20e</b> was dosed up to 150 mg/kg (salt form, freebase 130 mg/kg) in DSW formulation with pTSA, QD Ã 5, and was well-tolerated, no significant body weight loss (â1.4% on day 5), and MTD was not reached due to the limitation of compound supply. <b>20q</b> was troublesome to formulate due to its low solubility. In female NCr nude mice, 75 mg/kg QD Ã 5 (5day-on-2day-off) was toxic, but at 50 mg/kg, QD Ã 5 per week for 3 weeks, no loss of body weight was observed, hence the MTD was estimated at about 65 mg/kg for <b>20</b>q. MTD for <b>20o</b> was found at 150 mg/kg QD Ã 5 or higher. The following efficacy studies were focused on <b>20f</b> and <b>20e</b> as both were easy in affording clear and stable formulations.</div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> In Vivo Antitumor Efficacy Studies</h3><div class="NLM_p">In vivo oral efficacy of <b>20f</b> and <b>20e</b>, along with reference compound sorafenib and a combination for HDAC/PI3K dual inhibition (the combination of vorinostat with pictilisib), were evaluated in liver cancer models (e.g., HepG2, Hep3B, and HuH-7) (<a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a> and <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Efficacy of Orally Administered <b>20f</b> and <b>20e</b> in Various Xenograft Models</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tumor model<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">compd<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">schedule (po)<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">dose (mg/kg)<a class="ref internalNav" href="#t11fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">%TGI (day)<a class="ref internalNav" href="#t11fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">statistical significance (day)<a class="ref internalNav" href="#t11fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">body weight change (%) (day)<a class="ref internalNav" href="#t11fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center">survivors (day)<a class="ref internalNav" href="#t11fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="center">vehicle</td><td class="colsep0 rowsep0" align="center">QDÂ ÃÂ 5/wkÂ Ã3</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">+7.1Â (14)</td><td class="colsep0 rowsep0" align="center">9/9Â (18)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">+4.4Â (18)</td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center"><b>20f</b></td><td class="colsep0 rowsep0" align="center">QD Ã 5/wk Ã3</td><td class="colsep0 rowsep0" align="center">150</td><td class="colsep0 rowsep0" align="center">91Â (14)</td><td class="colsep0 rowsep0" align="center">* (14)</td><td class="colsep0 rowsep0" align="center">+4.1Â (14)</td><td class="colsep0 rowsep0" align="center">6/6Â (32)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">95Â (18)</td><td class="colsep0 rowsep0" align="center">** (18)</td><td class="colsep0 rowsep0" align="center">+3.5Â (18)</td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">sorafenib</td><td class="colsep0 rowsep0" align="center">5-on-1-offÂ Ã3</td><td class="colsep0 rowsep0" align="center">98</td><td class="colsep0 rowsep0" align="center">56Â (14)</td><td class="colsep0 rowsep0" align="center">ns (14)</td><td class="colsep0 rowsep0" align="center">â2.4Â (14)</td><td class="colsep0 rowsep0" align="center">5/5Â (26)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">72Â (18)</td><td class="colsep0 rowsep0" align="center">* (18)</td><td class="colsep0 rowsep0" align="center">â2.0Â (18)</td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="center">vehicle</td><td class="colsep0 rowsep0" align="center">QD Ã 5/wk Ã2</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">â0.8Â (14)</td><td class="colsep0 rowsep0" align="center">5/5Â (14)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center"><b>20e</b></td><td class="colsep0 rowsep0" align="center">QD Ã 5/wk Ã2</td><td class="colsep0 rowsep0" align="center">130</td><td class="colsep0 rowsep0" align="center">57Â (14)</td><td class="colsep0 rowsep0" align="center">* (14)</td><td class="colsep0 rowsep0" align="center">â2.2Â (5)</td><td class="colsep0 rowsep0" align="center">5/5Â (14)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">vorinostat + pictilisib</td><td class="colsep0 rowsep0" align="center">QD Ã 5/wk Ã2</td><td class="colsep0 rowsep0" align="center">[60Â +Â 75]</td><td class="colsep0 rowsep0" align="center">51Â (14)</td><td class="colsep0 rowsep0" align="center">* (14)</td><td class="colsep0 rowsep0" align="center">â4.5Â (12)</td><td class="colsep0 rowsep0" align="center">5/5Â (12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">â3.1Â (14)</td><td class="colsep0 rowsep0" align="center">4/5Â (14)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hep3B</td><td class="colsep0 rowsep0" align="center">vehicle</td><td class="colsep0 rowsep0" align="center">QDÂ ÃÂ 7Â +Â 2-off-5-onÂ Ã2</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">â8.9Â (15)</td><td class="colsep0 rowsep0" align="center">6/6Â (23)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center"><b>20f</b></td><td class="colsep0 rowsep0" align="center">QD Ã 7 + 2-off-5-on Ã2</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">82Â (21)</td><td class="colsep0 rowsep0" align="center">** (21)</td><td class="colsep0 rowsep0" align="center">â13.2Â (18)</td><td class="colsep0 rowsep0" align="center">7/7Â (23)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">86Â (23)</td><td class="colsep0 rowsep0" align="center">**Â (23)</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">sorafenib</td><td class="colsep0 rowsep0" align="center">QDÂ ÃÂ 7Â +Â 2-off-5-onÂ Ã2</td><td class="colsep0 rowsep0" align="center">60</td><td class="colsep0 rowsep0" align="center">71Â (21)</td><td class="colsep0 rowsep0" align="center">* (21)</td><td class="colsep0 rowsep0" align="center">â10.3Â (16)</td><td class="colsep0 rowsep0" align="center">5/5Â (23)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">73Â (23)</td><td class="colsep0 rowsep0" align="center">* (23)</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left">â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HuH-7</td><td class="colsep0 rowsep0" align="center">vehicle</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">â2.1Â (12)</td><td class="colsep0 rowsep0" align="center">10/10Â (19)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center"><b>20f</b></td><td class="colsep0 rowsep0" align="center">QD Ã 5/wk Ã2</td><td class="colsep0 rowsep0" align="center">150</td><td class="colsep0 rowsep0" align="center">78Â (12)</td><td class="colsep0 rowsep0" align="center">* (12)</td><td class="colsep0 rowsep0" align="center">â0.9Â (12)</td><td class="colsep0 rowsep0" align="center">5/5Â (22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">sorafenib</td><td class="colsep0 rowsep0" align="center">QD Ã 5/wk Ã2</td><td class="colsep0 rowsep0" align="center">80</td><td class="colsep0 rowsep0" align="center">61Â (12)</td><td class="colsep0 rowsep0" align="center">nsÂ (12)</td><td class="colsep0 rowsep0" align="center">â5.2Â (9)</td><td class="colsep0 rowsep0" align="center">5/5Â (23)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup>a</sup><p class="last">Female NCr nude mice (CrTac:NCr-<i>Foxn1</i><sup>nu</sup>, 5â6 weeks of age, InVivos Pte Ltd., Singapore) were inoculated in the right flank with liver cancer cell lines HepG2 (6 Ã 10<sup>6</sup>), HuH-7 (6 Ã 10<sup>6</sup>), or Hep3B (3.6 Ã 10<sup>6</sup>) in 50% Matrigel.</p></div><div class="footnote" id="t11fn2"><sup>b</sup><p class="last">Compounds <b>20e</b>, <b>20f</b>, vorinostat, and pictilisib were formulated in DMSO/solutol HS15/sterile water (v/v, 7:18:45). Small crystals of <i>p</i>-toluenesulfonic acid monohydrate (pTSA) were added to <b>20e</b> and pictilisib formulation to make clear solution (final pH 2â3).</p></div><div class="footnote" id="t11fn3"><sup>c</sup><p class="last">Dose schedule: po, QD Ã 5/wk = once daily for 5 days of treatment and 2 days without treatment (5-day-on-2-day-off) per week (wk); 5-on-1-off: QD Ã 5 with 1 day holiday in 6-day cycle; 2-off-5-on: 2 days holiday, then QD Ã 5.</p></div><div class="footnote" id="t11fn4"><sup>d</sup><p class="last">Dose: vehicle dosed at 10 mL/kg. Vorinostat and pictilisib were dosed at 60 and 75 mg/kg for combination, respectively.</p></div><div class="footnote" id="t11fn5"><sup>e</sup><p class="last">The percent tumor growth inhibition (% TGI) = (<i>C</i><sub>t</sub> â <i>T</i><sub>t</sub>)/(<i>C</i><sub>t</sub> â <i>C</i><sub>0</sub>) Ã 100. <i>C</i><sub>0</sub> and <i>C</i><sub>t</sub> are the mean tumor volumes for control group (vehicle) on day 0 (first day of the treatment) and day <i>t</i>, respectively. <i>T</i><sub>t</sub> is the mean tumor volume for treatment group on day t.</p></div><div class="footnote" id="t11fn6"><sup>f</sup><p class="last">Two-tailed unpaired <i>t</i> Test was used for comparing two groups, and one-way ANOVA followed by Dunnettâs Multiple Comparison Test were used for comparing three and more groups to determine the statistical significance of tumor volume between a treatment group and the control (vehicle) group, ns = not significant, * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001, and **** <i>p</i> â¤ 0.0001.</p></div><div class="footnote" id="t11fn7"><sup>g</sup><p class="last">Percentage body weight (BW) change was calculated by normalizing BW over day 0. Lowest %BW during the treatment period was reported as well as %BW on days of TGI calculated.</p></div><div class="footnote" id="t11fn8"><sup>h</sup><p class="last">Survivors: the number of animals still alive when the treatment cycle completed or experiment terminated</p></div></div></div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Doseâresponse of <b>20f</b> in HepG2 xenograft model. (A) HepG2 tumor-bearing CB17 scid mice were treated orally with vehicle (black squares), <b>20f</b> (150 (blue upward poiting triangles), 75 (violet downward pointing triangles), and 37.5 (green tilted squares) mg/kg), and sorafenib tosylate (red circles, 100 mg/kg QD Ã 5 Ã 2 then 80 mg/kg, QD Ã 5 Ã 2) for 4 weeks (QD Ã 5 per week) from day 0 with mean tumor volume about 240 mm<sup>3</sup>. Tumor volume (<i>y</i> axis) is expressed as mean Â± SEM * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001, and **** <i>p</i> â¤ 0.0001. (B) <b>20f</b> was well-tolerated at all dose levels, no significant body weight (BW) loss. Vehicle group had BW loss due to increasing tumor burden. Sorafenib tosylate (100 mg/kg) was not well-tolerated; its dose was reduced to 80 mg/kg in the third and fourth cycles. (C) Tumor volume at day 28 after 4 cycles of treatment. (D) Tumor image of mice on day 26 after last dose of the fourth cycle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Oral Efficacy in HepG2 NCr Mice Xenograft Model</h3><div class="NLM_p last">Both <b>20f</b> and <b>20e</b> were tested in HepG2 models. In the first experiment (<a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>), <b>20f</b> (150 mg/kg, QD Ã 5 per week) demonstrated significant oral efficacy in HepG2 xenograft model with tumor growth inhibition (TGI) values of 91% and 95% on day 14 and 18 (after last dose), respectively (<a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>). Reference sorafenib tosylate (98 mg/kg) was less effective, with TGI values of 56% (day 14) and 72% (day 18), respectively. In another HepG2 xenograft experiment, <b>20e</b> was also demonstrated efficacy with TGI of 57% (day 14) after two cycles of treatment. The combination of HDAC inhibitor vorinostat (60 mg/kg) with PI3K inhibitor pictilisib (75 mg/kg) was used to mimic the dual inhibition of both HDAC and PI3K, with half MTD or highest reported dose for each reference inhibitor. MTD of vorinostat in clear DSW solution was 120 mg/kg as we measured in a previous experiment. The highest daily dose of pictilisib in xenograft models was 150 mg/kg.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> For combination therapy, half MTD of vorinostat and half highest daily dosage of pictilisib were used; it is actually the same combination previously used in the Daudi NHL xenograft mouse model.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Oral Efficacy in Hep3B Xenograft Model</h3><div class="NLM_p last">At a lower dosage, 100 mg/kg, <b>20f</b> still effectively inhibited Hep3B tumors (<a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>) and achieved TGI values of 82% and 86% on day 21 and day 23, respectively, while TGI values for sorafenib (60 mg/kg) were 71% and 73%, respectively. Body weight loss was observed for all groups, probably due to the DCW formulation (DMSO/cremophor EL/water = 1:3:6, v/v) used, dosage regimen of the first week (QD Ã 7) applied, as well as the increased tumor burden.</div></div><div id="sec2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Oral Efficacy in HuH-7 Models</h3><div class="NLM_p last">HuH-7 tumor-bearing NCr nude mice were treated with either vehicle or <b>20f</b> (150 mg/kg) from day 0 (QD Ã 5 per week or per cycle). In HuH-7 models, <b>20f</b> was efficacious against established bigger tumors (day 0, 363 mm<sup>3</sup>) with TGI value of 78% (day 12, <i>p</i> = 0.0221) (<a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>) and sorafenib was dosed at 80 mg/kg with TGI value of 61% (day 12, <i>p</i> = 0.1054).</div></div><div id="sec2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Oral Efficacy in CB17 Scid Mice HepG2 Xenograft Model</h3><div class="NLM_p">As <b>20f</b> showed excellent antitumor activity in HepG2 tumor bearing NCr nude mice, it was further evaluated for doseâresponse in female CB17 scid mice (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). When the HepG2 tumor size was about 240 mm<sup>3</sup> in average, tumor-bearing mice were randomized and dosed orally with vehicle, <b>20f</b> (150, 75, and 37.5 mg/kg), and sorafenib tosylate for 4 weeks (QD Ã 5 per week) on day 0. <b>20f</b> demonstrated significant tumor inhibition in a dose-dependent manner (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). After the last dose of the fourth cycle, on day 26, TGI = 117%, 82%, 38%, and 98% for <b>20f</b> (150, 75, and 37.5 mg/kg) and sorafenib tosylate, respectively. <b>20f</b> was well-tolerated at all dose levels (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). Significant TGI with 5/5 regression in 150 mg/kg group (po, QD Ã 5/week) were achieved (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C,D).</div><div class="NLM_p">To facilitate the future preclinical evaluations, <b>20f</b> was tested in formulations without DMSO. <b>20f</b> can be formulated in solutol HS15 solution without DMSO, but overnight solubilization was necessary. Solubility of <b>20f</b> in nontoxic (2-hydroxypropyl)-Î²-cyclodextrin based formulation was over 30 mg/mL, and the oral bioavailability of <b>20f</b> in such a formulation was confirmed. <b>20q</b> and <b>20o</b> are yet to be evaluated with similar or new formulations.</div><div class="NLM_p last">Advanced HCC is generally resistant to chemotherapy, with sorafenib being the only FDA-approved drug for the first-line treatment of advanced HCC.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> However, its benefit is modest. For advanced HCC patients that develop drug resistance to sorafenib or are intolerant of sorafenib, there is currently no established systemic therapy. Targeting vascular endothelial growth factor (VEGFR), such as how sorafenib does in inhibiting tumor angiogenesis, is important and also effective, but a number of kinase inhibitors in this category have failed clinical trials.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> As it might be difficult to outperform sorafenib in antiangiogenesis, it is thus necessary to consider other targets/pathways which are significantly different from anti-VEGF because sorafenib or other similar classes of drugs and can take care of it very well. Our approach is to design and develop a multitarget drug to take care of additional and important targets/networks which are complementary to sorafenib therapy. These purine-based HDAC/PI3K inhibitors such as <b>20f</b> and <b>20e</b> had demonstrated oral efficacy in liver cancer models. With <b>3</b> in ongoing clinical trials and new purine-based analogues of <b>3</b> being reported recently,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> these dual or multifunctional HDAC inhibitors have yet to be validated in clinics for their safety and efficacy.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36174" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36174" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A series of fused-pyrimidine based hydroxamates were designed, synthesized, and evaluated. They inhibited HDAC enzymes, PI3K kinases, and the cell proliferation of a variety of human tumor cell lines. Most of the compounds demonstrated good drug-like properties (i.e., in vitro metabolic stability, solubility, and desirable lipophilicity). Selected compounds <b>20f</b> and <b>20q</b> also showed target modulation in both cancer cells and mice bearing tumors (i.e., hyperacetylation of histone 3 and Î±-tubulin and reduction of pAkt). <b>20f</b> also demonstrated excellent single agent oral anti-antitumor activity in HCC models and 4T1 mouse metastatic breast cancer models (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">Table S4</a>). These multitarget drug molecules may have the potential to be combined with current approved drugs such as sorafenib or regorafenib or other emerging therapies. With regard to immunotherapy, if it is successful in the treatment of HCC (e.g., nivolumab treatment of HCC patients)<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> or other cancers in the near future (e.g., pembrolizumab in combination with entinostat, an HDAC inhibitor, in lung cancer and melanoma),<a onclick="showRef(event, 'ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54">(51-54)</a> it will pave the way for more combinations of immunotherapy with HDAC inhibitors or multifunctional HDAC inhibitors. The encouraging single-agent oral efficacy data in HCC models, along with its favorable target profiles and tissue distribution, warrant further development of <b>20f</b>, either as monotherapy or, preferably, in combination with traditional approved drugs or immunotherapy. Other potential indications are for the treatment of subgroups of leukemia (i.e., AML) and non-Hodgkin lymphomas (i.e., diffuse large B-cell lymphoma).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Chemistry</h3><div class="NLM_p">Reagents were purchased from commercial suppliers, such as Sigma-Aldrich Pte Ltd. (Singapore 117528, Singapore), Boron Molecular Inc. (Raleigh, NC 27616, USA), or Combi-Blocks, Inc. (San Diego, CA 92126, USA). A CEM Discover microwave reactor was used for some reactions. Analytical thin-layer chromatography (TLC) was performed on glass-backed silica gel 60 F 254 plates (E Merck (0.25 mm)) and eluted with the appropriate solvent ratios (v/v) and visualized by UV absorption. The reactions were assayed by TLC and/or LCâMS and terminated as judged by the consumption of starting material or the formation of desire product. Flash column chromatography was conducted using silica gel 60 (Merck KGaA, 0.040â0.063 mm, 230â400 mesh ASTM). Reverse-phase preparative high performance liquid chromatography (RPHPLC) was conducted on a Gilson HPLC system (331/332 pumps, GX-271 liquid handler, 172 diode array doctor (DAD), Trilution LC software) using a Phenomenex column (Luna, 5 Î¼m, C18 100A, 150 mm Ã 21.2 mm) with adjustable solvent gradients, usually 5â95% of acetonitrile in water + 0.05% TFA in 15 or 20 min of gradient at flow rate of 20 mL/min, and was used for routine purification. The preliminary purity and identity of all compounds after purification were assessed by LCâMS analyses on a Waters Micromass ZQ mass spectrometer in electrospray ionization (ESI) positive mode after separation on a Waters 2795 separations module. The HPLC separations were performed on a Phenomenex column (Luna, 5 Î¼m, C18 100A, 50 mm Ã 2.00 mm) with a flow rate of 0.8 mL/min and a 4 min gradient of Xâ95% (X = 5, 30 or 50) of acetonitrile in water + 0.05% TFA, using a Waters 2996 photodiode array detector (method A) or with a flow of 0.6 mL/min and a 6 min gradient of Xâ95% (X = 5, 30 or 50) of methanol in water + 0.1% formic acid (method B). Purity and identity were assessed on the integrated UV chromatograms (220â400 nm) and the mass spectra. The final purity was determined using a Shimadzu LC-20AD UFLC system on a Phenomenex column (Luna, 5 Î¼m, C18 100A, 50 mm Ã 2.00 mm) with a flow rate of 0.8 mL/min and a 6 min gradient of Xâ95% (X = 5, 30 or 50) of acetonitrile in water + 0.05% TFA (method C). A longer column (Phenomenex Gemini 5 Î¼m C18, 110A, 4.6 mm Ã 150 mm) together with a flow rate of 1.0â1.2 mL/min and a 15 min gradient of 5â95% acetonitrile in water + 0.05% TFA was also used for purity check (method D). Purity was >95% for all target compounds.</div><div class="NLM_p">All NMR experiments were performed on a Bruker AVANCE-400 digital NMR spectrometer. NMR spectra are reported in ppm with reference to an internal tetramethylsilane standard (0.00 ppm for <sup>1</sup>H and <sup>13</sup>C) or solvent peak(s) of CDCl<sub>3</sub> (7.26 and 77.1 ppm) or CD<sub>3</sub>OD (3.31 and 49.0 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 and 39.5 ppm). Other NMR solvents were used as needed. Elemental analyses of CHN were performed on a PerkinElmer 2400 CHN/CHNS elemental analyzers. HRMS results were obtained from a Bruker micrOTOF-Q II (ESI, positive mode) with direct injection of purified compounds.</div><div class="NLM_p">Compounds <b>17a</b>â<b>d</b> were synthesized by procedures used for <b>17d</b>.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-(6-(2-Aminopyrimidin-5-yl)-2-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxybutanamide (<b>17a</b>)</h4><div class="NLM_p last">Obtained as powder (30 mg, 34%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 400.1. HPLC purity (254 nm): 99.9%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (s, 1H), 9.55 (s, 2H), 8.25 (s, 1H), 7.50 (s, 2H), 4.14 (t, <i>J</i> = 6.4 Hz, 2H), 3.82â3.77 (m, 4H), 3.75â3.70 (m, 4H), 2.11â2.01 (m, 2H), 2.01â1.93 (m, 2H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 5-(6-(2-Aminopyrimidin-5-yl)-2-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxypentanamide (<b>17b</b>)</h4><div class="NLM_p last">Obtained as powder (22 mg, 38%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 414.1. HPLC purity (254 nm): 98.6%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (s, 1H), 9.54 (s, 2H), 8.25 (s, 1H), 7.45 (s, 2H), 4.14 (t, <i>J</i> = 6.4 Hz, 2H), 3.82â3.77 (m, 4H), 3.75â3.70 (m, 4H), 1.99 (t, <i>J</i> = 7.2 Hz, 2H), 1.86â1.76 (m, 2H), 1.52â1.41 (m, 2H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-(6-(2-Aminopyrimidin-5-yl)-2-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyhexanamide (<b>17c</b>)</h4><div class="NLM_p last">Obtained as powder (41 mg, 38%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 428.1. HPLC purity (254 nm): 95.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 9.54 (s, 2H), 8.24 (s, 1H), 7.42 (s, 2H), 4.12 (t, <i>J</i> = 6.8 Hz, 2H), 3.82â3.76 (m, 4H), 3.75â3.69 (m, 4H), 1.95 (t, <i>J</i> = 7.6 Hz, 2H), 1.88â1.77 (m, 2H), 1.61â1.49 (m, 2H), 1.29â1.17 (m, 2H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 7-(6-(2-Aminopyrimidin-5-yl)-2-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, <b>17d</b>)</h4><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step 1. <i>N</i>-Alkylation</h5><div class="NLM_p last">To a prestirred solution of 2,6-dichloro-9<i>H</i>-purine <b>11a</b> (376 mg, 2.0 mmol) and ethyl 7-bromoheptanoate (521 mg, 2.2 mmol) in DMF (15 mL), was added anhydrous potassium carbonate (552 mg, 4.0 mmol) and NaI (64 mg, 0.4 mmol). The resulting mixture was stirred at 40 Â°C for 12 h, and the reaction was completed as indicated by LCâMS. After workup, the crude was purified by flash chromatography (silica, ethyl acetate/hexanes from 1:3 to 1:2) to afford ethyl 7-(2,6-dichloro-9<i>H</i>-purin-9-yl)heptanoate (<b>13d</b>) (480 mg, 69%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 345.1. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): Î´ 8.26 (s, 1H), 4.34 (t, <i>J</i> = 7.2 Hz, 2H), 4.12 (q, <i>J</i> = 7.1 Hz, 2H), 2.30 (t, <i>J</i> = 7.3 Hz, 2H), 1.99 (quint, <i>J</i> = 6.6 Hz, 2H), 1.63 (quint, <i>J</i> = 7.1 Hz, 2H), 1.48â1.35 (m, 4H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz): Î´ 173.3, 153.2, 152.6, 151.3, 146.1 (CH), 130.6, 60.1, 44.5, 33.8, 29.4, 28.3, 26.1, 24.5, 14.2.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step 2. Suzuki Coupling</h5><div class="NLM_p last">To a prestirred solution of <b>13d</b> (344 mg, 1.0 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro+lan-2-yl)pyrimidin-2-amine <b>14a</b> (240 mg, 1.1 mmol) in dioxane (15 mL) was added a solution of K<sub>2</sub>CO<sub>3</sub> (345 mg, 2.5 mmol) in DI water (2.0 mL). The mixture was degassed for 30 min and then was added Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (41 mg, 0.05 equiv). The resulting mixture was heated at 82 Â°C for 6 h. LCâMS showed the completed reaction. After workup, the crude was purified by flash chromatography (silica, 33% to 50% to 100% of ethyl acetate in hexanes) to afford ethyl 7-(6-(2-aminopyrimidin-5-yl)-2-chloro-9<i>H</i>-purin-9-yl)heptanoate (<b>15d</b>) (150 mg, 37%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 404.1.</div></div><div id="sec4_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step 3. Displacement with Morpholine</h5><div class="NLM_p last">To a prestirred solution of <b>15d</b> (150 mg, 0.37 mmol) in DMF (5 mL) was added morpholine (0.70 mL, 3.0 mmol). The resulting mixture was heated at 80 Â°C for 12 h. After workup, ethyl 7-(6-(2-aminopyrimidin-5-yl)-2-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>16d</b>) (120 mg, 72%) was obtained by recrystallization of the crude in 10% MeOH in DCM. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 455.1.</div></div><div id="sec4_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step 4. Hydroxamic Acid Formation</h5><div class="NLM_p">To a prestirred solution of <b>16d</b> (70 mg, 0.155 mmol), hydroxylamine hydrochloride (108 mg, 1.55 mmol) in dry MeOH (1.5 mL), precooled down over dry ice, was added slowly with sodium methoxide solution (25 wt % in methanol, 4.37 M) (901 Î¼L, 3.88 mmol). The resulting mixture was stirred at â20 Â°C for 1 h before it was warmed up to rt. LCâMS showed the reaction completed after 3 h. After workup, the crude was purified by RPHPLC to afford <b>17d</b> (15 mg, 21%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 442.1. HPLC purity (254 nm): 96.6%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (s, 1H), 9.54 (s, 2H), 8.25 (s, 1H), 7.45 (s, 2H), 4.12 (t, 2H, <i>J</i> = 6.8 Hz), 3.82â3.77 (m, 4H), 3.76â3.71 (m, 4H), 1.93 (t, <i>J</i> = 7.2 Hz, 2H), 1.87â1.77 (m, 2H), 1.52â1.43 (m, 2H), 1.36â1.18 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>27</sub>N<sub>9</sub>O<sub>3</sub> 442.2310, found 442.2308.</div><div class="NLM_p last">Compounds <b>20a</b>â<b>s</b> were synthesized by procedures used for <b>20f</b>.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 7-(2,6-Dimorpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20a</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 434.2. HPLC purity (254 nm): 96.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.31 (s, 1H), 7.87 (s, 1H), 4.27â4.05 (m, 4H), 4.00 (t, <i>J</i> = 6.9 Hz, 2H), 3.68 (t, <i>J</i> = 4.7 Hz, 4H), 3.66â3.58 (m, 8H), 1.91 (t, <i>J</i> = 7.3 Hz, 2H), 1.74 (quint, <i>J</i> = 6.9 Hz, 2H), 1.45 (quint, <i>J</i> = 7.3 Hz, 2H), 1.33â1.14 (m, 4H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-Hydroxy-6-(2-(6-methoxypyridin-3-yl)-6-morpholino-9<i>H</i>-purin-9-yl)hexanamide (<b>20b</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 442.2. HPLC purity (254 nm): 95.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.33 (s, 1H), 9.15 (d, <i>J</i> = 2.0 Hz, 1H), 8.58 (dd, <i>J</i> = 8.7 and 2.3 Hz, 1H), 8.22 (s, 1H), 6.92 (d, <i>J</i> = 8.7 Hz, 1H), 4.40â4.25 (m, 4H), 4.22 (t, <i>J</i> = 6.9 Hz, 2H), 3.93 (s, 3H), 3.77 (t-like, <i>J</i> = 4.6 Hz, 4H), 1.94 (t, <i>J</i> = 6.8 Hz, 2H), 1.87 (quint, <i>J</i> = 7.3 Hz, 2H), 1.57 (quint, <i>J</i> = 7.5 Hz, 2H), 1.25 (quint, <i>J</i> = 6.9 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>28</sub>N<sub>7</sub>O<sub>4</sub> 442.2197, found 442.2204.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-Hydroxy-7-(2-(6-methoxypyridin-3-yl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<b>20c</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 456.1. HPLC purity (254 nm): 98.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (s, 1H), 9.15 (d, <i>J</i> = 2.0 Hz, 1H), 8.58 (dd, <i>J</i> = 8.7 and 2.4 Hz, 1H), 8.22 (s, 1H), 6.92 (d, <i>J</i> = 8.6 Hz, 1H), 4.38â4.25 (br s, 4H), 4.22 (t, <i>J</i> = 7.0 Hz, 2H), 3.93 (s, 3H), 3.77 (t, <i>J</i> = 4.6 Hz, 4H), 1.93 (t, <i>J</i> = 7.2 Hz, 2H), 1.86 (quint, <i>J</i> = 6.9 Hz, 2H), 1.48 (quint, <i>J</i> = 7.1 Hz, 2H), 1.36â1.21 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>29</sub>N<sub>7</sub>O<sub>4</sub> 456.2354, found 456.2369.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-(2-(6-Aminopyridin-3-yl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyhexanamide (<b>20d</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 427.2. HPLC purity (254 nm): 96.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.33 (s, 1H), 8.79â8.73 (m or overlapped dd, 1H), 8.75 (s, 1H), 8.43 (br s, 2H), 8.24 (s, 1H), 7.09 (d-like, <i>J</i> = 10.1 Hz, 1H), 4.40â4.23 (m, 4H), 4.20 (t, <i>J</i> = 6.9 Hz, 2H), 3.76 (t, <i>J</i> = 4.6 Hz, 4H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.84 (quint, <i>J</i> = 7.3 Hz, 2H), 1.55 (quint, <i>J</i> = 7.5 Hz, 2H), 1.22 (quint, <i>J</i> = 7.3 Hz, 2H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 7-(2-(6-Aminopyridin-3-yl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20e</b>)</h4><div class="NLM_p last">Recrystallization of the freebase in MeOH with excess of formic acid afforded <b>20e</b> as formic acid âsaltâ (containing 1.0 Â± 0.3 equiv of formic acid as estimated by <sup>1</sup>H NMR). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 441.2. HPLC purity (254 nm): 97.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): formic acid salt Î´ 10.32 (s, 1H), 8.93 (d, <i>J</i> = 1.9 Hz, 1H), 8.30 (dd, <i>J</i> = 8.7 and 2.2 Hz, 1H), 8.15 (s, 1H), 8.13 (s, 0.7H, formic acid), 6.52 (d, <i>J</i> = 8.7 Hz, 1H), 6.32 (br s, 2H), 4.38â4.22 (br s, 4H), 4.18 (t, <i>J</i> = 6.8 Hz, 2H), 3.75 (t, <i>J</i> = 4.3 Hz, 4H), 1.93 (t, <i>J</i> = 7.2 Hz, 2H), 1.84 (quint, <i>J</i> = 6.7 Hz, 2H), 1.48 (quint, <i>J</i> = 7.0 Hz, 2H), 1.38â1.22 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): formic acid salt Î´ 169.0, 163.0, 160.5, 156.3, 152.9, 151.7, 148.3, 139.9, 136.4, 122.3, 117.6, 107.2, 66.2, 45.2 (br), 42.6, 32.1, 29.1, 27.9, 25.7, 24.9. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>29</sub>N<sub>8</sub>O<sub>3</sub> 441.2357, found 441.2374. Anal. (C<sub>21</sub>H<sub>28</sub>N<sub>8</sub>O<sub>3</sub>Â·0.7H<sub>2</sub>OÂ·HCO<sub>2</sub>H) C, N, H: calcd 6.34, found 6.84.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-Hydroxy-7-(2-(3-(hydroxymethyl)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, <b>20f</b>)</h4><div id="sec4_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Step 1. Displacement with Morpholine</h5><div class="NLM_p last">To a prestirred solution of <b>13d</b> (172 mg, 0.5 mmol) in DCM (5 mL), was added morpholine (218 mg, 2.5 mmol). The resulting mixture was stirred at 40 Â°C for 3 h. After simple workup, the crude product was purified by flash chromatography (silica, ethyl acetate/hexanes from 1:3 to 1:2) to afford ethyl 7-(2-chloro-6-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>18d</b>) (170 mg, 87%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 397.2. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): Î´ 7.70 (s, 1H), 4.56â4.11 (m, 6H), 4.12 (q, <i>J</i> = 7.2 Hz, 2H), 3.82 (t, <i>J</i> = 4.6 Hz, 4H), 2.27 (t, <i>J</i> = 7.2 Hz, 2H), 1.92â1.79 (m, 2H), 1.60 (quint, <i>J</i> = 7.0 Hz, 2H), 1.42â1.27 (m, 4H), 1.24 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz): Î´ 173.6, 153.94, 153.93, 152.2, 118.6, 66.9, 60.3, 45.7 (br), 43.8, 34.1, 29.8, 28.5, 26.3, 24.7, 14.3.</div></div><div id="sec4_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Step 2. Suzuki Coupling</h5><div class="NLM_p last">To a prestirred solution of <b>18d</b> (100 mg, 0.254 mmol) and (3-(hydroxymethyl)phenyl)boronic acid (<b>14f</b>, 76 mg, 0.5 mmol) in dioxane (5.0 mL) was added with potassium carbonate (86 mg, 0.62 mmol) and Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (10 mg). The resulting mixture was stirred at 150 Â°C for 1 h under the microwave irradiation. LCâMS showed the reaction completed after 1 h. After removing the solvent, the crude was suspended in DCM and purified by flash chromatography (silica, 1% to 2% MeOH in DCM) to afford ethyl 7-(2-(3-(hydroxymethyl)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>19f</b>) (30 mg, 25%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 468.3. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 8.34 (s, 1H), 8.27(dt-like, <i>J</i> = 7.2 Hz, 1H), 8.22 (s, 1H), 7.42 (t, <i>J</i> = 7.5 Hz, 1H), 7.39 (dt-like, <i>J</i> = 7.5 Hz, 1H), 5.27 (t, <i>J</i> = 5.0 Hz, 1H), 4.58 (d, <i>J</i> = 4.4 Hz, 2H), 4.38â4.25 (br s, 4H), 4.23 (t, <i>J</i> = 6.8 Hz, 2H), 4.01 (q, <i>J</i> = 7.2 Hz, 2H), 3.77 (t, <i>J</i> = 4.8 Hz, 4H), 2.24 (t, <i>J</i> = 7.2 Hz, 2H), 1.86 (quint, <i>J</i> = 7.2 Hz, 2H), 1.49 (quint, <i>J</i> = 7.4 Hz, 2H), 1.38â1.20 (m, 4H), 1.14 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): Î´ 173.3, 157.3, 153.5, 152.3, 142.9, 141.1, 138.6, 128.4, 128.3, 126.7, 126.2, 118.7, 66.7, 63.5, 60.1, 45.6, 43.2, 33.8, 29.5, 28.2, 26.1, 24.7, 14.5.</div></div><div id="sec4_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Step 3. Hydroxamic Acid Formation and Scale-up</h5><div class="NLM_p last">To a prestirred solution of <b>19f</b> (30 mg, 0.064 mmol) and hydroxylamine hydrochloride (67 mg, 0.96 mmol) in dry MeOH (1.0 mL), precooled down over dry ice, was added slowly with sodium methoxide solution (25 wt % in methanol, 0.37 mL, 1.62 mmol). The resulting mixture was stirred at â20 Â°C for 1 h before it was warmed up to rt. LCâMS showed the reaction completed after 2 h. After simple workup, the mixture was purified by RPHPLC to afford <b>20f</b> as white solid (8 mg, 22% as calcd as TFA salt). HPLC purity (254 nm): 97.4%. Scale-up of freebase: the <b>20f</b> TFA salt made from <b>19f</b> (500 mg) was dissolved in acetonitrile and water and then basified using saturated aqueous NaHCO<sub>3</sub> to pH around 8. After removal of acetonitrile under reduced pressure, the aqueous solution was extracted with ethyl acetate (Ã3). The combined organic layers was dried and evaporated, and the resulting product was further purified by recrystallization in MeOH to afford <b>20f</b> as freebase (381 mg, 78%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 455.1. HPLC purity (254 nm): 98.4%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 8.65 (s, 1H), 8.35 (s or t-like, 1H), 8.27 (dt-like, <i>J</i> = 7.3 Hz, 1H), 8.22 (s, 1H), 7.43 (t, <i>J</i> = 7.5 Hz, 1H), 7.39 (dt-like, <i>J</i> = 7.5 Hz, 1H), 5.29 (t-like, 1H), 4.58 (d, <i>J</i> = 3.8 Hz, 2H), 4.40â4.26 (m, 4H), 4.23 (t, <i>J</i> = 6.9 Hz, 2H), 3.77 (t, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.86 (quint, <i>J</i> = 6.8 Hz, 2H), 1.47 (quint, <i>J</i> = 7.1 Hz, 2H), 1.36â1.20 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): Î´ 169.0, 156.9, 153.0, 151.8, 142.5, 140.6, 138.2, 128.0, 127.9, 126.2, 125.8, 118.2, 66.3, 63.0, 45.1 (br), 42.8, 32.1, 29.1, 28.0, 25.7, 25.0. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub> 455.2402, found 455.2405. Anal. (C<sub>23</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub>Â·0.25H<sub>2</sub>O) C, H, N.</div></div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-Hydroxy-7-(2-(4-hydroxymethyl)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<b>20g</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 455.2. HPLC purity (254 nm): 97.0%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 8.35 (d, <i>J</i> = 8.2 Hz, 2H), 8.21 (s, 1H), 7.41 (d, <i>J</i> = 8.3 Hz, 2H), 4.56 (s, 2H), 4.40â4.25 (br s, 4H), 4.22 (t, <i>J</i> = 7.0 Hz, 2H), 3.77 (t, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 6.6 Hz, 2H), 1.85 (quint, <i>J</i> = 6.7 Hz, 2H), 1.46 (quint, <i>J</i> = 6.9 Hz, 2H), 1.36â1.20 (m, 4H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 7-(2-(2-Aminopyrimidin-5-yl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20h</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: 442.1 [M + H]<sup>+</sup>. HPLC purity (254 nm): 97.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.31 (s, 1H), 9.10 (s, 2H), 8.66 (br s, 1H), 8.16 (s, 1H), 7.04 (s, 2H), 4.40â4.22 (m, 4H), 4.18 (t, <i>J</i> = 6.8 Hz, 2H), 3.75 (t-like, <i>J</i> = 4.0 Hz, 4H), 1.92 (t, <i>J</i> = 7.2 Hz, 2H), 1.83 (quint, <i>J</i> = 6.6 Hz, 2H), 1.47 (quint, <i>J</i> = 6.9 Hz, 2H), 1.36â1.19 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>27</sub>N<sub>9</sub>O<sub>3</sub> 442.2310, found 442.2326.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-Hydroxy-7-(2-(4-(methylsulfonamido)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<b>20i</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 518.1. HPLC purity (254 nm): 96.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.33 (s, 1H), 9.96 (s, 1H), 8.34 (d, 2H, <i>J</i> = 8.8 Hz), 8.21 (s, 1H), 7.30 (d, <i>J</i> = 8.8 Hz, 2H), 4.42â4.25 (m, 4H), 4.22 (t, <i>J</i> = 7.0 Hz, 2H), 3.76 (t, <i>J</i> = 4.7 Hz, 4H), 3.05 (s, 3H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.85 (quint, <i>J</i> = 6.9 Hz, 2H), 1.47 (quint, <i>J</i> = 7.1 Hz, 2H), 1.35â1.20 (m, 4H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 7-(2-(3-Acetamidophenyl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20j</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 482.2. HPLC purity (254 nm): 98.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (s, 1H), 10.07 (s, 1H), 8.46 (s, 1H), 8.23 (s, 1H), 8.06 (d, <i>J</i> = 7.8 Hz, 1H), 7.82 (d, <i>J</i> = 7.9 Hz, 1H), 7.38 (t, <i>J</i> = 7.9 Hz, 1H), 4.80â4.25 (m, 4H), 4.22 (t, <i>J</i> = 6.9 Hz, 2H), 3.77 (t-like, <i>J</i> = 4.6 Hz, 4H), 2.08 (s, 3H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.86 (quint, <i>J</i> = 6.8 Hz, 2H), 1.47 (quint, <i>J</i> = 7.1 Hz, 2H), 1.36â1.20 (m, 4H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3-(9-(7-(Hydroxyamino)-7-oxoheptyl)-6-morpholino-9<i>H</i>-purin-2-yl)benzamide (<b>20k</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 468.2. HPLC purity (254 nm): 99.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 8.83 (t, <i>J</i> = 1.5 Hz, 1H), 8.53 (dt, <i>J</i> = 8.0 and 1.3 Hz, 1H), 8.25 (s, 1H), 8.11 (s, 1H), 7.93 (dt, <i>J</i> = 7.8 and 1.4 Hz, 1H), 7.55 (t, <i>J</i> = 7.7 Hz, 1H), 7.45 (s, 1H), 4.45â4.28 (m, 4H), 4.25 (t, <i>J</i> = 7.0 Hz, 2H), 3.78 (t, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.87 (quint, <i>J</i> = 6.8 Hz, 2H), 1.47 (quint, <i>J</i> = 7.0 Hz, 2H), 1.35â1.20 (m, 4H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-(9-(7-(Hydroxyamino)-7-oxoheptyl)-6-morpholino-9<i>H</i>-purin-2-yl)benzamide (<b>20l</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 468.2. HPLC purity (254 nm): 99.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.33 (s, 1H), 8.43 (d, <i>J</i> = 8.4 Hz, 2H), 8.25 (s, 1H), 8.04 (s, 1H), 7.96 (d, <i>J</i> = 8.4 Hz, 2H), 7.45 (s, 1H), 4.40â4.26 (m, 4H), 4.24 (t, <i>J</i> = 7.0 Hz, 2H), 3.77 (t-like, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.86 (quint, <i>J</i> = 6.8 Hz, 2H), 1.47 (quint, <i>J</i> = 7.0 Hz, 2H), 1.35â1.20 (m, 4H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-Hydroxy-7-(6-morpholino-2-(1<i>H</i>-pyrazol-4-yl)-9<i>H</i>-purin-9-yl)heptanamide (<b>20m</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 415.2. HPLC purity (254 nm): 97.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 8.17 (s, 2H), 8.13 (s, 1H), 4.37â4.19 (m, 4H), 4.16 (t, <i>J</i> = 7.0 Hz, 2H), 3.74 (t-like, <i>J</i> = 4.8 Hz, 4H), 1.92 (t, <i>J</i> = 7.1 Hz, 2H), 1.82 (quint, <i>J</i> = 6.9 Hz, 2H), 1.47 (quint, <i>J</i> = 7.2 Hz, 2H), 1.35â1.18 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>26</sub>N<sub>8</sub>O<sub>3</sub> 415.2201, found 415.2214.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 7-(2-(1<i>H</i>-Indazol-6-yl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20n</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 465.2. HPLC purity (254 nm): 98.0%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.36 (s, 1H), 8.58 (s, 1H), 8.24 (s, 1H), 8.22 (dd-like, <i>J</i> = 8.8 Hz, 1H), 8.11 (s, 1H), 7.82 (d, <i>J</i> = 8.8 Hz, 1H), 4.45â4.28 (m, 4H), 4.25 (t, <i>J</i> = 6.9 Hz, 2H), 3.79 (t, <i>J</i> = 4.6 Hz, 4H), 1.94 (t, <i>J</i> = 7.3 Hz, 2H), 1.86 (quint, <i>J</i> = 6.8 Hz, 2H), 1.49 (quint, <i>J</i> = 7.0 Hz, 2H), 1.40â1.22 (m, 4H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-Hydroxy-7-(2-(2-methoxypyrimidin-5-yl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<b>20o</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 457.2. HPLC purity (254 nm): 97.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 9.40 (s, 2H), 8.65 (s, 1H), 8.25 (s, 1H), 4.47â4.25 (m, 4H), 4.22 (t, <i>J</i> = 6.9 Hz, 2H), 3.99 (s, 3H), 3.76 (t, <i>J</i> = 4.5 Hz, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.85 (quint, <i>J</i> = 6.7 Hz, 2H), 1.47 (quint, <i>J</i> = 7.0 Hz, 2H), 1.35â1.20 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): Î´ 168.4, 165.0, 158.2, 152.7, 152.4, 150.8, 140.1, 125.2, 117.8, 65.6, 54.3, 45.1 (br), 42.3, 31.5, 28.5, 27.4, 25.1, 24.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>29</sub>N<sub>8</sub>O<sub>4</sub> 457.2306, found 457.2327.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 7-(2-(4-Fluoro-3-hydroxyphenyl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20p</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 459.1. HPLC purity (254 nm): 99.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.35 (s, 1H), 9.98 (br s, 1H), 8.20 (s, 1H), 8.04 (dd, <i>J</i> = 9.0 and 2.0 Hz, 1H), 7.83 (ddd, <i>J</i> = 8.5, 4.5, and 2.1 Hz, 1H), 7.20 (dd, <i>J</i> = 11.1 and 8.6 Hz, 1H), 4.40â4.23 (m, 4H), 4.20 (t, <i>J</i> = 7.0 Hz, 2H), 3.76 (t, <i>J</i> = 4.7 Hz, 4H), 1.93 (t, <i>J</i> = 7.3 Hz, 2H), 1.85 (quint, <i>J</i> = 6.9 Hz, 2H), 1.47 (quint, <i>J</i> = 7.1 Hz, 2H), 1.35â1.20 (m, 4H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 7-(2-(2-Aminopyrimidin-5-yl)-4-morpholino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-<i>N</i>-hydroxyheptanamide (<b>20q</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 441.2. HPLC purity (254 nm): 99.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.31 (s, 1H), 9.12 (s, 2H), 8.66 (s, 1H), 7.27 (d, <i>J</i> = 3.6 Hz, 1H), 6.97 (s, 2H), 6.65 (d, <i>J</i> = 3.6 Hz, 1H), 4.20 (t, <i>J</i> = 6.8 Hz, 2H), 3.92 (t, <i>J</i> = 4.6 Hz, 4H), 3.76 (t, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.78 (quint, <i>J</i> = 7.0 Hz, 2H), 1.46 (quint, <i>J</i> = 7.3 Hz, 2H), 1.37â1.17 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): Î´ 169.0, 163.8, 157.4, 156.5, 153.1, 151.5, 124.6, 120.9, 100.9, 100.6, 66.1, 45.4, 43.5, 32.2, 29.5, 28.0, 25.7, 25.0. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>29</sub>N<sub>8</sub>O<sub>3</sub> 441.2357, found 441.2373. Anal. (C<sub>21</sub>H<sub>28</sub>N<sub>8</sub>O<sub>3</sub>) H, N, C: calcd 57.26, found, 57.72.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-Hydroxy-7-(2-(3-hydroxyphenyl)-4-morpholino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)heptanamide (<b>20r</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 440.1. HPLC purity (254 nm): 100.0%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (br s, 1H), 7.86â7.82 (m, 2H), 7.34 (d, <i>J</i> = 3.6 Hz, 1H), 7.25 (t, <i>J</i> = 8.0 Hz, 1H), 6.81 (ddd, <i>J</i> = 8.0, 2.4, and 1.1 Hz, 1H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 4.23 (t, <i>J</i> = 6.9 Hz, 2H), 3.94 (t, <i>J</i> = 4.7 Hz, 4H), 3.78 (t, <i>J</i> = 4.7 Hz, 4H), 1.91 (t, <i>J</i> = 7.3 Hz, 2H), 1.80 (quint, <i>J</i> = 7.0 Hz, 2H), 1.46 (quint, <i>J</i> = 7.3 Hz, 2H), 1.35â1.16 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>30</sub>N<sub>5</sub>O<sub>4</sub> 440.2292, found 440.2306.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 6-(2-(4-Fluoro-3-hydroxyphenyl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyhexanamide (<b>20s</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 445.2. HPLC purity (254 nm): 98.0%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (br s, 1H), 8.21 (s, 1H), 8.03 (dd, <i>J</i> = 8.9 and 1.9 Hz, 1H), 7.83 (ddd, <i>J</i> = 8.4, 4.5, and 2.1 Hz, 1H), 7.19 (dd, <i>J</i> = 10.9 and 8.6 Hz, 1H,), 4.40â4.24 (m, 4H), 4.21 (t, <i>J</i> = 6.9 Hz, 2H), 3.76 (t, <i>J</i> = 4.5 Hz, 4H), 1.93 (t, <i>J</i> = 7.2 Hz, 2H), 1.85 (quint, <i>J</i> = 7.3 Hz, 2H), 1.55 (quint, <i>J</i> = 7.5 Hz, 2H), 1.23 (quint, <i>J</i> = 6.5 Hz, 2H).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-Hydroxy-7-(2-(3-(2-hydroxyethoxy)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<b>20t</b>)</h4><div class="NLM_p last">Ethyl 7-(2-(3-hydroxyphenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>19t</b>) was prepared by procedures used for <b>19f</b> but starting from <b>18d</b> and (3-hydroxyphenyl)boronic acid (<b>14n</b>). <b>19t</b> (152.5 mg, 0.34 mmol), 2-bromoethanol (127.5 mg, 1.02 mmol), and K<sub>2</sub>CO<sub>3</sub> (235 mg, 1.7 mmol) in DMF (3.5 mL) was heated at 90 Â°C to drive the reaction to completion. The mixture was diluted with water and extracted with ethyl acetate. After workup, the crude was purified by flash chromatography (silica, 30% to 50% ethyl acetate in hexanes) to afford ethyl 7-(2-(3-(2-hydroxyethoxy)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>19t2</b>) (36.2 mg, 21%), which was converted to hydroxamic acid <b>20t</b> by procedures used for <b>20f</b>. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 485.2. HPLC purity (254 nm): 99.1%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.31 (s, 1H), 8.22 (s, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.92â7.89 (m, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.02 (dd, <i>J</i> = 7.8 and 2.2 Hz, 1H), 4.45â4.25 (m, 4H), 4.22 (t, overlapped, 2H), 4.10â4.00 (m, 2H), 3.85â3.70 (m, 6H), 1.92â1.88 (t, 2H), 1.88â1.83 (m, 2H), 1.50â1.40 (m, 2H), 1.35â1.20 (m, 4H).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 7-(2-(4-Fluoro-3-(2-hydroxyethoxy)phenyl)-6-morpholino-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>20u</b>)</h4><div class="NLM_p last">It was synthesized similarly to <b>20t</b>. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 503.1. HPLC purity (254 nm): 97.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 8.23 (s, 1H), 8.12 (dd, <i>J</i> = 8.6 and 1.8 Hz, 1H), 7.98 (ddd, <i>J</i> = 8.4, 4.6, and 1.9 Hz, 1H), 7.30 (dd, <i>J</i> = 11.1 and 8.6 Hz, 1H), 4.40â4.25 (m, 4H), 4.22 (t, <i>J</i> = 6.9 Hz, 2H), 4.16 (t, <i>J</i> = 4.8 Hz, 2H), 3.79 (t, <i>J</i> = 4.9 Hz, 2H), 3.76 (t, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.86 (quint, <i>J</i> = 6.8 Hz, 2H), 1.47 (quint, <i>J</i> = 7.0 Hz, 2H), 1.36â1.20 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]+ calcd for C<sub>24</sub>H<sub>32</sub>FN<sub>6</sub>O<sub>5</sub> 503.2413, found 503.2432.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-Hydroxy-7-(2-(3-(hydroxymethyl)-4-methoxyphenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanamide (<b>20v</b>)</h4><div class="NLM_p last">Ethyl 7-(2-(3-formyl-4-methoxyphenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>19v</b>) was prepared by procedures used for <b>19f</b> but starting from <b>18d</b> and (3-formyl-4-methoxyphenyl)boronic acid (<b>14o</b>). <b>19v</b> (80 mg, 0.16 mmol) was reduced with NaBH<sub>4</sub> (60 mg, 1.6 mmol) in methanol, and the crude was purified by flash chromatography (silica, 1% MeOH in DCM) to afford ethyl 7-(2-(3-(hydroxymethyl)-4-methoxyphenyl)-6-morpholino-9<i>H</i>-purin-9-yl)heptanoate (<b>19w</b>) (80 mg, > 95%). <b>19w</b> was converted to hydroxamic acid <b>20v</b> by procedures used for <b>20f</b>. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 485.2. HPLC purity (254 nm): 97.9%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.32 (s, 1H), 8.43 (d, <i>J</i> = 2.2 Hz, 1H), 8.27 (dd, <i>J</i> = 8.6 and 2.2 Hz, 1H), 8.18 (s, 1H), 7.03 (d, <i>J</i> = 8.7 Hz, 1H), 4.54 (s, 2H), 4.35â4.25 (m, 4H), 4.21 (t, <i>J</i> = 6.9 Hz, 2H), 3.83 (s, 3H), 3.77 (t, <i>J</i> = 4.6 Hz, 4H), 1.92 (t, <i>J</i> = 7.2 Hz, 2H), 1.86 (quint, <i>J</i> = 6.9 Hz, 2H), 1.47 (quint, <i>J</i> = 7.2 Hz, 2H), 1.35â1.21 (m, 4H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>33</sub>N<sub>6</sub>O<sub>5</sub> 485.2507, found 485.2506</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 7-(2-(2-Aminopyrimidin-5-yl)-6-(4-(hydroxymethyl)piperidin-1-yl)-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>23a</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 470.1. HPLC purity (254 nm): 97.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.34 (br s, 1H), 9.15 (s, 2H), 8.15 (s, 1H), 7.54 (br s, 2H), 4.18 (t, <i>J</i> = 6.9 Hz, 2H), 3.28 (d, <i>J</i> = 5.9 Hz, 2H), 3.08 (br s, 2H), 1.92 (t, <i>J</i> = 7.3 Hz, 2H), 1.88â1.68 (m, 5H), 1.47 (quint, <i>J</i> = 7.1 Hz, 2H), 1.35â1.10 (m, 6H).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 7-(2-(2-Aminopyrimidin-5-yl)-6-(4-hydroxypiperidin-1-yl)-9<i>H</i>-purin-9-yl)-<i>N</i>-hydroxyheptanamide (<b>23b</b>)</h4><div class="NLM_p last">LCâMS <i>m</i>/<i>z</i>: ([M + H]<sup>+</sup> 456.1. HPLC purity (254 nm): 99.9%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.33 (br s, 1H), 9.12 (s, 2H), 8.14 (s, 1H), 7.25 (br s, 2H), 4.87 (m, 1H), 4.17 (t, <i>J</i> = 6.9 Hz, 2H), 3.84â3.75 (m, 2H), 3.74â3.57 (m, 2H), 1.96â1.76 (m, 6H), 1.52â1.36 (m, 4H), 1.35â1.19 (m, 4H).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (<i>E</i>)-<i>N</i>-Hydroxy-3-(4-(((2-(2-(6-methoxypyridin-3-yl)-6-morpholino-9<i>H</i>-purin-9-yl)ethyl)amino)methyl)phenyl)acrylamide (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, <b>29</b>)</h4><div id="sec4_1_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Step 1. Displacement with Morpholine</h5><div class="NLM_p last">Morpholine (1.39 mL, 15.87 mmol) was added to a solution of <b>11a</b> (1.00 g, 5.29 mmol) in THF (26 mL). The resulting mixture was stirred at rt for 16 h. White precipitate was observed immediately upon addition of morpholine. The white precipitate was filtered off and washed with water (Ã2) and methanol (Ã2) to afford 4-(2-chloro-9<i>H</i>-purin-6-yl)morpholine (<b>24</b>) (1.13 g, 90%). LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 240.1.</div></div><div id="sec4_1_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Step 2. <i>N</i>-Alkylation</h5><div class="NLM_p last">To a solution of <b>24</b> (1.18 g, 4.94 mmol) in acetonitrile/DMSO (19:1) was added 2-iodoacetonitrile (0.71 mL, 9.87 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.36 g, 9.87 mmol). The resulting mixture was heated at 60 Â°C for 3 h. Then the solvents were removed in vacuo and water was added. The aqueous layer was extracted with DCM (Ã2), and the combined organic layers was washed with brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo. The resulting crude oil was purified by flash chromatography (silica, 50% ethyl acetate in hexanes) to afford 2-(2-chloro-6-morpholino-9<i>H</i>-purin-9-yl)acetonitrile (<b>25</b>) (1.31 g, 95%) as pale-brown solid. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 279.1.</div></div><div id="sec4_1_29_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step 3. Reduction</h5><div class="NLM_p last">To a stirred solution of <b>25</b> (1.23 g, 4.42 mmol) and NiCl<sub>2</sub>Â·6H<sub>2</sub>O (105 mg, 0.44 mmol) in MeOH/THF (2:1) was added sodium borohydride (1.17 g, 30.97 mmol) in portions. The resulting mixture was allowed to stir at rt for 1 h. Then the solvents were removed in vacuo, and a saturated solution of sodium bicarbonate was added. The aqueous layer was extracted with DCM (Ã2), and the combined organic layers was washed with brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo. The crude was purified by flash chromatography (silica, 10% methanol in DCM) to afford 2-(2-chloro-6-morpholino-9<i>H</i>-purin-9-yl)ethanamine (<b>26</b>) (577 mg, 46%) as colorless oil. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 283.1.</div></div><div id="sec4_1_29_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step 4. Reductive Amination</h5><div class="NLM_p last">To a stirred solution of <b>26</b> (576 mg, 2.04 mmol) in DCE (10 mL) was added (<i>E</i>)-methyl 3-(4-formylphenyl)acrylate (466 mg, 2.45 mmol), acetic acid (0.12 mL, 2.04 mmol), and sodium triacetoxyborohydride (649 mg, 3.06 mmol) sequentially. The resulting mixture was stirred at rt for 5 h. A saturated solution of sodium bicarbonate was added to quench the reaction, and the aqueous layer was extracted with DCM (Ã2). The combined organic layers was washed with brine, dried over MgSO<sub>4</sub>, and evaporated in vacuo. The crude was purified by flash chromatography (silica, 4% methanol in DCM) to afford (<i>E</i>)-methyl 3-(4-(((2-(2-chloro-6-morpholino-9<i>H</i>-purin-9-yl)ethyl)amino)methyl)phenyl)acrylate (<b>27</b>) (414 mg, 44%) as off-white solid. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 457.2.</div></div><div id="sec4_1_29_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Steps 5 and 6</h5><div class="NLM_p last">By following procedures of Suzuki coupling and hydroxamic acid formation used for <b>20f</b>, the title compound (<b>29</b>) was obtained as TFA salt. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 531.3. HPLC purity (254 nm): 96.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 9.14 (d, <i>J</i> = 2.2 Hz, 1H), 9.06 (br s, 2H), 8.52 (dd, <i>J</i> = 8.8 and 2.3 Hz, 1H), 8.19 (s, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 2H), 7.45 (d, <i>J</i> = 7.8 Hz, 2H), 7.42 (d, overlapped, 1H), 6.87 (d, <i>J</i> = 8.7 Hz, 1H), 6.46 (d, <i>J</i> = 15.9 Hz, 1H), 4.59 (t, <i>J</i> = 5.5 Hz, 2H), 4.44â4.19 (m, 6H), 4.10â3.66 (m, 2H), 3.91 (s, 3H), 3.76 (t-like, <i>J</i> = 4.5 Hz, 4H), 3.65â3.52 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>31</sub>N<sub>8</sub>O<sub>4</sub> 531.2463, found 531.2473.</div></div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>E</i>)-3-(4-(((2-(2-(2-Aminopyrimidin-5-yl)-6-morpholino-9<i>H</i>-purin-9-yl)ethyl)amino)methyl)phenyl)-<i>N</i>-hydroxyacrylamide (<b>31</b>)</h4><div class="NLM_p last"><b>31</b> was prepared by procedures used for <b>29</b>. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 517.2. HPLC purity (254 nm): 97.8%. <sup>1</sup>HNMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 10.80 (br s, 1H), 9.14 (s, 2H), 9.00 (br s, 2H), 8.15 (s, 1H), 7.57 (d, <i>J</i> = 7.9 Hz, 2H), 7.45 (d, <i>J</i> = 7.9 Hz, 2H), 7.43 (d, overlapped, 1H), 7.15 (br s, 2H), 6.47 (d, <i>J</i> = 15.9 Hz, 1H), 4.57 (t, <i>J</i> = 5.3 Hz, 2H), 4.40â4.20 (m, 4H), 3.90â3.50 (m, 8H). HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>29</sub>N<sub>10</sub>O<sub>3</sub> 517.2419, found 517.2421.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>N</i>-Hydroxy-4-(((2-(2-(6-methoxypyridin-3-yl)-6-morpholino-9<i>H</i>-purin-9 yl)ethyl)amino)methyl)benzamide (<b>34</b>)</h4><div class="NLM_p last"><b>34</b> was analogously prepared by procedures used for <b>29</b>. LCâMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> 505.1. HPLC purity (254 nm): 97.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): Î´ 11.28 (br s, 1H), 9.17 (d, <i>J</i> = 1.9 Hz, 1H), 9.08 (br s, 2H), 8.55 (dd, <i>J</i> = 8.7 and 2.4 Hz, 1H), 8.19 (s, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 2H), 7.50 (d, <i>J</i> = 8.3 Hz, 2H), 6.89 (dd, <i>J</i> = 8.7 and 0.5 Hz, 1H), 4.60 (t, <i>J</i> = 5.8 Hz, 2H), 4.40â3.95 (m, 6H), 3.92 (s, 3H), 3.75 (t, <i>J</i> = 4.6 Hz, 4H), 3.59 (t-like, 2H).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> HDAC Enzyme Assay</h3><div class="NLM_p last">HeLa nuclear extracts were prepared in-house and were used as the source of HDACs in routine HDAC inhibition assays. The recombinant HDAC enzymes HDAC1 (catalogue no. 5005), HDAC3/NcoR2 (catalogue no. 50003), HDAC4 (catalogue no. 50004), HDAC6 (catalogue no. 50006), and HDAC8 (catalogue no. 50008) were purchased from BPS Bioscience Inc., United States. The assay was performed in 96-well format (black NBS half-area 96-well plate, Corning catalogue no. 3993) using a fluorescent-based HDAC activity assay. Substrates Boc-Lys(Ac)-AMC (catalogue no. I-1875) for HeLa nuclear extracts, HDACs 1, 2, 3, 6, and 10 and Boc-Lys(Tfa)-AMC (catalogue no. I-1985) for HDACs 4, 5, 7, 8, 9, and 11 were purchased from Bachem AG, Switzerland. The reaction mixture (50 Î¼L/well) was composed of assay buffer (25 mM Tris, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl<sub>2</sub>, and 0.1 mg/mL BSA), test compounds, an appropriate concentration of enzyme, and 50 Î¼M of substrate, and it was incubated at rt for 2 h. The reaction was stopped by addition of developer [50 Î¼L/well, containing trypsin (catalogue no. T4799, Sigma-Aldrich), 2 mg/mL, 50 mM Tris pH 8.0, and LAQ824 (CAS 404951-53-7), 4.5 Î¼M] and incubated at 37 Â°C for 30 min. The fluorescence was detected at the excitation wavelength of 360 nm and emission wavelength of 460 nm using a BioTek Synergy H4 Hybrid multimode microplate reader, and raw data were processed using BioTekâs Gen5 (v2.03.01) software. Vorinostat (SAHA) was used as positive control.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Kinase Enzyme Assay</h3><div class="NLM_p last">Lipid kinases PI3KÎ±: catalogue no. PV4788 from Invitrogen or catalogue no. 40620 from BPS Bioscience Inc., United States; p110Î±(H1047R)/p85Î± (catalogue no. 40641) from BPS, p110Î±(E545K)/p85Î± (catalogue no. P27-15H) from SignalChem. PI3KÎ²: catalogue no. P28-10H (SignalChem), catalogue no. 40622 (BPS). PI3KÎ´: catalogue no. P30-10H (SignalChem) were used in the ADP-Glo kinase assay (Promega). Serially diluted compounds solutions (5 Î¼L/well, 3-fold, 8-concentration) were added to a white NBS half-area 96-well plate (Corning catalogue no. 3992). Lipid PIP2:PS (1:3) mixture (0.167 mg/mL: 0.5 mg/mL) in lipid dilution buffer (25 mM HEPES, pH7.5, 0.5 mM EGTA) was diluted (1:1) with reaction buffer (3.33Ã) (159 mM HEPES, pH 7.5, 87 mM NaCl, 9.5 mM MgCl<sub>2</sub>, 0.08 mg/mL BSA) to make a 1.67Ã working solution, PI3K enzyme was diluted with the 1.67Ã working solution, and 15 Î¼L/well was used for reaction. ATP (125 Î¼M, 5 Î¼L/well) in DI water was added to initiate the reaction. After reaction at rt for 1 h, the reaction was stopped by addition of ADP-Glo solution (25 Î¼L/well) and incubated at rt for 40 min, then kinase detection solution (50 Î¼L/well) was added and incubated for 40 min, the luminescence was read on a Biotek Synergy H4 Hybrid multimode microplate reader, and raw data were processed using BioTekâs Gen5 (v2.03.01) software. Pictilisib and wortmannin were used as positive controls. IC<sub>50</sub> is defined as the concentration of compound required for 50% inhibition of enzyme activity.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Cell Culture and Antiproliferative Assays (Cellular IC<sub>50</sub>)</h3><div class="NLM_p last">All cell lines were purchased directly from ATCC except HuH-7 which were obtained from Dr. Manikanden Lakshmanan (IMCB). Cells were cultivated at 37 Â°C, 5% CO<sub>2</sub> in recommended media containing 10% FBS. Antibiotics (100 U/mL of penicillin and 100 Î¼g/mL of streptomycin) were added to the media used for compound dilution and cells in 96-well assay plates. For a typical screening experiment, cells (100 Î¼L/well) were inoculated into 96-well microtiter plates at plating densities ranging from 2000 to 30000 cells/well depending on the doubling time of individual cell lines and assay linearity. After cell inoculation, the microtiter plates were incubated overnight (up to 24 h) prior to addition of compounds for adherent cells. Suspension cells were treated with test compounds immediately after cell inoculation. Test compounds were serially diluted (3-fold, 8-concentration) using the same media and added to the plates (15â25 Î¼L/well). After 72 h of cultivation, the plates were assayed for cell cytotoxicity/viability by using the following two methods: Sulforhodamine B (SRB) method<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55, 56)</a> and CellTiter-Glo luminescent cell viability assay.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The raw data were processed using BioTekâs Software Gen5 (v2.03.01) to generate inhibitory IC<sub>50</sub> values. Vorinostat was used as positive control.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Cell Line Authentication and Mycoplasma Detection</h3><div class="NLM_p last">Cells were routinely monitored with MycoAlert PLUS mycoplasma detection kit (Lonza Walkersville, Inc.) to make sure they were mycoplasma free. Genomic DNA was isolated according to manufacturerâs protocol by using PureLink Genomic DNA Mini Kit (catalogue no. K1820-01, Invitrogen, Carlsbad, CA92008, USA). About 1 Ã 10<sup>5</sup> cells were used for DNA isolation. Cell line authentication was done at Genetica DNA Laboratories (1440 York Court, Burlington, NC 27215 USA) as well as in-house at The DNA Sequencing Facility (DSF, IMCB) by using Promega PowerPlex 16 HS System and Promega GenePrint 10 System, respectively. Cell line authentication data were verified and confirmed against ATCC database as well as published STR data.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> Mycoplasma detection was done at Genetica DNA Laboratories by using e-Myco plus mycoplasma PCR detection kit (iNtRON Biotechnology).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Caspase Activity Assays</h3><div class="NLM_p last">Cells were cultivated and treated with test compounds in 96-well plates as described in the <a class="ref internalNav" href="#sec4_4" aria-label="Cell Culture and Antiproliferative Assays">Cell Culture and Antiproliferative Assays</a> section. Caspase assay buffer [100 mM HEPES (pH7.5), 200 mM NaCl, 4 mM EDTA, 0.1% CHAPS, and freshly added 5 mM DTT and 50 Î¼M of caspase substrate Z-DEVD-R110 or (Z-Asp-Glu-Val-Asp)<sub>2</sub>-rhodamine 110 (catalogue no. M-2615, Bachem, Switzerland)] was added to cells (100 Î¼L/well), and the plates were incubated at rt and monitored for the caspase activity on a BioTek Synergy H4 reader (excitation, 496/9 nm; emission, 521/9 nm). Positive control was staurosporine.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Cell Viability/Cytotoxicity Assay</h3><div class="NLM_p last">The content of dead cells and viable cells were measured using CytoTox-Glo cytotoxicity assay kit (Promega) per manufactureâs protocol. Briefly, CytoTox-Glo cytotoxicity assay reagent (48 Î¼L/well) was added to the cells in 96-well plate, and the luminescent signals were recorded using a BioTek Synergy H4 reader, then Lysis Reagent (48 Î¼L/well) was added and the luminescent signals derived from both dead and viable cells were recorded. Viability was calculated by subtracting the luminescent signal resulting from experimental cell death from total luminescent values. Staurosporine was used as positive control.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Target Modulation of HDACs and PI3K/AKT/mTOR Pathway in Cancer Cells and Tumors: Western Blot Analysis</h3><div class="NLM_p last">Cells were cultivated and treated with test compounds as described in the above <a class="ref internalNav" href="#sec4_4" aria-label="Cell Culture and Antiproliferative Assays">Cell Culture and Antiproliferative Assays</a> section. Cells were washed with cold DPBS twice and cooled on ice and treated with lysis buffer [50 mM Tris (pH7.4), 2.5 mM Î²-glycerophosphate, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM sodium orthovanadate, 10 mM sodium fluoride, 1 mM EDTA and freshly added protease inhibitor PMSF (0.1 mM) and protease inhibitor cocktail (catalogue no. 03969, Nacalai Tesque, Inc. or catalogue no. 539134, Calbiochem)]. Lysates were cleared at 20000<i>g</i> for 20 Ã 2 min, and protein concentrations were determined using a BCA Protein Assay Kit (catalogue no. 71285-3, Novagen, USA). Proteins in cell lysates were resolved by SDS-PAGE and transferred to PVDF and probed with appropriate primary and secondary antibodies. Histone H3 (acetyl K9) (catalogue no. 9649), histone H3 (catalogue no. 9715), acetyl-Î±-tubulin (Lys40) (catalogue no. 5335), Î±-tubulin (catalogue no. 2125), pAkt (Ser473) (catalogue no. 4060), anti-Akt(pan) (catalogue no. 4685), pS6 ribosomal protein (Ser240/244) (catalogue no. 5364), S6 ribosomal protein (catalogue no. 2217), phospho-4E-BP1 (Thr37/46) (catalogue no. 2855), P70S6 kinase (catalogue no. 2708), phospho-P70 S6 kinase (Thr389) (catalogue no. 9234), and HRP-linked antirabbit IgG (catalogue no. 7074) antibodies were purchased from Cell Signaling Technology, Inc., USA. Anti-Î²-actin (catalogue no. ab8227) was from Abcam, and anti-GAPDH-HRP (catalogue no. sc-25778-HRP) was from Santa Cruz Biotechnology, Inc. The protein bands were detected using Pierce ECL Western Blotting Substrate (catalogue no. 3229) and captured using Fuji Super RX-N films, which were subsequently scanned and analyzed using ImageJ (1.47 V) software. Or the gel signals were captured and processed using ChemiDoc Touch Imaging System with Image Lab Touch Software (version 5.2.1 build 11, Nov 14, 2014, Bio-Rad Laboratories).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> In Vitro ADME and Drug-like Properties</h3><div class="NLM_p last">Lipophilicity (log <i>D</i> at pH 7.4), solubility, and microsomal stability were determined by using our previous published methods properties.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Microsomal Stability</h3><div class="NLM_p last">GIBIO pooled human liver microsomes (HLM) (catalogue no. HMMCPL), mouse liver microsomes (MLM) (catalogue no.  BCMCPL), and rat liver microsomes (RLM) (catalogue no. RTMCPL) were purchased from Life Technologies. The incubations consisted of test compound (5 Î¼M) or control compounds (verapamil and dextromethorphan), 0.5 mg/mL of microsomes, 3.3 mM MgCl<sub>2</sub>, 1.3 mM Î²-NADPH, and 100 mM potassium phosphate buffer (pH 7.4). Samples were incubated at different time points up to 60 min. Reaction was terminated with ice-cold acetonitrile 0.3% formic acid. Samples were subsequently centrifuged at 4 Â°C for 15 min at 20000<i>g</i>. The supernatant was analyzed by LCâMS.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Pharmacokinetics (PK) and Tissue Distribution<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a></h3><div class="NLM_p last">All animal studies were done as per approved protocols by the Institutional Animal Care and Use Committee at the Biological Resource Centre (BRC) in Singapore. BALB/c mice or tumor bearing NCR nude mice were dosed iv, po, and ip with a variety of formulated solutions or suspensions of compound examples. Blood was collected after serial bleeding and centrifuged, and the plasma was frozen at â80 Â°C. Tissues (e.g., livers, lungs, and kidney) were snap frozen on dry ice or in liquid nitrogen and kept at â80 Â°C until analysis. The plasma samples were added internal standard carbamazepine (CBZ) and processed as described previously.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Quantitative analysis was carried out on a Waters 2795 separations module equipped with a Waters 2996 photodiode array (PDA) detector and Micromass Quattro micro mass spectrometer. Sample was resolved on Phenomenex Luna C18(2), 2.0 mm Ã 50 mm column with a SecurityGuard Cartridge (C18 4 mm Ã 2.0 mm) at a flow of 0.5 mL/min with a 6 min gradient (Xâ95% of B, solvent A, ultrapure water with 0.1% of formic acid (FA), solvent B, methanol with 0.1% of FA, X is selected from 5 to 50), and data were acquired using multiple reaction monitoring and quantified by QuanLynx in MasLynx software (V 4.1, Waters Inc.).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> In Vivo Pharmacodynamics (PD) and Efficacy Studies</h3><div class="NLM_p last">All animal studies were done as per approved protocols by the Institutional Animal Care and Use Committee at the Biological Resource Centre (BRC) in Singapore. Female NCr nude mice (CrTac:NCr-<i>Foxn1</i><sup>nu</sup>), BALB/c nude mice, or C.B-17 scid mice (C.B-Igh-1<sup>b</sup>/IcrTac-Prkdc<sup>scid</sup>), 4â6 weeks of age, purchased from InVivos Pte Ltd., Singapore, were inoculated in the right flank with about 5 Ã 10<sup>6</sup> of tumor cells which were suspended in serum-free DMEM or RPMI1640 growth medium and Matrigel (catalogue no. 354234, Corning Discovery Labware) (1:1) and injected in a total volume of 100â150 Î¼L. Tumor were measured using a digital caliper, and tumor volumes were estimated by using the formula: tumor volume = length Ã width<sup>2</sup> Ã 0.5. Tumor growth inhibition (TGI%) = [1 â (<i>T</i><sub>t</sub> â <i>T</i><sub>0</sub>)/(<i>C</i><sub>t</sub> â <i>C</i><sub>0</sub>) Ã 100, and <i>C</i><sub>0</sub> and <i>C</i><sub>t</sub> are the mean tumor volumes for control group (vehicle) on day 0 and day <i>t</i>, respectively; <i>T</i><sub>0</sub> and <i>T</i><sub><i>t</i></sub> are the mean tumor volumes for treatment group on day 0 and day <i>t</i>, respectively. All statistics conducted were done using GraphPad Prism (v4.00 or v7.00, GraphPad Software Inc.), two-tailed unpaired <i>t</i>-Test was used for comparing two groups, and one way ANOVA followed by Dunnettâs Multiple Comparison Test were used for comparing three and more groups.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01465">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01465" class="ext-link">10.1021/acs.jmedchem.7b01465</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Source of reference compounds, hydroxamate (âCONHOH) <b>20f</b> vs acid (âCO<sub>2</sub>H) <b>20w</b>, KINOMEscan profiling of <b>20f</b> and <b>20q</b> at 1 Î¼M, lead compounds were screened against 39 cancer cell lines, efficacy of orally administered <b>20f</b> in murine triple negative breast cancer and lung metastatic cancer 4T1 models, modulation of HDACs and PI3K/Akt/mTOR in PC-3 and MCF7 cells, molecular docking of reference and target compounds, synthesis of <b>20w</b>, anchorage-dependent clonogenic assay and soft agar colony formation assay, and molecular docking studies (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_001.csv">jm7b01465_si_001.csv (3.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf">jm7b01465_si_002.pdf (945.53 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01465" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haishan Wang</span> - <span class="hlFld-Affiliation affiliation">Drug Development
Unit, Institute of Molecular and Cell Biology,
Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore</span>;Â 
    <span class="hlFld-Affiliation affiliation">Probit Pharmaceuticals Pte. Ltd., 10 Anson Road no. 26-04, Singapore 079903, Republic of Singapore</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7959-7377" title="Orcid link">http://orcid.org/0000-0002-7959-7377</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0f626c6d78677c4f68626e6663216c6062"><span class="__cf_email__" data-cfemail="c1aca2a3b6a9b281a6aca0a8adefa2aeac">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dizhong Chen</span> - <span class="hlFld-Affiliation affiliation">Drug Development
Unit, Institute of Molecular and Cell Biology,
Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chang Kai Soh</span> - <span class="hlFld-Affiliation affiliation">Drug Development
Unit, Institute of Molecular and Cell Biology,
Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Huang Goh</span> - <span class="hlFld-Affiliation affiliation">Drug Development
Unit, Institute of Molecular and Cell Biology,
Agency for Science, Technology and Research, 61 Biopolis Drive, Proteos, Singapore 138673, Republic of Singapore</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): HW, DC, and CKS are inventors of patent applications associated with this publication.<br /></br></p></li></ul></div><div class="ack" id="ACK-d163e7446-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the Institute of Molecular and Cell Biology for financial support, Xiaoli Xu (IMCB) for performing part of the animal work, Drs. Ken Chi Lik Lee and Li Yan Chan (Singapore Polytechnic) for providing NMR facility support, Dr. Manikanden Lakshmanan (IMCB) for ordering animals, Professor Wanjin Hong (IMCB) for valuable recommendations, the Experimental Therapeutics Centre (ETC) for supporting part of the outsourced enzymatic profiling work, interns from Singapore Polytechnic and Nanyang Polytechnic for chemical synthesis of the intermediates, and Zilong Wang for his help with the manuscript. The project was supported by the Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Republic of Singapore.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i94" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i94"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i95" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i95"> Abbreviations Used</h2><tr><td class="NLM_term">AcH3</td><td class="NLM_def"><p class="first last">acetyl histone H3</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc binding group</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>Development History and FDA Approval Process for Nexavar; <span class="NLM_publisher-name">Drugs.com</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="https://www.drugs.com/history/nexavar.html" class="extLink">https://www.drugs.com/history/nexavar.html</a> (accessed Aug 15, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Development+History+and+FDA+Approval+Process+for+Nexavar%3B+Drugs.com%2C+2007%3B+https%3A%2F%2Fwww.drugs.com%2Fhistory%2Fnexavar.html+%28accessed+Aug+15%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%2520History%2520and%2520FDA%2520Approval%2520Process%2520for%2520Nexavar%26pub%3DDrugs.com%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lencioni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llovet, J. M.</span><span> </span><span class="NLM_article-title">Modified RECIST (mRECIST) assessment for hepatocellular carcinoma</span> <span class="citation_source-journal">Semin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">052</span><span class="NLM_x">â</span> <span class="NLM_lpage">060</span><span class="refDoi">Â DOI: 10.1055/s-0030-1247132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1055%2Fs-0030-1247132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=20175033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFCqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=052-060&author=R.+Lencioniauthor=J.+M.+Llovet&title=Modified+RECIST+%28mRECIST%29+assessment+for+hepatocellular+carcinoma&doi=10.1055%2Fs-0030-1247132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Modified RECIST (mRECIST) assessment for hepatocellular carcinoma</span></div><div class="casAuthors">Lencioni, Riccardo; Llovet, Josep M.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-60</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  The endpoint in cancer research is overall survival.  Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used.  Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue.  The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Assocn. for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis.  Applying these guidelines, there was an assocn. between response rate and outcome prediction.  More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a method for measuring treatment response based on tumor shrinkage, which is a valuable measure of antitumor activity of cytotoxic drugs.  This method was initially adopted by regulatory agencies, such as the U.S.  Food and Drug Administration (FDA), for drug approval.  However, anat. tumor response metrics can be misleading when applied to mol.-targeted therapies or locoregional therapies in HCC.  In 2008, a group of experts convened by the American Assocn. for the Study of Liver Diseases (AASLD) developed a set of guidelines aimed at providing a common framework for the design of clin. trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiol. imaging techniques-to formally amend RECIST.  These amendments conformed the AASLD-JNCI (Journal of the National Cancer Institute) guidelines and are summarized and clarified in the current article.  They are referred to herein as the modified RECIST assessment (mRECIST).  Further studies are needed to confirm the accuracy of this measurement compared with conventional gold stds. such as pathol. studies of explanted livers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQP_LahEIq7Vg90H21EOLACvtfcHk0li61VIs6El9dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFCqtbk%253D&md5=0b04fc90e67821a2183d7b88330fc3fa</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1247132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1247132%26sid%3Dliteratum%253Aachs%26aulast%3DLencioni%26aufirst%3DR.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DModified%2520RECIST%2520%2528mRECIST%2529%2520assessment%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2010%26volume%3D30%26spage%3D052%26epage%3D060%26doi%3D10.1055%2Fs-0030-1247132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>Development History and FDA Approval Process for Stivarga; <span class="NLM_publisher-name">Drugs.com</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="https://www.drugs.com/history/stivarga.html" class="extLink">https://www.drugs.com/history/stivarga.html</a> (accessed Aug 18, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Development+History+and+FDA+Approval+Process+for+Stivarga%3B+Drugs.com%2C+2017%3B+https%3A%2F%2Fwww.drugs.com%2Fhistory%2Fstivarga.html+%28accessed+Aug+18%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%2520History%2520and%2520FDA%2520Approval%2520Process%2520for%2520Stivarga%26pub%3DDrugs.com%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Llovet, J. M.</span><span> </span><span class="NLM_article-title">Regorafenib in second-line setting for hepatocellular carcinoma: balancing benefit with toxicity</span>. The ASCO Post<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">, </span><a href="http://www.ascopost.com/issues/february-25-2017/regorafenib-in-second-line-setting-for-hepatocellular-carcinoma-balancing-benefit-with-toxicity/" class="extLink">http://www.ascopost.com/issues/february-25-2017/regorafenib-in-second-line-setting-for-hepatocellular-carcinoma-balancing-benefit-with-toxicity/</a> (accessed Aug 18, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+M.+Llovet&title=Regorafenib+in+second-line+setting+for+hepatocellular+carcinoma%3A+balancing+benefit+with+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DRegorafenib%2520in%2520second-line%2520setting%2520for%2520hepatocellular%2520carcinoma%253A%2520balancing%2520benefit%2520with%2520toxicity%26jtitle%3DThe%2520ASCO%2520Post%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assenat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, R. T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanc, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorval, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck-Radosavljevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jappe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perraud, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anak, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellami, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.-T.</span><span> </span><span class="NLM_article-title">Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the evolve-1 randomized clinical trial</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">â</span> <span class="NLM_lpage">67</span><span class="refDoi">Â DOI: 10.1001/jama.2014.7189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1001%2Fjama.2014.7189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ajsb3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=57-67&author=A.+X.+Zhuauthor=M.+Kudoauthor=E.+Assenatauthor=S.+Cattanauthor=Y.-K.+Kangauthor=H.+Y.+Limauthor=R.+T.+P.+Poonauthor=J.-F.+Blancauthor=A.+Vogelauthor=C.-L.+Chenauthor=E.+Dorvalauthor=M.+Peck-Radosavljevicauthor=A.+Santoroauthor=B.+Danieleauthor=J.+Furuseauthor=A.+Jappeauthor=K.+Perraudauthor=O.+Anakauthor=D.+B.+Sellamiauthor=L.-T.+Chen&title=Effect+of+everolimus+on+survival+in+advanced+hepatocellular+carcinoma+after+failure+of+sorafenib%3A+the+evolve-1+randomized+clinical+trial&doi=10.1001%2Fjama.2014.7189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial</span></div><div class="casAuthors">Zhu, Andrew X.; Kudo, Masatoshi; Assenat, Eric; Cattan, Stephane; Kang, Yoon-Koo; Lim, Ho Yeong; Poon, Ronnie T. P.; Blanc, Jean-Frederic; Vogel, Arndt; Chen, Chao-Long; Dorval, Etienne; Peck-Radosavljevic, Markus; Santoro, Armando; Daniele, Bruno; Furuse, Junji; Jappe, Annette; Perraud, Kevin; Anak, Oezlem; Sellami, Dalila B.; Chen, Li-Tzong</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma.  To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed.  EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib.  Patients were enrolled from 17 countries between May 2010 and March 2012.  Randomization was stratified by region (Asia vs rest of world) and macrovascular invasion (present vs absent). interventions Everolimus, 7.5 mg/d, or matching placebo, both given in combination with best supportive care and continued until disease progression or intolerable toxicity.  Per the 2:1 randomization scheme, 362 patients were randomized to the everolimus group and 184 patients to the placebo group. main outcomes and measures The primary end point was overall survival.  Secondary end points included time to progression and the disease control rate (the percentage of patients with a best overall response of complete or partial response or stable disease).  No significant difference in overall survival was seen between treatment groups, with 303 deaths (83.7%) in the everolimus group and 151 deaths (82.1%) in the placebo group (hazard ratio [HR], 1.05; 95% CI, 0.86-1.27; P = .68; median overall survival, 7.6 mo with everolimus, 7.3 mo with placebo).  Median time to progression with everolimus and placebo was 3.0 mo and 2.6 mo, resp. (HR, 0.93; 95% CI, 0.75-1.15), and disease control rate was 56.1% and 45.1%, resp. (P = .01).  The most common grade 3/4 adverse events for everolimus vs placebo were anemia (7.8% vs 3.3%, resp.), asthenia (7.8% vs 5.5%, resp.), and decreased appetite (6.1% vs 0.5%, resp.).  No patients experienced hepatitis C viral flare.  Based on central lab. results, hepatitis B viral reactivation was experienced by 39 patients (29 everolimus, 10 placebo); all cases were asymptomatic, but 3 everolimus recipients discontinued therapy.  Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmxZyfMYR3M7Vg90H21EOLACvtfcHk0lgqOIBfz5NJrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ajsb3M&md5=0340dd764397b4a9c25638769d569e4c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.7189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.7189%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DKudo%26aufirst%3DM.%26aulast%3DAssenat%26aufirst%3DE.%26aulast%3DCattan%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DY.-K.%26aulast%3DLim%26aufirst%3DH.%2BY.%26aulast%3DPoon%26aufirst%3DR.%2BT.%2BP.%26aulast%3DBlanc%26aufirst%3DJ.-F.%26aulast%3DVogel%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DDorval%26aufirst%3DE.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DDaniele%26aufirst%3DB.%26aulast%3DFuruse%26aufirst%3DJ.%26aulast%3DJappe%26aufirst%3DA.%26aulast%3DPerraud%26aufirst%3DK.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DSellami%26aufirst%3DD.%2BB.%26aulast%3DChen%26aufirst%3DL.-T.%26atitle%3DEffect%2520of%2520everolimus%2520on%2520survival%2520in%2520advanced%2520hepatocellular%2520carcinoma%2520after%2520failure%2520of%2520sorafenib%253A%2520the%2520evolve-1%2520randomized%2520clinical%2520trial%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D312%26spage%3D57%26epage%3D67%26doi%3D10.1001%2Fjama.2014.7189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ler, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, C. H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khin, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salto-Tellez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iau, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooi, S. C.</span><span> </span><span class="NLM_article-title">HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a southeast asian population</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">2238</span><span class="NLM_x">â</span> <span class="NLM_lpage">2250</span><span class="refDoi">Â DOI: 10.3892/or.2015.4263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.3892%2For.2015.4263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=26352599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslertQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=2238-2250&author=S.+Y.+Lerauthor=C.+H.+W.+Leungauthor=L.+W.+Khinauthor=G.-D.+Luauthor=M.+Salto-Tellezauthor=M.+Hartmanauthor=P.+T.+C.+Iauauthor=C.+T.+Yapauthor=S.+C.+Hooi&title=HDAC1+and+HDAC2+independently+predict+mortality+in+hepatocellular+carcinoma+by+a+competing+risk+regression+model+in+a+southeast+asian+population&doi=10.3892%2For.2015.4263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population</span></div><div class="casAuthors">Ler, Ser Yeng; Leung, Carol Ho Wing; Khin, Lay Wai; Lu, Guo-Dong; Salto-Tellez, Manuel; Hartman, Mikael; Iau, Philip Tsau Choong; Yap, Celestial T.; Hooi, Shing Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2238-2250</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are enzymes involved in transcriptional repression.  We aimed to examine the significance of HDAC1 and HDAC2 gene expression in the prediction of recurrence and survival in 156 patients with hepatocellular carcinoma (HCC) among a South East Asian population who underwent curative surgical resection in Singapore.  We found that HDAC1 and HDAC2 were upregulated in the majority of HCC tissues.  The presence of HDAC1 in tumor tissues was correlated with poor tumor differentiation.  Notably, HDAC1 expression in adjacent non-tumor hepatic tissues was correlated with the presence of satellite nodules and multiple lesions, suggesting that HDAC1 upregulation within the field of HCC may contribute to tumor spread.  Using competing risk regression anal., we found that increased cancer-specific mortality was significantly assocd. with HDAC2 expression.  Mortality was also increased with high HDAC1 expression.  In the liver cancer cell lines, HEP3B, HEPG2, PLC5, and a colorectal cancer cell line, HCT116, the combined knockdown of HDAC1 and HDAC2 increased cell death and reduced cell proliferation as well as colony formation.  In contrast, knockdown of either HDAC1 or HDAC2 alone had minimal effects on cell death and proliferation.  Taken together, our study suggests that both HDAC1 and HDAC2 exert pro-survival effects in HCC cells, and the combination of isoform-specific HDAC inhibitors against both HDACs may be effective in targeting HCC to reduce mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra_m8roQBnSLVg90H21EOLACvtfcHk0lg2L4-CesgJtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslertQ%253D%253D&md5=0bf5acf5c73654edf0b407175ce74d85</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3892%2For.2015.4263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.4263%26sid%3Dliteratum%253Aachs%26aulast%3DLer%26aufirst%3DS.%2BY.%26aulast%3DLeung%26aufirst%3DC.%2BH.%2BW.%26aulast%3DKhin%26aufirst%3DL.%2BW.%26aulast%3DLu%26aufirst%3DG.-D.%26aulast%3DSalto-Tellez%26aufirst%3DM.%26aulast%3DHartman%26aufirst%3DM.%26aulast%3DIau%26aufirst%3DP.%2BT.%2BC.%26aulast%3DYap%26aufirst%3DC.%2BT.%26aulast%3DHooi%26aufirst%3DS.%2BC.%26atitle%3DHDAC1%2520and%2520HDAC2%2520independently%2520predict%2520mortality%2520in%2520hepatocellular%2520carcinoma%2520by%2520a%2520competing%2520risk%2520regression%2520model%2520in%2520a%2520southeast%2520asian%2520population%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D34%26spage%3D2238%26epage%3D2250%26doi%3D10.3892%2For.2015.4263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wu, L.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S.-S.</span><span> </span><span class="NLM_article-title">Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e14460</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0014460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1371%2Fjournal.pone.0014460" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e14460&author=L.-M.+Wuauthor=Z.+Yangauthor=L.+Zhouauthor=F.+Zhangauthor=H.-Y.+Xieauthor=X.-W.+Fengauthor=J.+Wuauthor=S.-S.+Zheng&title=Identification+of+histone+deacetylase+3+as+a+biomarker+for+tumor+recurrence+following+liver+transplantation+in+HBV-associated+hepatocellular+carcinoma&doi=10.1371%2Fjournal.pone.0014460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0014460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0014460%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.-M.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DXie%26aufirst%3DH.-Y.%26aulast%3DFeng%26aufirst%3DX.-W.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.-S.%26atitle%3DIdentification%2520of%2520histone%2520deacetylase%25203%2520as%2520a%2520biomarker%2520for%2520tumor%2520recurrence%2520following%2520liver%2520transplantation%2520in%2520HBV-associated%2520hepatocellular%2520carcinoma%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De14460%26doi%3D10.1371%2Fjournal.pone.0014460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rikimaru, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taketomi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maehara, Y.</span><span> </span><span class="NLM_article-title">Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">â</span> <span class="NLM_lpage">74</span><span class="refDoi">Â DOI: 10.1159/000111106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1159%2F000111106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=18004079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyksL3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=69-74&author=T.+Rikimaruauthor=A.+Taketomiauthor=Y.+Yamashitaauthor=K.+Shirabeauthor=T.+Hamatsuauthor=M.+Shimadaauthor=Y.+Maehara&title=Clinical+significance+of+histone+deacetylase+1+expression+in+patients+with+hepatocellular+carcinoma&doi=10.1159%2F000111106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma</span></div><div class="casAuthors">Rikimaru, Tatsuya; Taketomi, Akinobu; Yamashita, Yo-ichi; Shirabe, Ken; Hamatsu, Takayuki; Shimada, Mitsuo; Maehara, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">ONCOBS</span>;
        ISSN:<span class="NLM_cas:issn">0030-2414</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play an important role in chromatin remodeling, gene repression and regulating cell cycle progression and differentiation.  This study was designed to clarify the role of HDAC1 expression in hepatocellular carcinoma (HCC).  The expression of HDAC1 in 47 patients with surgically resected HCC was immunohistochem. examd. and analyzed in relation to their clinicopathol. factors.  The patients were divided into 2 groups according to the expression status of HDAC1: a high HDAC1 group (n = 25) with more than 20% of pos. stained cells and a low HDAC1 group (n = 22) with 20% or fewer pos. stained cells.  A high HDAC1 expression indicated a higher incidence of cancer cell invasion into the portal vein, a poorer histol. differentiation, and a more advanced TNM stage.  The survival rates after a surgical resection in low and high HDAC1 patients at 1, 3, 5 and 10 years were 100, 95.5, 81.8 and 60.8% and 88.0, 60.0, 40.0 and 32.0%, resp. (p = 0.008).  A multivariate anal. using the Cox regression anal. showed that a high HDAC1 expression was an independent prognostic factor of HCC in patients after hepatic resection (relative risk: 10.1, p = 0.0018).  High HDAC1 expression might have an important role in the aggressiveness and cell dedifferentiation, and its expression status may be a useful biomarker for predicting the outcome of the patients with HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonHoUSPaFTvLVg90H21EOLACvtfcHk0lhpkiXmD_o3ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyksL3E&md5=f193014733ae61de5a3912679e95ce55</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000111106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000111106%26sid%3Dliteratum%253Aachs%26aulast%3DRikimaru%26aufirst%3DT.%26aulast%3DTaketomi%26aufirst%3DA.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DShirabe%26aufirst%3DK.%26aulast%3DHamatsu%26aufirst%3DT.%26aulast%3DShimada%26aufirst%3DM.%26aulast%3DMaehara%26aufirst%3DY.%26atitle%3DClinical%2520significance%2520of%2520histone%2520deacetylase%25201%2520expression%2520in%2520patients%2520with%2520hepatocellular%2520carcinoma%26jtitle%3DOncology%26date%3D2007%26volume%3D72%26spage%3D69%26epage%3D74%26doi%3D10.1159%2F000111106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Quint, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaimy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fazio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalbano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steindorf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellerbrand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neureiter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocker, M.</span><span> </span><span class="NLM_article-title">Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC</span> <span class="citation_source-journal">Virchows Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">459</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">â</span> <span class="NLM_lpage">139</span><span class="refDoi">Â DOI: 10.1007/s00428-011-1103-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1007%2Fs00428-011-1103-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=21713366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSiurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2011&pages=129-139&author=K.+Quintauthor=A.+Agaimyauthor=P.+Di+Fazioauthor=R.+Montalbanoauthor=C.+Steindorfauthor=R.+Jungauthor=C.+Hellerbrandauthor=A.+Hartmannauthor=H.+Sitterauthor=D.+Neureiterauthor=M.+Ocker&title=Clinical+significance+of+histone+deacetylases+1%2C+2%2C+3%2C+and+7%3A+HDAC2+is+an+independent+predictor+of+survival+in+HCC&doi=10.1007%2Fs00428-011-1103-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC</span></div><div class="casAuthors">Quint, Karl; Agaimy, Abbas; Fazio, Pietro; Montalbano, Roberta; Steindorf, Claudia; Jung, Rudolf; Hellerbrand, Claus; Hartmann, Arndt; Sitter, Helmut; Neureiter, Daniel; Ocker, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-139</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylases (HDAC) are responsible for the transcriptional control of genes through chromatin remodeling and control tumor suppressor genes.  In several tumors, their expression has been linked to clinicopathol. factors and patient survival.  This study investigates HDACs 1, 2, 3, and 7 expressions in hepatocellular carcinoma (HCC) and their correlation with clin. data and patient survival.  Tissue microarrays of 170 surgically resected primary HCCs and adjacent uninvolved tissue were evaluated immunohistochem. for the expression of HDACs 1, 2, 3, 7, and Ki-67 and were analyzed with respect to clinicopathol. data and patient survival.  HDACs 1, 2, 3, and Ki-67 were expressed significantly higher in cancer cells compared to normal tissue (HDAC1: p = 0.034, HDACs 2 and 3 and Ki-67: p < 0.001), while HDAC7 expression did not differ between HCC and non-cancerous liver tissue.  In tumor tissue HDACs 1-3 expression levels showed high concordance with each other, Ki-67 and tumor grade (p < 0.001).  High HDAC2 expression was assocd. with poor survival in low-grade and early-stage tumors (p < 0.05).  The expression of the HDACs 1, 2, and 3 (but not HDAC7) isoenzymes correlates with clinicopathol. factors, and HDAC2 expression has an impact on patient survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmO0NcXY0PrVg90H21EOLACvtfcHk0lhpkiXmD_o3ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSiurrL&md5=d30de32f518c9dc7a48e20e69e237ff4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00428-011-1103-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00428-011-1103-0%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%26aufirst%3DK.%26aulast%3DAgaimy%26aufirst%3DA.%26aulast%3DDi%2BFazio%26aufirst%3DP.%26aulast%3DMontalbano%26aufirst%3DR.%26aulast%3DSteindorf%26aufirst%3DC.%26aulast%3DJung%26aufirst%3DR.%26aulast%3DHellerbrand%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DSitter%26aufirst%3DH.%26aulast%3DNeureiter%26aufirst%3DD.%26aulast%3DOcker%26aufirst%3DM.%26atitle%3DClinical%2520significance%2520of%2520histone%2520deacetylases%25201%252C%25202%252C%25203%252C%2520and%25207%253A%2520HDAC2%2520is%2520an%2520independent%2520predictor%2520of%2520survival%2520in%2520HCC%26jtitle%3DVirchows%2520Arch.%26date%3D2011%26volume%3D459%26spage%3D129%26epage%3D139%26doi%3D10.1007%2Fs00428-011-1103-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Zhai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.-Y.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma</span> <span class="citation_source-journal">World J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">â</span> <span class="NLM_lpage">352</span><span class="refDoi">Â DOI: 10.4254/wjh.v5.i7.345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.4254%2Fwjh.v5.i7.345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23898367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A280%3ADC%252BC3sfltFCgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=345-352&author=B.+Zhaiauthor=X.-Y.+Sun&title=Mechanisms+of+resistance+to+sorafenib+and+the+corresponding+strategies+in+hepatocellular+carcinoma&doi=10.4254%2Fwjh.v5.i7.345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma</span></div><div class="casAuthors">Zhai Bo; Sun Xue-Ying</div><div class="citationInfo"><span class="NLM_cas:title">World journal of hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">345-52</span>
        ISSN:<span class="NLM_cas:issn">1948-5182</span>.
    </div><div class="casAbstract">Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching for effective agents to combat HCC for decades.  However, the overall outcomes are far from satisfactory.  One of the explanations is the genetic heterogeneity of HCC, which has led to identifying predictive biomarkers for primary resistance to sorafenib, and then applying the concept of personalized medicine, or seeking therapeutic strategies such as combining sorafenib with other anticancer agents.  Some of the combinations have demonstrated a better effectiveness than sorafenib alone, with good tolerance.  The acquired resistance to sorafenib has also drawn attention.  As a multikinase inhibitor, sorafenib targets several cellular signaling pathways but simultaneously or sequentially the addiction switches and compensatory pathways are activated.  Several mechanisms are involved in the acquired resistance to sorafenib, such as crosstalks involving PI3K/Akt and JAK-STAT pathways, hypoxia-inducible pathways, epithelial-mesenchymal transition, etc.  Based on the investigated mechanisms, some other molecular targeted drugs have been applied as second-line treatment for treat HCC after the failure of sorafenib therapy and more are under evaluation in clinical trials.  However, the exact mechanisms accounting for sorafenib resistance remains unclear.  Further investigation on the crosstalk and relationship of associated pathways will better our understanding of the mechanisms and help to find effective strategies for overcoming sorafenib resistance in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFVzS9begP0vxQvRxYU81tfW6udTcc2eYHbBN2m-ZVhbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfltFCgtQ%253D%253D&md5=2b9607c538718a8f513d310eb9f7c773</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4254%2Fwjh.v5.i7.345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4254%252Fwjh.v5.i7.345%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DX.-Y.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520sorafenib%2520and%2520the%2520corresponding%2520strategies%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DWorld%2520J.%2520Hepatol.%26date%3D2013%26volume%3D5%26spage%3D345%26epage%3D352%26doi%3D10.4254%2Fwjh.v5.i7.345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Janku, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaseb, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsimberidou, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3012</span><span class="NLM_x">â</span> <span class="NLM_lpage">3022</span><span class="refDoi">Â DOI: 10.18632/oncotarget.1687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.18632%2Foncotarget.1687" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3012-3022&author=F.+Jankuauthor=A.+O.+Kasebauthor=A.+M.+Tsimberidouauthor=R.+A.+Wolffauthor=R.+Kurzrock&title=Identification+of+novel+therapeutic+targets+in+the+PI3K%2FAKT%2FmTOR+pathway+in+hepatocellular+carcinoma+using+targeted+next+generation+sequencing&doi=10.18632%2Foncotarget.1687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1687%26sid%3Dliteratum%253Aachs%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DKaseb%26aufirst%3DA.%2BO.%26aulast%3DTsimberidou%26aufirst%3DA.%2BM.%26aulast%3DWolff%26aufirst%3DR.%2BA.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520novel%2520therapeutic%2520targets%2520in%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520in%2520hepatocellular%2520carcinoma%2520using%2520targeted%2520next%2520generation%2520sequencing%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D3012%26epage%3D3022%26doi%3D10.18632%2Foncotarget.1687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cigliano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calderaro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azoulay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demartis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribback, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utpatel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombrowski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvisi, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">10102</span><span class="NLM_x">â</span> <span class="NLM_lpage">10115</span><span class="refDoi">Â DOI: 10.18632/oncotarget.3546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.18632%2Foncotarget.3546" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10102-10115&author=X.+Liauthor=J.+Taoauthor=A.+Ciglianoauthor=M.+Siniauthor=J.+Calderaroauthor=D.+Azoulayauthor=C.+Wangauthor=Y.+Liuauthor=L.+Jiangauthor=K.+Evertauthor=M.+I.+Demartisauthor=S.+Ribbackauthor=K.+Utpatelauthor=F.+Dombrowskiauthor=M.+Evertauthor=D.+F.+Calvisiauthor=X.+Chen&title=Co-activation+of+PIK3CA+and+Yap+promotes+development+of+hepatocellular+and+cholangiocellular+tumors+in+mouse+and+human+liver&doi=10.18632%2Foncotarget.3546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3546%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DCigliano%26aufirst%3DA.%26aulast%3DSini%26aufirst%3DM.%26aulast%3DCalderaro%26aufirst%3DJ.%26aulast%3DAzoulay%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DEvert%26aufirst%3DK.%26aulast%3DDemartis%26aufirst%3DM.%2BI.%26aulast%3DRibback%26aufirst%3DS.%26aulast%3DUtpatel%26aufirst%3DK.%26aulast%3DDombrowski%26aufirst%3DF.%26aulast%3DEvert%26aufirst%3DM.%26aulast%3DCalvisi%26aufirst%3DD.%2BF.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DCo-activation%2520of%2520PIK3CA%2520and%2520Yap%2520promotes%2520development%2520of%2520hepatocellular%2520and%2520cholangiocellular%2520tumors%2520in%2520mouse%2520and%2520human%2520liver%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D10102%26epage%3D10115%26doi%3D10.18632%2Foncotarget.3546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Chen, K.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.-L.</span><span> </span><span class="NLM_article-title">Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">161</span><span class="refDoi">Â DOI: 10.1124/jpet.110.175786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1124%2Fjpet.110.175786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=21205925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGqurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=155-161&author=K.-F.+Chenauthor=H.-L.+Chenauthor=W.-T.+Taiauthor=W.-C.+Fengauthor=C.-H.+Hsuauthor=P.-J.+Chenauthor=A.-L.+Cheng&title=Activation+of+phosphatidylinositol+3-kinase%2FAkt+signaling+pathway+mediates+acquired+resistance+to+sorafenib+in+hepatocellular+carcinoma+cells&doi=10.1124%2Fjpet.110.175786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells</span></div><div class="casAuthors">Chen, Kuen-Feng; Chen, Hui-Ling; Tai, Wei-Tien; Feng, Wen-Chi; Hsu, Chih-Hung; Chen, Pei-Jer; Cheng, Ann-Lii</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-161</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human malignancies worldwide.  Sorafenib, a tyrosine kinase inhibitor, was recently approved by the United States Food and Drug Administration for HCC.  In this study, the authors established two sorafenib-resistant HCC cell lines from Huh7, a human HCC cell line, by long-term exposure of cells to sorafenib.  Sorafenib induced significant apoptosis in Huh7 cells; however, Huh7-R1 and Huh7-R2 showed significant resistance to sorafenib-induced apoptosis at the clin. relevant concns. (up to 10 Î¼M).  Thorough comparisons of the mol. changes between Huh7 and resistant cells showed that the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway played a significant role in mediating acquired resistance to sorafenib in Huh7-R1 and Huh7-R2 cells.  Phospho-Akt and p85 (a regulatory subunit of PI3K) were up-regulated, whereas tumor suppressor phosphatase and tensin homolog were down-regulated in these resistant cells.  In addn., ectopic expression of constitutive Akt in Huh7 demonstrated similar resistance to sorafenib.  The knockdown of Akt by RNA interference reversed resistance to sorafenib in Huh7-R1 cells, indicating the importance of Akt in drug sensitivity.  Furthermore, the combination of 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride (MK-2206), a novel allosteric Akt inhibitor, and sorafenib restored the sensitivity of resistant cells to sorafenib-induced apoptosis.  In conclusion, activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in HCC, and the combination of sorafenib and MK-2206, an Akt inhibitor, overcomes the resistance at clin. achievable concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBd1_2ZA7uLVg90H21EOLACvtfcHk0lioSrNiNDczEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGqurs%253D&md5=3132363a96b8d3c3bb10a4f97ff879cd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.175786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.175786%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.-F.%26aulast%3DChen%26aufirst%3DH.-L.%26aulast%3DTai%26aufirst%3DW.-T.%26aulast%3DFeng%26aufirst%3DW.-C.%26aulast%3DHsu%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DP.-J.%26aulast%3DCheng%26aufirst%3DA.-L.%26atitle%3DActivation%2520of%2520phosphatidylinositol%25203-kinase%252FAkt%2520signaling%2520pathway%2520mediates%2520acquired%2520resistance%2520to%2520sorafenib%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D155%26epage%3D161%26doi%3D10.1124%2Fjpet.110.175786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Bitzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganten, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">WÃ¶rns, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siveke, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollinger, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wege, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagonel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cillo, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevisani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montesarchio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzapfel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ammendola, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegoraro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauns, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henning, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentsch, B.</span><span> </span><span class="NLM_article-title">Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma â The SHELTER study</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span><span class="refDoi">Â DOI: 10.1016/j.jhep.2016.02.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jhep.2016.02.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=26952006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCks74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=280-288&author=M.+Bitzerauthor=M.+Horgerauthor=E.+G.+Gianniniauthor=T.+M.+Gantenauthor=M.+A.+W%C3%B6rnsauthor=J.+T.+Sivekeauthor=M.+M.+Dollingerauthor=G.+Gerkenauthor=M.+E.+Scheulenauthor=H.+Wegeauthor=V.+Zagonelauthor=U.+Cilloauthor=F.+Trevisaniauthor=A.+Santoroauthor=V.+Montesarchioauthor=N.+P.+Malekauthor=J.+Holzapfelauthor=T.+Herzauthor=A.+S.+Ammendolaauthor=S.+Pegoraroauthor=B.+Haunsauthor=A.+Maisauthor=U.+M.+Lauerauthor=S.+W.+Henningauthor=B.+Hentsch&title=Resminostat+plus+sorafenib+as+second-line+therapy+of+advanced+hepatocellular+carcinoma+%E2%80%93+The+SHELTER+study&doi=10.1016%2Fj.jhep.2016.02.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study</span></div><div class="casAuthors">Bitzer, Michael; Horger, Marius; Giannini, Edoardo G.; Ganten, Tom M.; Woerns, Marcus A.; Siveke, Jens T.; Dollinger, Matthias M.; Gerken, Guido; Scheulen, Max E.; Wege, Henning; Zagonel, Vittorina; Cillo, Umberto; Trevisani, Franco; Santoro, Armando; Montesarchio, Vincenzo; Malek, Nisar P.; Holzapfel, Julia; Herz, Thomas; Ammendola, Astrid S.; Pegoraro, Stefano; Hauns, Bernhard; Mais, Anna; Lauer, Ulrich M.; Henning, Stefan W.; Hentsch, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-288</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist.  This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the histone deacetylase inhibitor resminostat and a combination therapy with resminostat and sorafenib.  Patients with HCC and radiol. confirmed progression on sorafenib were treated in an exploratory, multi-center, open-label, uncontrolled, non-randomized, parallel group phase I/II study.  In the combination group (n = 38) four dose levels ranged from daily 200 to 600 mg resminostat plus 400 to 800 mg sorafenib.  The monotherapy group (n = 19) received 600 mg resminostat.57 patients received treatment.  Most common adverse events were gastrointestinal disorders, thrombocytopenia and fatigue.  Median maximal histone deacetylase inhibition and highest increase in H4-acetylation matched Tmax of resminostat.  Sorafenib or the Child-Pugh score did not affect typical pharmacokinetics characteristics of resminostat.  Efficacy assessment as progression-free survival-rate after 6 treatment cycles (12 wk, primary endpoint) was 12.5% for resminostat and 62.5% for resminostat plus sorafenib.  Median time to progression and overall survival were 1.8 and 4.1 mo for resminostat and 6.5 and 8.0 mo for the combination, resp.  Zinc finger protein 64 (ZFP64) baseline expression in blood cells was found to correlate with overall survival.The combination of sorafenib and resminostat in HCC patients was safe and showed early signs of efficacy.  Sorafenib did not alter the pharmacokinetic profile of resminostat or its histone deacetylase inhibitory activity in vivo.  A prognostic and potentially predictive role of ZFP64 for treatment with resminostat should be further investigated in HCC and possibly other cancer indications.  No established therapy for patients with advanced hepatocellular carcinoma and progression under first-line systemic treatment with sorafenib currently exists.  Epigenetic modulation by inhibition of histone deacetylases might be able to overcome therapy resistance.  This exploratory phase I/II clin. study in patients with radiol. confirmed progression under first-line treatment with sorafenib investigated the histone deacetylases inhibitor resminostat as single agent or in combination with continued application of sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvt1-ys6LWrVg90H21EOLACvtfcHk0lioSrNiNDczEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCks74%253D&md5=a13179d1bb5160e0bd06d2e9fe719313</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.02.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.02.043%26sid%3Dliteratum%253Aachs%26aulast%3DBitzer%26aufirst%3DM.%26aulast%3DHorger%26aufirst%3DM.%26aulast%3DGiannini%26aufirst%3DE.%2BG.%26aulast%3DGanten%26aufirst%3DT.%2BM.%26aulast%3DW%25C3%25B6rns%26aufirst%3DM.%2BA.%26aulast%3DSiveke%26aufirst%3DJ.%2BT.%26aulast%3DDollinger%26aufirst%3DM.%2BM.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DWege%26aufirst%3DH.%26aulast%3DZagonel%26aufirst%3DV.%26aulast%3DCillo%26aufirst%3DU.%26aulast%3DTrevisani%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DMontesarchio%26aufirst%3DV.%26aulast%3DMalek%26aufirst%3DN.%2BP.%26aulast%3DHolzapfel%26aufirst%3DJ.%26aulast%3DHerz%26aufirst%3DT.%26aulast%3DAmmendola%26aufirst%3DA.%2BS.%26aulast%3DPegoraro%26aufirst%3DS.%26aulast%3DHauns%26aufirst%3DB.%26aulast%3DMais%26aufirst%3DA.%26aulast%3DLauer%26aufirst%3DU.%2BM.%26aulast%3DHenning%26aufirst%3DS.%2BW.%26aulast%3DHentsch%26aufirst%3DB.%26atitle%3DResminostat%2520plus%2520sorafenib%2520as%2520second-line%2520therapy%2520of%2520advanced%2520hepatocellular%2520carcinoma%2520%25E2%2580%2593%2520The%2520SHELTER%2520study%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D280%26epage%3D288%26doi%3D10.1016%2Fj.jhep.2016.02.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lu, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulp, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-S.</span><span> </span><span class="NLM_article-title">Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">â</span> <span class="NLM_lpage">1130</span><span class="refDoi">Â DOI: 10.1002/hep.21804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fhep.21804" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=1119-1130&author=Y.-S.+Luauthor=Y.+Kashidaauthor=S.+K.+Kulpauthor=Y.-C.+Wangauthor=D.+Wangauthor=J.-H.+Hungauthor=M.+Tangauthor=Z.-Z.+Linauthor=T.-J.+Chenauthor=A.-L.+Chengauthor=C.-S.+Chen&title=Efficacy+of+a+novel+histone+deacetylase+inhibitor+in+murine+models+of+hepatocellular+carcinoma&doi=10.1002%2Fhep.21804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fhep.21804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21804%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.-S.%26aulast%3DKashida%26aufirst%3DY.%26aulast%3DKulp%26aufirst%3DS.%2BK.%26aulast%3DWang%26aufirst%3DY.-C.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHung%26aufirst%3DJ.-H.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.-Z.%26aulast%3DChen%26aufirst%3DT.-J.%26aulast%3DCheng%26aufirst%3DA.-L.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%2520in%2520murine%2520models%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DHepatology%26date%3D2007%26volume%3D46%26spage%3D1119%26epage%3D1130%26doi%3D10.1002%2Fhep.21804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Lachenmayer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toffanin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabellos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsinet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoshida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minguez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, H.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thung, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llovet, J. M.</span><span> </span><span class="NLM_article-title">Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1343</span><span class="NLM_x">â</span> <span class="NLM_lpage">1350</span><span class="refDoi">Â DOI: 10.1016/j.jhep.2012.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jhep.2012.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22322234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1343-1350&author=A.+Lachenmayerauthor=S.+Toffaninauthor=L.+Cabellosauthor=C.+Alsinetauthor=Y.+Hoshidaauthor=A.+Villanuevaauthor=B.+Minguezauthor=H.-W.+Tsaiauthor=S.+C.+Wardauthor=S.+Thungauthor=S.+L.+Friedmanauthor=J.+M.+Llovet&title=Combination+therapy+for+hepatocellular+carcinoma%3A+additive+preclinical+efficacy+of+the+HDAC+inhibitor+panobinostat+with+sorafenib&doi=10.1016%2Fj.jhep.2012.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span></div><div class="casAuthors">Lachenmayer, Anja; Toffanin, Sara; Cabellos, Laia; Alsinet, Clara; Hoshida, Yujin; Villanueva, Augusto; Minguez, Beatriz; Tsai, Hung-Wen; Ward, Stephen C.; Thung, Swan; Friedman, Scott L.; Llovet, Josep M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1343-1350</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy.  Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown.  We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclin. models of liver cancer.  Methods: Gene expression and copy no. changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model.  Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, resp.  Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy no. gains.  Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addn. of sorafenib.  Cell viability and proliferation declined, while apoptosis and autophagy increased.  Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1.  Combination therapy with panobinostat and sorafenib significantly decreased vessel d., and most significantly decreased tumor vol. and increased survival in HCC xenografts.  Conclusions: Aberrant expression of several HDACs and copy no. gains of HDAC3 and HDAC5 occur in HCC.  Treatment with panobinostat combined with sorafenib demonstrated the highest preclin. efficacy in HCC models, providing the rationale for clin. studies with this novel combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZoC3lwqUXBrVg90H21EOLACvtfcHk0li5jhqxt2v7ug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D&md5=ac47fb06e16c2b7ec1f4c868a983b752</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DLachenmayer%26aufirst%3DA.%26aulast%3DToffanin%26aufirst%3DS.%26aulast%3DCabellos%26aufirst%3DL.%26aulast%3DAlsinet%26aufirst%3DC.%26aulast%3DHoshida%26aufirst%3DY.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DMinguez%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DH.-W.%26aulast%3DWard%26aufirst%3DS.%2BC.%26aulast%3DThung%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DCombination%2520therapy%2520for%2520hepatocellular%2520carcinoma%253A%2520additive%2520preclinical%2520efficacy%2520of%2520the%2520HDAC%2520inhibitor%2520panobinostat%2520with%2520sorafenib%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D1343%26epage%3D1350%26doi%3D10.1016%2Fj.jhep.2012.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Yeo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, F. K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rha, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeung, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roh, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, J. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span> </span><span class="NLM_article-title">Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3361</span><span class="NLM_x">â</span> <span class="NLM_lpage">3367</span><span class="refDoi">Â DOI: 10.1200/JCO.2011.41.2395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1200%2FJCO.2011.41.2395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22915658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3361-3367&author=W.+Yeoauthor=H.+C.+Chungauthor=S.+L.+Chanauthor=L.+Z.+Wangauthor=R.+Limauthor=J.+Picusauthor=M.+Boyerauthor=F.+K.+F.+Moauthor=J.+Kohauthor=S.+Y.+Rhaauthor=E.+P.+Huiauthor=H.+C.+Jeungauthor=J.+K.+Rohauthor=S.+C.+H.+Yuauthor=K.+F.+Toauthor=Q.+Taoauthor=B.+B.+Maauthor=A.+W.+H.+Chanauthor=J.+H.+M.+Tongauthor=C.+Erlichmanauthor=A.+T.+C.+Chanauthor=B.+C.+Goh&title=Epigenetic+therapy+using+belinostat+for+patients+with+unresectable+hepatocellular+carcinoma%3A+a+multicenter+phase+I%2FII+study+with+biomarker+and+pharmacokinetic+analysis+of+tumors+from+patients+in+the+Mayo+phase+II+consortium+and+the+cancer+therapeutics+research+group&doi=10.1200%2FJCO.2011.41.2395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group</span></div><div class="casAuthors">Yeo, Winnie; Chung, Hyun C.; Chan, Stephen L.; Wang, Ling Z.; Lim, Robert; Picus, Joel; Boyer, Michael; Mo, Frankie K. F.; Koh, Jane; Rha, Sun Y.; Hui, Edwin P.; Jeung, Hei C.; Roh, Jae K.; Yu, Simon C. H.; To, Ka F.; Tao, Qian; Ma, Brigette B.; Chan, Anthony W. H.; Tong, Joanna H. M.; Erlichman, Charles; Chan, Anthony T. C.; Goh, Boon C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3361-3367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC).  In this study of patients with unresectable HCC and chronic liver disease, epigenetic therapy with the histone deacetylase inhibitor belinostat was assessed.  The objectives were to det. dose-limiting toxicity and max.-tolerated dose (MTD), to assess pharmacokinetics in phase I, and to assess activity of and explore potential biomarkers for response in phase II.  Patients and Methods Major eligibility criteria included histol. confirmed unresectable HCC, European Cooperative Oncol. Group performance score â¤ 2, and adequate organ function.  Phase I consisted of 18 patients; belinostat was given i.v. once per day on days 1 to 5 every 3 wk; dose levels were 600 mg/m2 per day (level 1), 900 mg/m2 per day (level 2), 1,200 mg/m2 per day (level 3), and 1,400 mg/m2 per day (level 4).  Phase II consisted of 42 patients.  The primary end point was progression-free survival (PFS), and the main secondary end points were response according to Response Evaluation Criteria in Solid Tumors (RECIST) and overall survival (OS).  Exploratory anal. was conducted on pretreatment tumor tissues to det. whether HR23B expression is a potential biomarker for response.  Results Belinostat pharmacokinetics were linear from 600 to 1,400 mg/m2 without significant accumulation.  The MTD was not reached at the max. dose administered.  Dose level 4 was used in phase II.  The median no. of cycles was two (range, one to 12).  The partial response (PR) and stable disease (SD) rates were 2.4% and 45.2%, resp.  The median PFS and OS were 2.64 and 6.60 mo, resp.  Exploratory anal. revealed that disease stabilization rate (complete response plus PR plus SD) in tumors having high and low HR23B histoscores were 58% and 14%, resp. (P = .036).  Conclusion Epigenetic therapy with belinostat demonstrates tumor stabilization and is generally well-tolerated.  HR23B expression was assocd. with disease stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIbj7iAVEZ7Vg90H21EOLACvtfcHk0lgy2m-tvxv3Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7zP&md5=cb1c61e11c974343e82f47e5d909ba32</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.41.2395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.41.2395%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DW.%26aulast%3DChung%26aufirst%3DH.%2BC.%26aulast%3DChan%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DPicus%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMo%26aufirst%3DF.%2BK.%2BF.%26aulast%3DKoh%26aufirst%3DJ.%26aulast%3DRha%26aufirst%3DS.%2BY.%26aulast%3DHui%26aufirst%3DE.%2BP.%26aulast%3DJeung%26aufirst%3DH.%2BC.%26aulast%3DRoh%26aufirst%3DJ.%2BK.%26aulast%3DYu%26aufirst%3DS.%2BC.%2BH.%26aulast%3DTo%26aufirst%3DK.%2BF.%26aulast%3DTao%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DB.%2BB.%26aulast%3DChan%26aufirst%3DA.%2BW.%2BH.%26aulast%3DTong%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DA.%2BT.%2BC.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26atitle%3DEpigenetic%2520therapy%2520using%2520belinostat%2520for%2520patients%2520with%2520unresectable%2520hepatocellular%2520carcinoma%253A%2520a%2520multicenter%2520phase%2520I%252FII%2520study%2520with%2520biomarker%2520and%2520pharmacokinetic%2520analysis%2520of%2520tumors%2520from%2520patients%2520in%2520the%2520Mayo%2520phase%2520II%2520consortium%2520and%2520the%2520cancer%2520therapeutics%2520research%2520group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3361%26epage%3D3367%26doi%3D10.1200%2FJCO.2011.41.2395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VillaseÃ±or, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novikov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liclican, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagpacan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papalia, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase Î´</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">8439</span><span class="NLM_x">â</span> <span class="NLM_lpage">8446</span><span class="refDoi">Â DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villase%C3%B1orauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase Î´</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3KÎ´ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3KÎ´.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3KÎ´.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110Î´ subunit of PI3KÎ´ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0ljeE6HEA6-bVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Scott, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentemann, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullion, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fracasso, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefranc, J.</span><span> </span><span class="NLM_article-title">Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: identification of copanlisib (BAY 80â6946)</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">â</span> <span class="NLM_lpage">1530</span><span class="refDoi">Â DOI: 10.1002/cmdc.201600148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fcmdc.201600148" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1517-1530&author=W.+J.+Scottauthor=M.+F.+Hentemannauthor=R.+B.+Rowleyauthor=C.+O.+Bullauthor=S.+Jenkinsauthor=A.+M.+Bullionauthor=J.+Johnsonauthor=A.+Redmanauthor=A.+H.+Robbinsauthor=W.+Eslerauthor=R.+P.+Fracassoauthor=T.+Garrisonauthor=M.+Hamiltonauthor=M.+Michelsauthor=J.+E.+Woodauthor=D.+P.+Wilkieauthor=H.+Xiaoauthor=J.+Levyauthor=E.+Stasikauthor=N.+Liuauthor=M.+Schaeferauthor=M.+Brandsauthor=J.+Lefranc&title=Discovery+and+SAR+of+novel+2%2C3-dihydroimidazo%5B1%2C2-c%5Dquinazoline+PI3K+Inhibitors%3A+identification+of+copanlisib+%28BAY+80%E2%80%936946%29&doi=10.1002%2Fcmdc.201600148"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600148%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DW.%2BJ.%26aulast%3DHentemann%26aufirst%3DM.%2BF.%26aulast%3DRowley%26aufirst%3DR.%2BB.%26aulast%3DBull%26aufirst%3DC.%2BO.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DBullion%26aufirst%3DA.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DRedman%26aufirst%3DA.%26aulast%3DRobbins%26aufirst%3DA.%2BH.%26aulast%3DEsler%26aufirst%3DW.%26aulast%3DFracasso%26aufirst%3DR.%2BP.%26aulast%3DGarrison%26aufirst%3DT.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%2BE.%26aulast%3DWilkie%26aufirst%3DD.%2BP.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLevy%26aufirst%3DJ.%26aulast%3DStasik%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DLefranc%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520novel%25202%252C3-dihydroimidazo%255B1%252C2-c%255Dquinazoline%2520PI3K%2520Inhibitors%253A%2520identification%2520of%2520copanlisib%2520%2528BAY%252080%25E2%2580%25936946%2529%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1517%26epage%3D1530%26doi%3D10.1002%2Fcmdc.201600148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hylander, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span> </span><span class="NLM_article-title">Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">â</span> <span class="NLM_lpage">183</span><span class="refDoi">Â DOI: 10.1016/j.jhep.2011.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jhep.2011.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=21835141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=176-183&author=H.+Shaoauthor=C.+Gaoauthor=H.+Tangauthor=H.+Zhangauthor=L.+R.+Robertsauthor=B.+L.+Hylanderauthor=E.+A.+Repaskyauthor=W.+W.+Maauthor=J.+Qiuauthor=A.+A.+Adjeiauthor=G.+K.+Dyauthor=C.+Yu&title=Dual+targeting+of+mTORC1%2FC2+complexes+enhances+histone+deacetylase+inhibitor-mediated+anti-tumor+efficacy+in+primary+HCC+cancer+in+vitro+and+in+vivo&doi=10.1016%2Fj.jhep.2011.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo</span></div><div class="casAuthors">Shao, Huanjie; Gao, Chun; Tang, Haikuo; Zhang, Hao; Roberts, Lewis R.; Hylander, Bonnie L.; Repasky, Elizabeth A.; Ma, Wen W.; Qiu, Jingxin; Adjei, Alex A.; Dy, Grace K.; Yu, Chunrong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-183</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: The mammalian target of rapamycin (mTOR) plays a pivotal role in hepatocellular carcinoma (HCC).  Previous studies indicated that inhibition of mTORC1 enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity, accompanied with feedback activation of AKT.  Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC.  Methods: The interactions between mTOR kinase inhibitors (mTORKis) (i.e., Pp242, AZD8055, OSI027) and HDACis (i.e., SAHA, LBH589) were examd. in vitro using HCC cell lines and in vivo using patient-derived primary HCC xenografts on SCID mice.  Results: mTORKis significantly enhanced HDACi-induced apoptosis in HCC cells.  The inhibition of both mTORC1/2 not only efficiently blocked mTORC1 signaling, but also abrogated AKT-feedback activation caused by selective mTORC1 inhibition.  The co-treatment of mTORKi and HDACi further inhibited AKT signaling and upregulated Bim.  Dysfunction of mTORC2 by shRNA significantly lowered the threshold of HDACi-induced cytotoxicity by abrogating AKT activation.  Knockdown of AKT1 sensitized Pp242/HDACi-induced apoptosis and ectopic expression of constitutively active AKT1 abrogated the combination-induced cytotoxicity, indicating AKT plays a vital role in the combination-induced effects.  Knockdown of Bim prevented Pp242/HDACis-induced cytotoxicity in HCC.  Lastly, in vivo studies indicated that the combination of AZD8055 and SAHA almost completely inhibited tumor-growth, without obvious adverse effects, by abrogating AKT and upregulating Bim; while either agent alone shows only 30% inhibition in primary HCC xenografts.  Conclusions: Our findings suggest that a combining-regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU2jGHiPLHLbVg90H21EOLACvtfcHk0ljeE6HEA6-bVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbjO&md5=8d80f8e1711ce999fd586487a41aae4d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DHylander%26aufirst%3DB.%2BL.%26aulast%3DRepasky%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DYu%26aufirst%3DC.%26atitle%3DDual%2520targeting%2520of%2520mTORC1%252FC2%2520complexes%2520enhances%2520histone%2520deacetylase%2520inhibitor-mediated%2520anti-tumor%2520efficacy%2520in%2520primary%2520HCC%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D176%26epage%3D183%26doi%3D10.1016%2Fj.jhep.2011.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gedaly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hundley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daily, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, B. M.</span><span> </span><span class="NLM_article-title">PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">â</span> <span class="NLM_lpage">548</span><span class="refDoi">Â DOI: 10.1016/j.jss.2011.10.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jss.2011.10.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22261591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2iurjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2012&pages=542-548&author=R.+Gedalyauthor=P.+Anguloauthor=J.+Hundleyauthor=M.+F.+Dailyauthor=C.+Chenauthor=B.+M.+Evers&title=PKI-587+and+sorafenib+targeting+PI3K%2FAKT%2FmTOR+and+Ras%2FRaf%2FMAPK+pathways+synergistically+inhibit+HCC+cell+proliferation&doi=10.1016%2Fj.jss.2011.10.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation</span></div><div class="casAuthors">Gedaly, Roberto; Angulo, Paul; Hundley, Jonathan; Daily, Michael F.; Chen, Changguo; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-548</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Deregulated Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC).  This study aimed to test the inhibitory effects of PKI-587 and sorafenib as single agents or in combination on HCC (Huh7 cell line) proliferation.3H-thymidine incorporation and MTT assay were used to assess Huh7 cell proliferation.  Phosphorylation of the key enzymes in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways was detected by Western blot.  We found that PKI-587 is a more potent PI3K/mTOR inhibitor than PI-103.  Combination of PKI-587 and sorafenib was a more effective inhibitor of Huh7 proliferation than the combination of PI-103 and sorafenib.  Combination of PKI-587 and sorafenib synergistically inhibited epidermal growth factor (EGF)-stimulated Huh7 proliferation compared with monodrug therapy.  EGF increased phosphorylation of Ras/Raf downstream signaling proteins MEK and ERK; EGF-stimulated activation was inhibited by sorafenib.  However, sorafenib, as a single agent, increased AKT (Ser473) phosphorylation.  EGF-stimulated AKT (ser473) activation was inhibited by PKI-587.  PKI-587 is a potent inhibitor of AKT (Ser473), mTOR (Ser2448), and S6K (Thr389) phosphorylation; in contrast, rapamycin stimulated mTOR complex 2 substrate AKT(Ser473) phosphorylation although it inhibited mTOR complex 1 substrate S6K phosphorylation.  PKI-587, as a single agent, stimulated MEK and ERK phosphorylation.  However, when PKI-587 and sorafenib were used in combination, they inhibited all the tested kinases in the Ras/Raf /MAPK and PI3K/AKT/mTOR pathways.  The combination of PKI-587 and sorafenib has the advantage over monodrug therapy on inhibition of HCC cell proliferation by blocking both PI3K/AKT/mTOR and Ras/Raf/MAPK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoks4j17-7Nk7Vg90H21EOLACvtfcHk0lgspaGxJqr3Yw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2iurjM&md5=0b3a2d1cb5b7f07c56c357fbd9e61952</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jss.2011.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jss.2011.10.045%26sid%3Dliteratum%253Aachs%26aulast%3DGedaly%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DP.%26aulast%3DHundley%26aufirst%3DJ.%26aulast%3DDaily%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DPKI-587%2520and%2520sorafenib%2520targeting%2520PI3K%252FAKT%252FmTOR%2520and%2520Ras%252FRaf%252FMAPK%2520pathways%2520synergistically%2520inhibit%2520HCC%2520cell%2520proliferation%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2012%26volume%3D176%26spage%3D542%26epage%3D548%26doi%3D10.1016%2Fj.jss.2011.10.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lye, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">StÃ¼nkel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entzeroth, M.</span><span> </span><span class="NLM_article-title">N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">â</span> <span class="NLM_lpage">1408</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.bmcl.2009.01.041" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1403-1408&author=H.+Wangauthor=N.+Yuauthor=H.+Songauthor=D.+Chenauthor=Y.+Zouauthor=W.+Dengauthor=P.+L.+Lyeauthor=J.+Changauthor=M.+Ngauthor=S.+Blanchardauthor=E.+T.+Sunauthor=K.+Sangthongpitagauthor=X.+Wangauthor=K.+C.+Gohauthor=X.+Wuauthor=H.+H.+Khngauthor=L.+Fangauthor=S.+K.+Gohauthor=W.+C.+Ongauthor=Z.+Bondayauthor=W.+St%C3%BCnkelauthor=A.+Poulsenauthor=M.+Entzeroth&title=N-Hydroxy-1%2C2-disubstituted-1H-benzimidazol-5-yl+acrylamides+as+novel+histone+deacetylase+inhibitors%3A+design%2C+synthesis%2C+SAR+studies%2C+and+in+vivo+antitumor+activity&doi=10.1016%2Fj.bmcl.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DSt%25C3%25BCnkel%26aufirst%3DW.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DEntzeroth%26aufirst%3DM.%26atitle%3DN-Hydroxy-1%252C2-disubstituted-1H-benzimidazol-5-yl%2520acrylamides%2520as%2520novel%2520histone%2520deacetylase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520SAR%2520studies%252C%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1403%26epage%3D1408%26doi%3D10.1016%2Fj.bmcl.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, Z.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span> </span><span class="NLM_article-title">Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: synthesis, SAR, and in vivo antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">â</span> <span class="NLM_lpage">3321</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.bmcl.2010.04.041" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3314-3321&author=H.+Wangauthor=Z.-Y.+Limauthor=Y.+Zhouauthor=M.+Ngauthor=T.+Luauthor=K.+Leeauthor=K.+Sangthongpitagauthor=K.+C.+Gohauthor=X.+Wangauthor=X.+Wuauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=W.+C.+Ongauthor=Z.+Bondayauthor=E.+T.+Sun&title=Acylurea+connected+straight+chain+hydroxamates+as+novel+histone+deacetylase+inhibitors%3A+synthesis%2C+SAR%2C+and+in+vivo+antitumor+activity&doi=10.1016%2Fj.bmcl.2010.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLim%26aufirst%3DZ.-Y.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DAcylurea%2520connected%2520straight%2520chain%2520hydroxamates%2520as%2520novel%2520histone%2520deacetylase%2520inhibitors%253A%2520synthesis%252C%2520SAR%252C%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3314%26epage%3D3321%26doi%3D10.1016%2Fj.bmcl.2010.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lye, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span> </span><span class="NLM_article-title">Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4694</span><span class="NLM_x">â</span> <span class="NLM_lpage">4720</span><span class="refDoi">Â DOI: 10.1021/jm2003552</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003552" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4694-4720&author=H.+Wangauthor=N.+Yuauthor=D.+Chenauthor=K.+C.+L.+Leeauthor=P.+L.+Lyeauthor=J.+W.+W.+Changauthor=W.+Dengauthor=M.+C.+Y.+Ngauthor=T.+Luauthor=M.+L.+Khooauthor=A.+Poulsenauthor=K.+Sangthongpitagauthor=X.+Wuauthor=C.+Huauthor=K.+C.+Gohauthor=X.+Wangauthor=L.+Fangauthor=K.+L.+Gohauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=P.+Yeoauthor=X.+Liuauthor=Z.+Bondayauthor=J.+M.+Woodauthor=B.+W.+Dymockauthor=E.+Kantharajauthor=E.+T.+Sun&title=Discovery+of+%282E%29-3-%7B2-butyl-1-%5B2-%28diethylamino%29ethyl%5D-1H-benzimidazol-5-yl%7D-N-hydroxyacrylamide+%28SB939%29%2C+an+orally+active+histone+deacetylase+inhibitor+with+a+superior+preclinical+profile&doi=10.1021%2Fjm2003552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile</span></div><div class="casAuthors">Wang, Haishan; Yu, Niefang; Chen, Dizhong; Lee, Ken Chi Lik; Lye, Pek Ling; Chang, Joyce Wei Wei; Deng, Weiping; Ng, Melvin Chi Yeh; Lu, Ting; Khoo, Mui Ling; Poulsen, Anders; Sangthongpitag, Kanda; Wu, Xiaofeng; Hu, Changyong; Goh, Kee Chuan; Wang, Xukun; Fang, Lijuan; Goh, Kay Lin; Khng, Hwee Hoon; Goh, Siok Kun; Yeo, Pauline; Liu, Xin; Bonday, Zahid; Wood, Jeanette M.; Dymock, Brian W.; Kantharaj, Ethirajulu; Sun, Eric T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4694-4720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(1,2-disubstituted-1H-benzimidazol-5-yl)-N-hydroxyacrylamides was designed and synthesized as HDAC inhibitors.  Extensive SARs have been established for in vitro potency (HDAC1 enzyme and COLO 205 cellular IC50), liver microsomal stability (t1/2), cytochrome P 450 inhibition (3A4 IC50), and clogP, among others.  These parameters were fine-tuned by carefully adjusting the substituents at positions 1 and 2 of the benzimidazole ring.  After comprehensive in vitro and in vivo profiling of the selected compds., SB939 (I) was identified as a preclin. development candidate.  I is a potent pan-HDAC inhibitor with excellent druglike properties, is highly efficacious in in vivo tumor models (HCT-116, PC-3, A2780, MV4-11, Ramos), and has high and dose-proportional oral exposures and very good ADME, safety, and pharmaceutical properties.  When orally dosed to tumor-bearing mice, I is enriched in tumor tissue which may contribute to its potent antitumor activity and prolonged duration of action.  I is currently being tested in phase I and phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd9r-fRIzdS7Vg90H21EOLACvtfcHk0lgMg6Y8W14Otg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D&md5=a69bf922fb86c47ddee9c9fc112cc9a2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm2003552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003552%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BL.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DM.%2BC.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DKhoo%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DK.%2BL.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DKantharaj%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DDiscovery%2520of%2520%25282E%2529-3-%257B2-butyl-1-%255B2-%2528diethylamino%2529ethyl%255D-1H-benzimidazol-5-yl%257D-N-hydroxyacrylamide%2520%2528SB939%2529%252C%2520an%2520orally%2520active%2520histone%2520deacetylase%2520inhibitor%2520with%2520a%2520superior%2520preclinical%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4694%26epage%3D4720%26doi%3D10.1021%2Fjm2003552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chng, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustafa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">161</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-0466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1535-7163.MCT-12-0466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23270925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=151-161&author=S.+Hartauthor=V.+Novotny-Diermayrauthor=K.+C.+Gohauthor=M.+Williamsauthor=Y.+C.+Tanauthor=L.+C.+Ongauthor=A.+Cheongauthor=B.+K.+Ngauthor=C.+Amaliniauthor=B.+Madanauthor=H.+Nagarajauthor=R.+Jayaramanauthor=K.+M.+Pashaauthor=K.+Ethirajuluauthor=W.+J.+Chngauthor=N.+Mustafaauthor=B.+C.+Gohauthor=C.+Benesauthor=U.+McDermottauthor=M.+Garnettauthor=B.+Dymockauthor=J.+M.+Wood&title=VS-5584%2C+a+novel+and+highly+selective+PI3K%2FmTOR+kinase+inhibitor+for+the+treatment+of+cancer&doi=10.1158%2F1535-7163.MCT-12-0466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Hart, Stefan; Novotny-Diermayr, Veronica; Goh, Kee Chuan; Williams, Meredith; Tan, Yong Cheng; Ong, Lai Chun; Cheong, Albert; Ng, Bee Kheng; Amalini, Chithra; Madan, Babita; Nagaraj, Harish; Jayaraman, Ramesh; Pasha, Khalid M.; Ethirajulu, Kantharaj; Chng, Wee Joo; Mustafa, Nurulhuda; Goh, Boon Cher; Benes, Cyril; McDermott, Ultan; Garnett, Mathew; Dymock, Brian; Wood, Jeanette M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers.  Moreover, this pathway activation is a poor prognostic marker for many tumor types and confers resistance to various cancer therapies.  Here, we describe VS-5584, a novel, low-mol. wt. compd. with equiv. potent activity against mTOR (IC50 = 37 nmol/L) and all class I phosphoinositide 3-kinase (PI3K) isoforms IC50: PI3KÎ± = 16 nmol/L; PI3KÎ² = 68 nmol/L; PI3KÎ³ = 25 nmol/L; PI3KÎ´ = 42 nmol/L, without relevant activity on 400 lipid and protein kinases.  VS-5584 shows robust modulation of cellular PI3K/mTOR pathways, inhibiting phosphorylation of substrates downstream of PI3K and mTORC1/2.  A large human cancer cell line panel screen (436 lines) revealed broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment.  VS-5584 exhibits favorable pharmacokinetic properties after oral dosing in mice and is well tolerated.  VS-5584 induces long-lasting and dose-dependent inhibition of PI3K/mTOR signaling in tumor tissue, leading to tumor growth inhibition in various rapalog-sensitive and -resistant human xenograft models.  Furthermore, VS-5584 is synergistic with an EGF receptor inhibitor in a gastric tumor model.  The unique selectivity profile and favorable pharmacol. and pharmaceutical properties of VS-5584 and its efficacy in a wide range of human tumor models supports further investigations of VS-5584 in clin. trials.  Mol Cancer Ther; 12(2); 151-61. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreO7JDy5Ta17Vg90H21EOLACvtfcHk0lgMg6Y8W14Otg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D&md5=5fac255eea66aed674cc863fc578d975</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0466%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DB.%2BK.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DK.%2BM.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DGarnett%26aufirst%3DM.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DVS-5584%252C%2520a%2520novel%2520and%2520highly%2520selective%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D151%26epage%3D161%26doi%3D10.1158%2F1535-7163.MCT-12-0466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3238</span><span class="NLM_x">â</span> <span class="NLM_lpage">3250</span><span class="refDoi">Â DOI: 10.1021/ci500493m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500493m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGgt7nM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=3238-3250&author=A.+Poulsenauthor=H.+Nagarajauthor=A.+Leeauthor=S.+Blanchardauthor=C.+K.+Sohauthor=D.+Chenauthor=H.+Wangauthor=S.+Hartauthor=K.+C.+Gohauthor=B.+Dymockauthor=M.+Williams&title=Structure+and+ligand-based+design+of+mTOR+and+PI3-kinase+inhibitors+leading+to+the+clinical+candidates+VS-5584+%28SB2343%29+and+SB2602&doi=10.1021%2Fci500493m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602</span></div><div class="casAuthors">Poulsen, Anders; Nagaraj, Harish; Lee, Angeline; Blanchard, Stephanie; Soh, Chang Kai; Chen, Dizhong; Wang, Haishan; Hart, Stefan; Goh, Kee Chuan; Dymock, Brian; Williams, Meredith</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3238-3250</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR) act as crit. effectors in a commonly deregulated cell signaling pathway in human cancers.  The abnormal activation of the PI3K/mTOR pathway has been shown to play a role in initiation, progression, and metastasis of human tumors.  Being one of the most frequently activated pathways in cancer, much effort has been directed toward inhibition of the PI3K/mTOR pathway as a novel oncol. therapy.  Previous work by a no. of groups has revealed several selective PI3K and dual mTOR/PI3K inhibitors.  However, there are few reports of therapeutic agents with a pan-PI3K/mTOR inhibitory profile within a narrow concn. range.  The authors therefore initiated a drug discovery project with the aim of discovering dual mTOR/PI3K inhibitors which would equipotently inhibit the 4 isoforms of PI3K, Î±, Î², Î³, and Î´, and mTOR a compelling profile for powerful blockage of the PI3K/mTOR pathway.  A pharmacophore model was generated and used for designing a series of novel compds., based on a purine scaffold, which potently inhibited mTOR and PI3Ks.  These compds. contained a phenol headgroup essential for binding to the target proteins.  Early efforts concd. on finding replacements for the phenol as it was rapidly conjugated resulting in a short half-life in vivo.  Compds. with a variety of headgroups were docked into the PI3KÎ± and mTOR ATP-binding sites, and aminopyrimidine and aminopyrazine were found to make excellent phenol replacements.  Further structure guided optimization of side chains in the 8- and 9-positions of the purine resulted in potent inhibitors with good PKDM properties.  As the PI3 kinases play a role in insulin signaling, it is believed that targeting mTOR selectively may give the benefit of blocking the AKT-pathway while avoiding the potential side effects assocd. with PI3K inhibition.  As a result the authors designed a further series of selective mTOR kinase inhibitors.  The project was successfully concluded by progressing both a dual mTOR/PI3K inhibitor I and a selective mTOR inhibitor II into preclin. development.  II has since entered phase 1 clin. development as VS-5584.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNUHrhUNZKi7Vg90H21EOLACvtfcHk0lhay2NHPxY79w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGgt7nM&md5=e9bb902719992d844430e4e8e85d3728</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci500493m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500493m%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DSoh%26aufirst%3DC.%2BK.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DStructure%2520and%2520ligand-based%2520design%2520of%2520mTOR%2520and%2520PI3-kinase%2520inhibitors%2520leading%2520to%2520the%2520clinical%2520candidates%2520VS-5584%2520%2528SB2343%2529%2520and%2520SB2602%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D3238%26epage%3D3250%26doi%3D10.1021%2Fci500493m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wang, H.; Chen, D.; Soh, C. K.</span><span> </span><span class="NLM_article-title">Fused Pyrimidine-based Hydroxamate Derivatives</span>. PCT Int. Appl. WO2015137887A1, September 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Wang&author=D.+Chen&author=C.+K.+Soh&title=Fused+Pyrimidine-based+Hydroxamate+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26atitle%3DFused%2520Pyrimidine-based%2520Hydroxamate%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Finnin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donigian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N.</span><span> </span><span class="NLM_article-title">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">â</span> <span class="NLM_lpage">193</span><span class="refDoi">Â DOI: 10.1038/43710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+Finninauthor=J.+Donigianauthor=A.+Cohenauthor=V.+Richonauthor=R.+Rifkindauthor=P.+Marksauthor=R.+Breslowauthor=N.+Pavletich&title=Structures+of+a+histone+deacetylase+homologue+bound+to+the+TSA+and+SAHA+inhibitors&doi=10.1038%2F43710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0ljPJckKy2Cx1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%26aulast%3DDonigian%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DRifkind%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%26atitle%3DStructures%2520of%2520a%2520histone%2520deacetylase%2520homologue%2520bound%2520to%2520the%2520TSA%2520and%2520SAHA%2520inhibitors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193%26doi%3D10.1038%2F43710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">New patented histone deacetylase inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">â</span> <span class="NLM_lpage">1757</span><span class="refDoi">Â DOI: 10.1517/13543770903393789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1517%2F13543770903393789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19939190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1727-1757&author=H.+Wangauthor=B.+W.+Dymock&title=New+patented+histone+deacetylase+inhibitors&doi=10.1517%2F13543770903393789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New patented histone deacetylase inhibitors</span></div><div class="casAuthors">Wang, Haishan; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1727-1757</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clin. trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created as dual or multifunctional inhibitors.  Given the breadth and depth of recent reporting of novel HDACis, there has emerged a need to review the field from a chemist's perspective in one compact article.  Areas covered in this review: This review provides a summary of published patent applications claiming novel HDACis from 2007 until mid-2009, covering mainly classes I, II and IV anticancer HDACis including those that have recently advanced to the clinic.  What the reader will gain: Readers will rapidly gain an overview of the majority of HDACi scaffolds with representative structure-activity relationships; they will learn how these new compds. were created, how their drug like properties were improved and which companies are the main players in the field.  Take home message: Although competition in this field is intense, the future application of HDACis to treat human disease either as single agents or in combination with existing drugs holds real promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9k6M0WIgm2rVg90H21EOLACvtfcHk0ljPJckKy2Cx1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK&md5=673162bef16012b32a8122c8fefd92ee</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F13543770903393789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903393789%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DNew%2520patented%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1727%26epage%3D1757%26doi%3D10.1517%2F13543770903393789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Stefano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1725</span><span class="NLM_x">â</span> <span class="NLM_lpage">1738</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-08-1200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1535-7163.MCT-08-1200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19584227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVynuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1725-1738&author=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Patelauthor=S.+Alixauthor=G.+Boxauthor=I.+Chuckowreeauthor=A.+Folkesauthor=S.+Gowanauthor=A.+De+Haven+Brandonauthor=F.+Di+Stefanoauthor=A.+Hayesauthor=A.+T.+Henleyauthor=L.+Lensunauthor=G.+Pergl-Wilsonauthor=A.+Robsonauthor=N.+Saghirauthor=A.+Zhyvoloupauthor=E.+McDonaldauthor=P.+Sheldrakeauthor=S.+Shuttleworthauthor=M.+Valentiauthor=N.+C.+Wanauthor=P.+A.+Clarkeauthor=P.+Workman&title=Biological+properties+of+potent+inhibitors+of+class+I+phosphatidylinositide+3-kinases%3A+from+PI-103+through+PI-540%2C+PI-620+to+the+oral+agent+GDC-0941&doi=10.1158%2F1535-7163.MCT-08-1200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941</span></div><div class="casAuthors">Raynaud, Florence I.; Eccles, Suzanne A.; Patel, Sonal; Alix, Sonia; Box, Gary; Chuckowree, Irina; Folkes, Adrian; Gowan, Sharon; De Haven Brandon, Alexis; Di Stefano, Francesca; Hayes, Angela; Henley, Alan T.; Lensun, Letitia; Pergl-Wilson, Giles; Robson, Anthony; Saghir, Nahid; Zhyvoloup, Alexander; McDonald, Edward; Sheldrake, Peter; Shuttleworth, Stephen; Valenti, Melanie; Wan, Nan Chi; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1725-1738</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositide 3-kinase pathway is frequently deregulated in human cancers and inhibitors offer considerable therapeutic potential.  We previously described the promising tricyclic pyridofuropyrimidine lead and chem. tool compd. PI-103.  We now report the properties of the pharmaceutically optimized bicyclic thienopyrimidine derivs. PI-540 and PI-620 and the resulting clin. development candidate GDC-0941.  All four compds. inhibited phosphatidylinositide 3-kinase p110Î± with IC50 â¤ 10 nmol/L.  Despite some differences in isoform selectivity, these agents exhibited similar in vitro antiproliferative properties to PI-103 in a panel of human cancer cell lines, with submicromolar potency in PTEN-neg. U87MG human glioblastoma cells and comparable phosphatidylinositide 3-kinase pathway modulation.  PI-540 and PI-620 exhibited improvements in soly. and metab. with high tissue distribution in mice.  Both compds. gave improved antitumor efficacy over PI-103, following i.p. dosing in U87MG glioblastoma tumor xenografts in athymic mice, with treated/control values of 34% (66% inhibition) and 27% (73% inhibition) for PI-540 (50 mg/kg b.i.d.) and PI-620 (25 mg/kg b.i.d.), resp.  GDC-0941 showed comparable in vitro antitumor activity to PI-103, PI-540, and PI-620 and exhibited 78% oral bioavailability in mice, with tumor exposure above 50% antiproliferative concns. for >8 h following 150 mg/kg p.o. and sustained phosphatidylinositide 3-kinase pathway inhibition.  These properties led to excellent dose-dependent oral antitumor activity, with daily p.o. dosing at 150 mg/kg achieving 98% and 80% growth inhibition of U87MG glioblastoma and IGROV-1 ovarian cancer xenografts, resp.  Together, these data support the development of GDC-0941 as a potent, orally bioavailable inhibitor of phosphatidylinositide 3-kinase.  GDC-0941 has recently entered phase I clin. trials. [Mol Cancer Ther 2009;8(7):1725-38] [Mol Cancer Ther 2009;8(7):1725-38].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-PRUGO7W3C7Vg90H21EOLACvtfcHk0lgRCWVtotIhFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVynuro%253D&md5=2c963517ef112c677fb19ec2f0040e14</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1200%26sid%3Dliteratum%253Aachs%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DGowan%26aufirst%3DS.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DDi%2BStefano%26aufirst%3DF.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DPergl-Wilson%26aufirst%3DG.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DSheldrake%26aufirst%3DP.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DBiological%2520properties%2520of%2520potent%2520inhibitors%2520of%2520class%2520I%2520phosphatidylinositide%25203-kinases%253A%2520from%2520PI-103%2520through%2520PI-540%252C%2520PI-620%2520to%2520the%2520oral%2520agent%2520GDC-0941%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1725%26epage%3D1738%26doi%3D10.1158%2F1535-7163.MCT-08-1200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">â</span> <span class="NLM_lpage">5532</span><span class="refDoi">Â DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110Î±.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lgRCWVtotIhFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sarker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristeleit, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredrickson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derynck, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">86</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1078-0432.CCR-14-0947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=25370471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=77-86&author=D.+Sarkerauthor=J.+E.+Angauthor=R.+Bairdauthor=R.+Kristeleitauthor=K.+Shahauthor=V.+Morenoauthor=P.+A.+Clarkeauthor=F.+I.+Raynaudauthor=G.+Levyauthor=J.+A.+Wareauthor=K.+Mazinaauthor=R.+Linauthor=J.+Wuauthor=J.+Fredricksonauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=Y.+Yanauthor=L.+S.+Friedmanauthor=S.+B.+Kayeauthor=M.+K.+Derynckauthor=P.+Workmanauthor=J.+S.+de+Bono&title=First-in-human+phase+I+study+of+pictilisib+%28GDC-0941%29%2C+a+potent+pan-class+I+phosphatidylinositol-3-kinase+%28PI3K%29+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A.; Raynaud, Florence I.; Levy, Gallia; Ware, Joseph A.; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M.; Lackner, Mark R.; Yan, Yibing; Friedman, Lori S.; Kaye, Stan B.; Derynck, Mika K.; Workman, Paul; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clin. activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).  Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels.  Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue.  Results: Pictilisib was well tolerated.  The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients).  The pharmacokinetic profile was dose-proportional and supported once-daily dosing.  Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 h after dose at the MTD and in tumor at pictilisib doses assocd. with AUC >20 hÂ·Î¼mol/L.  Significant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation.  A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, resp.  Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels â¥100 mg and signs of antitumor activity.  The recommended phase II dose was continuous dosing at 330 mg once-daily.  Clin Cancer Res; 21(1); 77-86. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-xdpJi9RV7Vg90H21EOLACvtfcHk0lhMAH0KcxVEqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D&md5=35d52a025e34f4f13844b2721014aca3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0947%26sid%3Dliteratum%253Aachs%26aulast%3DSarker%26aufirst%3DD.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLevy%26aufirst%3DG.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DMazina%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFredrickson%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DDerynck%26aufirst%3DM.%2BK.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520pictilisib%2520%2528GDC-0941%2529%252C%2520a%2520potent%2520pan-class%2520I%2520phosphatidylinositol-3-kinase%2520%2528PI3K%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D77%26epage%3D86%26doi%3D10.1158%2F1078-0432.CCR-14-0947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span> </span><span class="NLM_article-title">Dual inhibition of oncogenic targets for B-cell malignancies</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">â</span> <span class="NLM_lpage">549</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(16)00109-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2FS1470-2045%2816%2900109-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=27049458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A280%3ADC%252BC28fntVGmug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=547-549&author=P.+G.+Richardson&title=Dual+inhibition+of+oncogenic+targets+for+B-cell+malignancies&doi=10.1016%2FS1470-2045%2816%2900109-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of oncogenic targets for B-cell malignancies</span></div><div class="casAuthors">Richardson Paul G</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtyi3hH4A0Antlzo9xastyfW6udTcc2eaIQdgOevHhmbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fntVGmug%253D%253D&md5=5a166ed5200f7f17947ea82d865127bc</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2900109-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252900109-1%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DDual%2520inhibition%2520of%2520oncogenic%2520targets%2520for%2520B-cell%2520malignancies%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D547%26epage%3D549%26doi%3D10.1016%2FS1470-2045%2816%2900109-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Younes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdeja, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelapu, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clancy, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viner, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, Y.</span><span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">â</span> <span class="NLM_lpage">631</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged â¥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0lhOjTleXk5Wpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Cai, X.; Zhai, H.; Lai, C.; Qian, C.; Bao, R.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Inhibitor with a Zinc Binding Moiety</span>. U.S. Patent 8,710,219 B2, April 29,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=X.+Cai&author=H.+Zhai&author=C.+Lai&author=C.+Qian&author=R.+Bao&title=Phosphoinositide+3-Kinase+Inhibitor+with+a+Zinc+Binding+Moiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26atitle%3DPhosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520a%2520Zinc%2520Binding%2520Moiety%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A. W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4104</span><span class="NLM_x">â</span> <span class="NLM_lpage">4113</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.-J.+Laiauthor=R.+Baoauthor=D.-G.+Wangauthor=J.+Wangauthor=G.-X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+S.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.-X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lg336_ZKcJ6mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%2BS.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Flinn, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattaey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdeja, J. G.</span><span> </span><span class="NLM_article-title">A first-in-man phase 1 study of CUDC-907, a first-in-class chemically-designed dual inhibitor of PI3K and HDAC in patients with refractory or relapsed lymphoma and multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4363</span><span class="NLM_x">â</span> <span class="NLM_lpage">4363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=4363-4363&author=I.+W.+Flinnauthor=Y.+Okiauthor=A.+Coplandauthor=A.+Fattaeyauthor=C.-J.+Laiauthor=R.+Laliberteauthor=M.+Voiauthor=J.+G.+Berdeja&title=A+first-in-man+phase+1+study+of+CUDC-907%2C+a+first-in-class+chemically-designed+dual+inhibitor+of+PI3K+and+HDAC+in+patients+with+refractory+or+relapsed+lymphoma+and+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DOki%26aufirst%3DY.%26aulast%3DCopland%26aufirst%3DA.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26atitle%3DA%2520first-in-man%2520phase%25201%2520study%2520of%2520CUDC-907%252C%2520a%2520first-in-class%2520chemically-designed%2520dual%2520inhibitor%2520of%2520PI3K%2520and%2520HDAC%2520in%2520patients%2520with%2520refractory%2520or%2520relapsed%2520lymphoma%2520and%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D4363%26epage%3D4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Venugopal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristeleit, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourneau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellemans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsayed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcclue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forslund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span> </span><span class="NLM_article-title">A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4262</span><span class="NLM_x">â</span> <span class="NLM_lpage">4272</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-0312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1078-0432.CCR-13-0312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23741066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4262-4272&author=B.+Venugopalauthor=R.+Bairdauthor=R.+S.+Kristeleitauthor=R.+Plummerauthor=R.+Cowanauthor=A.+Stewartauthor=N.+Fourneauauthor=P.+Hellemansauthor=Y.+Elsayedauthor=S.+Mcclueauthor=J.+W.+Smitauthor=A.+Forslundauthor=C.+Phelpsauthor=J.+Cammauthor=T.+R.+J.+Evansauthor=J.+S.+de+Bonoauthor=U.+Banerji&title=A+phase+I+study+of+quisinostat+%28JNJ-26481585%29%2C+an+oral+hydroxamate+histone+deacetylase+inhibitor+with+evidence+of+target+modulation+and+antitumor+activity%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-13-0312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Venugopal, Balaji; Baird, Richard; Kristeleit, Rebecca S.; Plummer, Ruth; Cowan, Richard; Stewart, Adam; Fourneau, Nele; Hellemans, Peter; Elsayed, Yusri; McClue, Steve; Smit, Johan W.; Forslund, Ann; Phelps, Charles; Camm, John; Evans, T. R. Jeffry; de Bono, Johann S.; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4262-4272</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the max.-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).  Exptl. Design: In this first-in-human phase I study, quisinostat was administered orally, once daily in three weekly cycles to patients with advanced malignancies, using a two-stage accelerated titrn. design.  Three intermittent schedules were subsequently explored: four days on/three days off; every Monday, Wednesday, Friday (MWF); and every Monday and Thursday (M-Th).  Toxicity, pharmacokinetics, pharmacodynamics, and clin. efficacy were evaluated at each schedule.  Results: Ninety-two patients were treated in continuous daily (2-12 mg) and three intermittent dosing schedules (6-19 mg).  Treatment-emergent adverse events included: fatigue, nausea, decreased appetite, lethargy, and vomiting.  DLTs obsd. were predominantly cardiovascular, including nonsustained ventricular tachycardia, ST/T-wave abnormalities, and other tachyarhythmias.  Noncardiac DLTs were fatigue and abnormal liver function tests.  The max. plasma concn. (Cmax) and area under the plasma concn.-time curve (AUC) of quisinostat increased proportionally with dose.  Pharmacodynamic evaluation showed increased acetylated histone 3 in hair follicles, skin and tumor biopsies, and in peripheral blood mononuclear cells as well as decreased Ki67 in skin and tumor biopsies.  A partial response lasting five months was seen in one patient with melanoma.  Stable disease was seen in eight patients (duration 4-10.5 mo).  Conclusions: The adverse event profile of quisinostat was comparable with that of other HDACi.  Intermittent schedules were better tolerated than continuous schedules.  On the basis of tolerability, pharmacokinetic predictions, and pharmacodynamic effects, the recommended dose for phase II studies is 12 mg on the MWF schedule.  Clin Cancer Res; 19(15); 4262-72. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhELE0VMCPbVg90H21EOLACvtfcHk0lg336_ZKcJ6mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP&md5=f4db895a7878fddce61ea9640e427d4d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0312%26sid%3Dliteratum%253Aachs%26aulast%3DVenugopal%26aufirst%3DB.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DCowan%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DFourneau%26aufirst%3DN.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DElsayed%26aufirst%3DY.%26aulast%3DMcclue%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520quisinostat%2520%2528JNJ-26481585%2529%252C%2520an%2520oral%2520hydroxamate%2520histone%2520deacetylase%2520inhibitor%2520with%2520evidence%2520of%2520target%2520modulation%2520and%2520antitumor%2520activity%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4262%26epage%3D4272%26doi%3D10.1158%2F1078-0432.CCR-13-0312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Child, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Romero, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weichenthal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaglino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beylot-Barry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geskin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PÃ©rez-Ferriols, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellemans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsayed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forslund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinzani, P. L.</span><span> </span><span class="NLM_article-title">Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IBâIVA mycosis fungoides/SÃ©zary syndrome</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span><span class="refDoi">Â DOI: 10.1111/bjd.14427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1111%2Fbjd.14427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=26836950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KktbvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=80-88&author=F.+Childauthor=P.+L.+Ortiz-Romeroauthor=R.+Alvarezauthor=M.+Bagotauthor=R.+Stadlerauthor=M.+Weichenthalauthor=R.+Alvesauthor=P.+Quaglinoauthor=M.+Beylot-Barryauthor=R.+Cowanauthor=L.+J.+Geskinauthor=A.+P%C3%A9rez-Ferriolsauthor=P.+Hellemansauthor=Y.+Elsayedauthor=C.+Phelpsauthor=A.+Forslundauthor=M.+Kamidaauthor=P.+L.+Zinzani&title=Phase+II+multicentre+trial+of+oral+quisinostat%2C+a+histone+deacetylase+inhibitor%2C+in+patients+with+previously+treated+stage+IB%E2%80%93IVA+mycosis+fungoides%2FS%C3%A9zary+syndrome&doi=10.1111%2Fbjd.14427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sezary syndrome</span></div><div class="casAuthors">Child, F.; Ortiz-Romero, P. L.; Alvarez, R.; Bagot, M.; Stadler, R.; Weichenthal, M.; Alves, R.; Quaglino, P.; Beylot-Barry, M.; Cowan, R.; Geskin, L. J.; Perez-Ferriols, A.; Hellemans, P.; Elsayed, Y.; Phelps, C.; Forslund, A.; Kamida, M.; Zinzani, P. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-88</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor.  Objectives : To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).  Methods : Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles.  Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT).  Secondary end points included global RR, duration of response (DOR) in skin, progression-free survival (PFS), pruritus relief, safety and pharmacodynamic markers.  Results : Eight of 26 (25 evaluable) patients achieved â¥ 50% redn. in mSWAT score at least once, with confirmed cutaneous response in six (RR 24%).  There was a low global RR of 8%.  DOR in skin ranged from 2Â·8 to 6Â·9 mo.  Median PFS was 5Â·1 mo.  Pruritus relief was more frequent in cutaneous responders (67%) than nonresponders (32%).  Serial tumor biopsies revealed an increase in acetylated tubulin, indicating a target effect of histone deacetylase 6.  Twenty-one of 26 (81%) patients were withdrawn from the study before or at clin. cut-off; five (19%) continued to receive treatment with quisinostat.  The most common drug-related adverse events were nausea, diarrhea, asthenia, hypertension, thrombocytopenia and vomiting.  Grade 3 drug-related adverse events included hypertension, lethargy, pruritus, chills, hyperkalemia and pyrexia.  Conclusions : Quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, with an acceptable safety profile.  Combination therapy with other drugs active in CTCL may be appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU9KEEAMiIkbVg90H21EOLACvtfcHk0lgFXMhowLn1qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KktbvM&md5=0b64887cee81c36b3667927b3a724ba2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14427%26sid%3Dliteratum%253Aachs%26aulast%3DChild%26aufirst%3DF.%26aulast%3DOrtiz-Romero%26aufirst%3DP.%2BL.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DBagot%26aufirst%3DM.%26aulast%3DStadler%26aufirst%3DR.%26aulast%3DWeichenthal%26aufirst%3DM.%26aulast%3DAlves%26aufirst%3DR.%26aulast%3DQuaglino%26aufirst%3DP.%26aulast%3DBeylot-Barry%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DR.%26aulast%3DGeskin%26aufirst%3DL.%2BJ.%26aulast%3DP%25C3%25A9rez-Ferriols%26aufirst%3DA.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DElsayed%26aufirst%3DY.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DKamida%26aufirst%3DM.%26aulast%3DZinzani%26aufirst%3DP.%2BL.%26atitle%3DPhase%2520II%2520multicentre%2520trial%2520of%2520oral%2520quisinostat%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520in%2520patients%2520with%2520previously%2520treated%2520stage%2520IB%25E2%2580%2593IVA%2520mycosis%2520fungoides%252FS%25C3%25A9zary%2520syndrome%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D175%26spage%3D80%26epage%3D88%26doi%3D10.1111%2Fbjd.14427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Andrs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korabecny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodny, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuca, K.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) Inhibitors: importance of the morpholine ring</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">71</span><span class="refDoi">Â DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3-kinase+%28PI3K%29+and+phosphatidylinositol+3-kinase-related+kinase+%28PIKK%29+Inhibitors%3A+importance+of+the+morpholine+ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span></div><div class="casAuthors">Andrs, Martin; Korabecny, Jan; Jun, Daniel; Hodny, Zdenek; Bartek, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metab., migration, survival, and responses to diverse stresses including DNA damage.  To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied.  Despite their different nature, these two kinase families have related origin and share very similar kinase domains.  Therefore, chem. inhibitors of these kinases usually carry analogous structural motifs.  The most common feature of these inhibitors is a crit. hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chem. tool for development of many addnl. PI3K and PIKK inhibitors.  While several PI3K pathway inhibitors have recently shown promising clin. responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPlvsq-HTebVg90H21EOLACvtfcHk0lgFXMhowLn1qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE&md5=a8c22f580691084554036dec7d0cc95b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203-kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25203-kinase-related%2520kinase%2520%2528PIKK%2529%2520Inhibitors%253A%2520importance%2520of%2520the%2520morpholine%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Trott, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">â</span> <span class="NLM_lpage">461</span><span class="refDoi">Â DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+speed+and+accuracy+of+docking+with+a+new+scoring+function%2C+efficient+optimization%2C+and+multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lh5GXBUpphFbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520speed%2520and%2520accuracy%2520of%2520docking%2520with%2520a%2520new%2520scoring%2520function%252C%2520efficient%2520optimization%252C%2520and%2520multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Crystal structures of PI3KÎ± complexed with PI103 and Its derivatives: new directions for inhibitors design</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span><span class="refDoi">Â DOI: 10.1021/ml400378e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400378e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltL3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=138-142&author=Y.+Zhaoauthor=X.+Zhangauthor=Y.+Chenauthor=S.+Luauthor=Y.+Pengauthor=X.+Wangauthor=C.+Guoauthor=A.+Zhouauthor=J.+Zhangauthor=Y.+Luoauthor=Q.+Shenauthor=J.+Dingauthor=L.+Mengauthor=J.+Zhang&title=Crystal+structures+of+PI3K%CE%B1+complexed+with+PI103+and+Its+derivatives%3A+new+directions+for+inhibitors+design&doi=10.1021%2Fml400378e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of PI3KÎ± Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design</span></div><div class="casAuthors">Zhao, Yanlong; Zhang, Xi; Chen, Yingyi; Lu, Shaoyong; Peng, Yuefeng; Wang, Xiang; Guo, Chengliang; Zhou, Aiwu; Zhang, Jingmiao; Luo, Yu; Shen, Qian Cheng; Ding, Jian; Meng, Linghua; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-142</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival.  Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy.  We detd. the crystal structure of the human PI3KÎ±-PI103 complex to unravel mol. interactions.  Based on the structure, substitution at the R1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site.  Interestingly, the crystal structure of one of complexes revealed that the flexibility of Lys802 can also induce addnl. space at the catalytic site for further modification.  Thus, these crystal structures provide a mol. basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3KÎ± inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqa9dea7NarVg90H21EOLACvtfcHk0lh5GXBUpphFbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltL3M&md5=da8e03879de431fd9a350933cb73d17b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fml400378e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400378e%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520PI3K%25CE%25B1%2520complexed%2520with%2520PI103%2520and%2520Its%2520derivatives%253A%2520new%2520directions%2520for%2520inhibitors%2520design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D138%26epage%3D142%26doi%3D10.1021%2Fml400378e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Frew, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolden, J. E.</span><span> </span><span class="NLM_article-title">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">133</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2009.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.canlet.2009.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19359091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=125-133&author=A.+J.+Frewauthor=R.+W.+Johnstoneauthor=J.+E.+Bolden&title=Enhancing+the+apoptotic+and+therapeutic+effects+of+HDAC+inhibitors&doi=10.1016%2Fj.canlet.2009.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span></div><div class="casAuthors">Frew, Ailsa J.; Johnstone, Ricky W.; Bolden, Jessica E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that have moved rapidly through clin. development and in 2006 vorinostat (SAHA, Zolinza) was given FDA approval for the treatment of cutaneous T cell lymphoma.  Class I, II and IV HDACs that are targets for these compds. deacetylate histone proteins, resulting in chromatin remodelling and altered gene transcription.  In addn., numerous non-histone proteins are modified by acetylation and the inhibition of HDAC activity can therefore affect various mol. processes.  This broad effect on protein function may account for the pleiotropic anti-tumor responses elicited by HDACi that include induction of tumor cell apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune responses and altered angiogenesis.  The ability of HDACi to selectively induce tumor cells to undergo apoptosis is important for the therapeutic efficacy obsd. in pre-clin. models.  Moreover, HDACi can augment the apoptotic effects of other anti-cancer agents that have diverse mol. targets.  While HDACi are promising anti-cancer drugs, particularly given the scope to combine HDACi with other agents, identifying the key mol. events that det. the biol. response of cells to HDACi treatment remains a challenge.  Herein we focus on HDACi-induced apoptosis and discuss the various proteins and pathways that are affected by HDACi to mediate this programmed cell death response.  In addn., we highlight the ability of HDACi to synergise with other anti-cancer agents to potently kill tumor cells and discuss the possible mol. processes that underpin the combination effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp45hSsI-BaJ7Vg90H21EOLACvtfcHk0lh5GXBUpphFbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D&md5=2c647b927be73f7882b745b4edd1791f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DFrew%26aufirst%3DA.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26atitle%3DEnhancing%2520the%2520apoptotic%2520and%2520therapeutic%2520effects%2520of%2520HDAC%2520inhibitors%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D125%26epage%3D133%26doi%3D10.1016%2Fj.canlet.2009.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">van Malenstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekervel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verslype, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windmolders, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Pelt, J.</span><span> </span><span class="NLM_article-title">Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">329</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2012.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.canlet.2012.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23111106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWqtLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2013&pages=74-83&author=H.+van+Malensteinauthor=J.+Dekervelauthor=C.+Verslypeauthor=E.+Van+Cutsemauthor=P.+Windmoldersauthor=F.+Nevensauthor=J.+van+Pelt&title=Long-term+exposure+to+sorafenib+of+liver+cancer+cells+induces+resistance+with+epithelial-to-mesenchymal+transition%2C+increased+invasion+and+risk+of+rebound+growth&doi=10.1016%2Fj.canlet.2012.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth</span></div><div class="casAuthors">van Malenstein, Hannah; Dekervel, Jeroen; Verslype, Chris; Van Cutsem, Eric; Windmolders, Petra; Nevens, Frederik; van Pelt, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-83</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but its use is hampered by the occurrence of drug resistance.  To investigate the mol. mechanisms involved we developed five resistant human liver cell lines in which we studied morphol., gene expression and invasive potential.  The cells changed their appearance, lost E-cadherin and KRT19 and showed high expression of vimentin, indicating epithelial-to-mesenchymal transition.  Resistant cells showed reduced adherent growth, became more invasive and lost liver-specific gene expression.  Furthermore, following withdrawal of sorafenib, the resistant cells showed rebound growth, a phenomenon also found in patients.  This cell model was further used to investigate strategies for restoration of sensitivity to sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Dazw0QwqF7Vg90H21EOLACvtfcHk0ljClWPDTVT9xA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWqtLfE&md5=e84b1d13b495d8a580c5ebffff9e69fd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.10.021%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMalenstein%26aufirst%3DH.%26aulast%3DDekervel%26aufirst%3DJ.%26aulast%3DVerslype%26aufirst%3DC.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DWindmolders%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3Dvan%2BPelt%26aufirst%3DJ.%26atitle%3DLong-term%2520exposure%2520to%2520sorafenib%2520of%2520liver%2520cancer%2520cells%2520induces%2520resistance%2520with%2520epithelial-to-mesenchymal%2520transition%252C%2520increased%2520invasion%2520and%2520risk%2520of%2520rebound%2520growth%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D329%26spage%3D74%26epage%3D83%26doi%3D10.1016%2Fj.canlet.2012.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Gedaly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spear, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hundley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daily, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, B. M.</span><span> </span><span class="NLM_article-title">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2531</span><span class="NLM_x">â</span> <span class="NLM_lpage">2536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22753710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=2531-2536&author=R.+Gedalyauthor=P.+Anguloauthor=C.+Chenauthor=K.+T.+Creasyauthor=B.+T.+Spearauthor=J.+Hundleyauthor=M.+F.+Dailyauthor=M.+Shahauthor=B.+M.+Evers&title=The+role+of+PI3K%2FmTOR+inhibition+in+combination+with+sorafenib+in+hepatocellular+carcinoma+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span></div><div class="casAuthors">Gedaly, Roberto; Angulo, Paul; Chen, Changguo; Creasy, Kate Townsend; Spear, Brett T.; Hundley, Jonathan; Daily, Michael F.; Shah, Malay; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2531-2536</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC).  This study aimed to test the inhibitory effects of PI-103 (a small mol. inhibitor of PI3K and mTOR) and sorafenib as single agents and in combination on HCC tumorigenesis in an in vivo xenograft model.  Materials and Methods: In vitro study: Huh7 proliferation was assayed by 3H-thymidine incorporation and by thiazolyl blue tetrazolium bromide (MTT) assay.  Western blots were used to detect phosphorylation of the key enzymes in the two pathways.  In vivo study: Human HCC cell line Huh7 was inoculated into nude mice s.c. and the mice were treated with sorafenib (20 mg/kg/day) and PI-103 (5 mg/kg, every 4 days).  Tumor size was measured every other day.  Tumors were isolated for western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detection of apoptosis and signaling pathway enzymes.  Results: Our in vitro study found that combination of sorafenib and PI-103 additively inhibited Huh7 proliferation as compared to single-agent treatment.  Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in P13K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.  Combination of sorafenib and PI-103 inhibited all the key enzymes in the two pathways.  Our in vivo study demonstrated significant differences between control group, mono-drug groups and drug-combination group (p<0.05).  Combination of Sorafenib and PI-103 more efficiently inhibited tumorigenesis as compared to mono-drug treatments (p<0.032).  Conclusion: The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCZFrpeD720LVg90H21EOLACvtfcHk0ljClWPDTVT9xA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I&md5=921829aacb25e09d9261364e3806b111</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGedaly%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCreasy%26aufirst%3DK.%2BT.%26aulast%3DSpear%26aufirst%3DB.%2BT.%26aulast%3DHundley%26aufirst%3DJ.%26aulast%3DDaily%26aufirst%3DM.%2BF.%26aulast%3DShah%26aufirst%3DM.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DThe%2520role%2520of%2520PI3K%252FmTOR%2520inhibition%2520in%2520combination%2520with%2520sorafenib%2520in%2520hepatocellular%2520carcinoma%2520treatment%26jtitle%3DAnticancer%2520Res.%26date%3D2012%26volume%3D32%26spage%3D2531%26epage%3D2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span> </span><span class="NLM_article-title">Development and validation of high-performance liquid chromatographyâtandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies</span> <span class="citation_source-journal">Biomed. Chromatogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">â</span> <span class="NLM_lpage">189</span><span class="refDoi">Â DOI: 10.1002/bmc.734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fbmc.734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=17221921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVKkurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=184-189&author=P.+Yeoauthor=L.+Xinauthor=E.+Gohauthor=L.+S.+Newauthor=P.+Zengauthor=X.+Wuauthor=P.+Venkateshauthor=E.+Kantharaj&title=Development+and+validation+of+high-performance+liquid+chromatography%E2%80%93tandem+mass+spectrometry+assay+for+6-%283-benzoyl-ureido%29-hexanoic+acid+hydroxyamide%2C+a+novel+HDAC+inhibitor%2C+in+mouse+plasma+for+pharmacokinetic+studies&doi=10.1002%2Fbmc.734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies</span></div><div class="casAuthors">Yeo, Pauline; Xin, Liu; Goh, Evelyn; New, Lee Sun; Zeng, Peizi; Wu, Xiaofeng; Venkatesh, P.; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Chromatography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">BICHE2</span>;
        ISSN:<span class="NLM_cas:issn">0269-3879</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A liq. chromatog./tandem mass spectrometric method for the quantification of 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide (EX-2), a novel histone deacetylase (HDAC) inhibitor, in mouse plasma was developed to support inhouse pharmacokinetic (PK) studies in the lead optimization stage.  In order to det. the PK parameters for EX-2 in comparison to other HDAC inhibitors such as Suberoylanilide hydroxamic acid (SAHA), PXD-101, and LBH-589, which are currently in different stages of clin. trials, research-grade bio-anal. method validations were carried out for EX-2 and these ref. HDAC inhibitors, which were synthesized by inhouse medicinal chemists.  The components of validation consisted of specificity, extn. efficiency, signal-response of calibration stds., lower limit of quantification, autosampler stability, and accuracy and precision of quality control samples.  The validated LC/MS/MS methods were accurate and precise.  The calibration curve ranged from 1 to 1600 ng/mL for all the analytes.  The methods developed were used to quantify EX-2 and other HDAC inhibitors in mouse plasma obtained from pharmacokinetic studies.  The results suggest that EX-2 has better PK parameters compared with the ref. drugs and is a promising drug development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQByB7XcqcbVg90H21EOLACvtfcHk0ljClWPDTVT9xA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVKkurk%253D&md5=bca780089e84df598409e49febc66367</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fbmc.734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmc.734%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DZeng%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DVenkatesh%26aufirst%3DP.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520high-performance%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%2520assay%2520for%25206-%25283-benzoyl-ureido%2529-hexanoic%2520acid%2520hydroxyamide%252C%2520a%2520novel%2520HDAC%2520inhibitor%252C%2520in%2520mouse%2520plasma%2520for%2520pharmacokinetic%2520studies%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D2007%26volume%3D21%26spage%3D184%26epage%3D189%26doi%3D10.1002%2Fbmc.734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hui, K. M.; Toh, H. C.</span><span> </span><span class="NLM_article-title">Signature Programme: Liver Cancer</span>. <span class="NLM_publisher-name">National Cancer Centre Singapore (NCCS)</span>: <span class="NLM_publisher-loc">Singapore</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.nccs.com.sg/Research/programmes/Signature/Pages/LiverCancer.aspx" class="extLink">https://www.nccs.com.sg/Research/programmes/Signature/Pages/LiverCancer.aspx</a> (accessed Nov 18, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+M.+Hui&author=H.+C.+Toh&title=Signature+Programme%3A+Liver+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DK.%2BM.%26atitle%3DSignature%2520Programme%253A%2520Liver%2520Cancer%26pub%3DNational%2520Cancer%2520Centre%2520Singapore%2520%2528NCCS%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Ikeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusaka, T.</span><span> </span><span class="NLM_article-title">Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future</span> <span class="citation_source-journal">Diseases</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">â</span> <span class="NLM_lpage">381</span><span class="refDoi">Â DOI: 10.3390/diseases3040360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.3390%2Fdiseases3040360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=28943630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhvVOltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=360-381&author=M.+Ikedaauthor=S.+Mitsunagaauthor=I.+Ohnoauthor=Y.+Hashimotoauthor=H.+Takahashiauthor=K.+Watanabeauthor=K.+Umemotoauthor=T.+Okusaka&title=Systemic+chemotherapy+for+advanced+hepatocellular+carcinoma%3A+past%2C+present%2C+and+future&doi=10.3390%2Fdiseases3040360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future</span></div><div class="casAuthors">Ikeda Masafumi; Mitsunaga Shuichi; Ohno Izumi; Hashimoto Yusuke; Takahashi Hideaki; Watanabe Kazuo; Umemoto Kumiko; Okusaka Takuji</div><div class="citationInfo"><span class="NLM_cas:title">Diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">360-381</span>
        ISSN:<span class="NLM_cas:issn">2079-9721</span>.
    </div><div class="casAbstract">Systemic chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC).  Before the introduction of sorafenib, cytotoxic agents, hormonal therapies, or many combinations of these were the mainly used modalities for systemic chemotherapy of advanced HCC.  However, such regimens were of only limited value in clinical practice, because some randomized controlled studies comparing promising regimens with no treatment or doxorubicin alone failed to show any overall survival advantage.  In two pivotal phase III placebo-controlled studies, the SHARP trial and the Asia-Pacific trial, sorafenib was demonstrated to significantly delay the time to progression and the overall survival time in patients with advanced HCC.  Therefore, sorafenib therapy has come to be acknowledged as a standard therapy for advanced HCC worldwide.  After the introduction of sorafenib, a number of phase III trials of various molecular-targeted agents vs. sorafenib as first-line chemotherapy and of various molecular-targeted agents vs. placebo as second-line chemotherapy have been conducted to determine if any of these agents could offer a survival benefit, however, none of the agents examined so far has been demonstrated to provide any survival benefit over sorafenib or placebo.  Recently, favorable treatment efficacies have been reported in some clinical trials of molecular-targeted agents in the biomarker-enriched population.  Development of individualized cancer treatments using molecular-targeted agents based on the results of genome-sequencing is aggressively ongoing.  Furthermore, immune-oncologic agents, such as anti-CTLA-4 antibody and anti-PD-1/PD-L1 antibody, have been reported to provide promising outcomes.  Thus, various novel systemic chemotherapeutic agents are currently under development, and further improvements in the treatment outcomes are expected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3PXp_8XVTNENoizSOkG_FfW6udTcc2ebRYknDTW5bvbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhvVOltg%253D%253D&md5=d8398200cd11fdf5d3d51383c5fc0825</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3390%2Fdiseases3040360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fdiseases3040360%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DMitsunaga%26aufirst%3DS.%26aulast%3DOhno%26aufirst%3DI.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DUmemoto%26aufirst%3DK.%26aulast%3DOkusaka%26aufirst%3DT.%26atitle%3DSystemic%2520chemotherapy%2520for%2520advanced%2520hepatocellular%2520carcinoma%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DDiseases%26date%3D2015%26volume%3D3%26spage%3D360%26epage%3D381%26doi%3D10.3390%2Fdiseases3040360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">5488</span><span class="NLM_x">â</span> <span class="NLM_lpage">5504</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00579</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00579" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5488-5504&author=Y.+Chenauthor=X.+Wangauthor=W.+Xiangauthor=L.+Heauthor=M.+Tangauthor=F.+Wangauthor=T.+Wangauthor=Z.+Yangauthor=Y.+Yiauthor=H.+Wangauthor=T.+Niuauthor=L.+Zhengauthor=L.+Leiauthor=X.+Liauthor=H.+Songauthor=L.+Chen&title=Development+of+purine-based+hydroxamic+acid+derivatives%3A+potent+histone+deacetylase+inhibitors+with+marked+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Facs.jmedchem.6b00579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Chen, Yong; Wang, Xiaoyan; Xiang, Wei; He, Lin; Tang, Minghai; Wang, Fang; Wang, Taijin; Yang, Zhuang; Yi, Yuyao; Wang, Hairong; Niu, Ting; Zheng, Li; Lei, Lei; Li, Xiaobin; Song, Hang; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5488-5504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized.  Several compds. demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines.  Among them, compd. 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties.  Western blot anal. further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concn. in vitro.  In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body wt. and toxicity.  All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematol. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrTRI5NXFfLVg90H21EOLACvtfcHk0lgb90hTbe8edw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D&md5=3400d6c13519392827c72bba6f044121</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00579%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520purine-based%2520hydroxamic%2520acid%2520derivatives%253A%2520potent%2520histone%2520deacetylase%2520inhibitors%2520with%2520marked%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5488%26epage%3D5504%26doi%3D10.1021%2Facs.jmedchem.6b00579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span>Bristol-Myers Squibbâs Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib; <span class="NLM_publisher-name">Drugs.com</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="https://www.drugs.com/newdrugs/bristol-myers-squibb-s-opdivo-nivolumab-receives-fda-approval-hepatocellular-carcinoma-patients-4607.html" class="extLink">https://www.drugs.com/newdrugs/bristol-myers-squibb-s-opdivo-nivolumab-receives-fda-approval-hepatocellular-carcinoma-patients-4607.html</a> (accessed Sep 22, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bristol-Myers+Squibb%E2%80%99s+Opdivo+%28nivolumab%29+Receives+FDA+Approval+for+the+Treatment+of+Hepatocellular+Carcinoma+Patients+Previously+Treated+with+Sorafenib%3B+Drugs.com%2C+2017%3B+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Fbristol-myers-squibb-s-opdivo-nivolumab-receives-fda-approval-hepatocellular-carcinoma-patients-4607.html+%28accessed+Sep+22%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DBristol-Myers%2520Squibb%25E2%2580%2599s%2520Opdivo%2520%2528nivolumab%2529%2520Receives%2520FDA%2520Approval%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%2520Patients%2520Previously%2520Treated%2520with%2520Sorafenib%26pub%3DDrugs.com%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciesielski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotomayor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenstermaker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span> </span><span class="NLM_article-title">Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e30815</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0030815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1371%2Fjournal.pone.0030815" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e30815&author=L.+Shenauthor=M.+Ciesielskiauthor=S.+Ramakrishnanauthor=K.+M.+Milesauthor=L.+Ellisauthor=P.+Sotomayorauthor=P.+Shrikantauthor=R.+Fenstermakerauthor=R.+Pili&title=Class+I+histone+deacetylase+inhibitor+entinostat+suppresses+regulatory+T+cells+and+enhances+immunotherapies+in+renal+and+prostate+cancer+models&doi=10.1371%2Fjournal.pone.0030815"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0030815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0030815%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DCiesielski%26aufirst%3DM.%26aulast%3DRamakrishnan%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DK.%2BM.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DSotomayor%26aufirst%3DP.%26aulast%3DShrikant%26aufirst%3DP.%26aulast%3DFenstermaker%26aufirst%3DR.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DClass%2520I%2520histone%2520deacetylase%2520inhibitor%2520entinostat%2520suppresses%2520regulatory%2520T%2520cells%2520and%2520enhances%2520immunotherapies%2520in%2520renal%2520and%2520prostate%2520cancer%2520models%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De30815%26doi%3D10.1371%2Fjournal.pone.0030815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Yardley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail-Khan, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melichar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichinitser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munster, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruickshank, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span> </span><span class="NLM_article-title">Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on Treatment With a Nonsteroidal Aromatase Inhibitor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2128</span><span class="NLM_x">â</span> <span class="NLM_lpage">2135</span><span class="refDoi">Â DOI: 10.1200/JCO.2012.43.7251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1200%2FJCO.2012.43.7251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23650416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2128-2135&author=D.+A.+Yardleyauthor=R.+R.+Ismail-Khanauthor=B.+Melicharauthor=M.+Lichinitserauthor=P.+N.+Munsterauthor=P.+M.+Kleinauthor=S.+Cruickshankauthor=K.+D.+Millerauthor=M.+J.+Leeauthor=J.+B.+Trepel&title=Randomized+phase+II%2C+double-blind%2C+placebo-controlled+study+of+exemestane+with+or+without+entinostat+in+postmenopausal+women+with+locally+recurrent+or+metastatic+estrogen+receptor-positive+breast+cancer+progressing+on+Treatment+With+a+Nonsteroidal+Aromatase+Inhibitor&doi=10.1200%2FJCO.2012.43.7251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor</span></div><div class="casAuthors">Yardley, Denise A.; Ismail-Khan, Roohi R.; Melichar, Bohuslav; Lichinitser, Mikhail; Munster, Pamela N.; Klein, Pamela M.; Cruickshank, Scott; Miller, Kathy D.; Lee, Min J.; Trepel, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2128-2135</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-pos. (ER+) breast cancer.  This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane vs. exemestane alone.  Patients and Methods: Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor were randomly assigned to exemestane 25 mg daily plus entinostat 5 mg once per wk (EE) or exemestane plus placebo (EP).  The primary end point was progression-free survival (PFS).  Blood was collected in a subset of patients for evaluation of protein lysine acetylation as a biomarker of entinostat activity.  Results: One hundred thirty patients were randomly assigned (EE group, n = 64; EP group, n = 66).  Based on intent-to-treat anal., treatment with EE improved median PFS to 4.3 mo vs. 2.3 mo with EP (hazard ratio [HR], 0.73; 95% CI, 0.50 to 1.07; one-sided P = .055; two-sided P = .11 [predefined significance level of .10, one-sided]).  Median overall survival was an exploratory end point and improved to 28.1 mo with EE vs. 19.8 mo with EP (HR, 0.59; 95% CI, 0.36 to 0.97; P = .036).  Fatigue and neutropenia were the most frequent grade 3/4 toxicities.  Treatment discontinuation because of adverse events was higher in the EE group vs. the EP group (11% v 2%).  Protein lysine hyperacetylation in the EE biomarker subset was assocd. with prolonged PFS.  Conclusion: Entinostat added to exemestane is generally well tolerated and demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II study.  Acetylation changes may provide an opportunity to maximize clin. benefit with entinostat.  Plans for a confirmatory study are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopc-999rEFo7Vg90H21EOLACvtfcHk0lge2KlmnkzHPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF&md5=d11f73761ef87fe34fab169ae22e8390</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.7251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.7251%26sid%3Dliteratum%253Aachs%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DIsmail-Khan%26aufirst%3DR.%2BR.%26aulast%3DMelichar%26aufirst%3DB.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DKlein%26aufirst%3DP.%2BM.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26atitle%3DRandomized%2520phase%2520II%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520exemestane%2520with%2520or%2520without%2520entinostat%2520in%2520postmenopausal%2520women%2520with%2520locally%2520recurrent%2520or%2520metastatic%2520estrogen%2520receptor-positive%2520breast%2520cancer%2520progressing%2520on%2520Treatment%2520With%2520a%2520Nonsteroidal%2520Aromatase%2520Inhibitor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D2128%26epage%3D2135%26doi%3D10.1200%2FJCO.2012.43.7251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Wardley, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCaffrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett-Lee, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. T.</span><span> </span><span class="NLM_article-title">Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1052</span><span class="refDoi">Â DOI: 10.1200/jco.2010.28.15_suppl.1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1200%2Fjco.2010.28.15_suppl.1052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1052&author=A.+M.+Wardleyauthor=R.+Steinauthor=J.+McCaffreyauthor=J.+Crownauthor=Z.+Malikauthor=D.+Reaauthor=P.+J.+Barrett-Leeauthor=G.+T.+Lee&title=Phase+II+data+for+entinostat%2C+a+class+1+selective+histone+deacetylase+inhibitor%2C+in+patients+whose+breast+cancer+is+progressing+on+aromatase+inhibitor+therapy&doi=10.1200%2Fjco.2010.28.15_suppl.1052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1200%2Fjco.2010.28.15_suppl.1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2010.28.15_suppl.1052%26sid%3Dliteratum%253Aachs%26aulast%3DWardley%26aufirst%3DA.%2BM.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DMcCaffrey%26aufirst%3DJ.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DMalik%26aufirst%3DZ.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DG.%2BT.%26atitle%3DPhase%2520II%2520data%2520for%2520entinostat%252C%2520a%2520class%25201%2520selective%2520histone%2520deacetylase%2520inhibitor%252C%2520in%2520patients%2520whose%2520breast%2520cancer%2520is%2520progressing%2520on%2520aromatase%2520inhibitor%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1052%26doi%3D10.1200%2Fjco.2010.28.15_suppl.1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Hooker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkow, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, J. S.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitor MS-275 exhibits poor brain penetration: pharmacokinetic studies of [(11)C]MS-275 using positron emission tomography</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">73</span><span class="refDoi">Â DOI: 10.1021/cn9000268</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn9000268" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKms7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=65-73&author=J.+M.+Hookerauthor=S.+W.+Kimauthor=D.+Alexoffauthor=Y.+Xuauthor=C.+Sheaauthor=A.+Reidauthor=N.+Volkowauthor=J.+S.+Fowler&title=Histone+deacetylase+inhibitor+MS-275+exhibits+poor+brain+penetration%3A+pharmacokinetic+studies+of+%5B%2811%29C%5DMS-275+using+positron+emission+tomography&doi=10.1021%2Fcn9000268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography</span></div><div class="casAuthors">Hooker, Jacob M.; Kim, Sung Won; Alexoff, David; Xu, Youwen; Shea, Colleen; Reid, Alicia; Volkow, Nora; Fowler, Joanna S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MS-275 (entinostat) is a histone deacetylase (HDAC) inhibitor currently in clin. trials for the treatment of several types of cancer.  Recent reports have noted that MS-275 can cross the blood-brain barrier (BBB) and cause region-specific changes in rodent brain histone acetylation.  To characterize the pharmacokinetics and distribution of MS-275 in the brain using positron emission tomog. (PET), we labeled the carbamate carbon of MS-275 with carbon-11.  Using PET, we detd. that [11C]MS-275 has low uptake in brain tissue when administered i.v. to nonhuman primates.  In rodent studies, we obsd. that pharmacokinetics and brain accumulation of [11C]MS-275 were not changed by the coadministration of large doses of unlabeled MS-275.  These results, which both highlight the poor brain penetration of MS-275, clearly suggest its limitation as a therapeutic agent for the central nervous system (CNS).  Moreover, our study demonstrates the effectiveness of PET at providing brain pharmacokinetic data for HDAC inhibitors.  These data are important not only for the development of new compds. for peripheral cancer treatment (where CNS exclusion is often advantageous) but also for the treatment of neurol. disorders (where CNS penetration is crit.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-zU8bO0BcpLVg90H21EOLACvtfcHk0lhYeCyG9MB-KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKms7vL&md5=f1cf8e753ac80029fae6cf77193f172f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fcn9000268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn9000268%26sid%3Dliteratum%253Aachs%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DAlexoff%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DShea%26aufirst%3DC.%26aulast%3DReid%26aufirst%3DA.%26aulast%3DVolkow%26aufirst%3DN.%26aulast%3DFowler%26aufirst%3DJ.%2BS.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520MS-275%2520exhibits%2520poor%2520brain%2520penetration%253A%2520pharmacokinetic%2520studies%2520of%2520%255B%252811%2529C%255DMS-275%2520using%2520positron%2520emission%2520tomography%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D65%26epage%3D73%26doi%3D10.1021%2Fcn9000268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kim, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, D. H.</span><span> </span><span class="NLM_article-title">Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">169</span><span class="refDoi">Â DOI: 10.1016/S1056-8719(96)00113-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2FS1056-8719%2896%2900113-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=8959582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADyaK28XnsV2gu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=163-169&author=H.+M.+Kimauthor=S.+B.+Hanauthor=M.+S.+Kimauthor=J.+S.+Kangauthor=G.+T.+Ohauthor=D.+H.+Hong&title=Efficient+fixation+procedure+of+human+leukemia+cells+in+sulforhodamine+B+cytotoxicity+assay&doi=10.1016%2FS1056-8719%2896%2900113-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay</span></div><div class="casAuthors">Kim, Hwan Mook; Han, Sang Bae; Kim, Moon Soon; Kang, Jong Seong; Oh, Goo Taeg; Hong, Dong Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The fixation procedures in sulforhodamine B (SRB) assay for human leukemia cells were modified to produce more reliable results.  It was found that the concn. of the fixative agent, trichloroacetic acid (TCA), was crit. in the selective fixation of cellular protein.  While a TCA soln. of 80% fixed both cells and serum proteins, a 50% soln. fixed only cells with a very low interference of the serum proteins.  Accordingly, we selected 50% TCA as a fixative agent which made the final absorbance of the SRB assay to be exactly matched to the cell d. with a small deviation and a low background.  Besides the change of TCA concn., a precentrifugation of microplate just before fixation also improved the previous assay procedures in the two points of view.  The 2-h standing step was simply substituted for only 1 min of centrifugation.  Both the rapid and slow application of TCA soln. in fixation produced the same extents of fixation.  In an actual application, these two kinds of modifications in the previous SRB assay procedure were also proved to be effective in the detn. of cytotoxicities of doxorubicin by using human leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8aa3TRqbLb7Vg90H21EOLACvtfcHk0lhYeCyG9MB-KQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsV2gu7c%253D&md5=047df5a2bcbfada8982098e4bf315c5c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2896%2900113-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252896%252900113-X%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DHan%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DOh%26aufirst%3DG.%2BT.%26aulast%3DHong%26aufirst%3DD.%2BH.%26atitle%3DEfficient%2520fixation%2520procedure%2520of%2520human%2520leukemia%2520cells%2520in%2520sulforhodamine%2520B%2520cytotoxicity%2520assay%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D1996%26volume%3D36%26spage%3D163%26epage%3D169%26doi%3D10.1016%2FS1056-8719%2896%2900113-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Vichai, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirtikara, K.</span><span> </span><span class="NLM_article-title">Sulforhodamine B colorimetric assay for cytotoxicity screening</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1112</span><span class="NLM_x">â</span> <span class="NLM_lpage">1116</span><span class="refDoi">Â DOI: 10.1038/nprot.2006.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1038%2Fnprot.2006.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=17406391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=1112-1116&author=V.+Vichaiauthor=K.+Kirtikara&title=Sulforhodamine+B+colorimetric+assay+for+cytotoxicity+screening&doi=10.1038%2Fnprot.2006.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Sulforhodamine B colorimetric assay for cytotoxicity screening</span></div><div class="casAuthors">Vichai, Vanicha; Kirtikara, Kanyawim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1112-1116</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sulforhodamine B (SRB) assay is used for cell d. detn., based on the measurement of cellular protein content.  The method described here was optimized for the toxicity screening of compds. to adherent cells in a 96-well format.  After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid.  The protein-bound dye is dissolved in 10 mM Tris base soln. for OD detn. at 510 nm using a microplate reader.  The results are linear over a 20-fold range of cell nos. and the sensitivity is comparable to those of fluorometric methods.  The method not only allows a large no. of samples to be tested within a few days, but also requires only simple equipment and inexpensive reagents.  The SRB assay is therefore an efficient and highly cost-effective method for screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZ8pao808l7Vg90H21EOLACvtfcHk0ljVPSxtc6esNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O&md5=7173035a1f9eb3f02dd7f1a947bca659</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.179%26sid%3Dliteratum%253Aachs%26aulast%3DVichai%26aufirst%3DV.%26aulast%3DKirtikara%26aufirst%3DK.%26atitle%3DSulforhodamine%2520B%2520colorimetric%2520assay%2520for%2520cytotoxicity%2520screening%26jtitle%3DNat.%2520Protoc.%26date%3D2006%26volume%3D1%26spage%3D1112%26epage%3D1116%26doi%3D10.1038%2Fnprot.2006.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span>CellTiter-Glo Luminescent Cell Viability Assay: Instructions for Use of Products G7570, G7571, G7572, and G7573; <span class="NLM_publisher-name">Promega Corporation</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.promega.sg/~/media/Files/Resources/Protocols/Technical%20Bulletins/0/CellTiter%20Glo%20Luminescent%20Cell%20Viability%20Assay%20Protocol.pdf" class="extLink">https://www.promega.sg/~/media/Files/Resources/Protocols/Technical%20Bulletins/0/CellTiter%20Glo%20Luminescent%20Cell%20Viability%20Assay%20Protocol.pdf</a> (accessed Dec 9, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CellTiter-Glo+Luminescent+Cell+Viability+Assay%3A+Instructions+for+Use+of+Products+G7570%2C+G7571%2C+G7572%2C+and+G7573%3B+Promega+Corporation%3A+Madison%2C+WI%2C+2015%3B+https%3A%2F%2Fwww.promega.sg%2F%7E%2Fmedia%2FFiles%2FResources%2FProtocols%2FTechnical%2520Bulletins%2F0%2FCellTiter%2520Glo%2520Luminescent%2520Cell%2520Viability%2520Assay%2520Protocol.pdf+%28accessed+Dec+9%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DCellTiter-Glo%2520Luminescent%2520Cell%2520Viability%2520Assay%253A%2520Instructions%2520for%2520Use%2520of%2520Products%2520G7570%252C%2520G7571%252C%2520G7572%252C%2520and%2520G7573%26pub%3DPromega%2520Corporation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Lorenzi, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhold, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanock, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span> </span><span class="NLM_article-title">DNA fingerprinting of the NCI-60 cell line panel</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">â</span> <span class="NLM_lpage">724</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-08-0921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1535-7163.MCT-08-0921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19372543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1amsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=713-724&author=P.+L.+Lorenziauthor=W.+C.+Reinholdauthor=S.+Varmaauthor=A.+A.+Hutchinsonauthor=Y.+Pommierauthor=S.+J.+Chanockauthor=J.+N.+Weinstein&title=DNA+fingerprinting+of+the+NCI-60+cell+line+panel&doi=10.1158%2F1535-7163.MCT-08-0921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">DNA fingerprinting of the NCI-60 cell line panel</span></div><div class="casAuthors">Lorenzi, Philip L.; Reinhold, William C.; Varma, Sudhir; Hutchinson, Amy A.; Pommier, Yves; Chanock, Stephen J.; Weinstein, John N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The National Cancer Institute's NCI-60 cell line panel, the most extensively characterized set of cells in existence and a public resource, is frequently used as a screening tool for drug discovery.  Because many labs. around the world rely on data from the NCI-60 cells, confirmation of their genetic identities represents an essential step in validating results from them.  Given the consequences of cell line contamination or misidentification, quality control measures should routinely include DNA fingerprinting.  We have, therefore, used std. DNA microsatellite short tandem repeats to profile the NCI-60, and the resulting DNA fingerprints are provided here as a ref.  Consistent with previous reports, the fingerprints suggest that several NCI-60 lines have common origins: the melanoma lines MDA-MB-435, MDA-N, and M14; the central nervous system lines U251 and SNB-19; the ovarian lines OVCAR-8 and OVCAR-8/ADR (also called NCI/ADR); and the prostate lines DU-145, DU-145 (ATCC), and RC0.1.  Those lines also show that the ability to connect two fingerprints to the same origin is not affected by stable transfection or by the development of multidrug resistance.  As expected, DNA fingerprints were not able to distinguish different tissues-of-origin.  The fingerprints serve principally as a barcodes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPvXV_U0kPbVg90H21EOLACvtfcHk0li0Rk-rIDU_Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1amsLY%253D&md5=7b5b1e052c1fb8c3cef5d43302286de7</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0921%26sid%3Dliteratum%253Aachs%26aulast%3DLorenzi%26aufirst%3DP.%2BL.%26aulast%3DReinhold%26aufirst%3DW.%2BC.%26aulast%3DVarma%26aufirst%3DS.%26aulast%3DHutchinson%26aufirst%3DA.%2BA.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DChanock%26aufirst%3DS.%2BJ.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26atitle%3DDNA%2520fingerprinting%2520of%2520the%2520NCI-60%2520cell%2520line%2520panel%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D713%26epage%3D724%26doi%3D10.1158%2F1535-7163.MCT-08-0921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span> </span><span class="NLM_article-title">Investigation of cross-contamination and misidentification of 278 widely used tumor cell lines</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0170384</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0170384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1371%2Fjournal.pone.0170384" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0170384&author=Y.+Huangauthor=Y.+Liuauthor=C.+Zhengauthor=C.+Shen&title=Investigation+of+cross-contamination+and+misidentification+of+278+widely+used+tumor+cell+lines&doi=10.1371%2Fjournal.pone.0170384"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0170384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0170384%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DC.%26atitle%3DInvestigation%2520of%2520cross-contamination%2520and%2520misidentification%2520of%2520278%2520widely%2520used%2520tumor%2520cell%2520lines%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0170384%26doi%3D10.1371%2Fjournal.pone.0170384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Venkatesh, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, P. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span> </span><span class="NLM_article-title">In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preelinical species</span> <span class="citation_source-journal">Biol. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1021</span><span class="NLM_x">â</span> <span class="NLM_lpage">1024</span><span class="refDoi">Â DOI: 10.1248/bpb.30.1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1248%2Fbpb.30.1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=17473456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlKks7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=1021-1024&author=P.+R.+Venkateshauthor=E.+Gohauthor=P.+Z.+Zengauthor=L.+S.+Newauthor=L.+Xinauthor=M.+K.+Pashaauthor=K.+Sangthongpitagauthor=P.+Yeoauthor=E.+Kantharaj&title=In+vitro+phase+I+cytochrome+P450+metabolism%2C+permeability+and+pharmacokinetics+of+SB639%2C+a+novel+histone+deacetylase+inhibitor+in+preelinical+species&doi=10.1248%2Fbpb.30.1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species</span></div><div class="casAuthors">Venkatesh, Pilla Reddy; Goh, Evelyn; Zeng, Peizi; New, Lee Sun; Xin, Liu; Pasha, Mohammed Khalid; Sangthongpitag, Kanda; Yeo, Pauline; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1024</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">In vitro liver microsomal stability, permeability, pharmacokinetics (PK) and oral bioavailability of SB639, a novel HDACi (Histone Deacetylase inhibitor), were detd.  The in vitro metab. was examd. in mouse, rat, dog and human liver microsomes.  The permeability and efflux potential of SB639 were detd. using Caco-2 cell monolayers.  To det. pharmacokinetics and oral bioavailability, blood samples were drawn at pre-detd. intervals up to 24 h post-dose after single i.v. or oral (p.o.) administration of SB639 to mouse or rat.  The concns. of SB639 in plasma samples were detd. by a validated LC-MS/MS method.  In vitro liver microsomal stability data revealed that SB639 was stable in human and dog liver microsomes, unstable in mouse and rat liver microsomes.  The Caco-2 data has shown that SB639 is highly permeable with an apparent permeability of 3.01 Ã 10-6 cm/s at 10 Î¼M.  After oral administration, max. concns. of SB639 were achieved within 0.5 h of post dose.  Following i.v. administration, the concn. of SB639 declined in a bi-exponential fashion with terminal elimination half-life of 1.67 h for mice and 1.12 h for rats.  The systemic clearance and vol. of distribution of SB639 in mice were 15.8 l/h/kg and 38 l/kg, resp., while the resp. values in rats were 3.84 l/h/kg and 3.67 l/kg.  Elimination half-life in rats ranged between 1.12-2.26 h.  Abs. oral bioavailability of SB639 in mouse and rat was 13% and 10%, resp.  In conclusion, the superior potency, physicochem. and PK properties of SB639 compared to the recently FDA approved drug Zolinza (Suberoylanilide hydroxamic acid or Vorinostat) in the preclin. setting makes it a potential clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQPXNOqMkzN7Vg90H21EOLACvtfcHk0li0Rk-rIDU_Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlKks7Y%253D&md5=c6dc4488d0a8762b1fe563e8ba04e499</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1248%2Fbpb.30.1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.30.1021%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesh%26aufirst%3DP.%2BR.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DZeng%26aufirst%3DP.%2BZ.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DIn%2520vitro%2520phase%2520I%2520cytochrome%2520P450%2520metabolism%252C%2520permeability%2520and%2520pharmacokinetics%2520of%2520SB639%252C%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%2520in%2520preelinical%2520species%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2007%26volume%3D30%26spage%3D1021%26epage%3D1024%26doi%3D10.1248%2Fbpb.30.1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span> </span><span class="NLM_article-title">Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase (HDAC) inhibitor, and prediction of human pharmacokinetics</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2219</span><span class="NLM_x">â</span> <span class="NLM_lpage">2232</span><span class="refDoi">Â DOI: 10.1124/dmd.111.041558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1124%2Fdmd.111.041558" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2219-2232&author=R.+Jayaramanauthor=V.+P.+Reddyauthor=M.+K.+Pashaauthor=H.+Wangauthor=K.+Sangthongpitagauthor=P.+Yeoauthor=C.+Y.+Huauthor=X.+Wuauthor=L.+Xinauthor=E.+Gohauthor=L.+S.+Newauthor=K.+Ethirajulu&title=Preclinical+metabolism+and+disposition+of+SB939+%28Pracinostat%29%2C+an+orally+active+histone+deacetylase+%28HDAC%29+inhibitor%2C+and+prediction+of+human+pharmacokinetics&doi=10.1124%2Fdmd.111.041558"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.041558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.041558%26sid%3Dliteratum%253Aachs%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DEthirajulu%26aufirst%3DK.%26atitle%3DPreclinical%2520metabolism%2520and%2520disposition%2520of%2520SB939%2520%2528Pracinostat%2529%252C%2520an%2520orally%2520active%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%252C%2520and%2520prediction%2520of%2520human%2520pharmacokinetics%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2219%26epage%3D2232%26doi%3D10.1124%2Fdmd.111.041558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yecheng Li, Chongze Zhao, Jianhua Zhang, Shiyang Zhai, Boyan Wei, <span class="NLM_string-name hlFld-ContribAuthor">Ling Wang</span>. </span><span class="cited-content_cbyCitation_article-title">HybridMolDB: A Manually Curated Database Dedicated to Hybrid Molecules for Chemical Biology and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (10)
                                     , 4063-4069. <a href="https://doi.org/10.1021/acs.jcim.9b00314" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00314%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DHybridMolDB%25253A%252BA%252BManually%252BCurated%252BDatabase%252BDedicated%252Bto%252BHybrid%252BMolecules%252Bfor%252BChemical%252BBiology%252Band%252BDrug%252BDiscovery%26aulast%3DLi%26aufirst%3DYecheng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16042019%26date%3D25092019%26date%3D16092019%26volume%3D59%26issue%3D10%26spage%3D4063%26epage%3D4069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kehui Zhang, Fangfang Lai, Songwen Lin, Ming Ji, Jingbo Zhang, Yan Zhang, Jing Jin, Rong Fu, Deyu Wu, Hua Tian, Nina Xue, Li Sheng, Xiaowen Zou, Yan Li, Xiaoguang Chen, <span class="NLM_string-name hlFld-ContribAuthor">Heng Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6992-7014. <a href="https://doi.org/10.1021/acs.jmedchem.9b00390" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00390%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B4-Methyl%252BQuinazoline%252BDerivatives%252Bas%252BAnticancer%252BAgents%252BSimultaneously%252BTargeting%252BPhosphoinositide%252B3-Kinases%252Band%252BHistone%252BDeacetylases%26aulast%3DZhang%26aufirst%3DKehui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03032019%26date%3D29052019%26date%3D22052019%26volume%3D62%26issue%3D15%26spage%3D6992%26epage%3D7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Pengqin  Chen</span>, <span class="hlFld-ContribAuthor ">Yongli  Duan</span>, <span class="hlFld-ContribAuthor ">Hehua  Xiong</span>, <span class="hlFld-ContribAuthor ">Hongmin  Li</span>, <span class="hlFld-ContribAuthor ">Yao  Zeng</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>, <span class="hlFld-ContribAuthor ">Qidong  Tang</span>, <span class="hlFld-ContribAuthor ">Di  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113273. <a href="https://doi.org/10.1016/j.ejmech.2021.113273" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113273</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113273%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bcontaining%252B1%25252C8-naphthyridine-4-one%252Bfragment%26aulast%3DZhang%26aufirst%3DJianqing%26date%3D2021%26volume%3D215%26spage%3D113273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositolâ3âkinase (PI3K): Current and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 448-457. <a href="https://doi.org/10.1002/cmdc.202000643" title="DOI URL">https://doi.org/10.1002/cmdc.202000643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000643%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMultitarget%252BInhibition%252Bof%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252Band%252BPhosphatidylinositol%2525E2%252580%2525903%2525E2%252580%252590kinase%252B%252528PI3K%252529%25253A%252BCurrent%252Band%252BFuture%252BProspects%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D448%26epage%3D457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of âclassicalâ HDAC inhibitors to âhybridâ HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">FrÃ©dÃ©ric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long  Li</span>, <span class="hlFld-ContribAuthor ">JunâDong  Liu</span>, <span class="hlFld-ContribAuthor ">GuoâDong  Gao</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">YuâWei  Song</span>, <span class="hlFld-ContribAuthor ">HongâBo  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Puerarin 6â³âOâxyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2020,</strong> <em>9 </em>
                                    (17)
                                     , 6399-6410. <a href="https://doi.org/10.1002/cam4.3285" title="DOI URL">https://doi.org/10.1002/cam4.3285</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.3285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.3285%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DPuerarin%252B6%2525E2%252580%2525B3%2525E2%252580%252590O%2525E2%252580%252590xyloside%252Bsuppressed%252BHCC%252Bvia%252Bregulating%252Bproliferation%25252C%252Bstemness%25252C%252Band%252Bapoptosis%252Bwith%252Binhibited%252BPI3K%25252FAKT%25252FmTOR%26aulast%3DLi%26aufirst%3DLong%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D17%26spage%3D6399%26epage%3D6410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chu  Tang</span>, <span class="hlFld-ContribAuthor ">Yang  Du</span>, <span class="hlFld-ContribAuthor ">Qian  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Jie  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging and Biology</span><span> <strong>2020,</strong> <em>22 </em>
                                    (3)
                                     , 476-485. <a href="https://doi.org/10.1007/s11307-019-01389-4" title="DOI URL">https://doi.org/10.1007/s11307-019-01389-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11307-019-01389-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11307-019-01389-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%2520and%2520Biology%26atitle%3DDevelopment%252Bof%252Ba%252BNovel%252BHistone%252BDeacetylase-Targeted%252BNear-Infrared%252BProbe%252Bfor%252BHepatocellular%252BCarcinoma%252BImaging%252Band%252BFluorescence%252BImage-Guided%252BSurgery%26aulast%3DTang%26aufirst%3DChu%26date%3D2020%26date%3D2019%26volume%3D22%26issue%3D3%26spage%3D476%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dizhong  Chen</span>, <span class="hlFld-ContribAuthor ">Chang Kai  Soh</span>, <span class="hlFld-ContribAuthor ">Wei Huang  Goh</span>, <span class="hlFld-ContribAuthor ">Zilong  Wang</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103724. <a href="https://doi.org/10.1016/j.bioorg.2020.103724" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103724%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B6-phenylpurine%252Blinked%252Bhydroxamates%252Bas%252Bnovel%252Bhistone%252Bdeacetylase%252Binhibitors%26aulast%3DChen%26aufirst%3DDizhong%26date%3D2020%26volume%3D98%26spage%3D103724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Fabiana S.  Guerra</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena M. Pinheiro</span>, <span class="hlFld-ContribAuthor ">Marina A.  Alves</span>, <span class="hlFld-ContribAuthor ">Sreekanth  Thota</span>, <span class="hlFld-ContribAuthor ">Lorrane S.  Chaves</span>, <span class="hlFld-ContribAuthor ">Carlos M. R.  Sant'Anna</span>, <span class="hlFld-ContribAuthor ">PatrÃ­cia D.  Fernandes</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Pharmacological Evaluation of FirstâinâClass Multitarget
              N
              âAcylhydrazone Derivatives as Selective HDAC6/8 and PI3KÎ± Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 539-551. <a href="https://doi.org/10.1002/cmdc.201900716" title="DOI URL">https://doi.org/10.1002/cmdc.201900716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900716%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPharmacological%252BEvaluation%252Bof%252BFirst%2525E2%252580%252590in%2525E2%252580%252590Class%252BMultitarget%252BN%252B%2525E2%252580%252590Acylhydrazone%252BDerivatives%252Bas%252BSelective%252BHDAC6%25252F8%252Band%252BPI3K%2525CE%2525B1%252BInhibitors%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D539%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Yu</span>, <span class="hlFld-ContribAuthor ">Minghui  Zeng</span>, <span class="hlFld-ContribAuthor ">Zhaoping  Pan</span>, <span class="hlFld-ContribAuthor ">Fengbo  Wu</span>, <span class="hlFld-ContribAuthor ">Li  Guo</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel akt1 inhibitor induces autophagy associated death in hepatocellular carcinoma cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112076. <a href="https://doi.org/10.1016/j.ejmech.2020.112076" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112076%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bakt1%252Binhibitor%252Binduces%252Bautophagy%252Bassociated%252Bdeath%252Bin%252Bhepatocellular%252Bcarcinoma%252Bcells%26aulast%3DYu%26aufirst%3DMeng%26date%3D2020%26volume%3D189%26spage%3D112076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Tomaselli</span>, <span class="hlFld-ContribAuthor ">Alessia  Lucidi</span>, <span class="hlFld-ContribAuthor ">Dante  Rotili</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic polypharmacology: A new frontier for epiâdrug discovery. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (1)
                                     , 190-244. <a href="https://doi.org/10.1002/med.21600" title="DOI URL">https://doi.org/10.1002/med.21600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21600%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEpigenetic%252Bpolypharmacology%25253A%252BA%252Bnew%252Bfrontier%252Bfor%252Bepi%2525E2%252580%252590drug%252Bdiscovery%26aulast%3DTomaselli%26aufirst%3DDaniela%26date%3D2020%26date%3D2019%26volume%3D40%26issue%3D1%26spage%3D190%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solventâexposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">LÃ­dia M.  Lima</span>, <span class="hlFld-ContribAuthor ">Marina A.  Alves</span>, <span class="hlFld-ContribAuthor ">Daniel N.  do Amaral</span>. </span><span class="cited-content_cbyCitation_article-title">Homologation: A Versatile Molecular Modification Strategy to Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (19)
                                     , 1734-1750. <a href="https://doi.org/10.2174/1568026619666190808145235" title="DOI URL">https://doi.org/10.2174/1568026619666190808145235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190808145235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190808145235%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DHomologation%25253A%252BA%252BVersatile%252BMolecular%252BModification%252BStrategy%252Bto%252BDrug%252BDiscovery%26aulast%3DLima%26aufirst%3DL%25C3%25ADdia%2BM.%26date%3D2019%26volume%3D19%26issue%3D19%26spage%3D1734%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah Ama  Baidoo</span>, <span class="hlFld-ContribAuthor ">Emmanuel Konadu  Sarkodie</span>, <span class="hlFld-ContribAuthor ">Kofi Oti  Boakye-Yiadom</span>, <span class="hlFld-ContribAuthor ">Samuel  Kesse</span>. </span><span class="cited-content_cbyCitation_article-title">Nanomedicinal delivery systems for intelligent treatment of hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Delivery Science and Technology</span><span> <strong>2019,</strong> <em>53 </em>, 101152. <a href="https://doi.org/10.1016/j.jddst.2019.101152" title="DOI URL">https://doi.org/10.1016/j.jddst.2019.101152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jddst.2019.101152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jddst.2019.101152%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Delivery%2520Science%2520and%2520Technology%26atitle%3DNanomedicinal%252Bdelivery%252Bsystems%252Bfor%252Bintelligent%252Btreatment%252Bof%252Bhepatocellular%252Bcarcinoma%26aulast%3DBaidoo%26aufirst%3DSarah%2BAma%26date%3D2019%26volume%3D53%26spage%3D101152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Stazi</span>, <span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Andrea  Mattevi</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 89-100. <a href="https://doi.org/10.1016/j.cbpa.2019.03.002" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DHistone%252Bdeacetylases%252Bas%252Ban%252Bepigenetic%252Bpillar%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhybrid%252Binhibitors%252Bin%252Bcancer%26aulast%3DStazi%26aufirst%3DGiulia%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bohong  Liao</span>, <span class="hlFld-ContribAuthor ">Lingrong  Peng</span>, <span class="hlFld-ContribAuthor ">Jin  Zhou</span>, <span class="hlFld-ContribAuthor ">Huiting  Mo</span>, <span class="hlFld-ContribAuthor ">Jialan  Zhao</span>, <span class="hlFld-ContribAuthor ">Zike  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Guo</span>, <span class="hlFld-ContribAuthor ">Peiquan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhibo  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Activity Evaluation of Nasopharyngeal Carcinoma Inhibitors Based on 6â(Pyrimidinâ4âyl)â1
              H
              âindazole. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2019,</strong> <em>16 </em>
                                    (5)
                                     , e1800598. <a href="https://doi.org/10.1002/cbdv.201800598" title="DOI URL">https://doi.org/10.1002/cbdv.201800598</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201800598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201800598%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DSynthesis%252Band%252BActivity%252BEvaluation%252Bof%252BNasopharyngeal%252BCarcinoma%252BInhibitors%252BBased%252Bon%252B6%2525E2%252580%252590%252528Pyrimidin%2525E2%252580%2525904%2525E2%252580%252590yl%252529%2525E2%252580%2525901%252BH%252B%2525E2%252580%252590indazole%26aulast%3DLiao%26aufirst%3DBohong%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D5%26spage%3De1800598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima  Arshad</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Lalit Mohan  Nainwal</span>, <span class="hlFld-ContribAuthor ">Sumit Kumar  Kaushik</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Suhel  Parvez</span>, <span class="hlFld-ContribAuthor ">Syed Misbahul  Hasan</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing quinquennial anticancer journey of morpholine: A SAR based review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 324-356. <a href="https://doi.org/10.1016/j.ejmech.2019.02.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRevealing%252Bquinquennial%252Banticancer%252Bjourney%252Bof%252Bmorpholine%25253A%252BA%252BSAR%252Bbased%252Breview%26aulast%3DArshad%26aufirst%3DFatima%26date%3D2019%26volume%3D167%26spage%3D324%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahrous A.  Abou-Salim</span>, <span class="hlFld-ContribAuthor ">Mohamed A.  Shaaban</span>, <span class="hlFld-ContribAuthor ">Mohammed K.  Abd El Hameid</span>, <span class="hlFld-ContribAuthor ">Yaseen A.M.M.  Elshaier</span>, <span class="hlFld-ContribAuthor ">Fathi  Halaweish</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>85 </em>, 515-533. <a href="https://doi.org/10.1016/j.bioorg.2019.01.068" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.01.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.01.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.01.068%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bstudy%252Bof%252Bhybrid%252Bdrug%252Bcandidates%252Bof%252Bnitric%252Boxide%252Breleasing%252Bcucurbitacin-inspired%252Bestrone%252Banalogs%252Bfor%252Btreatment%252Bof%252Bhepatocellular%252Bcarcinoma%26aulast%3DAbou-Salim%26aufirst%3DMahrous%2BA.%26date%3D2019%26volume%3D85%26spage%3D515%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keywan  Mortezaee</span>. </span><span class="cited-content_cbyCitation_article-title">Human hepatocellular carcinoma: Protection by melatonin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2018,</strong> <em>233 </em>
                                    (10)
                                     , 6486-6508. <a href="https://doi.org/10.1002/jcp.26586" title="DOI URL">https://doi.org/10.1002/jcp.26586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.26586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.26586%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DHuman%252Bhepatocellular%252Bcarcinoma%25253A%252BProtection%252Bby%252Bmelatonin%26aulast%3DMortezaee%26aufirst%3DKeywan%26date%3D2018%26date%3D2018%26volume%3D233%26issue%3D10%26spage%3D6486%26epage%3D6508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba M.  Hesham</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (6)
                                     , 2058-2109. <a href="https://doi.org/10.1002/med.21505" title="DOI URL">https://doi.org/10.1002/med.21505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21505%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DChimeric%252BHDAC%252Binhibitors%25253A%252BComprehensive%252Breview%252Bon%252Bthe%252BHDAC-based%252Bstrategies%252Bdeveloped%252Bto%252Bcombat%252Bcancer%26aulast%3DHesham%26aufirst%3DHeba%2BM.%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D6%26spage%3D2058%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanwen  Chen</span>, <span class="hlFld-ContribAuthor ">Peiming  Zhang</span>, <span class="hlFld-ContribAuthor ">Huali  Chen</span>, <span class="hlFld-ContribAuthor ">Pu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Yu</span>, <span class="hlFld-ContribAuthor ">Zongjie  Gan</span>. </span><span class="cited-content_cbyCitation_article-title">An Improved and Efficient Synthesis of Panobinostat. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2018,</strong> <em>42 </em>
                                    (9)
                                     , 471-473. <a href="https://doi.org/10.3184/174751918X15357309308931" title="DOI URL">https://doi.org/10.3184/174751918X15357309308931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751918X15357309308931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751918X15357309308931%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DAn%252BImproved%252Band%252BEfficient%252BSynthesis%252Bof%252BPanobinostat%26aulast%3DChen%26aufirst%3DShanwen%26date%3D2018%26date%3D2018%26volume%3D42%26issue%3D9%26spage%3D471%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Schiedel</span>, <span class="hlFld-ContribAuthor ">Stuart J  Conway</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules as tools to study the chemical epigenetics of lysine acetylation. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2018,</strong> <em>45 </em>, 166-178. <a href="https://doi.org/10.1016/j.cbpa.2018.06.015" title="DOI URL">https://doi.org/10.1016/j.cbpa.2018.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2018.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DSmall%252Bmolecules%252Bas%252Btools%252Bto%252Bstudy%252Bthe%252Bchemical%252Bepigenetics%252Bof%252Blysine%252Bacetylation%26aulast%3DSchiedel%26aufirst%3DMatthias%26date%3D2018%26volume%3D45%26spage%3D166%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples and chemical structure features of HDAC inhibitors (HDACi), PI3K/mTOR inhibitors, and HDAC/PI3K dual inhibitor. <b>3</b> (CUDC-907) is considered to be a hybrid derivative of pictilisib and quisinostat. Both idelalisib and panobinostat were issued with a boxed warning by FDA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design and chemical types of inhibitors targeting HDACs, PI3Ks, and mTOR. IC<sub>50</sub> data of Cpd-38 (<b>6</b>) and Cpd-51 (<b>8</b>) were extracted from ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">26</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of N-9 Substituted Purines <b>17a</b>â<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaI (0.2 equiv), anhydrous K<sub>2</sub>CO<sub>3</sub> (2 equiv), Br(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>5</sup> (<b>12a</b>â<b>d</b>, m = 3,4,5,6, R<sup>5</sup> = Et or Me; 1.1 equiv), DMF, 40 Â°C, 12 h, 61â78%; (b) <b>14a</b> (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), 82 Â°C for 6 h, 24â72%; (c) morpholine, DMF, 80 Â°C, 12 h, 56â72%; (d) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt, 21â38%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 2-Aryl-9-substituted Purines and Pyrrolo[2,3-<i>d</i>]pyrimidines <b>20a</b>â<b>v</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine (3 equiv), DCM, 40 Â°C, 3 h or rt overnight, 87â99%; (b) boronic acid or ester <b>14a</b>â<b>o</b> (1.1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), 82 Â°C for 6 h, 28â90%; (c) neat morpholine (excess), 78 Â°C, overnight; (d) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt; (e) 2-bromoethanol (3 equiv), K<sub>2</sub>CO<sub>3</sub> (5 equiv), DMF, 90 Â°C; (f) NaBH<sub>4</sub> (10 equiv), MeOH, rt, 95%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 6-Substituted Purines <b>23a</b> and <b>23b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>13d</b> (1 equiv), piperidin-4-ylmethanol or piperidin-4-ol (6 equiv), Et<sub>3</sub>N (6 equiv), DCM, 40 Â°C, overnight; (b) <b>14a</b> (3 equiv), K<sub>2</sub>CO<sub>3</sub> (4 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), microwave 150 Â°C, 10â30 min; (c) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of N-9 Aryl linked Purine Hydroxamates <b>29</b>, <b>31</b>, and <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) morpholine (3 equiv), rt, THF; (b) ICH<sub>2</sub>CN (2 equiv), anhydrous K<sub>2</sub>CO<sub>3</sub> (2 equiv), MeCN-DMSO (19:1, v/v), 60 Â°C; (c) NiCl<sub>2</sub>Â·6H<sub>2</sub>O (0.1 equiv), NaBH<sub>4</sub> (7 equiv), THF/MeOH (1:2); (d) methyl 3-(4-formylphenyl)acrylate (1.2 equiv), NaBH(OAc)<sub>3</sub> (1.5 equiv), HOAc (1 equiv), DCE, rt; (e) <b>14a</b> or <b>14d</b> (2.0 equiv, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), dioxane/water, Pd(dppf)Cl<sub>2</sub>Â·CH<sub>2</sub>Cl<sub>2</sub> (0.05 equiv), microwave 15â30 min; (f) NH<sub>2</sub>OHÂ·HCl (10 equiv)/NaOMe (25 equiv)/MeOH, â20 Â°C to rt; (g) <i>p</i>-BrCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>CH<sub>3</sub> (1.1 equiv), Et<sub>3</sub>N (1.2 equiv), THF, rt, 2 h.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Caspase activity induction and cell death in MV4-11 cells. (A) Maximal caspase activity at 24 h. MV4-11 cells were treated with <b>20f</b> (blue downward pointing triangles), vorinostat (red circles), and pictilisib (black tilted squares), respectively. Caspase 3/7 activity was monitored at 6, 24, 48, and 72 h, respectively. Maximal activity was found and shown at 24 h, expressed as fold of change (treated vs vehicle, mean Â± SD). (B) Maximal cell death occurred at 48 h. MV4-11 cells were treated with <b>20f</b> (blue downward pointing triangles) vorinostat (red circles), and pictilisib (black tilted squares), respectively. Cell death was monitored at 24, 48, and 72 h. Maximal cell death as fold of treated vs vehicle was occurred at 48 h. <i>y</i>-Axis is expressed as mean Â± SD. EC<sub>50</sub> value was calculated by fitting the doseâresponse curve with Prism 4.0.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Clonogenic and soft agar assays and IC<sub>50</sub> values. <b>20f</b> inhibited colony formation of Hep3B and HuH-7 cells under anchorage-dependent conditions and inhibited colony formation of NCI-H460 and 4T1 (murine triple negative breast cancer) cells in soft agar assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Modulation of HDACs and PI3K/Akt/mTOR pathway in liver cancer cells. (A) HepG2 cells were serum starved overnight (20 h), then treated with vehicle (0.1% DMSO) or compounds for 4 h, followed by stimulation with growth factors FGF2 (50 ng/mL), IGF-1 (100 ng/mL), and EGF (50 ng/mL) for 15 min, respectively. Veh: vehicle. (B) HuH-7 cells were treated with vehicle (0.1% DMSO) or compounds in serum-free media for 4 h including last 12 min stimulated with VEGF (20 ng/mL). Vor, vorinostat; Pic, pictilisib; Sor, sorafenib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Modulation of HDACs in tumor-bearing mice models. (A) Hyperacetylation of H3 in MV4-11 tumors induced by <b>20f</b> and <b>20q</b>. Tumor bearing BALB/c nude mice were treated with vehicle [DMSO/PEG400/sterile water (10:40:50)] (3 h, po, 10 mL/kg), <b>20f</b>, which was administered in three routes (po, 150 mg/kg; iv, 50 mg/kg and ip, 100 mg/kg), and <b>20q</b>, which was administered in two routes (po, 100 mg/kg and iv, 25 mg/kg). (B) Intensity of normalized AcH3 (Lys9) bands in A. (C) Hyperacetylation of H3 and Î±-tubulin in HepG2 tumors induced by <b>20f</b>. Tumor bearing NCr nude mice were treated with vehicle (3 h, po, 10 mL/kg) and <b>20f</b>, which was administered in two routes: po (150 mg/kg, 1 and 3 h) and ip (75 mg/kg, 4 and 19 h).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Tissue distribution of <b>20f</b> (po, 100 mg/kg) in Hep3B tumor bearing NCr nude mice. AUCs (1â24 h) of liver (blue upward pointing triangles) and Hep3B tumor (green downward pointing triangles) were 21- and 5.4-fold that of plasma (red circles), respectively. Drug in tumor tissue had a similar terminal half-life as plasma (6.5 vs 6.0 h), but the drug in liver had a longer terminal half-life of 11.1 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/medium/jm-2017-01465h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Doseâresponse of <b>20f</b> in HepG2 xenograft model. (A) HepG2 tumor-bearing CB17 scid mice were treated orally with vehicle (black squares), <b>20f</b> (150 (blue upward poiting triangles), 75 (violet downward pointing triangles), and 37.5 (green tilted squares) mg/kg), and sorafenib tosylate (red circles, 100 mg/kg QD Ã 5 Ã 2 then 80 mg/kg, QD Ã 5 Ã 2) for 4 weeks (QD Ã 5 per week) from day 0 with mean tumor volume about 240 mm<sup>3</sup>. Tumor volume (<i>y</i> axis) is expressed as mean Â± SEM * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001, and **** <i>p</i> â¤ 0.0001. (B) <b>20f</b> was well-tolerated at all dose levels, no significant body weight (BW) loss. Vehicle group had BW loss due to increasing tumor burden. Sorafenib tosylate (100 mg/kg) was not well-tolerated; its dose was reduced to 80 mg/kg in the third and fourth cycles. (C) Tumor volume at day 28 after 4 cycles of treatment. (D) Tumor image of mice on day 26 after last dose of the fourth cycle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01465/20180215/images/large/jm-2017-01465h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01465&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38823" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38823" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>Development History and FDA Approval Process for Nexavar; <span class="NLM_publisher-name">Drugs.com</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="https://www.drugs.com/history/nexavar.html" class="extLink">https://www.drugs.com/history/nexavar.html</a> (accessed Aug 15, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Development+History+and+FDA+Approval+Process+for+Nexavar%3B+Drugs.com%2C+2007%3B+https%3A%2F%2Fwww.drugs.com%2Fhistory%2Fnexavar.html+%28accessed+Aug+15%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%2520History%2520and%2520FDA%2520Approval%2520Process%2520for%2520Nexavar%26pub%3DDrugs.com%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lencioni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llovet, J. M.</span><span> </span><span class="NLM_article-title">Modified RECIST (mRECIST) assessment for hepatocellular carcinoma</span> <span class="citation_source-journal">Semin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">052</span><span class="NLM_x">â</span> <span class="NLM_lpage">060</span><span class="refDoi">Â DOI: 10.1055/s-0030-1247132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1055%2Fs-0030-1247132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=20175033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFCqtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=052-060&author=R.+Lencioniauthor=J.+M.+Llovet&title=Modified+RECIST+%28mRECIST%29+assessment+for+hepatocellular+carcinoma&doi=10.1055%2Fs-0030-1247132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Modified RECIST (mRECIST) assessment for hepatocellular carcinoma</span></div><div class="casAuthors">Lencioni, Riccardo; Llovet, Josep M.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-60</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  The endpoint in cancer research is overall survival.  Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used.  Measurement of response rate in hepatocellular carcinoma (HCC) has become a controversial issue.  The World Health Organization (WHO) criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Assocn. for the Study of the Liver (EASL) to take into account treatment-induced tumor necrosis.  Applying these guidelines, there was an assocn. between response rate and outcome prediction.  More recently, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was proposed as a method for measuring treatment response based on tumor shrinkage, which is a valuable measure of antitumor activity of cytotoxic drugs.  This method was initially adopted by regulatory agencies, such as the U.S.  Food and Drug Administration (FDA), for drug approval.  However, anat. tumor response metrics can be misleading when applied to mol.-targeted therapies or locoregional therapies in HCC.  In 2008, a group of experts convened by the American Assocn. for the Study of Liver Diseases (AASLD) developed a set of guidelines aimed at providing a common framework for the design of clin. trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiol. imaging techniques-to formally amend RECIST.  These amendments conformed the AASLD-JNCI (Journal of the National Cancer Institute) guidelines and are summarized and clarified in the current article.  They are referred to herein as the modified RECIST assessment (mRECIST).  Further studies are needed to confirm the accuracy of this measurement compared with conventional gold stds. such as pathol. studies of explanted livers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQP_LahEIq7Vg90H21EOLACvtfcHk0lg2C7OlSRvZhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFCqtbk%253D&md5=0b04fc90e67821a2183d7b88330fc3fa</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1247132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1247132%26sid%3Dliteratum%253Aachs%26aulast%3DLencioni%26aufirst%3DR.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DModified%2520RECIST%2520%2528mRECIST%2529%2520assessment%2520for%2520hepatocellular%2520carcinoma%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2010%26volume%3D30%26spage%3D052%26epage%3D060%26doi%3D10.1055%2Fs-0030-1247132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>Development History and FDA Approval Process for Stivarga; <span class="NLM_publisher-name">Drugs.com</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="https://www.drugs.com/history/stivarga.html" class="extLink">https://www.drugs.com/history/stivarga.html</a> (accessed Aug 18, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Development+History+and+FDA+Approval+Process+for+Stivarga%3B+Drugs.com%2C+2017%3B+https%3A%2F%2Fwww.drugs.com%2Fhistory%2Fstivarga.html+%28accessed+Aug+18%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDevelopment%2520History%2520and%2520FDA%2520Approval%2520Process%2520for%2520Stivarga%26pub%3DDrugs.com%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Llovet, J. M.</span><span> </span><span class="NLM_article-title">Regorafenib in second-line setting for hepatocellular carcinoma: balancing benefit with toxicity</span>. The ASCO Post<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">, </span><a href="http://www.ascopost.com/issues/february-25-2017/regorafenib-in-second-line-setting-for-hepatocellular-carcinoma-balancing-benefit-with-toxicity/" class="extLink">http://www.ascopost.com/issues/february-25-2017/regorafenib-in-second-line-setting-for-hepatocellular-carcinoma-balancing-benefit-with-toxicity/</a> (accessed Aug 18, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+M.+Llovet&title=Regorafenib+in+second-line+setting+for+hepatocellular+carcinoma%3A+balancing+benefit+with+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DRegorafenib%2520in%2520second-line%2520setting%2520for%2520hepatocellular%2520carcinoma%253A%2520balancing%2520benefit%2520with%2520toxicity%26jtitle%3DThe%2520ASCO%2520Post%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assenat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, R. T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanc, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorval, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck-Radosavljevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jappe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perraud, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anak, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellami, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.-T.</span><span> </span><span class="NLM_article-title">Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the evolve-1 randomized clinical trial</span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">â</span> <span class="NLM_lpage">67</span><span class="refDoi">Â DOI: 10.1001/jama.2014.7189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1001%2Fjama.2014.7189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ajsb3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=57-67&author=A.+X.+Zhuauthor=M.+Kudoauthor=E.+Assenatauthor=S.+Cattanauthor=Y.-K.+Kangauthor=H.+Y.+Limauthor=R.+T.+P.+Poonauthor=J.-F.+Blancauthor=A.+Vogelauthor=C.-L.+Chenauthor=E.+Dorvalauthor=M.+Peck-Radosavljevicauthor=A.+Santoroauthor=B.+Danieleauthor=J.+Furuseauthor=A.+Jappeauthor=K.+Perraudauthor=O.+Anakauthor=D.+B.+Sellamiauthor=L.-T.+Chen&title=Effect+of+everolimus+on+survival+in+advanced+hepatocellular+carcinoma+after+failure+of+sorafenib%3A+the+evolve-1+randomized+clinical+trial&doi=10.1001%2Fjama.2014.7189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial</span></div><div class="casAuthors">Zhu, Andrew X.; Kudo, Masatoshi; Assenat, Eric; Cattan, Stephane; Kang, Yoon-Koo; Lim, Ho Yeong; Poon, Ronnie T. P.; Blanc, Jean-Frederic; Vogel, Arndt; Chen, Chao-Long; Dorval, Etienne; Peck-Radosavljevic, Markus; Santoro, Armando; Daniele, Bruno; Furuse, Junji; Jappe, Annette; Perraud, Kevin; Anak, Oezlem; Sellami, Dalila B.; Chen, Li-Tzong</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma.  To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed.  EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib.  Patients were enrolled from 17 countries between May 2010 and March 2012.  Randomization was stratified by region (Asia vs rest of world) and macrovascular invasion (present vs absent). interventions Everolimus, 7.5 mg/d, or matching placebo, both given in combination with best supportive care and continued until disease progression or intolerable toxicity.  Per the 2:1 randomization scheme, 362 patients were randomized to the everolimus group and 184 patients to the placebo group. main outcomes and measures The primary end point was overall survival.  Secondary end points included time to progression and the disease control rate (the percentage of patients with a best overall response of complete or partial response or stable disease).  No significant difference in overall survival was seen between treatment groups, with 303 deaths (83.7%) in the everolimus group and 151 deaths (82.1%) in the placebo group (hazard ratio [HR], 1.05; 95% CI, 0.86-1.27; P = .68; median overall survival, 7.6 mo with everolimus, 7.3 mo with placebo).  Median time to progression with everolimus and placebo was 3.0 mo and 2.6 mo, resp. (HR, 0.93; 95% CI, 0.75-1.15), and disease control rate was 56.1% and 45.1%, resp. (P = .01).  The most common grade 3/4 adverse events for everolimus vs placebo were anemia (7.8% vs 3.3%, resp.), asthenia (7.8% vs 5.5%, resp.), and decreased appetite (6.1% vs 0.5%, resp.).  No patients experienced hepatitis C viral flare.  Based on central lab. results, hepatitis B viral reactivation was experienced by 39 patients (29 everolimus, 10 placebo); all cases were asymptomatic, but 3 everolimus recipients discontinued therapy.  Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmxZyfMYR3M7Vg90H21EOLACvtfcHk0lh0hPzasbLp0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ajsb3M&md5=0340dd764397b4a9c25638769d569e4c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.7189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.7189%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DKudo%26aufirst%3DM.%26aulast%3DAssenat%26aufirst%3DE.%26aulast%3DCattan%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DY.-K.%26aulast%3DLim%26aufirst%3DH.%2BY.%26aulast%3DPoon%26aufirst%3DR.%2BT.%2BP.%26aulast%3DBlanc%26aufirst%3DJ.-F.%26aulast%3DVogel%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DDorval%26aufirst%3DE.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DDaniele%26aufirst%3DB.%26aulast%3DFuruse%26aufirst%3DJ.%26aulast%3DJappe%26aufirst%3DA.%26aulast%3DPerraud%26aufirst%3DK.%26aulast%3DAnak%26aufirst%3DO.%26aulast%3DSellami%26aufirst%3DD.%2BB.%26aulast%3DChen%26aufirst%3DL.-T.%26atitle%3DEffect%2520of%2520everolimus%2520on%2520survival%2520in%2520advanced%2520hepatocellular%2520carcinoma%2520after%2520failure%2520of%2520sorafenib%253A%2520the%2520evolve-1%2520randomized%2520clinical%2520trial%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D312%26spage%3D57%26epage%3D67%26doi%3D10.1001%2Fjama.2014.7189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ler, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, C. H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khin, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salto-Tellez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iau, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooi, S. C.</span><span> </span><span class="NLM_article-title">HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a southeast asian population</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">2238</span><span class="NLM_x">â</span> <span class="NLM_lpage">2250</span><span class="refDoi">Â DOI: 10.3892/or.2015.4263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.3892%2For.2015.4263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=26352599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslertQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=2238-2250&author=S.+Y.+Lerauthor=C.+H.+W.+Leungauthor=L.+W.+Khinauthor=G.-D.+Luauthor=M.+Salto-Tellezauthor=M.+Hartmanauthor=P.+T.+C.+Iauauthor=C.+T.+Yapauthor=S.+C.+Hooi&title=HDAC1+and+HDAC2+independently+predict+mortality+in+hepatocellular+carcinoma+by+a+competing+risk+regression+model+in+a+southeast+asian+population&doi=10.3892%2For.2015.4263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population</span></div><div class="casAuthors">Ler, Ser Yeng; Leung, Carol Ho Wing; Khin, Lay Wai; Lu, Guo-Dong; Salto-Tellez, Manuel; Hartman, Mikael; Iau, Philip Tsau Choong; Yap, Celestial T.; Hooi, Shing Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2238-2250</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are enzymes involved in transcriptional repression.  We aimed to examine the significance of HDAC1 and HDAC2 gene expression in the prediction of recurrence and survival in 156 patients with hepatocellular carcinoma (HCC) among a South East Asian population who underwent curative surgical resection in Singapore.  We found that HDAC1 and HDAC2 were upregulated in the majority of HCC tissues.  The presence of HDAC1 in tumor tissues was correlated with poor tumor differentiation.  Notably, HDAC1 expression in adjacent non-tumor hepatic tissues was correlated with the presence of satellite nodules and multiple lesions, suggesting that HDAC1 upregulation within the field of HCC may contribute to tumor spread.  Using competing risk regression anal., we found that increased cancer-specific mortality was significantly assocd. with HDAC2 expression.  Mortality was also increased with high HDAC1 expression.  In the liver cancer cell lines, HEP3B, HEPG2, PLC5, and a colorectal cancer cell line, HCT116, the combined knockdown of HDAC1 and HDAC2 increased cell death and reduced cell proliferation as well as colony formation.  In contrast, knockdown of either HDAC1 or HDAC2 alone had minimal effects on cell death and proliferation.  Taken together, our study suggests that both HDAC1 and HDAC2 exert pro-survival effects in HCC cells, and the combination of isoform-specific HDAC inhibitors against both HDACs may be effective in targeting HCC to reduce mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra_m8roQBnSLVg90H21EOLACvtfcHk0lh0hPzasbLp0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslertQ%253D%253D&md5=0bf5acf5c73654edf0b407175ce74d85</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3892%2For.2015.4263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2015.4263%26sid%3Dliteratum%253Aachs%26aulast%3DLer%26aufirst%3DS.%2BY.%26aulast%3DLeung%26aufirst%3DC.%2BH.%2BW.%26aulast%3DKhin%26aufirst%3DL.%2BW.%26aulast%3DLu%26aufirst%3DG.-D.%26aulast%3DSalto-Tellez%26aufirst%3DM.%26aulast%3DHartman%26aufirst%3DM.%26aulast%3DIau%26aufirst%3DP.%2BT.%2BC.%26aulast%3DYap%26aufirst%3DC.%2BT.%26aulast%3DHooi%26aufirst%3DS.%2BC.%26atitle%3DHDAC1%2520and%2520HDAC2%2520independently%2520predict%2520mortality%2520in%2520hepatocellular%2520carcinoma%2520by%2520a%2520competing%2520risk%2520regression%2520model%2520in%2520a%2520southeast%2520asian%2520population%26jtitle%3DOncol.%2520Rep.%26date%3D2015%26volume%3D34%26spage%3D2238%26epage%3D2250%26doi%3D10.3892%2For.2015.4263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wu, L.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S.-S.</span><span> </span><span class="NLM_article-title">Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e14460</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0014460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1371%2Fjournal.pone.0014460" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e14460&author=L.-M.+Wuauthor=Z.+Yangauthor=L.+Zhouauthor=F.+Zhangauthor=H.-Y.+Xieauthor=X.-W.+Fengauthor=J.+Wuauthor=S.-S.+Zheng&title=Identification+of+histone+deacetylase+3+as+a+biomarker+for+tumor+recurrence+following+liver+transplantation+in+HBV-associated+hepatocellular+carcinoma&doi=10.1371%2Fjournal.pone.0014460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0014460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0014460%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.-M.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DXie%26aufirst%3DH.-Y.%26aulast%3DFeng%26aufirst%3DX.-W.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DS.-S.%26atitle%3DIdentification%2520of%2520histone%2520deacetylase%25203%2520as%2520a%2520biomarker%2520for%2520tumor%2520recurrence%2520following%2520liver%2520transplantation%2520in%2520HBV-associated%2520hepatocellular%2520carcinoma%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De14460%26doi%3D10.1371%2Fjournal.pone.0014460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rikimaru, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taketomi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamatsu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maehara, Y.</span><span> </span><span class="NLM_article-title">Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">â</span> <span class="NLM_lpage">74</span><span class="refDoi">Â DOI: 10.1159/000111106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1159%2F000111106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=18004079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyksL3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=69-74&author=T.+Rikimaruauthor=A.+Taketomiauthor=Y.+Yamashitaauthor=K.+Shirabeauthor=T.+Hamatsuauthor=M.+Shimadaauthor=Y.+Maehara&title=Clinical+significance+of+histone+deacetylase+1+expression+in+patients+with+hepatocellular+carcinoma&doi=10.1159%2F000111106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma</span></div><div class="casAuthors">Rikimaru, Tatsuya; Taketomi, Akinobu; Yamashita, Yo-ichi; Shirabe, Ken; Hamatsu, Takayuki; Shimada, Mitsuo; Maehara, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">ONCOBS</span>;
        ISSN:<span class="NLM_cas:issn">0030-2414</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play an important role in chromatin remodeling, gene repression and regulating cell cycle progression and differentiation.  This study was designed to clarify the role of HDAC1 expression in hepatocellular carcinoma (HCC).  The expression of HDAC1 in 47 patients with surgically resected HCC was immunohistochem. examd. and analyzed in relation to their clinicopathol. factors.  The patients were divided into 2 groups according to the expression status of HDAC1: a high HDAC1 group (n = 25) with more than 20% of pos. stained cells and a low HDAC1 group (n = 22) with 20% or fewer pos. stained cells.  A high HDAC1 expression indicated a higher incidence of cancer cell invasion into the portal vein, a poorer histol. differentiation, and a more advanced TNM stage.  The survival rates after a surgical resection in low and high HDAC1 patients at 1, 3, 5 and 10 years were 100, 95.5, 81.8 and 60.8% and 88.0, 60.0, 40.0 and 32.0%, resp. (p = 0.008).  A multivariate anal. using the Cox regression anal. showed that a high HDAC1 expression was an independent prognostic factor of HCC in patients after hepatic resection (relative risk: 10.1, p = 0.0018).  High HDAC1 expression might have an important role in the aggressiveness and cell dedifferentiation, and its expression status may be a useful biomarker for predicting the outcome of the patients with HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonHoUSPaFTvLVg90H21EOLACvtfcHk0lh0hPzasbLp0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyksL3E&md5=f193014733ae61de5a3912679e95ce55</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000111106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000111106%26sid%3Dliteratum%253Aachs%26aulast%3DRikimaru%26aufirst%3DT.%26aulast%3DTaketomi%26aufirst%3DA.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DShirabe%26aufirst%3DK.%26aulast%3DHamatsu%26aufirst%3DT.%26aulast%3DShimada%26aufirst%3DM.%26aulast%3DMaehara%26aufirst%3DY.%26atitle%3DClinical%2520significance%2520of%2520histone%2520deacetylase%25201%2520expression%2520in%2520patients%2520with%2520hepatocellular%2520carcinoma%26jtitle%3DOncology%26date%3D2007%26volume%3D72%26spage%3D69%26epage%3D74%26doi%3D10.1159%2F000111106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Quint, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaimy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fazio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalbano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steindorf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellerbrand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neureiter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocker, M.</span><span> </span><span class="NLM_article-title">Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC</span> <span class="citation_source-journal">Virchows Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">459</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">â</span> <span class="NLM_lpage">139</span><span class="refDoi">Â DOI: 10.1007/s00428-011-1103-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1007%2Fs00428-011-1103-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=21713366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSiurrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2011&pages=129-139&author=K.+Quintauthor=A.+Agaimyauthor=P.+Di+Fazioauthor=R.+Montalbanoauthor=C.+Steindorfauthor=R.+Jungauthor=C.+Hellerbrandauthor=A.+Hartmannauthor=H.+Sitterauthor=D.+Neureiterauthor=M.+Ocker&title=Clinical+significance+of+histone+deacetylases+1%2C+2%2C+3%2C+and+7%3A+HDAC2+is+an+independent+predictor+of+survival+in+HCC&doi=10.1007%2Fs00428-011-1103-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC</span></div><div class="casAuthors">Quint, Karl; Agaimy, Abbas; Fazio, Pietro; Montalbano, Roberta; Steindorf, Claudia; Jung, Rudolf; Hellerbrand, Claus; Hartmann, Arndt; Sitter, Helmut; Neureiter, Daniel; Ocker, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-139</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylases (HDAC) are responsible for the transcriptional control of genes through chromatin remodeling and control tumor suppressor genes.  In several tumors, their expression has been linked to clinicopathol. factors and patient survival.  This study investigates HDACs 1, 2, 3, and 7 expressions in hepatocellular carcinoma (HCC) and their correlation with clin. data and patient survival.  Tissue microarrays of 170 surgically resected primary HCCs and adjacent uninvolved tissue were evaluated immunohistochem. for the expression of HDACs 1, 2, 3, 7, and Ki-67 and were analyzed with respect to clinicopathol. data and patient survival.  HDACs 1, 2, 3, and Ki-67 were expressed significantly higher in cancer cells compared to normal tissue (HDAC1: p = 0.034, HDACs 2 and 3 and Ki-67: p < 0.001), while HDAC7 expression did not differ between HCC and non-cancerous liver tissue.  In tumor tissue HDACs 1-3 expression levels showed high concordance with each other, Ki-67 and tumor grade (p < 0.001).  High HDAC2 expression was assocd. with poor survival in low-grade and early-stage tumors (p < 0.05).  The expression of the HDACs 1, 2, and 3 (but not HDAC7) isoenzymes correlates with clinicopathol. factors, and HDAC2 expression has an impact on patient survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmO0NcXY0PrVg90H21EOLACvtfcHk0lhhEhU3kaYmoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSiurrL&md5=d30de32f518c9dc7a48e20e69e237ff4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00428-011-1103-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00428-011-1103-0%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%26aufirst%3DK.%26aulast%3DAgaimy%26aufirst%3DA.%26aulast%3DDi%2BFazio%26aufirst%3DP.%26aulast%3DMontalbano%26aufirst%3DR.%26aulast%3DSteindorf%26aufirst%3DC.%26aulast%3DJung%26aufirst%3DR.%26aulast%3DHellerbrand%26aufirst%3DC.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DSitter%26aufirst%3DH.%26aulast%3DNeureiter%26aufirst%3DD.%26aulast%3DOcker%26aufirst%3DM.%26atitle%3DClinical%2520significance%2520of%2520histone%2520deacetylases%25201%252C%25202%252C%25203%252C%2520and%25207%253A%2520HDAC2%2520is%2520an%2520independent%2520predictor%2520of%2520survival%2520in%2520HCC%26jtitle%3DVirchows%2520Arch.%26date%3D2011%26volume%3D459%26spage%3D129%26epage%3D139%26doi%3D10.1007%2Fs00428-011-1103-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Zhai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.-Y.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma</span> <span class="citation_source-journal">World J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">â</span> <span class="NLM_lpage">352</span><span class="refDoi">Â DOI: 10.4254/wjh.v5.i7.345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.4254%2Fwjh.v5.i7.345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23898367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A280%3ADC%252BC3sfltFCgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=345-352&author=B.+Zhaiauthor=X.-Y.+Sun&title=Mechanisms+of+resistance+to+sorafenib+and+the+corresponding+strategies+in+hepatocellular+carcinoma&doi=10.4254%2Fwjh.v5.i7.345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma</span></div><div class="casAuthors">Zhai Bo; Sun Xue-Ying</div><div class="citationInfo"><span class="NLM_cas:title">World journal of hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">345-52</span>
        ISSN:<span class="NLM_cas:issn">1948-5182</span>.
    </div><div class="casAbstract">Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching for effective agents to combat HCC for decades.  However, the overall outcomes are far from satisfactory.  One of the explanations is the genetic heterogeneity of HCC, which has led to identifying predictive biomarkers for primary resistance to sorafenib, and then applying the concept of personalized medicine, or seeking therapeutic strategies such as combining sorafenib with other anticancer agents.  Some of the combinations have demonstrated a better effectiveness than sorafenib alone, with good tolerance.  The acquired resistance to sorafenib has also drawn attention.  As a multikinase inhibitor, sorafenib targets several cellular signaling pathways but simultaneously or sequentially the addiction switches and compensatory pathways are activated.  Several mechanisms are involved in the acquired resistance to sorafenib, such as crosstalks involving PI3K/Akt and JAK-STAT pathways, hypoxia-inducible pathways, epithelial-mesenchymal transition, etc.  Based on the investigated mechanisms, some other molecular targeted drugs have been applied as second-line treatment for treat HCC after the failure of sorafenib therapy and more are under evaluation in clinical trials.  However, the exact mechanisms accounting for sorafenib resistance remains unclear.  Further investigation on the crosstalk and relationship of associated pathways will better our understanding of the mechanisms and help to find effective strategies for overcoming sorafenib resistance in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFVzS9begP0vxQvRxYU81tfW6udTcc2eYUh59xQBZ0Jbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfltFCgtQ%253D%253D&md5=2b9607c538718a8f513d310eb9f7c773</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.4254%2Fwjh.v5.i7.345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4254%252Fwjh.v5.i7.345%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DX.-Y.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520sorafenib%2520and%2520the%2520corresponding%2520strategies%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DWorld%2520J.%2520Hepatol.%26date%3D2013%26volume%3D5%26spage%3D345%26epage%3D352%26doi%3D10.4254%2Fwjh.v5.i7.345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Janku, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaseb, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsimberidou, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3012</span><span class="NLM_x">â</span> <span class="NLM_lpage">3022</span><span class="refDoi">Â DOI: 10.18632/oncotarget.1687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.18632%2Foncotarget.1687" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3012-3022&author=F.+Jankuauthor=A.+O.+Kasebauthor=A.+M.+Tsimberidouauthor=R.+A.+Wolffauthor=R.+Kurzrock&title=Identification+of+novel+therapeutic+targets+in+the+PI3K%2FAKT%2FmTOR+pathway+in+hepatocellular+carcinoma+using+targeted+next+generation+sequencing&doi=10.18632%2Foncotarget.1687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1687%26sid%3Dliteratum%253Aachs%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DKaseb%26aufirst%3DA.%2BO.%26aulast%3DTsimberidou%26aufirst%3DA.%2BM.%26aulast%3DWolff%26aufirst%3DR.%2BA.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520novel%2520therapeutic%2520targets%2520in%2520the%2520PI3K%252FAKT%252FmTOR%2520pathway%2520in%2520hepatocellular%2520carcinoma%2520using%2520targeted%2520next%2520generation%2520sequencing%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D3012%26epage%3D3022%26doi%3D10.18632%2Foncotarget.1687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cigliano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calderaro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azoulay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demartis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribback, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utpatel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombrowski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvisi, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">10102</span><span class="NLM_x">â</span> <span class="NLM_lpage">10115</span><span class="refDoi">Â DOI: 10.18632/oncotarget.3546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.18632%2Foncotarget.3546" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10102-10115&author=X.+Liauthor=J.+Taoauthor=A.+Ciglianoauthor=M.+Siniauthor=J.+Calderaroauthor=D.+Azoulayauthor=C.+Wangauthor=Y.+Liuauthor=L.+Jiangauthor=K.+Evertauthor=M.+I.+Demartisauthor=S.+Ribbackauthor=K.+Utpatelauthor=F.+Dombrowskiauthor=M.+Evertauthor=D.+F.+Calvisiauthor=X.+Chen&title=Co-activation+of+PIK3CA+and+Yap+promotes+development+of+hepatocellular+and+cholangiocellular+tumors+in+mouse+and+human+liver&doi=10.18632%2Foncotarget.3546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3546%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DCigliano%26aufirst%3DA.%26aulast%3DSini%26aufirst%3DM.%26aulast%3DCalderaro%26aufirst%3DJ.%26aulast%3DAzoulay%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DEvert%26aufirst%3DK.%26aulast%3DDemartis%26aufirst%3DM.%2BI.%26aulast%3DRibback%26aufirst%3DS.%26aulast%3DUtpatel%26aufirst%3DK.%26aulast%3DDombrowski%26aufirst%3DF.%26aulast%3DEvert%26aufirst%3DM.%26aulast%3DCalvisi%26aufirst%3DD.%2BF.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DCo-activation%2520of%2520PIK3CA%2520and%2520Yap%2520promotes%2520development%2520of%2520hepatocellular%2520and%2520cholangiocellular%2520tumors%2520in%2520mouse%2520and%2520human%2520liver%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D10102%26epage%3D10115%26doi%3D10.18632%2Foncotarget.3546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Chen, K.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.-L.</span><span> </span><span class="NLM_article-title">Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">161</span><span class="refDoi">Â DOI: 10.1124/jpet.110.175786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1124%2Fjpet.110.175786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=21205925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGqurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=155-161&author=K.-F.+Chenauthor=H.-L.+Chenauthor=W.-T.+Taiauthor=W.-C.+Fengauthor=C.-H.+Hsuauthor=P.-J.+Chenauthor=A.-L.+Cheng&title=Activation+of+phosphatidylinositol+3-kinase%2FAkt+signaling+pathway+mediates+acquired+resistance+to+sorafenib+in+hepatocellular+carcinoma+cells&doi=10.1124%2Fjpet.110.175786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells</span></div><div class="casAuthors">Chen, Kuen-Feng; Chen, Hui-Ling; Tai, Wei-Tien; Feng, Wen-Chi; Hsu, Chih-Hung; Chen, Pei-Jer; Cheng, Ann-Lii</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-161</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human malignancies worldwide.  Sorafenib, a tyrosine kinase inhibitor, was recently approved by the United States Food and Drug Administration for HCC.  In this study, the authors established two sorafenib-resistant HCC cell lines from Huh7, a human HCC cell line, by long-term exposure of cells to sorafenib.  Sorafenib induced significant apoptosis in Huh7 cells; however, Huh7-R1 and Huh7-R2 showed significant resistance to sorafenib-induced apoptosis at the clin. relevant concns. (up to 10 Î¼M).  Thorough comparisons of the mol. changes between Huh7 and resistant cells showed that the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway played a significant role in mediating acquired resistance to sorafenib in Huh7-R1 and Huh7-R2 cells.  Phospho-Akt and p85 (a regulatory subunit of PI3K) were up-regulated, whereas tumor suppressor phosphatase and tensin homolog were down-regulated in these resistant cells.  In addn., ectopic expression of constitutive Akt in Huh7 demonstrated similar resistance to sorafenib.  The knockdown of Akt by RNA interference reversed resistance to sorafenib in Huh7-R1 cells, indicating the importance of Akt in drug sensitivity.  Furthermore, the combination of 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride (MK-2206), a novel allosteric Akt inhibitor, and sorafenib restored the sensitivity of resistant cells to sorafenib-induced apoptosis.  In conclusion, activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in HCC, and the combination of sorafenib and MK-2206, an Akt inhibitor, overcomes the resistance at clin. achievable concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQBd1_2ZA7uLVg90H21EOLACvtfcHk0lj9w2ohGrBBOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGqurs%253D&md5=3132363a96b8d3c3bb10a4f97ff879cd</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.175786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.175786%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.-F.%26aulast%3DChen%26aufirst%3DH.-L.%26aulast%3DTai%26aufirst%3DW.-T.%26aulast%3DFeng%26aufirst%3DW.-C.%26aulast%3DHsu%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DP.-J.%26aulast%3DCheng%26aufirst%3DA.-L.%26atitle%3DActivation%2520of%2520phosphatidylinositol%25203-kinase%252FAkt%2520signaling%2520pathway%2520mediates%2520acquired%2520resistance%2520to%2520sorafenib%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D155%26epage%3D161%26doi%3D10.1124%2Fjpet.110.175786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Bitzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganten, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">WÃ¶rns, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siveke, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dollinger, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wege, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagonel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cillo, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevisani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montesarchio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzapfel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ammendola, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegoraro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauns, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauer, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henning, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentsch, B.</span><span> </span><span class="NLM_article-title">Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma â The SHELTER study</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">â</span> <span class="NLM_lpage">288</span><span class="refDoi">Â DOI: 10.1016/j.jhep.2016.02.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jhep.2016.02.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=26952006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVCks74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=280-288&author=M.+Bitzerauthor=M.+Horgerauthor=E.+G.+Gianniniauthor=T.+M.+Gantenauthor=M.+A.+W%C3%B6rnsauthor=J.+T.+Sivekeauthor=M.+M.+Dollingerauthor=G.+Gerkenauthor=M.+E.+Scheulenauthor=H.+Wegeauthor=V.+Zagonelauthor=U.+Cilloauthor=F.+Trevisaniauthor=A.+Santoroauthor=V.+Montesarchioauthor=N.+P.+Malekauthor=J.+Holzapfelauthor=T.+Herzauthor=A.+S.+Ammendolaauthor=S.+Pegoraroauthor=B.+Haunsauthor=A.+Maisauthor=U.+M.+Lauerauthor=S.+W.+Henningauthor=B.+Hentsch&title=Resminostat+plus+sorafenib+as+second-line+therapy+of+advanced+hepatocellular+carcinoma+%E2%80%93+The+SHELTER+study&doi=10.1016%2Fj.jhep.2016.02.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study</span></div><div class="casAuthors">Bitzer, Michael; Horger, Marius; Giannini, Edoardo G.; Ganten, Tom M.; Woerns, Marcus A.; Siveke, Jens T.; Dollinger, Matthias M.; Gerken, Guido; Scheulen, Max E.; Wege, Henning; Zagonel, Vittorina; Cillo, Umberto; Trevisani, Franco; Santoro, Armando; Montesarchio, Vincenzo; Malek, Nisar P.; Holzapfel, Julia; Herz, Thomas; Ammendola, Astrid S.; Pegoraro, Stefano; Hauns, Bernhard; Mais, Anna; Lauer, Ulrich M.; Henning, Stefan W.; Hentsch, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-288</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist.  This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the histone deacetylase inhibitor resminostat and a combination therapy with resminostat and sorafenib.  Patients with HCC and radiol. confirmed progression on sorafenib were treated in an exploratory, multi-center, open-label, uncontrolled, non-randomized, parallel group phase I/II study.  In the combination group (n = 38) four dose levels ranged from daily 200 to 600 mg resminostat plus 400 to 800 mg sorafenib.  The monotherapy group (n = 19) received 600 mg resminostat.57 patients received treatment.  Most common adverse events were gastrointestinal disorders, thrombocytopenia and fatigue.  Median maximal histone deacetylase inhibition and highest increase in H4-acetylation matched Tmax of resminostat.  Sorafenib or the Child-Pugh score did not affect typical pharmacokinetics characteristics of resminostat.  Efficacy assessment as progression-free survival-rate after 6 treatment cycles (12 wk, primary endpoint) was 12.5% for resminostat and 62.5% for resminostat plus sorafenib.  Median time to progression and overall survival were 1.8 and 4.1 mo for resminostat and 6.5 and 8.0 mo for the combination, resp.  Zinc finger protein 64 (ZFP64) baseline expression in blood cells was found to correlate with overall survival.The combination of sorafenib and resminostat in HCC patients was safe and showed early signs of efficacy.  Sorafenib did not alter the pharmacokinetic profile of resminostat or its histone deacetylase inhibitory activity in vivo.  A prognostic and potentially predictive role of ZFP64 for treatment with resminostat should be further investigated in HCC and possibly other cancer indications.  No established therapy for patients with advanced hepatocellular carcinoma and progression under first-line systemic treatment with sorafenib currently exists.  Epigenetic modulation by inhibition of histone deacetylases might be able to overcome therapy resistance.  This exploratory phase I/II clin. study in patients with radiol. confirmed progression under first-line treatment with sorafenib investigated the histone deacetylases inhibitor resminostat as single agent or in combination with continued application of sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvt1-ys6LWrVg90H21EOLACvtfcHk0lj9w2ohGrBBOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVCks74%253D&md5=a13179d1bb5160e0bd06d2e9fe719313</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.02.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.02.043%26sid%3Dliteratum%253Aachs%26aulast%3DBitzer%26aufirst%3DM.%26aulast%3DHorger%26aufirst%3DM.%26aulast%3DGiannini%26aufirst%3DE.%2BG.%26aulast%3DGanten%26aufirst%3DT.%2BM.%26aulast%3DW%25C3%25B6rns%26aufirst%3DM.%2BA.%26aulast%3DSiveke%26aufirst%3DJ.%2BT.%26aulast%3DDollinger%26aufirst%3DM.%2BM.%26aulast%3DGerken%26aufirst%3DG.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DWege%26aufirst%3DH.%26aulast%3DZagonel%26aufirst%3DV.%26aulast%3DCillo%26aufirst%3DU.%26aulast%3DTrevisani%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DMontesarchio%26aufirst%3DV.%26aulast%3DMalek%26aufirst%3DN.%2BP.%26aulast%3DHolzapfel%26aufirst%3DJ.%26aulast%3DHerz%26aufirst%3DT.%26aulast%3DAmmendola%26aufirst%3DA.%2BS.%26aulast%3DPegoraro%26aufirst%3DS.%26aulast%3DHauns%26aufirst%3DB.%26aulast%3DMais%26aufirst%3DA.%26aulast%3DLauer%26aufirst%3DU.%2BM.%26aulast%3DHenning%26aufirst%3DS.%2BW.%26aulast%3DHentsch%26aufirst%3DB.%26atitle%3DResminostat%2520plus%2520sorafenib%2520as%2520second-line%2520therapy%2520of%2520advanced%2520hepatocellular%2520carcinoma%2520%25E2%2580%2593%2520The%2520SHELTER%2520study%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D65%26spage%3D280%26epage%3D288%26doi%3D10.1016%2Fj.jhep.2016.02.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lu, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulp, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-S.</span><span> </span><span class="NLM_article-title">Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">â</span> <span class="NLM_lpage">1130</span><span class="refDoi">Â DOI: 10.1002/hep.21804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fhep.21804" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=1119-1130&author=Y.-S.+Luauthor=Y.+Kashidaauthor=S.+K.+Kulpauthor=Y.-C.+Wangauthor=D.+Wangauthor=J.-H.+Hungauthor=M.+Tangauthor=Z.-Z.+Linauthor=T.-J.+Chenauthor=A.-L.+Chengauthor=C.-S.+Chen&title=Efficacy+of+a+novel+histone+deacetylase+inhibitor+in+murine+models+of+hepatocellular+carcinoma&doi=10.1002%2Fhep.21804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fhep.21804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.21804%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.-S.%26aulast%3DKashida%26aufirst%3DY.%26aulast%3DKulp%26aufirst%3DS.%2BK.%26aulast%3DWang%26aufirst%3DY.-C.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHung%26aufirst%3DJ.-H.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.-Z.%26aulast%3DChen%26aufirst%3DT.-J.%26aulast%3DCheng%26aufirst%3DA.-L.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%2520in%2520murine%2520models%2520of%2520hepatocellular%2520carcinoma%26jtitle%3DHepatology%26date%3D2007%26volume%3D46%26spage%3D1119%26epage%3D1130%26doi%3D10.1002%2Fhep.21804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Lachenmayer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toffanin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabellos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsinet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoshida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minguez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, H.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thung, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llovet, J. M.</span><span> </span><span class="NLM_article-title">Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1343</span><span class="NLM_x">â</span> <span class="NLM_lpage">1350</span><span class="refDoi">Â DOI: 10.1016/j.jhep.2012.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jhep.2012.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22322234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1343-1350&author=A.+Lachenmayerauthor=S.+Toffaninauthor=L.+Cabellosauthor=C.+Alsinetauthor=Y.+Hoshidaauthor=A.+Villanuevaauthor=B.+Minguezauthor=H.-W.+Tsaiauthor=S.+C.+Wardauthor=S.+Thungauthor=S.+L.+Friedmanauthor=J.+M.+Llovet&title=Combination+therapy+for+hepatocellular+carcinoma%3A+additive+preclinical+efficacy+of+the+HDAC+inhibitor+panobinostat+with+sorafenib&doi=10.1016%2Fj.jhep.2012.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib</span></div><div class="casAuthors">Lachenmayer, Anja; Toffanin, Sara; Cabellos, Laia; Alsinet, Clara; Hoshida, Yujin; Villanueva, Augusto; Minguez, Beatriz; Tsai, Hung-Wen; Ward, Stephen C.; Thung, Swan; Friedman, Scott L.; Llovet, Josep M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1343-1350</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy.  Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown.  We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclin. models of liver cancer.  Methods: Gene expression and copy no. changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model.  Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, resp.  Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy no. gains.  Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addn. of sorafenib.  Cell viability and proliferation declined, while apoptosis and autophagy increased.  Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1.  Combination therapy with panobinostat and sorafenib significantly decreased vessel d., and most significantly decreased tumor vol. and increased survival in HCC xenografts.  Conclusions: Aberrant expression of several HDACs and copy no. gains of HDAC3 and HDAC5 occur in HCC.  Treatment with panobinostat combined with sorafenib demonstrated the highest preclin. efficacy in HCC models, providing the rationale for clin. studies with this novel combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZoC3lwqUXBrVg90H21EOLACvtfcHk0lixcX4NNPWe0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt12mtrc%253D&md5=ac47fb06e16c2b7ec1f4c868a983b752</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DLachenmayer%26aufirst%3DA.%26aulast%3DToffanin%26aufirst%3DS.%26aulast%3DCabellos%26aufirst%3DL.%26aulast%3DAlsinet%26aufirst%3DC.%26aulast%3DHoshida%26aufirst%3DY.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DMinguez%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DH.-W.%26aulast%3DWard%26aufirst%3DS.%2BC.%26aulast%3DThung%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26atitle%3DCombination%2520therapy%2520for%2520hepatocellular%2520carcinoma%253A%2520additive%2520preclinical%2520efficacy%2520of%2520the%2520HDAC%2520inhibitor%2520panobinostat%2520with%2520sorafenib%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D1343%26epage%3D1350%26doi%3D10.1016%2Fj.jhep.2012.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Yeo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, F. K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rha, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeung, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roh, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, J. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span> </span><span class="NLM_article-title">Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3361</span><span class="NLM_x">â</span> <span class="NLM_lpage">3367</span><span class="refDoi">Â DOI: 10.1200/JCO.2011.41.2395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1200%2FJCO.2011.41.2395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22915658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3361-3367&author=W.+Yeoauthor=H.+C.+Chungauthor=S.+L.+Chanauthor=L.+Z.+Wangauthor=R.+Limauthor=J.+Picusauthor=M.+Boyerauthor=F.+K.+F.+Moauthor=J.+Kohauthor=S.+Y.+Rhaauthor=E.+P.+Huiauthor=H.+C.+Jeungauthor=J.+K.+Rohauthor=S.+C.+H.+Yuauthor=K.+F.+Toauthor=Q.+Taoauthor=B.+B.+Maauthor=A.+W.+H.+Chanauthor=J.+H.+M.+Tongauthor=C.+Erlichmanauthor=A.+T.+C.+Chanauthor=B.+C.+Goh&title=Epigenetic+therapy+using+belinostat+for+patients+with+unresectable+hepatocellular+carcinoma%3A+a+multicenter+phase+I%2FII+study+with+biomarker+and+pharmacokinetic+analysis+of+tumors+from+patients+in+the+Mayo+phase+II+consortium+and+the+cancer+therapeutics+research+group&doi=10.1200%2FJCO.2011.41.2395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group</span></div><div class="casAuthors">Yeo, Winnie; Chung, Hyun C.; Chan, Stephen L.; Wang, Ling Z.; Lim, Robert; Picus, Joel; Boyer, Michael; Mo, Frankie K. F.; Koh, Jane; Rha, Sun Y.; Hui, Edwin P.; Jeung, Hei C.; Roh, Jae K.; Yu, Simon C. H.; To, Ka F.; Tao, Qian; Ma, Brigette B.; Chan, Anthony W. H.; Tong, Joanna H. M.; Erlichman, Charles; Chan, Anthony T. C.; Goh, Boon C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3361-3367</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC).  In this study of patients with unresectable HCC and chronic liver disease, epigenetic therapy with the histone deacetylase inhibitor belinostat was assessed.  The objectives were to det. dose-limiting toxicity and max.-tolerated dose (MTD), to assess pharmacokinetics in phase I, and to assess activity of and explore potential biomarkers for response in phase II.  Patients and Methods Major eligibility criteria included histol. confirmed unresectable HCC, European Cooperative Oncol. Group performance score â¤ 2, and adequate organ function.  Phase I consisted of 18 patients; belinostat was given i.v. once per day on days 1 to 5 every 3 wk; dose levels were 600 mg/m2 per day (level 1), 900 mg/m2 per day (level 2), 1,200 mg/m2 per day (level 3), and 1,400 mg/m2 per day (level 4).  Phase II consisted of 42 patients.  The primary end point was progression-free survival (PFS), and the main secondary end points were response according to Response Evaluation Criteria in Solid Tumors (RECIST) and overall survival (OS).  Exploratory anal. was conducted on pretreatment tumor tissues to det. whether HR23B expression is a potential biomarker for response.  Results Belinostat pharmacokinetics were linear from 600 to 1,400 mg/m2 without significant accumulation.  The MTD was not reached at the max. dose administered.  Dose level 4 was used in phase II.  The median no. of cycles was two (range, one to 12).  The partial response (PR) and stable disease (SD) rates were 2.4% and 45.2%, resp.  The median PFS and OS were 2.64 and 6.60 mo, resp.  Exploratory anal. revealed that disease stabilization rate (complete response plus PR plus SD) in tumors having high and low HR23B histoscores were 58% and 14%, resp. (P = .036).  Conclusion Epigenetic therapy with belinostat demonstrates tumor stabilization and is generally well-tolerated.  HR23B expression was assocd. with disease stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdIbj7iAVEZ7Vg90H21EOLACvtfcHk0lixcX4NNPWe0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7zP&md5=cb1c61e11c974343e82f47e5d909ba32</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.41.2395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.41.2395%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DW.%26aulast%3DChung%26aufirst%3DH.%2BC.%26aulast%3DChan%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DPicus%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMo%26aufirst%3DF.%2BK.%2BF.%26aulast%3DKoh%26aufirst%3DJ.%26aulast%3DRha%26aufirst%3DS.%2BY.%26aulast%3DHui%26aufirst%3DE.%2BP.%26aulast%3DJeung%26aufirst%3DH.%2BC.%26aulast%3DRoh%26aufirst%3DJ.%2BK.%26aulast%3DYu%26aufirst%3DS.%2BC.%2BH.%26aulast%3DTo%26aufirst%3DK.%2BF.%26aulast%3DTao%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DB.%2BB.%26aulast%3DChan%26aufirst%3DA.%2BW.%2BH.%26aulast%3DTong%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DA.%2BT.%2BC.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26atitle%3DEpigenetic%2520therapy%2520using%2520belinostat%2520for%2520patients%2520with%2520unresectable%2520hepatocellular%2520carcinoma%253A%2520a%2520multicenter%2520phase%2520I%252FII%2520study%2520with%2520biomarker%2520and%2520pharmacokinetic%2520analysis%2520of%2520tumors%2520from%2520patients%2520in%2520the%2520Mayo%2520phase%2520II%2520consortium%2520and%2520the%2520cancer%2520therapeutics%2520research%2520group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3361%26epage%3D3367%26doi%3D10.1200%2FJCO.2011.41.2395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VillaseÃ±or, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novikov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liclican, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagpacan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papalia, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase Î´</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">8439</span><span class="NLM_x">â</span> <span class="NLM_lpage">8446</span><span class="refDoi">Â DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villase%C3%B1orauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase Î´</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3KÎ´ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3KÎ´.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3KÎ´.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110Î´ subunit of PI3KÎ´ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0ljWA-KiCV5Eyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Scott, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentemann, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullion, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fracasso, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brands, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefranc, J.</span><span> </span><span class="NLM_article-title">Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: identification of copanlisib (BAY 80â6946)</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1517</span><span class="NLM_x">â</span> <span class="NLM_lpage">1530</span><span class="refDoi">Â DOI: 10.1002/cmdc.201600148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fcmdc.201600148" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1517-1530&author=W.+J.+Scottauthor=M.+F.+Hentemannauthor=R.+B.+Rowleyauthor=C.+O.+Bullauthor=S.+Jenkinsauthor=A.+M.+Bullionauthor=J.+Johnsonauthor=A.+Redmanauthor=A.+H.+Robbinsauthor=W.+Eslerauthor=R.+P.+Fracassoauthor=T.+Garrisonauthor=M.+Hamiltonauthor=M.+Michelsauthor=J.+E.+Woodauthor=D.+P.+Wilkieauthor=H.+Xiaoauthor=J.+Levyauthor=E.+Stasikauthor=N.+Liuauthor=M.+Schaeferauthor=M.+Brandsauthor=J.+Lefranc&title=Discovery+and+SAR+of+novel+2%2C3-dihydroimidazo%5B1%2C2-c%5Dquinazoline+PI3K+Inhibitors%3A+identification+of+copanlisib+%28BAY+80%E2%80%936946%29&doi=10.1002%2Fcmdc.201600148"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600148%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DW.%2BJ.%26aulast%3DHentemann%26aufirst%3DM.%2BF.%26aulast%3DRowley%26aufirst%3DR.%2BB.%26aulast%3DBull%26aufirst%3DC.%2BO.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DBullion%26aufirst%3DA.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DRedman%26aufirst%3DA.%26aulast%3DRobbins%26aufirst%3DA.%2BH.%26aulast%3DEsler%26aufirst%3DW.%26aulast%3DFracasso%26aufirst%3DR.%2BP.%26aulast%3DGarrison%26aufirst%3DT.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DJ.%2BE.%26aulast%3DWilkie%26aufirst%3DD.%2BP.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLevy%26aufirst%3DJ.%26aulast%3DStasik%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DLefranc%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520novel%25202%252C3-dihydroimidazo%255B1%252C2-c%255Dquinazoline%2520PI3K%2520Inhibitors%253A%2520identification%2520of%2520copanlisib%2520%2528BAY%252080%25E2%2580%25936946%2529%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1517%26epage%3D1530%26doi%3D10.1002%2Fcmdc.201600148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hylander, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span> </span><span class="NLM_article-title">Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">â</span> <span class="NLM_lpage">183</span><span class="refDoi">Â DOI: 10.1016/j.jhep.2011.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jhep.2011.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=21835141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=176-183&author=H.+Shaoauthor=C.+Gaoauthor=H.+Tangauthor=H.+Zhangauthor=L.+R.+Robertsauthor=B.+L.+Hylanderauthor=E.+A.+Repaskyauthor=W.+W.+Maauthor=J.+Qiuauthor=A.+A.+Adjeiauthor=G.+K.+Dyauthor=C.+Yu&title=Dual+targeting+of+mTORC1%2FC2+complexes+enhances+histone+deacetylase+inhibitor-mediated+anti-tumor+efficacy+in+primary+HCC+cancer+in+vitro+and+in+vivo&doi=10.1016%2Fj.jhep.2011.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo</span></div><div class="casAuthors">Shao, Huanjie; Gao, Chun; Tang, Haikuo; Zhang, Hao; Roberts, Lewis R.; Hylander, Bonnie L.; Repasky, Elizabeth A.; Ma, Wen W.; Qiu, Jingxin; Adjei, Alex A.; Dy, Grace K.; Yu, Chunrong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-183</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: The mammalian target of rapamycin (mTOR) plays a pivotal role in hepatocellular carcinoma (HCC).  Previous studies indicated that inhibition of mTORC1 enhanced histone deacetylase inhibitors (HDACis)-mediated anti-tumor activity, accompanied with feedback activation of AKT.  Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC.  Methods: The interactions between mTOR kinase inhibitors (mTORKis) (i.e., Pp242, AZD8055, OSI027) and HDACis (i.e., SAHA, LBH589) were examd. in vitro using HCC cell lines and in vivo using patient-derived primary HCC xenografts on SCID mice.  Results: mTORKis significantly enhanced HDACi-induced apoptosis in HCC cells.  The inhibition of both mTORC1/2 not only efficiently blocked mTORC1 signaling, but also abrogated AKT-feedback activation caused by selective mTORC1 inhibition.  The co-treatment of mTORKi and HDACi further inhibited AKT signaling and upregulated Bim.  Dysfunction of mTORC2 by shRNA significantly lowered the threshold of HDACi-induced cytotoxicity by abrogating AKT activation.  Knockdown of AKT1 sensitized Pp242/HDACi-induced apoptosis and ectopic expression of constitutively active AKT1 abrogated the combination-induced cytotoxicity, indicating AKT plays a vital role in the combination-induced effects.  Knockdown of Bim prevented Pp242/HDACis-induced cytotoxicity in HCC.  Lastly, in vivo studies indicated that the combination of AZD8055 and SAHA almost completely inhibited tumor-growth, without obvious adverse effects, by abrogating AKT and upregulating Bim; while either agent alone shows only 30% inhibition in primary HCC xenografts.  Conclusions: Our findings suggest that a combining-regimen of mTORKi and HDACi may be an effective therapeutic strategy for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU2jGHiPLHLbVg90H21EOLACvtfcHk0lgybiH6Kqmj0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsbjO&md5=8d80f8e1711ce999fd586487a41aae4d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DHylander%26aufirst%3DB.%2BL.%26aulast%3DRepasky%26aufirst%3DE.%2BA.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DYu%26aufirst%3DC.%26atitle%3DDual%2520targeting%2520of%2520mTORC1%252FC2%2520complexes%2520enhances%2520histone%2520deacetylase%2520inhibitor-mediated%2520anti-tumor%2520efficacy%2520in%2520primary%2520HCC%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D56%26spage%3D176%26epage%3D183%26doi%3D10.1016%2Fj.jhep.2011.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gedaly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hundley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daily, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, B. M.</span><span> </span><span class="NLM_article-title">PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">542</span><span class="NLM_x">â</span> <span class="NLM_lpage">548</span><span class="refDoi">Â DOI: 10.1016/j.jss.2011.10.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.jss.2011.10.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22261591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2iurjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2012&pages=542-548&author=R.+Gedalyauthor=P.+Anguloauthor=J.+Hundleyauthor=M.+F.+Dailyauthor=C.+Chenauthor=B.+M.+Evers&title=PKI-587+and+sorafenib+targeting+PI3K%2FAKT%2FmTOR+and+Ras%2FRaf%2FMAPK+pathways+synergistically+inhibit+HCC+cell+proliferation&doi=10.1016%2Fj.jss.2011.10.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation</span></div><div class="casAuthors">Gedaly, Roberto; Angulo, Paul; Hundley, Jonathan; Daily, Michael F.; Chen, Changguo; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-548</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Deregulated Ras/Raf/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC).  This study aimed to test the inhibitory effects of PKI-587 and sorafenib as single agents or in combination on HCC (Huh7 cell line) proliferation.3H-thymidine incorporation and MTT assay were used to assess Huh7 cell proliferation.  Phosphorylation of the key enzymes in the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways was detected by Western blot.  We found that PKI-587 is a more potent PI3K/mTOR inhibitor than PI-103.  Combination of PKI-587 and sorafenib was a more effective inhibitor of Huh7 proliferation than the combination of PI-103 and sorafenib.  Combination of PKI-587 and sorafenib synergistically inhibited epidermal growth factor (EGF)-stimulated Huh7 proliferation compared with monodrug therapy.  EGF increased phosphorylation of Ras/Raf downstream signaling proteins MEK and ERK; EGF-stimulated activation was inhibited by sorafenib.  However, sorafenib, as a single agent, increased AKT (Ser473) phosphorylation.  EGF-stimulated AKT (ser473) activation was inhibited by PKI-587.  PKI-587 is a potent inhibitor of AKT (Ser473), mTOR (Ser2448), and S6K (Thr389) phosphorylation; in contrast, rapamycin stimulated mTOR complex 2 substrate AKT(Ser473) phosphorylation although it inhibited mTOR complex 1 substrate S6K phosphorylation.  PKI-587, as a single agent, stimulated MEK and ERK phosphorylation.  However, when PKI-587 and sorafenib were used in combination, they inhibited all the tested kinases in the Ras/Raf /MAPK and PI3K/AKT/mTOR pathways.  The combination of PKI-587 and sorafenib has the advantage over monodrug therapy on inhibition of HCC cell proliferation by blocking both PI3K/AKT/mTOR and Ras/Raf/MAPK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoks4j17-7Nk7Vg90H21EOLACvtfcHk0lgybiH6Kqmj0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2iurjM&md5=0b3a2d1cb5b7f07c56c357fbd9e61952</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jss.2011.10.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jss.2011.10.045%26sid%3Dliteratum%253Aachs%26aulast%3DGedaly%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DP.%26aulast%3DHundley%26aufirst%3DJ.%26aulast%3DDaily%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DPKI-587%2520and%2520sorafenib%2520targeting%2520PI3K%252FAKT%252FmTOR%2520and%2520Ras%252FRaf%252FMAPK%2520pathways%2520synergistically%2520inhibit%2520HCC%2520cell%2520proliferation%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2012%26volume%3D176%26spage%3D542%26epage%3D548%26doi%3D10.1016%2Fj.jss.2011.10.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lye, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">StÃ¼nkel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entzeroth, M.</span><span> </span><span class="NLM_article-title">N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">â</span> <span class="NLM_lpage">1408</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.bmcl.2009.01.041" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1403-1408&author=H.+Wangauthor=N.+Yuauthor=H.+Songauthor=D.+Chenauthor=Y.+Zouauthor=W.+Dengauthor=P.+L.+Lyeauthor=J.+Changauthor=M.+Ngauthor=S.+Blanchardauthor=E.+T.+Sunauthor=K.+Sangthongpitagauthor=X.+Wangauthor=K.+C.+Gohauthor=X.+Wuauthor=H.+H.+Khngauthor=L.+Fangauthor=S.+K.+Gohauthor=W.+C.+Ongauthor=Z.+Bondayauthor=W.+St%C3%BCnkelauthor=A.+Poulsenauthor=M.+Entzeroth&title=N-Hydroxy-1%2C2-disubstituted-1H-benzimidazol-5-yl+acrylamides+as+novel+histone+deacetylase+inhibitors%3A+design%2C+synthesis%2C+SAR+studies%2C+and+in+vivo+antitumor+activity&doi=10.1016%2Fj.bmcl.2009.01.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DSt%25C3%25BCnkel%26aufirst%3DW.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DEntzeroth%26aufirst%3DM.%26atitle%3DN-Hydroxy-1%252C2-disubstituted-1H-benzimidazol-5-yl%2520acrylamides%2520as%2520novel%2520histone%2520deacetylase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520SAR%2520studies%252C%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1403%26epage%3D1408%26doi%3D10.1016%2Fj.bmcl.2009.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, Z.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span> </span><span class="NLM_article-title">Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: synthesis, SAR, and in vivo antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3314</span><span class="NLM_x">â</span> <span class="NLM_lpage">3321</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.bmcl.2010.04.041" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3314-3321&author=H.+Wangauthor=Z.-Y.+Limauthor=Y.+Zhouauthor=M.+Ngauthor=T.+Luauthor=K.+Leeauthor=K.+Sangthongpitagauthor=K.+C.+Gohauthor=X.+Wangauthor=X.+Wuauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=W.+C.+Ongauthor=Z.+Bondayauthor=E.+T.+Sun&title=Acylurea+connected+straight+chain+hydroxamates+as+novel+histone+deacetylase+inhibitors%3A+synthesis%2C+SAR%2C+and+in+vivo+antitumor+activity&doi=10.1016%2Fj.bmcl.2010.04.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLim%26aufirst%3DZ.-Y.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DAcylurea%2520connected%2520straight%2520chain%2520hydroxamates%2520as%2520novel%2520histone%2520deacetylase%2520inhibitors%253A%2520synthesis%252C%2520SAR%252C%2520and%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3314%26epage%3D3321%26doi%3D10.1016%2Fj.bmcl.2010.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lye, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span> </span><span class="NLM_article-title">Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4694</span><span class="NLM_x">â</span> <span class="NLM_lpage">4720</span><span class="refDoi">Â DOI: 10.1021/jm2003552</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003552" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4694-4720&author=H.+Wangauthor=N.+Yuauthor=D.+Chenauthor=K.+C.+L.+Leeauthor=P.+L.+Lyeauthor=J.+W.+W.+Changauthor=W.+Dengauthor=M.+C.+Y.+Ngauthor=T.+Luauthor=M.+L.+Khooauthor=A.+Poulsenauthor=K.+Sangthongpitagauthor=X.+Wuauthor=C.+Huauthor=K.+C.+Gohauthor=X.+Wangauthor=L.+Fangauthor=K.+L.+Gohauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=P.+Yeoauthor=X.+Liuauthor=Z.+Bondayauthor=J.+M.+Woodauthor=B.+W.+Dymockauthor=E.+Kantharajauthor=E.+T.+Sun&title=Discovery+of+%282E%29-3-%7B2-butyl-1-%5B2-%28diethylamino%29ethyl%5D-1H-benzimidazol-5-yl%7D-N-hydroxyacrylamide+%28SB939%29%2C+an+orally+active+histone+deacetylase+inhibitor+with+a+superior+preclinical+profile&doi=10.1021%2Fjm2003552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile</span></div><div class="casAuthors">Wang, Haishan; Yu, Niefang; Chen, Dizhong; Lee, Ken Chi Lik; Lye, Pek Ling; Chang, Joyce Wei Wei; Deng, Weiping; Ng, Melvin Chi Yeh; Lu, Ting; Khoo, Mui Ling; Poulsen, Anders; Sangthongpitag, Kanda; Wu, Xiaofeng; Hu, Changyong; Goh, Kee Chuan; Wang, Xukun; Fang, Lijuan; Goh, Kay Lin; Khng, Hwee Hoon; Goh, Siok Kun; Yeo, Pauline; Liu, Xin; Bonday, Zahid; Wood, Jeanette M.; Dymock, Brian W.; Kantharaj, Ethirajulu; Sun, Eric T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4694-4720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(1,2-disubstituted-1H-benzimidazol-5-yl)-N-hydroxyacrylamides was designed and synthesized as HDAC inhibitors.  Extensive SARs have been established for in vitro potency (HDAC1 enzyme and COLO 205 cellular IC50), liver microsomal stability (t1/2), cytochrome P 450 inhibition (3A4 IC50), and clogP, among others.  These parameters were fine-tuned by carefully adjusting the substituents at positions 1 and 2 of the benzimidazole ring.  After comprehensive in vitro and in vivo profiling of the selected compds., SB939 (I) was identified as a preclin. development candidate.  I is a potent pan-HDAC inhibitor with excellent druglike properties, is highly efficacious in in vivo tumor models (HCT-116, PC-3, A2780, MV4-11, Ramos), and has high and dose-proportional oral exposures and very good ADME, safety, and pharmaceutical properties.  When orally dosed to tumor-bearing mice, I is enriched in tumor tissue which may contribute to its potent antitumor activity and prolonged duration of action.  I is currently being tested in phase I and phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd9r-fRIzdS7Vg90H21EOLACvtfcHk0lhOBBdzCj6Azg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D&md5=a69bf922fb86c47ddee9c9fc112cc9a2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm2003552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003552%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BL.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DM.%2BC.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DKhoo%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DK.%2BL.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DKantharaj%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DDiscovery%2520of%2520%25282E%2529-3-%257B2-butyl-1-%255B2-%2528diethylamino%2529ethyl%255D-1H-benzimidazol-5-yl%257D-N-hydroxyacrylamide%2520%2528SB939%2529%252C%2520an%2520orally%2520active%2520histone%2520deacetylase%2520inhibitor%2520with%2520a%2520superior%2520preclinical%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4694%26epage%3D4720%26doi%3D10.1021%2Fjm2003552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chng, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustafa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">â</span> <span class="NLM_lpage">161</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-12-0466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1535-7163.MCT-12-0466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23270925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=151-161&author=S.+Hartauthor=V.+Novotny-Diermayrauthor=K.+C.+Gohauthor=M.+Williamsauthor=Y.+C.+Tanauthor=L.+C.+Ongauthor=A.+Cheongauthor=B.+K.+Ngauthor=C.+Amaliniauthor=B.+Madanauthor=H.+Nagarajauthor=R.+Jayaramanauthor=K.+M.+Pashaauthor=K.+Ethirajuluauthor=W.+J.+Chngauthor=N.+Mustafaauthor=B.+C.+Gohauthor=C.+Benesauthor=U.+McDermottauthor=M.+Garnettauthor=B.+Dymockauthor=J.+M.+Wood&title=VS-5584%2C+a+novel+and+highly+selective+PI3K%2FmTOR+kinase+inhibitor+for+the+treatment+of+cancer&doi=10.1158%2F1535-7163.MCT-12-0466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Hart, Stefan; Novotny-Diermayr, Veronica; Goh, Kee Chuan; Williams, Meredith; Tan, Yong Cheng; Ong, Lai Chun; Cheong, Albert; Ng, Bee Kheng; Amalini, Chithra; Madan, Babita; Nagaraj, Harish; Jayaraman, Ramesh; Pasha, Khalid M.; Ethirajulu, Kantharaj; Chng, Wee Joo; Mustafa, Nurulhuda; Goh, Boon Cher; Benes, Cyril; McDermott, Ultan; Garnett, Mathew; Dymock, Brian; Wood, Jeanette M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-161</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers.  Moreover, this pathway activation is a poor prognostic marker for many tumor types and confers resistance to various cancer therapies.  Here, we describe VS-5584, a novel, low-mol. wt. compd. with equiv. potent activity against mTOR (IC50 = 37 nmol/L) and all class I phosphoinositide 3-kinase (PI3K) isoforms IC50: PI3KÎ± = 16 nmol/L; PI3KÎ² = 68 nmol/L; PI3KÎ³ = 25 nmol/L; PI3KÎ´ = 42 nmol/L, without relevant activity on 400 lipid and protein kinases.  VS-5584 shows robust modulation of cellular PI3K/mTOR pathways, inhibiting phosphorylation of substrates downstream of PI3K and mTORC1/2.  A large human cancer cell line panel screen (436 lines) revealed broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment.  VS-5584 exhibits favorable pharmacokinetic properties after oral dosing in mice and is well tolerated.  VS-5584 induces long-lasting and dose-dependent inhibition of PI3K/mTOR signaling in tumor tissue, leading to tumor growth inhibition in various rapalog-sensitive and -resistant human xenograft models.  Furthermore, VS-5584 is synergistic with an EGF receptor inhibitor in a gastric tumor model.  The unique selectivity profile and favorable pharmacol. and pharmaceutical properties of VS-5584 and its efficacy in a wide range of human tumor models supports further investigations of VS-5584 in clin. trials.  Mol Cancer Ther; 12(2); 151-61. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreO7JDy5Ta17Vg90H21EOLACvtfcHk0lhOBBdzCj6Azg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisr0%253D&md5=5fac255eea66aed674cc863fc578d975</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0466%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DB.%2BK.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DK.%2BM.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DGarnett%26aufirst%3DM.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DVS-5584%252C%2520a%2520novel%2520and%2520highly%2520selective%2520PI3K%252FmTOR%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D151%26epage%3D161%26doi%3D10.1158%2F1535-7163.MCT-12-0466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span> </span><span class="NLM_article-title">Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3238</span><span class="NLM_x">â</span> <span class="NLM_lpage">3250</span><span class="refDoi">Â DOI: 10.1021/ci500493m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500493m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGgt7nM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=3238-3250&author=A.+Poulsenauthor=H.+Nagarajauthor=A.+Leeauthor=S.+Blanchardauthor=C.+K.+Sohauthor=D.+Chenauthor=H.+Wangauthor=S.+Hartauthor=K.+C.+Gohauthor=B.+Dymockauthor=M.+Williams&title=Structure+and+ligand-based+design+of+mTOR+and+PI3-kinase+inhibitors+leading+to+the+clinical+candidates+VS-5584+%28SB2343%29+and+SB2602&doi=10.1021%2Fci500493m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602</span></div><div class="casAuthors">Poulsen, Anders; Nagaraj, Harish; Lee, Angeline; Blanchard, Stephanie; Soh, Chang Kai; Chen, Dizhong; Wang, Haishan; Hart, Stefan; Goh, Kee Chuan; Dymock, Brian; Williams, Meredith</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3238-3250</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR) act as crit. effectors in a commonly deregulated cell signaling pathway in human cancers.  The abnormal activation of the PI3K/mTOR pathway has been shown to play a role in initiation, progression, and metastasis of human tumors.  Being one of the most frequently activated pathways in cancer, much effort has been directed toward inhibition of the PI3K/mTOR pathway as a novel oncol. therapy.  Previous work by a no. of groups has revealed several selective PI3K and dual mTOR/PI3K inhibitors.  However, there are few reports of therapeutic agents with a pan-PI3K/mTOR inhibitory profile within a narrow concn. range.  The authors therefore initiated a drug discovery project with the aim of discovering dual mTOR/PI3K inhibitors which would equipotently inhibit the 4 isoforms of PI3K, Î±, Î², Î³, and Î´, and mTOR a compelling profile for powerful blockage of the PI3K/mTOR pathway.  A pharmacophore model was generated and used for designing a series of novel compds., based on a purine scaffold, which potently inhibited mTOR and PI3Ks.  These compds. contained a phenol headgroup essential for binding to the target proteins.  Early efforts concd. on finding replacements for the phenol as it was rapidly conjugated resulting in a short half-life in vivo.  Compds. with a variety of headgroups were docked into the PI3KÎ± and mTOR ATP-binding sites, and aminopyrimidine and aminopyrazine were found to make excellent phenol replacements.  Further structure guided optimization of side chains in the 8- and 9-positions of the purine resulted in potent inhibitors with good PKDM properties.  As the PI3 kinases play a role in insulin signaling, it is believed that targeting mTOR selectively may give the benefit of blocking the AKT-pathway while avoiding the potential side effects assocd. with PI3K inhibition.  As a result the authors designed a further series of selective mTOR kinase inhibitors.  The project was successfully concluded by progressing both a dual mTOR/PI3K inhibitor I and a selective mTOR inhibitor II into preclin. development.  II has since entered phase 1 clin. development as VS-5584.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNUHrhUNZKi7Vg90H21EOLACvtfcHk0lhBfN2hUXoxWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGgt7nM&md5=e9bb902719992d844430e4e8e85d3728</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fci500493m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500493m%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DSoh%26aufirst%3DC.%2BK.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DM.%26atitle%3DStructure%2520and%2520ligand-based%2520design%2520of%2520mTOR%2520and%2520PI3-kinase%2520inhibitors%2520leading%2520to%2520the%2520clinical%2520candidates%2520VS-5584%2520%2528SB2343%2529%2520and%2520SB2602%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D3238%26epage%3D3250%26doi%3D10.1021%2Fci500493m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wang, H.; Chen, D.; Soh, C. K.</span><span> </span><span class="NLM_article-title">Fused Pyrimidine-based Hydroxamate Derivatives</span>. PCT Int. Appl. WO2015137887A1, September 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Wang&author=D.+Chen&author=C.+K.+Soh&title=Fused+Pyrimidine-based+Hydroxamate+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26atitle%3DFused%2520Pyrimidine-based%2520Hydroxamate%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Finnin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donigian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N.</span><span> </span><span class="NLM_article-title">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">â</span> <span class="NLM_lpage">193</span><span class="refDoi">Â DOI: 10.1038/43710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+Finninauthor=J.+Donigianauthor=A.+Cohenauthor=V.+Richonauthor=R.+Rifkindauthor=P.+Marksauthor=R.+Breslowauthor=N.+Pavletich&title=Structures+of+a+histone+deacetylase+homologue+bound+to+the+TSA+and+SAHA+inhibitors&doi=10.1038%2F43710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0lhBfN2hUXoxWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%26aulast%3DDonigian%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%26aulast%3DRifkind%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%26atitle%3DStructures%2520of%2520a%2520histone%2520deacetylase%2520homologue%2520bound%2520to%2520the%2520TSA%2520and%2520SAHA%2520inhibitors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193%26doi%3D10.1038%2F43710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">New patented histone deacetylase inhibitors</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">â</span> <span class="NLM_lpage">1757</span><span class="refDoi">Â DOI: 10.1517/13543770903393789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1517%2F13543770903393789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19939190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1727-1757&author=H.+Wangauthor=B.+W.+Dymock&title=New+patented+histone+deacetylase+inhibitors&doi=10.1517%2F13543770903393789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New patented histone deacetylase inhibitors</span></div><div class="casAuthors">Wang, Haishan; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1727-1757</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clin. trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created as dual or multifunctional inhibitors.  Given the breadth and depth of recent reporting of novel HDACis, there has emerged a need to review the field from a chemist's perspective in one compact article.  Areas covered in this review: This review provides a summary of published patent applications claiming novel HDACis from 2007 until mid-2009, covering mainly classes I, II and IV anticancer HDACis including those that have recently advanced to the clinic.  What the reader will gain: Readers will rapidly gain an overview of the majority of HDACi scaffolds with representative structure-activity relationships; they will learn how these new compds. were created, how their drug like properties were improved and which companies are the main players in the field.  Take home message: Although competition in this field is intense, the future application of HDACis to treat human disease either as single agents or in combination with existing drugs holds real promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9k6M0WIgm2rVg90H21EOLACvtfcHk0lhlQSbh2547VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1WhtLfK&md5=673162bef16012b32a8122c8fefd92ee</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F13543770903393789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770903393789%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DNew%2520patented%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26spage%3D1727%26epage%3D1757%26doi%3D10.1517%2F13543770903393789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Stefano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1725</span><span class="NLM_x">â</span> <span class="NLM_lpage">1738</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-08-1200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1535-7163.MCT-08-1200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19584227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVynuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1725-1738&author=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Patelauthor=S.+Alixauthor=G.+Boxauthor=I.+Chuckowreeauthor=A.+Folkesauthor=S.+Gowanauthor=A.+De+Haven+Brandonauthor=F.+Di+Stefanoauthor=A.+Hayesauthor=A.+T.+Henleyauthor=L.+Lensunauthor=G.+Pergl-Wilsonauthor=A.+Robsonauthor=N.+Saghirauthor=A.+Zhyvoloupauthor=E.+McDonaldauthor=P.+Sheldrakeauthor=S.+Shuttleworthauthor=M.+Valentiauthor=N.+C.+Wanauthor=P.+A.+Clarkeauthor=P.+Workman&title=Biological+properties+of+potent+inhibitors+of+class+I+phosphatidylinositide+3-kinases%3A+from+PI-103+through+PI-540%2C+PI-620+to+the+oral+agent+GDC-0941&doi=10.1158%2F1535-7163.MCT-08-1200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941</span></div><div class="casAuthors">Raynaud, Florence I.; Eccles, Suzanne A.; Patel, Sonal; Alix, Sonia; Box, Gary; Chuckowree, Irina; Folkes, Adrian; Gowan, Sharon; De Haven Brandon, Alexis; Di Stefano, Francesca; Hayes, Angela; Henley, Alan T.; Lensun, Letitia; Pergl-Wilson, Giles; Robson, Anthony; Saghir, Nahid; Zhyvoloup, Alexander; McDonald, Edward; Sheldrake, Peter; Shuttleworth, Stephen; Valenti, Melanie; Wan, Nan Chi; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1725-1738</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositide 3-kinase pathway is frequently deregulated in human cancers and inhibitors offer considerable therapeutic potential.  We previously described the promising tricyclic pyridofuropyrimidine lead and chem. tool compd. PI-103.  We now report the properties of the pharmaceutically optimized bicyclic thienopyrimidine derivs. PI-540 and PI-620 and the resulting clin. development candidate GDC-0941.  All four compds. inhibited phosphatidylinositide 3-kinase p110Î± with IC50 â¤ 10 nmol/L.  Despite some differences in isoform selectivity, these agents exhibited similar in vitro antiproliferative properties to PI-103 in a panel of human cancer cell lines, with submicromolar potency in PTEN-neg. U87MG human glioblastoma cells and comparable phosphatidylinositide 3-kinase pathway modulation.  PI-540 and PI-620 exhibited improvements in soly. and metab. with high tissue distribution in mice.  Both compds. gave improved antitumor efficacy over PI-103, following i.p. dosing in U87MG glioblastoma tumor xenografts in athymic mice, with treated/control values of 34% (66% inhibition) and 27% (73% inhibition) for PI-540 (50 mg/kg b.i.d.) and PI-620 (25 mg/kg b.i.d.), resp.  GDC-0941 showed comparable in vitro antitumor activity to PI-103, PI-540, and PI-620 and exhibited 78% oral bioavailability in mice, with tumor exposure above 50% antiproliferative concns. for >8 h following 150 mg/kg p.o. and sustained phosphatidylinositide 3-kinase pathway inhibition.  These properties led to excellent dose-dependent oral antitumor activity, with daily p.o. dosing at 150 mg/kg achieving 98% and 80% growth inhibition of U87MG glioblastoma and IGROV-1 ovarian cancer xenografts, resp.  Together, these data support the development of GDC-0941 as a potent, orally bioavailable inhibitor of phosphatidylinositide 3-kinase.  GDC-0941 has recently entered phase I clin. trials. [Mol Cancer Ther 2009;8(7):1725-38] [Mol Cancer Ther 2009;8(7):1725-38].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-PRUGO7W3C7Vg90H21EOLACvtfcHk0lhlQSbh2547VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVynuro%253D&md5=2c963517ef112c677fb19ec2f0040e14</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-1200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-1200%26sid%3Dliteratum%253Aachs%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%26aulast%3DFolkes%26aufirst%3DA.%26aulast%3DGowan%26aufirst%3DS.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DDi%2BStefano%26aufirst%3DF.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DPergl-Wilson%26aufirst%3DG.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DSheldrake%26aufirst%3DP.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DBiological%2520properties%2520of%2520potent%2520inhibitors%2520of%2520class%2520I%2520phosphatidylinositide%25203-kinases%253A%2520from%2520PI-103%2520through%2520PI-540%252C%2520PI-620%2520to%2520the%2520oral%2520agent%2520GDC-0941%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1725%26epage%3D1738%26doi%3D10.1158%2F1535-7163.MCT-08-1200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmadi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderton, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alix, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuckowree, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugendradas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lensun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pergl-Wilson, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallweber, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhyvoloup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span> </span><span class="NLM_article-title">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5522</span><span class="NLM_x">â</span> <span class="NLM_lpage">5532</span><span class="refDoi">Â DOI: 10.1021/jm800295d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800295d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5522-5532&author=A.+J.+Folkesauthor=K.+Ahmadiauthor=W.+K.+Aldertonauthor=S.+Alixauthor=S.+J.+Bakerauthor=G.+Boxauthor=I.+S.+Chuckowreeauthor=P.+A.+Clarkeauthor=P.+Depledgeauthor=S.+A.+Ecclesauthor=L.+S.+Friedmanauthor=A.+Hayesauthor=T.+C.+Hancoxauthor=A.+Kugendradasauthor=L.+Lensunauthor=P.+Mooreauthor=A.+G.+Oliveroauthor=J.+Pangauthor=S.+Patelauthor=G.+H.+Pergl-Wilsonauthor=F.+I.+Raynaudauthor=A.+Robsonauthor=N.+Saghirauthor=L.+Salphatiauthor=S.+Sohalauthor=M.+H.+Ultschauthor=M.+Valentiauthor=H.+J.+Wallweberauthor=N.+C.+Wanauthor=C.+Wiesmannauthor=P.+Workmanauthor=A.+Zhyvoloupauthor=M.+J.+Zvelebilauthor=S.+J.+Shuttleworth&title=The+identification+of+2-%281H-indazol-4-yl%29-6-%284-methanesulfonyl-piperazin-1-ylmethyl%29-4-morpholin-4-yl-thieno%5B3%2C2-d%5Dpyrimidine+%28GDC-0941%29+as+a+potent%2C+selective%2C+orally+bioavailable+inhibitor+of+class+I+PI3+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm800295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer</span></div><div class="casAuthors">Folkes, Adrian J.; Ahmadi, Khatereh; Alderton, Wendy K.; Alix, Sonia; Baker, Stewart J.; Box, Gary; Chuckowree, Irina S.; Clarke, Paul A.; Depledge, Paul; Eccles, Suzanne A.; Friedman, Lori S.; Hayes, Angela; Hancox, Timothy C.; Kugendradas, Arumugam; Lensun, Letitia; Moore, Pauline; Olivero, Alan G.; Pang, Jodie; Patel, Sonal; Pergl-Wilson, Giles H.; Raynaud, Florence I.; Robson, Anthony; Saghir, Nahid; Salphati, Laurent; Sohal, Sukhjit; Ultsch, Mark H.; Valenti, Melanie; Wallweber, Heidi J. A.; Wan, Nan Chi; Wiesmann, Christian; Workman, Paul; Zhyvoloup, Alexander; Zvelebil, Marketa J.; Shuttleworth, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5522-5532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors.  A series of thieno[3,2-d]pyrimidine derivs. were prepd. and evaluated as inhibitors of PI3 kinase p110Î±.  The synthesis, biol. activity, and further profiling of these compds. are described.  This work resulted in the discovery of GDC-0941 (I) which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkFv29FXqO7Vg90H21EOLACvtfcHk0lhlQSbh2547VQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCmsr7E&md5=742084954685353ceaf18660ab3a0703</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm800295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800295d%26sid%3Dliteratum%253Aachs%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DAlderton%26aufirst%3DW.%2BK.%26aulast%3DAlix%26aufirst%3DS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DChuckowree%26aufirst%3DI.%2BS.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHancox%26aufirst%3DT.%2BC.%26aulast%3DKugendradas%26aufirst%3DA.%26aulast%3DLensun%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DP.%26aulast%3DOlivero%26aufirst%3DA.%2BG.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPergl-Wilson%26aufirst%3DG.%2BH.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRobson%26aufirst%3DA.%26aulast%3DSaghir%26aufirst%3DN.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%2BH.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%2BJ.%26aulast%3DWan%26aufirst%3DN.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DZhyvoloup%26aufirst%3DA.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520identification%2520of%25202-%25281H-indazol-4-yl%2529-6-%25284-methanesulfonyl-piperazin-1-ylmethyl%2529-4-morpholin-4-yl-thieno%255B3%252C2-d%255Dpyrimidine%2520%2528GDC-0941%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520inhibitor%2520of%2520class%2520I%2520PI3%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5522%26epage%3D5532%26doi%3D10.1021%2Fjm800295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sarker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristeleit, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredrickson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackner, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derynck, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">86</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-0947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1078-0432.CCR-14-0947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=25370471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=77-86&author=D.+Sarkerauthor=J.+E.+Angauthor=R.+Bairdauthor=R.+Kristeleitauthor=K.+Shahauthor=V.+Morenoauthor=P.+A.+Clarkeauthor=F.+I.+Raynaudauthor=G.+Levyauthor=J.+A.+Wareauthor=K.+Mazinaauthor=R.+Linauthor=J.+Wuauthor=J.+Fredricksonauthor=J.+M.+Spoerkeauthor=M.+R.+Lacknerauthor=Y.+Yanauthor=L.+S.+Friedmanauthor=S.+B.+Kayeauthor=M.+K.+Derynckauthor=P.+Workmanauthor=J.+S.+de+Bono&title=First-in-human+phase+I+study+of+pictilisib+%28GDC-0941%29%2C+a+potent+pan-class+I+phosphatidylinositol-3-kinase+%28PI3K%29+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Sarker, Debashis; Ang, Joo Ern; Baird, Richard; Kristeleit, Rebecca; Shah, Krunal; Moreno, Victor; Clarke, Paul A.; Raynaud, Florence I.; Levy, Gallia; Ware, Joseph A.; Mazina, Kathryn; Lin, Ray; Wu, Jenny; Fredrickson, Jill; Spoerke, Jill M.; Lackner, Mark R.; Yan, Yibing; Friedman, Lori S.; Kaye, Stan B.; Derynck, Mika K.; Workman, Paul; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clin. activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K).  Patients and Methods: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels.  Pharmacodynamic studies incorporated 18F-FDG-PET, and assessment of phosphorylated AKT and S6 ribosomal protein in platelet-rich plasma (PRP) and tumor tissue.  Results: Pictilisib was well tolerated.  The most common toxicities were grade 1-2 nausea, rash, and fatigue, whereas the DLT was grade 3 maculopapular rash (450 mg, 2 of 3 patients; 330 mg, 1 of 7 patients).  The pharmacokinetic profile was dose-proportional and supported once-daily dosing.  Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 h after dose at the MTD and in tumor at pictilisib doses assocd. with AUC >20 hÂ·Î¼mol/L.  Significant increase in plasma insulin and glucose levels, and >25% decrease in 18F-FDG uptake by PET in 7 of 32 evaluable patients confirmed target modulation.  A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, resp.  Conclusion: Pictilisib was safely administered with a dose-proportional pharmacokinetic profile, on-target pharmacodynamic activity at dose levels â¥100 mg and signs of antitumor activity.  The recommended phase II dose was continuous dosing at 330 mg once-daily.  Clin Cancer Res; 21(1); 77-86. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-xdpJi9RV7Vg90H21EOLACvtfcHk0lhnKgdMhMHNxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis12ltw%253D%253D&md5=35d52a025e34f4f13844b2721014aca3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0947%26sid%3Dliteratum%253Aachs%26aulast%3DSarker%26aufirst%3DD.%26aulast%3DAng%26aufirst%3DJ.%2BE.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DV.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DLevy%26aufirst%3DG.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DMazina%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DFredrickson%26aufirst%3DJ.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DLackner%26aufirst%3DM.%2BR.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DDerynck%26aufirst%3DM.%2BK.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520pictilisib%2520%2528GDC-0941%2529%252C%2520a%2520potent%2520pan-class%2520I%2520phosphatidylinositol-3-kinase%2520%2528PI3K%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D77%26epage%3D86%26doi%3D10.1158%2F1078-0432.CCR-14-0947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span> </span><span class="NLM_article-title">Dual inhibition of oncogenic targets for B-cell malignancies</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">â</span> <span class="NLM_lpage">549</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(16)00109-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2FS1470-2045%2816%2900109-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=27049458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A280%3ADC%252BC28fntVGmug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=547-549&author=P.+G.+Richardson&title=Dual+inhibition+of+oncogenic+targets+for+B-cell+malignancies&doi=10.1016%2FS1470-2045%2816%2900109-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of oncogenic targets for B-cell malignancies</span></div><div class="casAuthors">Richardson Paul G</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtyi3hH4A0Antlzo9xastyfW6udTcc2eb9tF-pRBGLt7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fntVGmug%253D%253D&md5=5a166ed5200f7f17947ea82d865127bc</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2900109-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252900109-1%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DDual%2520inhibition%2520of%2520oncogenic%2520targets%2520for%2520B-cell%2520malignancies%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D547%26epage%3D549%26doi%3D10.1016%2FS1470-2045%2816%2900109-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Younes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdeja, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flinn, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelapu, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clancy, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viner, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, Y.</span><span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">â</span> <span class="NLM_lpage">631</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged â¥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0lhwNziI-fTZNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Cai, X.; Zhai, H.; Lai, C.; Qian, C.; Bao, R.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Inhibitor with a Zinc Binding Moiety</span>. U.S. Patent 8,710,219 B2, April 29,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=X.+Cai&author=H.+Zhai&author=C.+Lai&author=C.+Qian&author=R.+Bao&title=Phosphoinositide+3-Kinase+Inhibitor+with+a+Zinc+Binding+Moiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26atitle%3DPhosphoinositide%25203-Kinase%2520Inhibitor%2520with%2520a%2520Zinc%2520Binding%2520Moiety%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A. W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4104</span><span class="NLM_x">â</span> <span class="NLM_lpage">4113</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.-J.+Laiauthor=R.+Baoauthor=D.-G.+Wangauthor=J.+Wangauthor=G.-X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+S.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.-X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. Â©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lhwNziI-fTZNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%2BS.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Flinn, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattaey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdeja, J. G.</span><span> </span><span class="NLM_article-title">A first-in-man phase 1 study of CUDC-907, a first-in-class chemically-designed dual inhibitor of PI3K and HDAC in patients with refractory or relapsed lymphoma and multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4363</span><span class="NLM_x">â</span> <span class="NLM_lpage">4363</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=4363-4363&author=I.+W.+Flinnauthor=Y.+Okiauthor=A.+Coplandauthor=A.+Fattaeyauthor=C.-J.+Laiauthor=R.+Laliberteauthor=M.+Voiauthor=J.+G.+Berdeja&title=A+first-in-man+phase+1+study+of+CUDC-907%2C+a+first-in-class+chemically-designed+dual+inhibitor+of+PI3K+and+HDAC+in+patients+with+refractory+or+relapsed+lymphoma+and+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DOki%26aufirst%3DY.%26aulast%3DCopland%26aufirst%3DA.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26atitle%3DA%2520first-in-man%2520phase%25201%2520study%2520of%2520CUDC-907%252C%2520a%2520first-in-class%2520chemically-designed%2520dual%2520inhibitor%2520of%2520PI3K%2520and%2520HDAC%2520in%2520patients%2520with%2520refractory%2520or%2520relapsed%2520lymphoma%2520and%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D4363%26epage%3D4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Venugopal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristeleit, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourneau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellemans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsayed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcclue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forslund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, T. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span> </span><span class="NLM_article-title">A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4262</span><span class="NLM_x">â</span> <span class="NLM_lpage">4272</span><span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-0312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1078-0432.CCR-13-0312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23741066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4262-4272&author=B.+Venugopalauthor=R.+Bairdauthor=R.+S.+Kristeleitauthor=R.+Plummerauthor=R.+Cowanauthor=A.+Stewartauthor=N.+Fourneauauthor=P.+Hellemansauthor=Y.+Elsayedauthor=S.+Mcclueauthor=J.+W.+Smitauthor=A.+Forslundauthor=C.+Phelpsauthor=J.+Cammauthor=T.+R.+J.+Evansauthor=J.+S.+de+Bonoauthor=U.+Banerji&title=A+phase+I+study+of+quisinostat+%28JNJ-26481585%29%2C+an+oral+hydroxamate+histone+deacetylase+inhibitor+with+evidence+of+target+modulation+and+antitumor+activity%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-13-0312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Venugopal, Balaji; Baird, Richard; Kristeleit, Rebecca S.; Plummer, Ruth; Cowan, Richard; Stewart, Adam; Fourneau, Nele; Hellemans, Peter; Elsayed, Yusri; McClue, Steve; Smit, Johan W.; Forslund, Ann; Phelps, Charles; Camm, John; Evans, T. R. Jeffry; de Bono, Johann S.; Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4262-4272</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the max.-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).  Exptl. Design: In this first-in-human phase I study, quisinostat was administered orally, once daily in three weekly cycles to patients with advanced malignancies, using a two-stage accelerated titrn. design.  Three intermittent schedules were subsequently explored: four days on/three days off; every Monday, Wednesday, Friday (MWF); and every Monday and Thursday (M-Th).  Toxicity, pharmacokinetics, pharmacodynamics, and clin. efficacy were evaluated at each schedule.  Results: Ninety-two patients were treated in continuous daily (2-12 mg) and three intermittent dosing schedules (6-19 mg).  Treatment-emergent adverse events included: fatigue, nausea, decreased appetite, lethargy, and vomiting.  DLTs obsd. were predominantly cardiovascular, including nonsustained ventricular tachycardia, ST/T-wave abnormalities, and other tachyarhythmias.  Noncardiac DLTs were fatigue and abnormal liver function tests.  The max. plasma concn. (Cmax) and area under the plasma concn.-time curve (AUC) of quisinostat increased proportionally with dose.  Pharmacodynamic evaluation showed increased acetylated histone 3 in hair follicles, skin and tumor biopsies, and in peripheral blood mononuclear cells as well as decreased Ki67 in skin and tumor biopsies.  A partial response lasting five months was seen in one patient with melanoma.  Stable disease was seen in eight patients (duration 4-10.5 mo).  Conclusions: The adverse event profile of quisinostat was comparable with that of other HDACi.  Intermittent schedules were better tolerated than continuous schedules.  On the basis of tolerability, pharmacokinetic predictions, and pharmacodynamic effects, the recommended dose for phase II studies is 12 mg on the MWF schedule.  Clin Cancer Res; 19(15); 4262-72. Â©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhELE0VMCPbVg90H21EOLACvtfcHk0lhucFXIZ_zBcw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zP&md5=f4db895a7878fddce61ea9640e427d4d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0312%26sid%3Dliteratum%253Aachs%26aulast%3DVenugopal%26aufirst%3DB.%26aulast%3DBaird%26aufirst%3DR.%26aulast%3DKristeleit%26aufirst%3DR.%2BS.%26aulast%3DPlummer%26aufirst%3DR.%26aulast%3DCowan%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%26aulast%3DFourneau%26aufirst%3DN.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DElsayed%26aufirst%3DY.%26aulast%3DMcclue%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520quisinostat%2520%2528JNJ-26481585%2529%252C%2520an%2520oral%2520hydroxamate%2520histone%2520deacetylase%2520inhibitor%2520with%2520evidence%2520of%2520target%2520modulation%2520and%2520antitumor%2520activity%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4262%26epage%3D4272%26doi%3D10.1158%2F1078-0432.CCR-13-0312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Child, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Romero, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weichenthal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaglino, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beylot-Barry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geskin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PÃ©rez-Ferriols, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellemans, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsayed, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forslund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinzani, P. L.</span><span> </span><span class="NLM_article-title">Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IBâIVA mycosis fungoides/SÃ©zary syndrome</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">â</span> <span class="NLM_lpage">88</span><span class="refDoi">Â DOI: 10.1111/bjd.14427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1111%2Fbjd.14427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=26836950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KktbvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=80-88&author=F.+Childauthor=P.+L.+Ortiz-Romeroauthor=R.+Alvarezauthor=M.+Bagotauthor=R.+Stadlerauthor=M.+Weichenthalauthor=R.+Alvesauthor=P.+Quaglinoauthor=M.+Beylot-Barryauthor=R.+Cowanauthor=L.+J.+Geskinauthor=A.+P%C3%A9rez-Ferriolsauthor=P.+Hellemansauthor=Y.+Elsayedauthor=C.+Phelpsauthor=A.+Forslundauthor=M.+Kamidaauthor=P.+L.+Zinzani&title=Phase+II+multicentre+trial+of+oral+quisinostat%2C+a+histone+deacetylase+inhibitor%2C+in+patients+with+previously+treated+stage+IB%E2%80%93IVA+mycosis+fungoides%2FS%C3%A9zary+syndrome&doi=10.1111%2Fbjd.14427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sezary syndrome</span></div><div class="casAuthors">Child, F.; Ortiz-Romero, P. L.; Alvarez, R.; Bagot, M.; Stadler, R.; Weichenthal, M.; Alves, R.; Quaglino, P.; Beylot-Barry, M.; Cowan, R.; Geskin, L. J.; Perez-Ferriols, A.; Hellemans, P.; Elsayed, Y.; Phelps, C.; Forslund, A.; Kamida, M.; Zinzani, P. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-88</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor.  Objectives : To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL).  Methods : Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles.  Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT).  Secondary end points included global RR, duration of response (DOR) in skin, progression-free survival (PFS), pruritus relief, safety and pharmacodynamic markers.  Results : Eight of 26 (25 evaluable) patients achieved â¥ 50% redn. in mSWAT score at least once, with confirmed cutaneous response in six (RR 24%).  There was a low global RR of 8%.  DOR in skin ranged from 2Â·8 to 6Â·9 mo.  Median PFS was 5Â·1 mo.  Pruritus relief was more frequent in cutaneous responders (67%) than nonresponders (32%).  Serial tumor biopsies revealed an increase in acetylated tubulin, indicating a target effect of histone deacetylase 6.  Twenty-one of 26 (81%) patients were withdrawn from the study before or at clin. cut-off; five (19%) continued to receive treatment with quisinostat.  The most common drug-related adverse events were nausea, diarrhea, asthenia, hypertension, thrombocytopenia and vomiting.  Grade 3 drug-related adverse events included hypertension, lethargy, pruritus, chills, hyperkalemia and pyrexia.  Conclusions : Quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, with an acceptable safety profile.  Combination therapy with other drugs active in CTCL may be appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU9KEEAMiIkbVg90H21EOLACvtfcHk0lhucFXIZ_zBcw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KktbvM&md5=0b64887cee81c36b3667927b3a724ba2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14427%26sid%3Dliteratum%253Aachs%26aulast%3DChild%26aufirst%3DF.%26aulast%3DOrtiz-Romero%26aufirst%3DP.%2BL.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DBagot%26aufirst%3DM.%26aulast%3DStadler%26aufirst%3DR.%26aulast%3DWeichenthal%26aufirst%3DM.%26aulast%3DAlves%26aufirst%3DR.%26aulast%3DQuaglino%26aufirst%3DP.%26aulast%3DBeylot-Barry%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DR.%26aulast%3DGeskin%26aufirst%3DL.%2BJ.%26aulast%3DP%25C3%25A9rez-Ferriols%26aufirst%3DA.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DElsayed%26aufirst%3DY.%26aulast%3DPhelps%26aufirst%3DC.%26aulast%3DForslund%26aufirst%3DA.%26aulast%3DKamida%26aufirst%3DM.%26aulast%3DZinzani%26aufirst%3DP.%2BL.%26atitle%3DPhase%2520II%2520multicentre%2520trial%2520of%2520oral%2520quisinostat%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520in%2520patients%2520with%2520previously%2520treated%2520stage%2520IB%25E2%2580%2593IVA%2520mycosis%2520fungoides%252FS%25C3%25A9zary%2520syndrome%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D175%26spage%3D80%26epage%3D88%26doi%3D10.1111%2Fbjd.14427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Andrs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korabecny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodny, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuca, K.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) Inhibitors: importance of the morpholine ring</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">â</span> <span class="NLM_lpage">71</span><span class="refDoi">Â DOI: 10.1021/jm501026z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501026z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=41-71&author=M.+Andrsauthor=J.+Korabecnyauthor=D.+Junauthor=Z.+Hodnyauthor=J.+Bartekauthor=K.+Kuca&title=Phosphatidylinositol+3-kinase+%28PI3K%29+and+phosphatidylinositol+3-kinase-related+kinase+%28PIKK%29+Inhibitors%3A+importance+of+the+morpholine+ring&doi=10.1021%2Fjm501026z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring</span></div><div class="casAuthors">Andrs, Martin; Korabecny, Jan; Jun, Daniel; Hodny, Zdenek; Bartek, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-71</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) and phosphatidylinositol 3-kinase-related protein kinases (PIKKs) are two related families of kinases that play key roles in regulation of cell proliferation, metab., migration, survival, and responses to diverse stresses including DNA damage.  To design novel efficient strategies for treatment of cancer and other diseases, these kinases have been extensively studied.  Despite their different nature, these two kinase families have related origin and share very similar kinase domains.  Therefore, chem. inhibitors of these kinases usually carry analogous structural motifs.  The most common feature of these inhibitors is a crit. hydrogen bond to morpholine oxygen, initially present in the early nonspecific PI3K and PIKK inhibitor 3 (LY294002), which served as a valuable chem. tool for development of many addnl. PI3K and PIKK inhibitors.  While several PI3K pathway inhibitors have recently shown promising clin. responses, inhibitors of the DNA damage-related PIKKs remain thus far largely in preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPlvsq-HTebVg90H21EOLACvtfcHk0lixhyJUHFn4Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLzE&md5=a8c22f580691084554036dec7d0cc95b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501026z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501026z%26sid%3Dliteratum%253Aachs%26aulast%3DAndrs%26aufirst%3DM.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DHodny%26aufirst%3DZ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DPhosphatidylinositol%25203-kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25203-kinase-related%2520kinase%2520%2528PIKK%2529%2520Inhibitors%253A%2520importance%2520of%2520the%2520morpholine%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D41%26epage%3D71%26doi%3D10.1021%2Fjm501026z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Trott, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">â</span> <span class="NLM_lpage">461</span><span class="refDoi">Â DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+speed+and+accuracy+of+docking+with+a+new+scoring+function%2C+efficient+optimization%2C+and+multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lixhyJUHFn4Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520speed%2520and%2520accuracy%2520of%2520docking%2520with%2520a%2520new%2520scoring%2520function%252C%2520efficient%2520optimization%252C%2520and%2520multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">Crystal structures of PI3KÎ± complexed with PI103 and Its derivatives: new directions for inhibitors design</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span><span class="refDoi">Â DOI: 10.1021/ml400378e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400378e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltL3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=138-142&author=Y.+Zhaoauthor=X.+Zhangauthor=Y.+Chenauthor=S.+Luauthor=Y.+Pengauthor=X.+Wangauthor=C.+Guoauthor=A.+Zhouauthor=J.+Zhangauthor=Y.+Luoauthor=Q.+Shenauthor=J.+Dingauthor=L.+Mengauthor=J.+Zhang&title=Crystal+structures+of+PI3K%CE%B1+complexed+with+PI103+and+Its+derivatives%3A+new+directions+for+inhibitors+design&doi=10.1021%2Fml400378e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of PI3KÎ± Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design</span></div><div class="casAuthors">Zhao, Yanlong; Zhang, Xi; Chen, Yingyi; Lu, Shaoyong; Peng, Yuefeng; Wang, Xiang; Guo, Chengliang; Zhou, Aiwu; Zhang, Jingmiao; Luo, Yu; Shen, Qian Cheng; Ding, Jian; Meng, Linghua; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-142</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays important roles in cell proliferation, growth, and survival.  Hyperactivated PI3K is frequently found in a wide variety of human cancers, validating it as a promising target for cancer therapy.  We detd. the crystal structure of the human PI3KÎ±-PI103 complex to unravel mol. interactions.  Based on the structure, substitution at the R1 position of the phenol portion of PI103 was demonstrated to improve binding affinity via forming a new H-bond with Lys802 at the bottom of the ATP catalytic site.  Interestingly, the crystal structure of one of complexes revealed that the flexibility of Lys802 can also induce addnl. space at the catalytic site for further modification.  Thus, these crystal structures provide a mol. basis for the strong and specific interactions and demonstrate the important role of Lys802 in the design of novel PI3KÎ± inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqa9dea7NarVg90H21EOLACvtfcHk0lj545aed2w1qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltL3M&md5=da8e03879de431fd9a350933cb73d17b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fml400378e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400378e%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520PI3K%25CE%25B1%2520complexed%2520with%2520PI103%2520and%2520Its%2520derivatives%253A%2520new%2520directions%2520for%2520inhibitors%2520design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D138%26epage%3D142%26doi%3D10.1021%2Fml400378e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Frew, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolden, J. E.</span><span> </span><span class="NLM_article-title">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">133</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2009.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.canlet.2009.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19359091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=125-133&author=A.+J.+Frewauthor=R.+W.+Johnstoneauthor=J.+E.+Bolden&title=Enhancing+the+apoptotic+and+therapeutic+effects+of+HDAC+inhibitors&doi=10.1016%2Fj.canlet.2009.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing the apoptotic and therapeutic effects of HDAC inhibitors</span></div><div class="casAuthors">Frew, Ailsa J.; Johnstone, Ricky W.; Bolden, Jessica E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that have moved rapidly through clin. development and in 2006 vorinostat (SAHA, Zolinza) was given FDA approval for the treatment of cutaneous T cell lymphoma.  Class I, II and IV HDACs that are targets for these compds. deacetylate histone proteins, resulting in chromatin remodelling and altered gene transcription.  In addn., numerous non-histone proteins are modified by acetylation and the inhibition of HDAC activity can therefore affect various mol. processes.  This broad effect on protein function may account for the pleiotropic anti-tumor responses elicited by HDACi that include induction of tumor cell apoptosis, cell cycle arrest, differentiation and senescence, modulation of immune responses and altered angiogenesis.  The ability of HDACi to selectively induce tumor cells to undergo apoptosis is important for the therapeutic efficacy obsd. in pre-clin. models.  Moreover, HDACi can augment the apoptotic effects of other anti-cancer agents that have diverse mol. targets.  While HDACi are promising anti-cancer drugs, particularly given the scope to combine HDACi with other agents, identifying the key mol. events that det. the biol. response of cells to HDACi treatment remains a challenge.  Herein we focus on HDACi-induced apoptosis and discuss the various proteins and pathways that are affected by HDACi to mediate this programmed cell death response.  In addn., we highlight the ability of HDACi to synergise with other anti-cancer agents to potently kill tumor cells and discuss the possible mol. processes that underpin the combination effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp45hSsI-BaJ7Vg90H21EOLACvtfcHk0lj545aed2w1qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtrY%253D&md5=2c647b927be73f7882b745b4edd1791f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DFrew%26aufirst%3DA.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DBolden%26aufirst%3DJ.%2BE.%26atitle%3DEnhancing%2520the%2520apoptotic%2520and%2520therapeutic%2520effects%2520of%2520HDAC%2520inhibitors%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D125%26epage%3D133%26doi%3D10.1016%2Fj.canlet.2009.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">van Malenstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekervel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verslype, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windmolders, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevens, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Pelt, J.</span><span> </span><span class="NLM_article-title">Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">329</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2012.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2Fj.canlet.2012.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23111106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWqtLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2013&pages=74-83&author=H.+van+Malensteinauthor=J.+Dekervelauthor=C.+Verslypeauthor=E.+Van+Cutsemauthor=P.+Windmoldersauthor=F.+Nevensauthor=J.+van+Pelt&title=Long-term+exposure+to+sorafenib+of+liver+cancer+cells+induces+resistance+with+epithelial-to-mesenchymal+transition%2C+increased+invasion+and+risk+of+rebound+growth&doi=10.1016%2Fj.canlet.2012.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth</span></div><div class="casAuthors">van Malenstein, Hannah; Dekervel, Jeroen; Verslype, Chris; Van Cutsem, Eric; Windmolders, Petra; Nevens, Frederik; van Pelt, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-83</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but its use is hampered by the occurrence of drug resistance.  To investigate the mol. mechanisms involved we developed five resistant human liver cell lines in which we studied morphol., gene expression and invasive potential.  The cells changed their appearance, lost E-cadherin and KRT19 and showed high expression of vimentin, indicating epithelial-to-mesenchymal transition.  Resistant cells showed reduced adherent growth, became more invasive and lost liver-specific gene expression.  Furthermore, following withdrawal of sorafenib, the resistant cells showed rebound growth, a phenomenon also found in patients.  This cell model was further used to investigate strategies for restoration of sensitivity to sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Dazw0QwqF7Vg90H21EOLACvtfcHk0lj545aed2w1qA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWqtLfE&md5=e84b1d13b495d8a580c5ebffff9e69fd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.10.021%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMalenstein%26aufirst%3DH.%26aulast%3DDekervel%26aufirst%3DJ.%26aulast%3DVerslype%26aufirst%3DC.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DWindmolders%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3Dvan%2BPelt%26aufirst%3DJ.%26atitle%3DLong-term%2520exposure%2520to%2520sorafenib%2520of%2520liver%2520cancer%2520cells%2520induces%2520resistance%2520with%2520epithelial-to-mesenchymal%2520transition%252C%2520increased%2520invasion%2520and%2520risk%2520of%2520rebound%2520growth%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D329%26spage%3D74%26epage%3D83%26doi%3D10.1016%2Fj.canlet.2012.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Gedaly, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angulo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creasy, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spear, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hundley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daily, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evers, B. M.</span><span> </span><span class="NLM_article-title">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2531</span><span class="NLM_x">â</span> <span class="NLM_lpage">2536</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=22753710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=2531-2536&author=R.+Gedalyauthor=P.+Anguloauthor=C.+Chenauthor=K.+T.+Creasyauthor=B.+T.+Spearauthor=J.+Hundleyauthor=M.+F.+Dailyauthor=M.+Shahauthor=B.+M.+Evers&title=The+role+of+PI3K%2FmTOR+inhibition+in+combination+with+sorafenib+in+hepatocellular+carcinoma+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment</span></div><div class="casAuthors">Gedaly, Roberto; Angulo, Paul; Chen, Changguo; Creasy, Kate Townsend; Spear, Brett T.; Hundley, Jonathan; Daily, Michael F.; Shah, Malay; Evers, B. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2531-2536</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Deregulated RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways are found in hepatocellular carcinoma (HCC).  This study aimed to test the inhibitory effects of PI-103 (a small mol. inhibitor of PI3K and mTOR) and sorafenib as single agents and in combination on HCC tumorigenesis in an in vivo xenograft model.  Materials and Methods: In vitro study: Huh7 proliferation was assayed by 3H-thymidine incorporation and by thiazolyl blue tetrazolium bromide (MTT) assay.  Western blots were used to detect phosphorylation of the key enzymes in the two pathways.  In vivo study: Human HCC cell line Huh7 was inoculated into nude mice s.c. and the mice were treated with sorafenib (20 mg/kg/day) and PI-103 (5 mg/kg, every 4 days).  Tumor size was measured every other day.  Tumors were isolated for western blot and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detection of apoptosis and signaling pathway enzymes.  Results: Our in vitro study found that combination of sorafenib and PI-103 additively inhibited Huh7 proliferation as compared to single-agent treatment.  Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in P13K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.  Combination of sorafenib and PI-103 inhibited all the key enzymes in the two pathways.  Our in vivo study demonstrated significant differences between control group, mono-drug groups and drug-combination group (p<0.05).  Combination of Sorafenib and PI-103 more efficiently inhibited tumorigenesis as compared to mono-drug treatments (p<0.032).  Conclusion: The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCZFrpeD720LVg90H21EOLACvtfcHk0lg0JAxPjEeDfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aks73I&md5=921829aacb25e09d9261364e3806b111</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGedaly%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCreasy%26aufirst%3DK.%2BT.%26aulast%3DSpear%26aufirst%3DB.%2BT.%26aulast%3DHundley%26aufirst%3DJ.%26aulast%3DDaily%26aufirst%3DM.%2BF.%26aulast%3DShah%26aufirst%3DM.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DThe%2520role%2520of%2520PI3K%252FmTOR%2520inhibition%2520in%2520combination%2520with%2520sorafenib%2520in%2520hepatocellular%2520carcinoma%2520treatment%26jtitle%3DAnticancer%2520Res.%26date%3D2012%26volume%3D32%26spage%3D2531%26epage%3D2536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatesh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span> </span><span class="NLM_article-title">Development and validation of high-performance liquid chromatographyâtandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies</span> <span class="citation_source-journal">Biomed. Chromatogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">â</span> <span class="NLM_lpage">189</span><span class="refDoi">Â DOI: 10.1002/bmc.734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1002%2Fbmc.734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=17221921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVKkurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=184-189&author=P.+Yeoauthor=L.+Xinauthor=E.+Gohauthor=L.+S.+Newauthor=P.+Zengauthor=X.+Wuauthor=P.+Venkateshauthor=E.+Kantharaj&title=Development+and+validation+of+high-performance+liquid+chromatography%E2%80%93tandem+mass+spectrometry+assay+for+6-%283-benzoyl-ureido%29-hexanoic+acid+hydroxyamide%2C+a+novel+HDAC+inhibitor%2C+in+mouse+plasma+for+pharmacokinetic+studies&doi=10.1002%2Fbmc.734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies</span></div><div class="casAuthors">Yeo, Pauline; Xin, Liu; Goh, Evelyn; New, Lee Sun; Zeng, Peizi; Wu, Xiaofeng; Venkatesh, P.; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Chromatography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">BICHE2</span>;
        ISSN:<span class="NLM_cas:issn">0269-3879</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A liq. chromatog./tandem mass spectrometric method for the quantification of 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide (EX-2), a novel histone deacetylase (HDAC) inhibitor, in mouse plasma was developed to support inhouse pharmacokinetic (PK) studies in the lead optimization stage.  In order to det. the PK parameters for EX-2 in comparison to other HDAC inhibitors such as Suberoylanilide hydroxamic acid (SAHA), PXD-101, and LBH-589, which are currently in different stages of clin. trials, research-grade bio-anal. method validations were carried out for EX-2 and these ref. HDAC inhibitors, which were synthesized by inhouse medicinal chemists.  The components of validation consisted of specificity, extn. efficiency, signal-response of calibration stds., lower limit of quantification, autosampler stability, and accuracy and precision of quality control samples.  The validated LC/MS/MS methods were accurate and precise.  The calibration curve ranged from 1 to 1600 ng/mL for all the analytes.  The methods developed were used to quantify EX-2 and other HDAC inhibitors in mouse plasma obtained from pharmacokinetic studies.  The results suggest that EX-2 has better PK parameters compared with the ref. drugs and is a promising drug development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQByB7XcqcbVg90H21EOLACvtfcHk0lg0JAxPjEeDfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVKkurk%253D&md5=bca780089e84df598409e49febc66367</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fbmc.734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmc.734%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DZeng%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DVenkatesh%26aufirst%3DP.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520high-performance%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%2520assay%2520for%25206-%25283-benzoyl-ureido%2529-hexanoic%2520acid%2520hydroxyamide%252C%2520a%2520novel%2520HDAC%2520inhibitor%252C%2520in%2520mouse%2520plasma%2520for%2520pharmacokinetic%2520studies%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D2007%26volume%3D21%26spage%3D184%26epage%3D189%26doi%3D10.1002%2Fbmc.734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hui, K. M.; Toh, H. C.</span><span> </span><span class="NLM_article-title">Signature Programme: Liver Cancer</span>. <span class="NLM_publisher-name">National Cancer Centre Singapore (NCCS)</span>: <span class="NLM_publisher-loc">Singapore</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.nccs.com.sg/Research/programmes/Signature/Pages/LiverCancer.aspx" class="extLink">https://www.nccs.com.sg/Research/programmes/Signature/Pages/LiverCancer.aspx</a> (accessed Nov 18, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+M.+Hui&author=H.+C.+Toh&title=Signature+Programme%3A+Liver+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DK.%2BM.%26atitle%3DSignature%2520Programme%253A%2520Liver%2520Cancer%26pub%3DNational%2520Cancer%2520Centre%2520Singapore%2520%2528NCCS%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Ikeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okusaka, T.</span><span> </span><span class="NLM_article-title">Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future</span> <span class="citation_source-journal">Diseases</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">â</span> <span class="NLM_lpage">381</span><span class="refDoi">Â DOI: 10.3390/diseases3040360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.3390%2Fdiseases3040360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=28943630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhvVOltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=360-381&author=M.+Ikedaauthor=S.+Mitsunagaauthor=I.+Ohnoauthor=Y.+Hashimotoauthor=H.+Takahashiauthor=K.+Watanabeauthor=K.+Umemotoauthor=T.+Okusaka&title=Systemic+chemotherapy+for+advanced+hepatocellular+carcinoma%3A+past%2C+present%2C+and+future&doi=10.3390%2Fdiseases3040360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future</span></div><div class="casAuthors">Ikeda Masafumi; Mitsunaga Shuichi; Ohno Izumi; Hashimoto Yusuke; Takahashi Hideaki; Watanabe Kazuo; Umemoto Kumiko; Okusaka Takuji</div><div class="citationInfo"><span class="NLM_cas:title">Diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">360-381</span>
        ISSN:<span class="NLM_cas:issn">2079-9721</span>.
    </div><div class="casAbstract">Systemic chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC).  Before the introduction of sorafenib, cytotoxic agents, hormonal therapies, or many combinations of these were the mainly used modalities for systemic chemotherapy of advanced HCC.  However, such regimens were of only limited value in clinical practice, because some randomized controlled studies comparing promising regimens with no treatment or doxorubicin alone failed to show any overall survival advantage.  In two pivotal phase III placebo-controlled studies, the SHARP trial and the Asia-Pacific trial, sorafenib was demonstrated to significantly delay the time to progression and the overall survival time in patients with advanced HCC.  Therefore, sorafenib therapy has come to be acknowledged as a standard therapy for advanced HCC worldwide.  After the introduction of sorafenib, a number of phase III trials of various molecular-targeted agents vs. sorafenib as first-line chemotherapy and of various molecular-targeted agents vs. placebo as second-line chemotherapy have been conducted to determine if any of these agents could offer a survival benefit, however, none of the agents examined so far has been demonstrated to provide any survival benefit over sorafenib or placebo.  Recently, favorable treatment efficacies have been reported in some clinical trials of molecular-targeted agents in the biomarker-enriched population.  Development of individualized cancer treatments using molecular-targeted agents based on the results of genome-sequencing is aggressively ongoing.  Furthermore, immune-oncologic agents, such as anti-CTLA-4 antibody and anti-PD-1/PD-L1 antibody, have been reported to provide promising outcomes.  Thus, various novel systemic chemotherapeutic agents are currently under development, and further improvements in the treatment outcomes are expected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3PXp_8XVTNENoizSOkG_FfW6udTcc2eZ2Jf6CpmVXvrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhvVOltg%253D%253D&md5=d8398200cd11fdf5d3d51383c5fc0825</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3390%2Fdiseases3040360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fdiseases3040360%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DMitsunaga%26aufirst%3DS.%26aulast%3DOhno%26aufirst%3DI.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DUmemoto%26aufirst%3DK.%26aulast%3DOkusaka%26aufirst%3DT.%26atitle%3DSystemic%2520chemotherapy%2520for%2520advanced%2520hepatocellular%2520carcinoma%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DDiseases%26date%3D2015%26volume%3D3%26spage%3D360%26epage%3D381%26doi%3D10.3390%2Fdiseases3040360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">Development of purine-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">5488</span><span class="NLM_x">â</span> <span class="NLM_lpage">5504</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00579</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00579" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5488-5504&author=Y.+Chenauthor=X.+Wangauthor=W.+Xiangauthor=L.+Heauthor=M.+Tangauthor=F.+Wangauthor=T.+Wangauthor=Z.+Yangauthor=Y.+Yiauthor=H.+Wangauthor=T.+Niuauthor=L.+Zhengauthor=L.+Leiauthor=X.+Liauthor=H.+Songauthor=L.+Chen&title=Development+of+purine-based+hydroxamic+acid+derivatives%3A+potent+histone+deacetylase+inhibitors+with+marked+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Facs.jmedchem.6b00579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities</span></div><div class="casAuthors">Chen, Yong; Wang, Xiaoyan; Xiang, Wei; He, Lin; Tang, Minghai; Wang, Fang; Wang, Taijin; Yang, Zhuang; Yi, Yuyao; Wang, Hairong; Niu, Ting; Zheng, Li; Lei, Lei; Li, Xiaobin; Song, Hang; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5488-5504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized.  Several compds. demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines.  Among them, compd. 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties.  Western blot anal. further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concn. in vitro.  In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body wt. and toxicity.  All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematol. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrTRI5NXFfLVg90H21EOLACvtfcHk0lj2B7sMGlkYUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVyks7w%253D&md5=3400d6c13519392827c72bba6f044121</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00579%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520purine-based%2520hydroxamic%2520acid%2520derivatives%253A%2520potent%2520histone%2520deacetylase%2520inhibitors%2520with%2520marked%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5488%26epage%3D5504%26doi%3D10.1021%2Facs.jmedchem.6b00579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span>Bristol-Myers Squibbâs Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib; <span class="NLM_publisher-name">Drugs.com</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="https://www.drugs.com/newdrugs/bristol-myers-squibb-s-opdivo-nivolumab-receives-fda-approval-hepatocellular-carcinoma-patients-4607.html" class="extLink">https://www.drugs.com/newdrugs/bristol-myers-squibb-s-opdivo-nivolumab-receives-fda-approval-hepatocellular-carcinoma-patients-4607.html</a> (accessed Sep 22, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bristol-Myers+Squibb%E2%80%99s+Opdivo+%28nivolumab%29+Receives+FDA+Approval+for+the+Treatment+of+Hepatocellular+Carcinoma+Patients+Previously+Treated+with+Sorafenib%3B+Drugs.com%2C+2017%3B+https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Fbristol-myers-squibb-s-opdivo-nivolumab-receives-fda-approval-hepatocellular-carcinoma-patients-4607.html+%28accessed+Sep+22%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DBristol-Myers%2520Squibb%25E2%2580%2599s%2520Opdivo%2520%2528nivolumab%2529%2520Receives%2520FDA%2520Approval%2520for%2520the%2520Treatment%2520of%2520Hepatocellular%2520Carcinoma%2520Patients%2520Previously%2520Treated%2520with%2520Sorafenib%26pub%3DDrugs.com%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciesielski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramakrishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotomayor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrikant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenstermaker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span> </span><span class="NLM_article-title">Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e30815</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0030815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1371%2Fjournal.pone.0030815" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e30815&author=L.+Shenauthor=M.+Ciesielskiauthor=S.+Ramakrishnanauthor=K.+M.+Milesauthor=L.+Ellisauthor=P.+Sotomayorauthor=P.+Shrikantauthor=R.+Fenstermakerauthor=R.+Pili&title=Class+I+histone+deacetylase+inhibitor+entinostat+suppresses+regulatory+T+cells+and+enhances+immunotherapies+in+renal+and+prostate+cancer+models&doi=10.1371%2Fjournal.pone.0030815"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0030815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0030815%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DCiesielski%26aufirst%3DM.%26aulast%3DRamakrishnan%26aufirst%3DS.%26aulast%3DMiles%26aufirst%3DK.%2BM.%26aulast%3DEllis%26aufirst%3DL.%26aulast%3DSotomayor%26aufirst%3DP.%26aulast%3DShrikant%26aufirst%3DP.%26aulast%3DFenstermaker%26aufirst%3DR.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DClass%2520I%2520histone%2520deacetylase%2520inhibitor%2520entinostat%2520suppresses%2520regulatory%2520T%2520cells%2520and%2520enhances%2520immunotherapies%2520in%2520renal%2520and%2520prostate%2520cancer%2520models%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De30815%26doi%3D10.1371%2Fjournal.pone.0030815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Yardley, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail-Khan, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melichar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichinitser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munster, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruickshank, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span> </span><span class="NLM_article-title">Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on Treatment With a Nonsteroidal Aromatase Inhibitor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2128</span><span class="NLM_x">â</span> <span class="NLM_lpage">2135</span><span class="refDoi">Â DOI: 10.1200/JCO.2012.43.7251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1200%2FJCO.2012.43.7251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=23650416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2128-2135&author=D.+A.+Yardleyauthor=R.+R.+Ismail-Khanauthor=B.+Melicharauthor=M.+Lichinitserauthor=P.+N.+Munsterauthor=P.+M.+Kleinauthor=S.+Cruickshankauthor=K.+D.+Millerauthor=M.+J.+Leeauthor=J.+B.+Trepel&title=Randomized+phase+II%2C+double-blind%2C+placebo-controlled+study+of+exemestane+with+or+without+entinostat+in+postmenopausal+women+with+locally+recurrent+or+metastatic+estrogen+receptor-positive+breast+cancer+progressing+on+Treatment+With+a+Nonsteroidal+Aromatase+Inhibitor&doi=10.1200%2FJCO.2012.43.7251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor</span></div><div class="casAuthors">Yardley, Denise A.; Ismail-Khan, Roohi R.; Melichar, Bohuslav; Lichinitser, Mikhail; Munster, Pamela N.; Klein, Pamela M.; Cruickshank, Scott; Miller, Kathy D.; Lee, Min J.; Trepel, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2128-2135</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-pos. (ER+) breast cancer.  This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane vs. exemestane alone.  Patients and Methods: Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor were randomly assigned to exemestane 25 mg daily plus entinostat 5 mg once per wk (EE) or exemestane plus placebo (EP).  The primary end point was progression-free survival (PFS).  Blood was collected in a subset of patients for evaluation of protein lysine acetylation as a biomarker of entinostat activity.  Results: One hundred thirty patients were randomly assigned (EE group, n = 64; EP group, n = 66).  Based on intent-to-treat anal., treatment with EE improved median PFS to 4.3 mo vs. 2.3 mo with EP (hazard ratio [HR], 0.73; 95% CI, 0.50 to 1.07; one-sided P = .055; two-sided P = .11 [predefined significance level of .10, one-sided]).  Median overall survival was an exploratory end point and improved to 28.1 mo with EE vs. 19.8 mo with EP (HR, 0.59; 95% CI, 0.36 to 0.97; P = .036).  Fatigue and neutropenia were the most frequent grade 3/4 toxicities.  Treatment discontinuation because of adverse events was higher in the EE group vs. the EP group (11% v 2%).  Protein lysine hyperacetylation in the EE biomarker subset was assocd. with prolonged PFS.  Conclusion: Entinostat added to exemestane is generally well tolerated and demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II study.  Acetylation changes may provide an opportunity to maximize clin. benefit with entinostat.  Plans for a confirmatory study are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopc-999rEFo7Vg90H21EOLACvtfcHk0lj2B7sMGlkYUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF&md5=d11f73761ef87fe34fab169ae22e8390</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.7251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.7251%26sid%3Dliteratum%253Aachs%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DIsmail-Khan%26aufirst%3DR.%2BR.%26aulast%3DMelichar%26aufirst%3DB.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DKlein%26aufirst%3DP.%2BM.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26atitle%3DRandomized%2520phase%2520II%252C%2520double-blind%252C%2520placebo-controlled%2520study%2520of%2520exemestane%2520with%2520or%2520without%2520entinostat%2520in%2520postmenopausal%2520women%2520with%2520locally%2520recurrent%2520or%2520metastatic%2520estrogen%2520receptor-positive%2520breast%2520cancer%2520progressing%2520on%2520Treatment%2520With%2520a%2520Nonsteroidal%2520Aromatase%2520Inhibitor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D2128%26epage%3D2135%26doi%3D10.1200%2FJCO.2012.43.7251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Wardley, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCaffrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rea, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett-Lee, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. T.</span><span> </span><span class="NLM_article-title">Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1052</span><span class="refDoi">Â DOI: 10.1200/jco.2010.28.15_suppl.1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1200%2Fjco.2010.28.15_suppl.1052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1052&author=A.+M.+Wardleyauthor=R.+Steinauthor=J.+McCaffreyauthor=J.+Crownauthor=Z.+Malikauthor=D.+Reaauthor=P.+J.+Barrett-Leeauthor=G.+T.+Lee&title=Phase+II+data+for+entinostat%2C+a+class+1+selective+histone+deacetylase+inhibitor%2C+in+patients+whose+breast+cancer+is+progressing+on+aromatase+inhibitor+therapy&doi=10.1200%2Fjco.2010.28.15_suppl.1052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1200%2Fjco.2010.28.15_suppl.1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2010.28.15_suppl.1052%26sid%3Dliteratum%253Aachs%26aulast%3DWardley%26aufirst%3DA.%2BM.%26aulast%3DStein%26aufirst%3DR.%26aulast%3DMcCaffrey%26aufirst%3DJ.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DMalik%26aufirst%3DZ.%26aulast%3DRea%26aufirst%3DD.%26aulast%3DBarrett-Lee%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DG.%2BT.%26atitle%3DPhase%2520II%2520data%2520for%2520entinostat%252C%2520a%2520class%25201%2520selective%2520histone%2520deacetylase%2520inhibitor%252C%2520in%2520patients%2520whose%2520breast%2520cancer%2520is%2520progressing%2520on%2520aromatase%2520inhibitor%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1052%26doi%3D10.1200%2Fjco.2010.28.15_suppl.1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Hooker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shea, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkow, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fowler, J. S.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitor MS-275 exhibits poor brain penetration: pharmacokinetic studies of [(11)C]MS-275 using positron emission tomography</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">â</span> <span class="NLM_lpage">73</span><span class="refDoi">Â DOI: 10.1021/cn9000268</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn9000268" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKms7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=65-73&author=J.+M.+Hookerauthor=S.+W.+Kimauthor=D.+Alexoffauthor=Y.+Xuauthor=C.+Sheaauthor=A.+Reidauthor=N.+Volkowauthor=J.+S.+Fowler&title=Histone+deacetylase+inhibitor+MS-275+exhibits+poor+brain+penetration%3A+pharmacokinetic+studies+of+%5B%2811%29C%5DMS-275+using+positron+emission+tomography&doi=10.1021%2Fcn9000268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography</span></div><div class="casAuthors">Hooker, Jacob M.; Kim, Sung Won; Alexoff, David; Xu, Youwen; Shea, Colleen; Reid, Alicia; Volkow, Nora; Fowler, Joanna S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MS-275 (entinostat) is a histone deacetylase (HDAC) inhibitor currently in clin. trials for the treatment of several types of cancer.  Recent reports have noted that MS-275 can cross the blood-brain barrier (BBB) and cause region-specific changes in rodent brain histone acetylation.  To characterize the pharmacokinetics and distribution of MS-275 in the brain using positron emission tomog. (PET), we labeled the carbamate carbon of MS-275 with carbon-11.  Using PET, we detd. that [11C]MS-275 has low uptake in brain tissue when administered i.v. to nonhuman primates.  In rodent studies, we obsd. that pharmacokinetics and brain accumulation of [11C]MS-275 were not changed by the coadministration of large doses of unlabeled MS-275.  These results, which both highlight the poor brain penetration of MS-275, clearly suggest its limitation as a therapeutic agent for the central nervous system (CNS).  Moreover, our study demonstrates the effectiveness of PET at providing brain pharmacokinetic data for HDAC inhibitors.  These data are important not only for the development of new compds. for peripheral cancer treatment (where CNS exclusion is often advantageous) but also for the treatment of neurol. disorders (where CNS penetration is crit.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-zU8bO0BcpLVg90H21EOLACvtfcHk0ljqyL-DSq_c1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKms7vL&md5=f1cf8e753ac80029fae6cf77193f172f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fcn9000268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn9000268%26sid%3Dliteratum%253Aachs%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DAlexoff%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DShea%26aufirst%3DC.%26aulast%3DReid%26aufirst%3DA.%26aulast%3DVolkow%26aufirst%3DN.%26aulast%3DFowler%26aufirst%3DJ.%2BS.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520MS-275%2520exhibits%2520poor%2520brain%2520penetration%253A%2520pharmacokinetic%2520studies%2520of%2520%255B%252811%2529C%255DMS-275%2520using%2520positron%2520emission%2520tomography%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D65%26epage%3D73%26doi%3D10.1021%2Fcn9000268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kim, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, D. H.</span><span> </span><span class="NLM_article-title">Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">169</span><span class="refDoi">Â DOI: 10.1016/S1056-8719(96)00113-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1016%2FS1056-8719%2896%2900113-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=8959582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADyaK28XnsV2gu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1996&pages=163-169&author=H.+M.+Kimauthor=S.+B.+Hanauthor=M.+S.+Kimauthor=J.+S.+Kangauthor=G.+T.+Ohauthor=D.+H.+Hong&title=Efficient+fixation+procedure+of+human+leukemia+cells+in+sulforhodamine+B+cytotoxicity+assay&doi=10.1016%2FS1056-8719%2896%2900113-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay</span></div><div class="casAuthors">Kim, Hwan Mook; Han, Sang Bae; Kim, Moon Soon; Kang, Jong Seong; Oh, Goo Taeg; Hong, Dong Ho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The fixation procedures in sulforhodamine B (SRB) assay for human leukemia cells were modified to produce more reliable results.  It was found that the concn. of the fixative agent, trichloroacetic acid (TCA), was crit. in the selective fixation of cellular protein.  While a TCA soln. of 80% fixed both cells and serum proteins, a 50% soln. fixed only cells with a very low interference of the serum proteins.  Accordingly, we selected 50% TCA as a fixative agent which made the final absorbance of the SRB assay to be exactly matched to the cell d. with a small deviation and a low background.  Besides the change of TCA concn., a precentrifugation of microplate just before fixation also improved the previous assay procedures in the two points of view.  The 2-h standing step was simply substituted for only 1 min of centrifugation.  Both the rapid and slow application of TCA soln. in fixation produced the same extents of fixation.  In an actual application, these two kinds of modifications in the previous SRB assay procedure were also proved to be effective in the detn. of cytotoxicities of doxorubicin by using human leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8aa3TRqbLb7Vg90H21EOLACvtfcHk0lguATwof5RuVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsV2gu7c%253D&md5=047df5a2bcbfada8982098e4bf315c5c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1056-8719%2896%2900113-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8719%252896%252900113-X%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DHan%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DOh%26aufirst%3DG.%2BT.%26aulast%3DHong%26aufirst%3DD.%2BH.%26atitle%3DEfficient%2520fixation%2520procedure%2520of%2520human%2520leukemia%2520cells%2520in%2520sulforhodamine%2520B%2520cytotoxicity%2520assay%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D1996%26volume%3D36%26spage%3D163%26epage%3D169%26doi%3D10.1016%2FS1056-8719%2896%2900113-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Vichai, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirtikara, K.</span><span> </span><span class="NLM_article-title">Sulforhodamine B colorimetric assay for cytotoxicity screening</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1112</span><span class="NLM_x">â</span> <span class="NLM_lpage">1116</span><span class="refDoi">Â DOI: 10.1038/nprot.2006.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1038%2Fnprot.2006.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=17406391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=1112-1116&author=V.+Vichaiauthor=K.+Kirtikara&title=Sulforhodamine+B+colorimetric+assay+for+cytotoxicity+screening&doi=10.1038%2Fnprot.2006.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Sulforhodamine B colorimetric assay for cytotoxicity screening</span></div><div class="casAuthors">Vichai, Vanicha; Kirtikara, Kanyawim</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1112-1116</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sulforhodamine B (SRB) assay is used for cell d. detn., based on the measurement of cellular protein content.  The method described here was optimized for the toxicity screening of compds. to adherent cells in a 96-well format.  After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid.  The protein-bound dye is dissolved in 10 mM Tris base soln. for OD detn. at 510 nm using a microplate reader.  The results are linear over a 20-fold range of cell nos. and the sensitivity is comparable to those of fluorometric methods.  The method not only allows a large no. of samples to be tested within a few days, but also requires only simple equipment and inexpensive reagents.  The SRB assay is therefore an efficient and highly cost-effective method for screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZ8pao808l7Vg90H21EOLACvtfcHk0lguATwof5RuVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOitL3O&md5=7173035a1f9eb3f02dd7f1a947bca659</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.179%26sid%3Dliteratum%253Aachs%26aulast%3DVichai%26aufirst%3DV.%26aulast%3DKirtikara%26aufirst%3DK.%26atitle%3DSulforhodamine%2520B%2520colorimetric%2520assay%2520for%2520cytotoxicity%2520screening%26jtitle%3DNat.%2520Protoc.%26date%3D2006%26volume%3D1%26spage%3D1112%26epage%3D1116%26doi%3D10.1038%2Fnprot.2006.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span>CellTiter-Glo Luminescent Cell Viability Assay: Instructions for Use of Products G7570, G7571, G7572, and G7573; <span class="NLM_publisher-name">Promega Corporation</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.promega.sg/~/media/Files/Resources/Protocols/Technical%20Bulletins/0/CellTiter%20Glo%20Luminescent%20Cell%20Viability%20Assay%20Protocol.pdf" class="extLink">https://www.promega.sg/~/media/Files/Resources/Protocols/Technical%20Bulletins/0/CellTiter%20Glo%20Luminescent%20Cell%20Viability%20Assay%20Protocol.pdf</a> (accessed Dec 9, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CellTiter-Glo+Luminescent+Cell+Viability+Assay%3A+Instructions+for+Use+of+Products+G7570%2C+G7571%2C+G7572%2C+and+G7573%3B+Promega+Corporation%3A+Madison%2C+WI%2C+2015%3B+https%3A%2F%2Fwww.promega.sg%2F%7E%2Fmedia%2FFiles%2FResources%2FProtocols%2FTechnical%2520Bulletins%2F0%2FCellTiter%2520Glo%2520Luminescent%2520Cell%2520Viability%2520Assay%2520Protocol.pdf+%28accessed+Dec+9%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DCellTiter-Glo%2520Luminescent%2520Cell%2520Viability%2520Assay%253A%2520Instructions%2520for%2520Use%2520of%2520Products%2520G7570%252C%2520G7571%252C%2520G7572%252C%2520and%2520G7573%26pub%3DPromega%2520Corporation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Lorenzi, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhold, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchinson, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanock, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span> </span><span class="NLM_article-title">DNA fingerprinting of the NCI-60 cell line panel</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">â</span> <span class="NLM_lpage">724</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-08-0921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1158%2F1535-7163.MCT-08-0921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=19372543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1amsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=713-724&author=P.+L.+Lorenziauthor=W.+C.+Reinholdauthor=S.+Varmaauthor=A.+A.+Hutchinsonauthor=Y.+Pommierauthor=S.+J.+Chanockauthor=J.+N.+Weinstein&title=DNA+fingerprinting+of+the+NCI-60+cell+line+panel&doi=10.1158%2F1535-7163.MCT-08-0921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">DNA fingerprinting of the NCI-60 cell line panel</span></div><div class="casAuthors">Lorenzi, Philip L.; Reinhold, William C.; Varma, Sudhir; Hutchinson, Amy A.; Pommier, Yves; Chanock, Stephen J.; Weinstein, John N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The National Cancer Institute's NCI-60 cell line panel, the most extensively characterized set of cells in existence and a public resource, is frequently used as a screening tool for drug discovery.  Because many labs. around the world rely on data from the NCI-60 cells, confirmation of their genetic identities represents an essential step in validating results from them.  Given the consequences of cell line contamination or misidentification, quality control measures should routinely include DNA fingerprinting.  We have, therefore, used std. DNA microsatellite short tandem repeats to profile the NCI-60, and the resulting DNA fingerprints are provided here as a ref.  Consistent with previous reports, the fingerprints suggest that several NCI-60 lines have common origins: the melanoma lines MDA-MB-435, MDA-N, and M14; the central nervous system lines U251 and SNB-19; the ovarian lines OVCAR-8 and OVCAR-8/ADR (also called NCI/ADR); and the prostate lines DU-145, DU-145 (ATCC), and RC0.1.  Those lines also show that the ability to connect two fingerprints to the same origin is not affected by stable transfection or by the development of multidrug resistance.  As expected, DNA fingerprints were not able to distinguish different tissues-of-origin.  The fingerprints serve principally as a barcodes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPvXV_U0kPbVg90H21EOLACvtfcHk0ljHev3hHH6rlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1amsLY%253D&md5=7b5b1e052c1fb8c3cef5d43302286de7</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0921%26sid%3Dliteratum%253Aachs%26aulast%3DLorenzi%26aufirst%3DP.%2BL.%26aulast%3DReinhold%26aufirst%3DW.%2BC.%26aulast%3DVarma%26aufirst%3DS.%26aulast%3DHutchinson%26aufirst%3DA.%2BA.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DChanock%26aufirst%3DS.%2BJ.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26atitle%3DDNA%2520fingerprinting%2520of%2520the%2520NCI-60%2520cell%2520line%2520panel%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D713%26epage%3D724%26doi%3D10.1158%2F1535-7163.MCT-08-0921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.</span><span> </span><span class="NLM_article-title">Investigation of cross-contamination and misidentification of 278 widely used tumor cell lines</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0170384</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0170384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1371%2Fjournal.pone.0170384" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0170384&author=Y.+Huangauthor=Y.+Liuauthor=C.+Zhengauthor=C.+Shen&title=Investigation+of+cross-contamination+and+misidentification+of+278+widely+used+tumor+cell+lines&doi=10.1371%2Fjournal.pone.0170384"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0170384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0170384%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DC.%26atitle%3DInvestigation%2520of%2520cross-contamination%2520and%2520misidentification%2520of%2520278%2520widely%2520used%2520tumor%2520cell%2520lines%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0170384%26doi%3D10.1371%2Fjournal.pone.0170384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Venkatesh, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, P. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span> </span><span class="NLM_article-title">In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preelinical species</span> <span class="citation_source-journal">Biol. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1021</span><span class="NLM_x">â</span> <span class="NLM_lpage">1024</span><span class="refDoi">Â DOI: 10.1248/bpb.30.1021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1248%2Fbpb.30.1021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=17473456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntlKks7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=1021-1024&author=P.+R.+Venkateshauthor=E.+Gohauthor=P.+Z.+Zengauthor=L.+S.+Newauthor=L.+Xinauthor=M.+K.+Pashaauthor=K.+Sangthongpitagauthor=P.+Yeoauthor=E.+Kantharaj&title=In+vitro+phase+I+cytochrome+P450+metabolism%2C+permeability+and+pharmacokinetics+of+SB639%2C+a+novel+histone+deacetylase+inhibitor+in+preelinical+species&doi=10.1248%2Fbpb.30.1021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species</span></div><div class="casAuthors">Venkatesh, Pilla Reddy; Goh, Evelyn; Zeng, Peizi; New, Lee Sun; Xin, Liu; Pasha, Mohammed Khalid; Sangthongpitag, Kanda; Yeo, Pauline; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1024</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">In vitro liver microsomal stability, permeability, pharmacokinetics (PK) and oral bioavailability of SB639, a novel HDACi (Histone Deacetylase inhibitor), were detd.  The in vitro metab. was examd. in mouse, rat, dog and human liver microsomes.  The permeability and efflux potential of SB639 were detd. using Caco-2 cell monolayers.  To det. pharmacokinetics and oral bioavailability, blood samples were drawn at pre-detd. intervals up to 24 h post-dose after single i.v. or oral (p.o.) administration of SB639 to mouse or rat.  The concns. of SB639 in plasma samples were detd. by a validated LC-MS/MS method.  In vitro liver microsomal stability data revealed that SB639 was stable in human and dog liver microsomes, unstable in mouse and rat liver microsomes.  The Caco-2 data has shown that SB639 is highly permeable with an apparent permeability of 3.01 Ã 10-6 cm/s at 10 Î¼M.  After oral administration, max. concns. of SB639 were achieved within 0.5 h of post dose.  Following i.v. administration, the concn. of SB639 declined in a bi-exponential fashion with terminal elimination half-life of 1.67 h for mice and 1.12 h for rats.  The systemic clearance and vol. of distribution of SB639 in mice were 15.8 l/h/kg and 38 l/kg, resp., while the resp. values in rats were 3.84 l/h/kg and 3.67 l/kg.  Elimination half-life in rats ranged between 1.12-2.26 h.  Abs. oral bioavailability of SB639 in mouse and rat was 13% and 10%, resp.  In conclusion, the superior potency, physicochem. and PK properties of SB639 compared to the recently FDA approved drug Zolinza (Suberoylanilide hydroxamic acid or Vorinostat) in the preclin. setting makes it a potential clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQPXNOqMkzN7Vg90H21EOLACvtfcHk0lhJBj2xm1Y7NA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntlKks7Y%253D&md5=c6dc4488d0a8762b1fe563e8ba04e499</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1248%2Fbpb.30.1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.30.1021%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesh%26aufirst%3DP.%2BR.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DZeng%26aufirst%3DP.%2BZ.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DIn%2520vitro%2520phase%2520I%2520cytochrome%2520P450%2520metabolism%252C%2520permeability%2520and%2520pharmacokinetics%2520of%2520SB639%252C%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%2520in%2520preelinical%2520species%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2007%26volume%3D30%26spage%3D1021%26epage%3D1024%26doi%3D10.1248%2Fbpb.30.1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">New, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span> </span><span class="NLM_article-title">Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase (HDAC) inhibitor, and prediction of human pharmacokinetics</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2219</span><span class="NLM_x">â</span> <span class="NLM_lpage">2232</span><span class="refDoi">Â DOI: 10.1124/dmd.111.041558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;key=10.1124%2Fdmd.111.041558" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2219-2232&author=R.+Jayaramanauthor=V.+P.+Reddyauthor=M.+K.+Pashaauthor=H.+Wangauthor=K.+Sangthongpitagauthor=P.+Yeoauthor=C.+Y.+Huauthor=X.+Wuauthor=L.+Xinauthor=E.+Gohauthor=L.+S.+Newauthor=K.+Ethirajulu&title=Preclinical+metabolism+and+disposition+of+SB939+%28Pracinostat%29%2C+an+orally+active+histone+deacetylase+%28HDAC%29+inhibitor%2C+and+prediction+of+human+pharmacokinetics&doi=10.1124%2Fdmd.111.041558"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.041558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.041558%26sid%3Dliteratum%253Aachs%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXin%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DNew%26aufirst%3DL.%2BS.%26aulast%3DEthirajulu%26aufirst%3DK.%26atitle%3DPreclinical%2520metabolism%2520and%2520disposition%2520of%2520SB939%2520%2528Pracinostat%2529%252C%2520an%2520orally%2520active%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitor%252C%2520and%2520prediction%2520of%2520human%2520pharmacokinetics%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2219%26epage%3D2232%26doi%3D10.1124%2Fdmd.111.041558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4L23" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4L23','PDB','4L23'); return false;">PDB: 4L23</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01465">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22356"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01465">10.1021/acs.jmedchem.7b01465</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Source of reference compounds, hydroxamate (âCONHOH) <b>20f</b> vs acid (âCO<sub>2</sub>H) <b>20w</b>, KINOMEscan profiling of <b>20f</b> and <b>20q</b> at 1 Î¼M, lead compounds were screened against 39 cancer cell lines, efficacy of orally administered <b>20f</b> in murine triple negative breast cancer and lung metastatic cancer 4T1 models, modulation of HDACs and PI3K/Akt/mTOR in PC-3 and MCF7 cells, molecular docking of reference and target compounds, synthesis of <b>20w</b>, anchorage-dependent clonogenic assay and soft agar colony formation assay, and molecular docking studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_001.csv">jm7b01465_si_001.csv (3.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01465/suppl_file/jm7b01465_si_002.pdf">jm7b01465_si_002.pdf (945.53 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01465&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01465%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01465" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798963ca092254","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
